

;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 100.0%; Score 1333; DB 15; Length 1333;

Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTTCGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTTCGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACCAAGTGTAATACCTCGAATCCCTTGCTACATTTGATGAGCTGAAGAC 180
DB 121 TGATTACAGAAATCCTATAGACCAAGTGTAATACCTCGAATCCCTTGCTACATTTGATGAGCTGAAGAC 180
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTTGTGACAGAGTGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTTGTGACAGAGTGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTTGGCATATCATATTGGAGGTATATGAGTACACAGTGATGAG 300
DB 241 TCTCAATATGCCCTCTTTGGCATATCATATTGGAGGTATATGAGTACACAGTGATGAG 300
QY 301 TGGCCCGAGACTCTATGACCCCTACCAATCATGAATGAGTATTTAGCATATTGCA 360
DB 301 TGGCCCGAGACTCTATGACCCCTACCAATCATGAATGAGTATTTAGCATATTGCA 360
QY 361 GAAGGAAGGATGGTCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAAGTCTTTAGAAACAAACACAGAGAAATTCGTCCAGTAAAT 480
DB 421 CATGATCTATGTTTGGTGAAGTCTTTAGAAACAAACACAGAGAAATTCGTCCAGTAAAT 480
QY 481 GCATGCAAAAAGCACCACAAATGAAGGGATTTCTATCCAGAGAGTCTCTCAAGAGTAC 540
DB 481 GCATGCAAAAAGCACCACAAATGAAGGGATTTCTATCCAGAGAGTCTCTCAAGAGTAC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGTGGAAGAGTCTTTTCAATGTTTACTCAGATAAAGATTTAAATGGTAT 660
DB 601 TTTTGTCTTGTGGAAGAGTCTTTTCAATGTTTACTCAGATAAAGATTTAAATGGTAT 660
QY 661 TACGTATAAATAATATAAATAAGTACTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
DB 661 TACGTATAAATAATATAAATAAGTACTCTGTTGTTGACAGGTTTGAACCTTGACATTC 720
QY 721 TTAAGGAAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACAT 780
DB 721 TTAAGGAAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACAT 780
QY 781 GAAGCTTTTGTATAGGAAGTCTTACGGCTCATTTTGGTTTTCATTTGAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAAGTCTTACGGCTCATTTTGGTTTTCATTTGAAACAGTATCTAA 840
QY 841 TTATAAATTAAGTCTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
DB 841 TTATAAATTAAGTCTAGATATCAGGTGCTTCTGATGAAGTGAATAATGATATCTGACTAG 900
QY 901 TGGGAAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGAATATTTAC 960
DB 901 TGGGAAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGAATATTTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCCGCTTGAATATATCCCTGATATATGATGATGAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCCGCTTGAATATATATCCCTGATATATGATGATGAT 1020
QY 1021 CAGAGATTTCCCATATTTTCCATCAGAGTAATAAATAATCTGCTTAAATCTTAAAGATA 1080

Db 1021 GAGAGATTCCCATATTTCCATCAGAGTAATAATATATCTTGCTTTAATCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTTATTTGTAAGACATTAATTAAGAAATGCTTTATTAATGCTTACTG 1200
Db 1141 TTAATGCTGTTTTATTTGTAAGACATTAATTAAGAAATGCTTTATTAATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGATTAATTTAAGAAATTTGAGGTAATTAATTAATGCTTACTG 1260
Db 1201 TTCTAATCTGCTGTAAGATTAATTTAAGAAATTTGAGGTAATTAATTAATGCTTACTG 1260
QY 1261 GAATGAGAGAAAATTTGATATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAAATTTGATATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 185

US-10-013-924A-321
; Sequence 321, Application US/10013924A
; Publication No. US20030199021A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C76
; CURRENT APPLICATION NUMBER: US/10/013,924A
; CURRENT FILING DATE: 2002-12-10
; PRIOR APPLICATION NUMBER: 09/918595
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/065364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632

; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-013-924A-321

Query Match 100.0%; Score 1333; DB 15; Length 1333;

Best Local Similarity 100.0%; Pred. No. 1.8e-303;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GCCACGCGTCCGATGGCGTTACGTTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTGCT	60
Db	1	GCCACGCGTCCGATGGCGTTACGTTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTGCT	60
Qy	61	CATGCGCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC	120
Db	61	CATGCGCGCTCATCTTCTTCGCCATTTGGCACAATATAGCATTTGATGAGCTGAAGAC	120
Qy	121	TGATTACAAGATCCTATAGACCAGTGAATACCTGAATCCCTTGTATCTCCAGAGTA	180
Db	121	TGATTACAAGATCCTATAGACCAGTGAATACCTGAATCCCTTGTATCTCCAGAGTA	180
Qy	181	CCATCCAGCTTCTTCTGTCATGTTCTTTGTGACGAGGCTTACACTGGG	240
Db	181	CCATCCAGCTTCTTCTGTCATGTTCTTTGTGACGAGGCTTACACTGGG	240
Qy	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGAGACAGTGAAG	300
Db	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGAGACAGTGAAG	300
Qy	301	TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCATATTGCTCA	360
Db	301	TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCATATTGCTCA	360
Qy	361	GAAGGAGGAGTGTGCAAAATAGCTTTTATCTCTAGCATATTTTACCTATATGG	420
Db	361	GAAGGAGGAGTGTGCAAAATAGCTTTTATCTCTAGCATATTTTACCTATATGG	420
Qy	421	CATGATCTATGTTTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT	480
Db	421	CATGATCTATGTTTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT	480
Qy	481	GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC	540
Db	481	GCATGCAAAAGCCCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC	540
Qy	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTCTATTTTAAATGTTTCCACAT	600
Db	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTCTATTTTAAATGTTTCCACAT	600
Qy	601	TTTTGCTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGCTAT	660
Db	601	TTTTGCTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGCTAT	660
Qy	661	TAGTATTAATTAATAAATGATTAACCTCTGCTGTGACGAGTTGAACCTTGCACCTTC	720
Db	661	TAGTATTAATTAATAAATGATTAACCTCTGCTGTGACGAGTTGAACCTTGCACCTTC	720
Qy	721	TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATG	780
Db	721	TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATG	780
Qy	781	GAAGCTTTGTTTATAGGAATTTGTAGGCTCAATTTGGTTTCAATTAAGACAGTATCTAA	840
Db	781	GAAGCTTTGTTTATAGGAATTTGTAGGCTCAATTTGGTTTCAATTAAGACAGTATCTAA	840

Db 841 TTATAAATTAGCTGTAGATATACAGGTGCTTCTGATGAAGTGAATGATAATGATATCTGACTAG 900
Qy TGGGAACCTTCATGGGTTTCTCTCATCTCTCATCTGTCATGTCGATGATATATATGATATGATATAC 960
Db TGGGAACCTTCATGGGTTTCTCTCATCTCTCATCTGTCATGTCGATGATATATATGATATGATATAC 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATGATGATGAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATGAGAGTAATAATATATCTTCTTAAATCTTAAAGCAT 1080
Db 1021 GAGAGATTTCCATATTTCCATGAGAGTAATAATATATCTTCTTAAATCTTAAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATATCTTCTTAAATCTTAAAGCAT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTTCTTAAATCTTAAAGCAT 1140
Qy 1141 TTAATGTTGTTTATTTTGAAGCATATCTTAAAGCATATCTTAAAGCATATCTTAAAGCAT 1200
Db 1141 TTAATGTTGTTTATTTTGAAGCATATCTTAAAGCATATCTTAAAGCATATCTTAAAGCAT 1200
Qy 1201 TTCTAATCTGGTGAAGGATTTCTTAAAGCATATCTTAAAGCATATCTTAAAGCAT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAAGCATATCTTAAAGCATATCTTAAAGCAT 1260
Qy 1261 GAATGAGAGAAAATTTGTATATACCATCTCTGCTGCTTAAAGCATATCTTAAAGCATATCTT 1320
Db 1261 GAATGAGAGAAAATTTGTATATACCATCTCTGCTGCTTAAAGCATATCTTAAAGCATATCTT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 187

US-10-017-085A-321
; Sequence 321, Application US/10017085A
; Publication No. US20030204055A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C73
; CURRENT APPLICATION NUMBER: US/10/017, 085A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-085A-321

Query Match
Best Local Similarity 100.0%; Score 1333; DB 16; Length 1333;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCACCGCTCCGATGCGGTTACAGTTGCGGCGCTTCTGTCATGTCGCGCTGCTGCT 60
Db 1 GCCCACCGCTCCGATGCGGTTACAGTTGCGGCGCTTCTGTCATGTCGCGCTGCTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTTGGCCATTGCGCATTATAGCATTTCATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTGGCCATTGCGCATTATAGCATTTCATGAGCTGAAGAC 120
Qy 121 TGATTACAAGAACTCTATAGACCAAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACCAAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
Qy 181 CCTCATCCAGCTTCTTCTTGTGTCACTTCTTGTGTCAGCAGAGTGGCTTACCTGG 240
Db 181 CCTCATCCAGCTTCTTCTTGTGTCACTTCTTGTGTCAGCAGAGTGGCTTACCTGG 240
Qy 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGTAG 300
Db 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGTAG 300
Qy 301 TGGCCAGGAGTCTATGACCCCTACACCATCATGAATGCGAGATATTCAGCATATGTCA 360
Db 301 TGGCCAGGAGTCTATGACCCCTACACCATCATGAATGCGAGATATTCAGCATATGTCA 360
Qy 361 GAGGAAGGATGTTGCAAAATTTAGCTTTTATCTTCTAGCATTTTTTCTACCTATATGG 420
Db 361 GAGGAAGGATGTTGCAAAATTTAGCTTTTATCTTCTAGCATTTTTTCTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAGAAATTTGGTCCAGTAA 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAGAAATTTGGTCCAGTAA 480
Qy 481 GCATGCAAAAGGCGACCAAAATGAAGGATCTATTCAGCAAGATCCCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAGGCGACCAAAATGAAGGATCTATTCAGCAAGATCCCTGTCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAAAATGTTTCC 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAAAATGTTTCC 600
Qy 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATATAAGATTTTAAATG 660
Db 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATATAAGATTTTAAATG 660
Qy 661 TAGCTATAATTAATATAAATGATTTACCTCTGTTGTCAGGTTTGAACCTTGCATTC 720
Db 661 TAGCTATAATTAATATAAATGATTTACCTCTGTTGTCAGGTTTGAACCTTGCATTC 720
Qy 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Qy 901 TGGGAAACTTTCATGGGTTTCCCTCATCTCTCATCTGTCATGTCGATGATATATGATAT 960

Db 901 TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTATATATATGATACATTTAC 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATCCATGAAT 1020
Db 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATCCATGAAT 1020
QY 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAAATATATATCTGCTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAAATATATATCTGCTTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAAATATATATGCTGATTTACTTTGTAAGAAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATATGCTGATTTACTTTGTAAGAAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGCTGTTTATTTCTTAAGACATTAATTAAGAAATGCTTTTAAATTTCTTAAGCTATT 1200
Db 1141 TTAATATGCTGTTTATTTTGAAGACATTAATTAAGAAATGCTTTTAAATTTCTTAAGCTATT 1200
QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAAATTTGTAACCATCTGCTGCTTTCTTTAGTCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAAATTTGTAACCATCTGCTGCTTTCTTTAGTCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 188

US-10-013-916A-321
; Sequence 321, Application US/10013916A
; Publication No. US20030206915A1

GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630P1C79
; CURRENT APPLICATION NUMBER: US/10/013,916A
; CURRENT FILING DATE: 2002-04-30
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-013-916A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTCCAGTTTCGCGCGCTTCTGCTACATGCTCGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGGCGTTCCAGTTTCGCGCGCTTCTGCTACATGCTCGCGCTGCTGCT 60
QY 61 CACTCGCGCGCTCCTCTTCTGCGCATATTTGGCAGATTTGAGATTTGAGCTGAAGAC 120
Db 61 CACTCGCGCGCTCCTCTTCTGCGCATATTTGGCAGATTTGAGATTTGAGCTGAAGAC 120
QY 121 TGATTAACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTAATCCCAAGTA 180
Db 121 TGATTAACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTAATCCCAAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTCAGATTTCTTTGTCAGAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCAGCTTCTTCTGTCAGATTTCTTTGTCAGAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTAGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTAGAG 300
QY 301 TGGCCCGAGACTCTATAGACCTTACCAACCATCATGAATGCAGATATTTCTAGCATATTGCA 360
Db 301 TGGCCCGAGACTCTATAGACCTTACCAACCATCATGAATGCAGATATTTCTAGCATATTGCA 360
QY 361 GAAGGAAGATGGTGCAGAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGATGGTGCAGAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAACAACAACAACAACAACAACA 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAACAACAACAACAACAACAACA 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAATTAATAAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTA 720
Db 661 TACGATATAATTAATAAATGATTAATGATTAATGATTAATGATTAATGATTAATGATTA 720
QY 721 TTAAGGAACAGCCATAATCCCTGATGATTAATGATTAATGATTAATGATTAATGATTA 780
Db 721 TTAAGGAACAGCCATAATCCCTGATGATTAATGATTAATGATTAATGATTAATGATTA 780
QY 781 GAAGCTTTTGTATAGGAACCTTTGAGGCTCATTTTGGTTTCAATTTTCAATTTTCAAT 840
Db 781 GAAGCTTTTGTATAGGAACCTTTGAGGCTCATTTTGGTTTCAATTTTCAATTTTCAAT 840
QY 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAATAGCTGTAGATATCAGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATATATATATAT 960
Db 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATATATATATATATAT 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATCCATGAAT 1020

Db 961 AAAAATAAAGCGGAATTTTCCTCGCTTGATATATATCCCTGTATATTCATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTTGTCTTTAATCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTTGTCTTTAATCTTAAGCATA 1080
Qy 1081 AGTAACATGATATAAATAATATCTGCTGAATATCTTGTGAAGAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATCTGCTGAATATCTTGTGAAGAATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATGCTTACTG 1200
Db 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATGCTTACTG 1200
Qy 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTAATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTAATTTTCAAAACT 1260
Qy 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTTCCCTTTAGTGCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTTCCCTTTAGTGCAATACAAATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 189

US-10-143-026B-321
; Sequence 321, Application US/10143026B
; Publication No US20030207803A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P26301C58
; CURRENT APPLICATION NUMBER: US/10/143, 026B
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364

; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-143-026B-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60
Db 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60

Qy 61 CACTGGCGCTCATCTTCTTCCCATTTGGCACATTTAGCATTTGAGCAGTGAAGAC 120
Db 61 CACTGGCGCTCATCTTCTTCCCATTTGGCACATTTAGCATTTGAGCAGTGAAGAC 120

Qy 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCGTAATCCCTGTTACTTCCAGAGTA 180
Db 121 TGATTACAAGATCCCTATAGACCAGTGTATACCCGTAATCCCTGTTACTTCCAGAGTA 180

Qy 181 CCTCATCCAGCGTTTCTTCTGCTCATGTTTCTTGTGACAGAGAGTGCTTACACTGGG 240
Db 181 CCTCATCCAGCGTTTCTTCTGCTCATGTTTCTTGTGACAGAGAGTGCTTACACTGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300

Qy 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTC 360
Db 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTC 360

Qy 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480

Qy 481 GCATGCAAAAGCCACCAATGAAGGATTTATCCAGCAAGATCTCTGCTCCAGAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATTTATCCAGCAAGATCTCTGCTCCAGAGTAGC 540

Qy 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600

Qy 601 TTTTGTCTGTGAAAGACGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGAAAGACGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660

Qy 661 TAGGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGAACCTGACTTC 720
Db 661 TAGGTATAAATTAATAAATGATTACCTCTGGTGTGTCACAGGTTTGAACCTGACTTC 720

Qy 721 TTAAGGAACAGCAATATCCCTGATGATGATTAATTAATGACTGCTCTAGTACATGG 780
Db 721 TTAAGGAACAGCAATATCCCTGATGATGATTAATTAATGACTGCTCTAGTACATGG 780

Db 721 TTAAGGAACAGCATAATCTCTGAATGATGATTAATTAATGAGCTGCTAGTACATTG 780
Qy 781 GAAGCTTTTGTATAGGAAGCTTTAGGGCTCATTTTGGTTTCATTTGTAAGACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAAGCTTTAGGGCTCATTTTGGTTTCATTTGTAAGACAGTATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGAAATGATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGAAATGATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATGGAATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATGGAATACATTTAC 960
Qy 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTTATATGATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTTATATGATGAT 1020
Qy 1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATGATATAAATAATATATCTGATGTCGATGATATATGATGATGATGAT 1140
Db 1081 AGTAACATGATATAAATAATATATCTGATGTCGATGATATATGATGATGATGAT 1140
Qy 1141 TTAATGTTTATTTTGTAGACATTTTCCCTTCGCTTGAATATATATCCCTGTTATATGATGAT 1200
Db 1141 TTAATGTTTATTTTGTAGACATTTTCCCTTCGCTTGAATATATATCCCTGTTATATGATGAT 1200
Qy 1201 TTCTAATCTGTTGTAAGGTTATTTCTTAAGGTTATTTGAGGTTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGTTGTAAGGTTATTTCTTAAGGTTATTTGAGGTTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGGAAATTTGATACCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Db 1261 GAATGAGGAAATTTGATACCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 190

US-10-013-918A-321
Sequence 321, Application US/10013918A

Publication No. US20030211091A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kljavin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel

APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C77
CURRENT APPLICATION NUMBER: US/10/013,918A
CURRENT FILING DATE: 2002-03-25
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/068364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078990
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08

;; PRIOR APPLICATION NUMBER: 60/081049
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081071
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081195
;; PRIOR FILING DATE: 1998-04-08
;; PRIOR APPLICATION NUMBER: 60/081203
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081229
;; PRIOR FILING DATE: 1998-04-09
;; PRIOR APPLICATION NUMBER: 60/081955
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081817
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081819
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081952
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/081838
;; PRIOR FILING DATE: 1998-04-15
;; PRIOR APPLICATION NUMBER: 60/082568
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082569
;; PRIOR FILING DATE: 1998-04-21
;; PRIOR APPLICATION NUMBER: 60/082704
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082804
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082700
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082797
;; PRIOR FILING DATE: 1998-04-22
;; PRIOR APPLICATION NUMBER: 60/082796
;; PRIOR FILING DATE: 1998-04-23
;; PRIOR APPLICATION NUMBER: 60/083336
;; PRIOR FILING DATE: 1998-04-27
;; PRIOR APPLICATION NUMBER: 60/083322
;; PRIOR FILING DATE: 1998-04-28
;; PRIOR APPLICATION NUMBER: 60/083392
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083495
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083496
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083499
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083545
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083554
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083558
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083559
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083500
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/083742
;; PRIOR FILING DATE: 1998-04-30
;; PRIOR APPLICATION NUMBER: 60/084366
;; PRIOR FILING DATE: 1998-05-05
;; PRIOR APPLICATION NUMBER: 60/084414
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084441
;; PRIOR FILING DATE: 1998-05-06
;; PRIOR APPLICATION NUMBER: 60/084637
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084639
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084640
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084598
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084600

;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084627
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/084643
;; PRIOR FILING DATE: 1998-05-07
;; PRIOR APPLICATION NUMBER: 60/085339
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085338
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085323
;; PRIOR FILING DATE: 1998-05-13
;; PRIOR APPLICATION NUMBER: 60/085582
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085700
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085689
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085579
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085580
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085573
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085704
;; PRIOR FILING DATE: 1998-05-15
;; PRIOR APPLICATION NUMBER: 60/085697

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGGTTTCAGTTTCGGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCCCTTGTACTCCAGAGTA 180
Qy 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACCTGGG 240
Db 181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACCTGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGGTGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGGTGATGAG 300
Qy 301 TGGCCAGGACTATGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
Db 301 TGGCCAGGACTATGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAAGAAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCCAAAATGAAGGATTCATATCCAGCAAGATCTCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTCATATCCAGCAAGATCTCTGTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAAAATGACTCCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAAAATGACTCCTCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTGTGGAAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGTTAT 660
Db 601 TTTTGTGTGGAAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGTTAT

Db 361 GAAGGAAGGATGGTGCMAATTAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGCAGCTCTTAGAACAACACACAGAGAATTTGGTTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGCAGCTCTTAGAACAACACACAGAGAATTTGGTTCAGTTAAGT 480
QY 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGAGTAGC 540
Db 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGAGTAGC 540
QY 541 CTGTGAATCTGATCAGTTACTTTAAAAAAGACCTCTTATTTTTTAAATGTTTCCACAT 600
Db 541 CTGTGAATCTGATCAGTTACTTTAAAAAAGACCTCTTATTTTTTAAATGTTTCCACAT 600
QY 601 TTTTCTCTGTGGAAGAGCTGTTTTCATATGTTTATCTAGATTAAGATTTTAAATGGTAT 660
Db 601 TTTTCTCTGTGGAAGAGCTGTTTTCATATGTTTATCTAGATTAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTTGAACAGTTTGAACCTTGACATTC 720
Db 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTTGAACAGTTTGAACCTTGACATTC 720
QY 721 TTAAGGAACAGCATAATCTCTGATGATGATTAATCTGATCTGCTAGTACATTTG 780
Db 721 TTAAGGAACAGCATAATCTCTGATGATGATTAATCTGATCTGCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATTAGGAACCTGTAGGCTCATTTTGGTTTCAATGGAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATTAGGAACCTGTAGGCTCATTTTGGTTTCAATGGAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
Db 841 TTATAAATAGCTGTAGATATCAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900
QY 901 TGGGAACCTTCAATGGTCTCTCATCTCTGATGATGATTAATGGAATACATTTAC 960
Db 901 TGGGAACCTTCAATGGTCTCTCATCTCTGATGATGATTAATGGAATACATTTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATTTGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATTTGATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATATACTTGTCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATATACTTGTCTTAAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATCTGATGATGATTAATGGAATGATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATCTGATGATGATTAATGGAATGATTTAAAGCTATT 1140
QY 1141 TTAATCTGTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
Db 1141 TTAATCTGTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
QY 1201 TTTCAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATTTACAGATTTTCAAAACT 1260
Db 1201 TTTCAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATTTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTATACCAATCTCTGCTGTTTCTTTAGTGAATACATAAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTATACCAATCTCTGCTGTTTCTTTAGTGAATACATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 192

US-10-162-522A-321

; Sequence 321, Application US/10162522A

; Publication No. US20030215908A1

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi

; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavini, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630F1C56
; CURRENT APPLICATION NUMBER: US/10162,522A
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-162-522A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGTCCGATCGCTTACGTTCCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60
Db 1 GCCACGGTCCGATCGCTTACGTTCCGGGCTTCTGCTACATGCTGCGCTGCTGCT 60
QY 61 CACTGCGGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAGAC 120
Db 61 CACTGCGGCTCATCTTCTTCCCATTTGGCACATTATAGCATTTGATGAGCTGAGAC 120
QY 121 TGATTACAAAGATCCCTATAGACCCAGTGTAAATCCCTGTGATCCCTCCAGGTA 180

1261 GAATGAGAGAAATTCCTATACCATCTCTGCTGTTCTTTAGTGAATACATAAACTCT 1320
 1261 GAATGAGAGAAATTCCTATACCATCTCTGCTGTTCTTTAGTGAATACATAAACTCT 1320
 1321 GAAATTAAGACTC 1333
 1321 GAAATTAAGACTC 1333

RESULT 193

US-10-013-923A-321
 ; Sequence 321, Application US/10013923A
 ; Publication No: US20030216305A1

GENERAL INFORMATION:

APPLICANT: Ashkenazi, Avi
 APPLICANT: Baker Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan
 APPLICANT: Ferrara, Napoleon
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Godowski, Paul J.
 APPLICANT: Grimaldi, J. Christopher
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth J.
 APPLICANT: Kijavlin, Ivar J.
 APPLICANT: Kuo, Sophia S.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James;
 APPLICANT: Paoni, Nicholas F.
 APPLICANT: Roy, Margaret Ann
 APPLICANT: Shelton, David L.
 APPLICANT: Stewart, Timothy A.
 APPLICANT: Tamas, Daniel
 APPLICANT: Williams, P. Mickey
 APPLICANT: Wood, William I.
 TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
 FILE REFERENCE: P2630P1C87
 CURRENT FILING DATE: 2001-10-25
 Prior Application removed - See Palm or File Wrapper
 NUMBER OF SEQ ID NOS: 624
 SEQ ID NO 321
 LENGTH: 1333
 TYPE: DNA
 ORGANISM: Homo sapiens
 US-10-013-923A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 1.8e-303; Indels 0; Gaps 0;
 Matches 1333; Conservative 0; Mismatches 0;

QY 1 GCCCAGCGCTCGAGTGGCGTTCCAGCTTCGCGGCCCTTCTGCTACATCTGCGCGCTGCTGCT 60
 DB 1 GCCCAGCGCTCGAGTGGCGTTCCAGCTTCGCGGCCCTTCTGCTACATCTGCGCGCTGCTGCT 60
 QY 61 CACTGCGCGCTCACTCTCTTCCCATTTGGCAGCATATATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCGCGCTCACTCTCTTCCCATTTGGCAGCATATATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTAACAAGATCCCTATAGACAGGTGTAATACCCCTGTAATCCCTTGTACTCCACAGTA 180
 DB 121 TGATTAACAAGATCCCTATAGACAGGTGTAATACCCCTGTAATCCCTTGTACTCCACAGTA 180
 QY 181 CCTCATCCAGCTTCTCTCTGCTCATGTTTCTTTGTCAGCAGAGTGCGTTACATCGG 240

121 TGATTACAAGAACTCTATAGACAGGTGTAATACCTGATCCCTTCTACTCCACAGTA 180
 QY 181 CCTCATCCAGCTTCTCTCTGCTCATGTTTCTTTGTCAGCAGGTGTAATACCTGATCCCTTCTACTCCACAGTA 240
 DB 181 CCTCATCCAGCTTCTCTCTGCTCATGTTTCTTTGTCAGCAGGTGTAATACCTGATCCCTTCTACTCCACAGTA 240
 QY 241 TCTCAATATGCGCTCTTGGCATATCATATTTGGAGGTATATAGTACACAGTGAATGAG 300
 DB 241 TCTCAATATGCGCTCTTGGCATATCATATTTGGAGGTATATAGTACACAGTGAATGAG 300
 QY 301 TGGCCCGAGCTCTATGAGCCCTTACAAACATCATGAATCAGATATCTTAGCATATGTCA 360
 DB 301 TGGCCCGAGCTCTATGAGCCCTTACAAACATCATGAATCAGATATCTTAGCATATGTCA 360
 QY 361 GAAGGAAGGATGCTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACTCTATATGG 420
 DB 361 GAAGGAAGGATGCTCAAAATAGCTTTTATCTCTAGCATTTTCTACTACTCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATTTGTCAGTTAAGT 480
 QY 481 GCATGAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCOAAGTAGC 540
 DB 481 GCATGAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCOAAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTTAAATGATGCTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTTAAATGATGCTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTGTTGGAAGAGCTGTTTCAATGTTATCTAGATTAAGATTTTAAATGTTAT 660
 DB 601 TTTTGTGTTGGAAGAGCTGTTTCAATGTTATCTAGATTAAGATTTTAAATGTTAT 660
 QY 661 TACGTATAAATTAATAAATGATGCTCTGTTGTTGACAGTTTGAATTCACATTC 720
 DB 661 TACGTATAAATTAATAAATGATGCTCTGTTGTTGACAGTTTGAATTCACATTC 720
 QY 721 TTAAGGAACAGCCATATCTCTGAATGATGCTCTGTTGTTGACAGTTTGAATTCACATTC 780
 DB 721 TTAAGGAACAGCCATATCTCTGAATGATGCTCTGTTGTTGACAGTTTGAATTCACATTC 780
 QY 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCAATTTGGTTTCAATTTGAATGAAGTATCTAA 840
 DB 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCAATTTGGTTTCAATTTGAATGAAGTATCTAA 840
 QY 841 TTATAAATTAGCTGATGATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGATGATCAGGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
 QY 901 TGGGAACCTCTATGCTGTTTCCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
 DB 901 TGGGAACCTCTATGCTGTTTCCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
 QY 961 AAAAAATAAAGCGGAATTTTCCCTTCGCTGATATATATCTGCTGATATTTGCAAT 1020
 DB 961 AAAAAATAAAGCGGAATTTTCCCTTCGCTGATATATATCTGCTGATATTTGCAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGATGATATATATCTGCTGATATTTGCAAT 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGATGATATATATCTGCTGATATTTGCAAT 1080
 QY 1081 AGTAAACATGATATATAAATATATGCTGATATTTCTGTAAGATGATATTAAGCTATT 1140
 DB 1081 AGTAAACATGATATATAAATATATGCTGATATTTCTGTAAGATGATATTAAGCTATT 1140
 QY 1141 TTAATGTTTATTTGTAAGCATTAATTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
 DB 1141 TTAATGTTTATTTGTAAGCATTAATTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
 QY 1201 TTTCAATCTGTTGTAAGGATTTCTTTAAGAAATTTGAGGTTTACAGATTTTCAAAACT 1260
 DB 1201 TTTCAATCTGTTGTAAGGATTTCTTTAAGAAATTTGAGGTTTACAGATTTTCAAAACT 1260

Db 181 CCTCATCCACGCTTTCTTCTGTGTCAATGTTTCTGTGCAGCAGAGTGGCTTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGTAACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGTAACAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
Db 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
QY 361 GAAGGAGGATGGTCAAAATAGCTTTTATCTTCTAGCATATTTTCTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTCAAAATAGCTTTTATCTTCTAGCATATTTTCTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTGAAGCAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTGAAGCAACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGTAGC 540
QY 541 CTGTGGATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
QY 661 TACGTATAAATTAATAAATAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTGACTTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGGACACCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
Db 721 TTAAGGACACCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
QY 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTTTGAGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGATGATGATGATGATGATGATGATG 900
QY 901 TGGGAAACTTTCATGAGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATG 960
Db 901 TGGGAAACTTTCATGAGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATG 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTCCCTGTATATTTGATGAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTCCCTGTATATTTGATGAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGATATTAATAATATATATATATATATATATATAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGATATTAATAATATATATATATATATATATATAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGATGATGATGATGAT 1140
QY 1141 TTAATGTTTGTATTTGTAAGACATTTTAAAGAAATTTGTTTATATGCTTACTG 1200
Db 1141 TTAATGTTTGTATTTGTAAGACATTTTAAAGAAATTTGTTTATATGCTTACTG 1200
QY 1201 TTCTAAATCTGTTGTAAGATTTCTTAAAGATTTGAGGATGATGATGATGATGATGATG 1260
Db 1201 TTCTAAATCTGTTGTAAGATTTCTTAAAGATTTGAGGATGATGATGATGATGATGATG 1260
QY 1261 GAATGAGAGAAAATTTGATATACCATCTCTGCTGTTTCTTGTAGTGAATACATATAA 1320
Db 1261 GAATGAGAGAAAATTTGATATACCATCTCTGCTGTTTCTTGTAGTGAATACATATAA 1320

QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 194

US-10-013-925A-321
; Sequence 321, Application US/10013925A
; Publication No. US20030216560A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnayers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630F1C83
; CURRENT APPLICATION NUMBER: US/10/013,925A
; CURRENT FILING DATE: 2002-05-03
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-013-925A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGTTTCAGGTTCCGCGCTTCTGCTACATGCTGGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGCGGTTTCAGGTTCCGCGCTTCTGCTACATGCTGGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCCCATTTGGCACATTTATAGCATTTTATGAGCTGGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCCCATTTGGCACATTTATAGCATTTTATGAGCTGGAAGAC 120
QY 121 TGATTACAGAATCCTATAGACAGAGTGTATACCTGGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAATCCTATAGACAGAGTGTATACCTGGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGCTGCTATGTTTCTTGTGAGAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTCTTCTGCTGCTATGTTTCTTGTGAGAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGTGATATCATATTTTGGAGGTATATGATGATGATGATGATGATG 300
Db 241 TCTCAATATGCCCTCTTGTGATATCATATTTTGGAGGTATATGATGATGATGATGATGATG 300

Db	241	TCTCAATATGCCCCCTCTTTGGCATCATCAATTTGGAGGTATATAGTAGAGCCAGTGAAG	300
Qy	301	TGGCCCAAGGACTCTATGACCCCTCAACCACTCATGAATGCAGATATCTAGCATATGTGCA	360
Db	301	TGGCCCAAGGACTCTATGACCCCTCAACCACTCATGAATGCAGATATCTAGCATATGTGCA	360
Qy	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTTTATCTTCTAGCAATTTTTTATCTATATGG	420
Db	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTTTATCTTCTAGCAATTTTTTATCTATATGG	420
Qy	421	CATGATCTATGTTTTTGGTGAGCTCTTAGAACAACACACAGAAGAAATTTGGTCCAGTTAAGT	480
Db	421	CATGATCTATGTTTTTGGTGAGCTCTTAGAACAACACACAGAAGAAATTTGGTCCAGTTAAGT	480
Qy	481	GCATGCAAAAAGCCACCAATGAAGGAAATCTATCCAGCAAGATCCCTGTCCAAGAGTAGC	540
Db	481	GCATGCAAAAAGCCACCAATGAAGGAAATCTATCCAGCAAGATCCCTGTCCAAGAGTAGC	540
Qy	541	CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
Db	541	CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
Qy	601	TTTTTGCTTTGGAAAGACTGTTTTCAATATGTATATCTCAGATAAAGATTTTAAATGGTAT	660
Db	601	TTTTTGCTTTGGAAAGACTGTTTTCAATATGTATATCTCAGATAAAGATTTTAAATGGTAT	660
Qy	661	TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC	720
Db	661	TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC	720
Qy	721	TTAAGGAACAGCCATAATCCCTCAATGATGCATTAATTACTGACTCTCCTAGTACATATG	780
Db	721	TTAAGGAACAGCCATAATCCCTCAATGATGCATTAATTACTGACTCTCCTAGTACATATG	780
Qy	781	GAAGCTTTTGTTTATAGGAACCTTGAGGGCTCATTTTGGTTTCATTTGAAAACAGTATCTAA	840
Db	781	GAAGCTTTTGTTTATAGGAACCTTGAGGGCTCATTTTGGTTTCATTTGAAAACAGTATCTAA	840
Qy	841	TTATAAATTAGCTCTGAGATATCAGGTGCTCTCGATGAAGTGAAAATCTATATCTGACTAG	900
Db	841	TTATAAATTAGCTCTGAGATATCAGGTGCTCTCGATGAAGTGAAAATCTATATCTGACTAG	900
Qy	901	TGGAAACTTTCATCGGTTTTCTCATCTGTCATGTCGATGATATATATGAGTACATTTAC	960
Db	901	TGGAAACTTTCATCGGTTTTCTCATCTGTCATGTCGATGATATATATGAGTACATTTAC	960
Qy	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGATATATTCGATGAAT	1020
Db	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATATTCGATGAAT	1020
Qy	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAATACTTGGCTTTAAATCTTTAAGCATTA	1080
Db	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAATACTTGGCTTTAAATCTTTAAGCATTA	1080
Qy	1081	AGTAAACATGATATAAATAATATGCTGAATATACCTGTGGAAGATGCATTTAAGCTATT	1140
Db	1081	AGTAAACATGATATAAATAATATGCTGAATATACCTGTGGAAGATGCATTTAAGCTATT	1140
Qy	1141	TTAAATGTGTTTTTATTTTGTAAAGCATATCTTATTAAGAAATTTGGTTATATGCTTACTG	1200
Db	1141	TTAAATGTGTTTTTATTTTGTAAAGCATATCTTATTAAGAAATTTGGTTATATGCTTACTG	1200
Qy	1201	TTCTAATCTGTGGTAAAGGTATTTCTTAAGAAATTTGCAAGTATGCAGATTTTCAAAACT	1260
Db	1201	TTCTAATCTGTGGTAAAGGTATTTCTTAAGAAATTTGCAAGTATGCAGATTTTCAAAACT	1260
Qy	1261	GAATGAGAGAAAATTTGTATAACCACTCTGCTGTTTCCCTTTAGTGCATAATCAAACTCT	1320
Db	1261	GAATGAGAGAAAATTTGTATAACCACTCTGCTGTTTCCCTTTAGTGCATAATCAAACTCT	1320
Qy	1321	GAATTAAGACTC 1333	
Db	1321	GAATTAAGACTC 1333	

```

RESULT 195
US-10-013-927A-321
; Sequence 321, Application US/10013927A
; Publication No. US20030216561A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William L.
; TITLE OF INVENTION: Secreted and Transmitted
; FILE REFERENCE: Acids Encoding tRNA
; CURRENT APPLICATION NUMBER: US/10/013-927A-321
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See File 10013927A
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
US-10-013-927A-321

```

Query Match	100.0%	Score 1333;	DB 16;	Length 1333;
Best Local Similarity	100.0%;	Pred. No. 1.8e-303;		
Matches 1333;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
QY	1	GCCACGGCTCCGATGGCGTTTCACGTTTCGGCGCCTTCGTACATGCTGGCGCTGCTGCT	60	
DB	1	GCCACGGCTCCGATGGCGTTTCACGTTTCGGCGCCTTCGTACATGCTGGCGCTGCTGCT	60	
QY	61	CAC TGCCGCGCTCATCTTCTTCGGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC	120	
DB	61	CAC TGCCGCGCTCATCTTCTTCGGCCATTGGCCACATTATAGCATTTGATGAGCTGAAGAC	120	
QY	121	TGATTAACAGAAATCCTATACACAGAGTGTATACCCCTGAATCCCTCTGTACTCCACAGTA	180	
DB	121	TGATTAACAGAAATCCTATAGACAGTGTAAATACCCCTGAATCCCTCTGTACTCCACAGTA	180	
QY	181	CCTCATCCACGCTTCTTCTGTGTCACTGTTTCTTTGTGCACAGAGTGGCTTTACACTGGG	240	
DB	181	CCTCATCCACGCTTCTTCTGTGTCACTGTTTCTTTGTGCACAGAGTGGCTTTACACTGGG	240	
QY	241	TCTCAATATGCCCCCTCTTGGCATATCATATTTTGGAGGTATATGATGTAGACCAAGTATGAG	300	
DB	241	TCTCAATATGCCCCCTCTTGGCATATCATATTTTGGAGGTATATGATGTAGACCAAGTATGAG	300	
QY	301	TGGCCACGAGACTCTATGACCCCTCAACCAATCATGAATGCAGATATTTCTATGCATATTTGCTCA	360	

Db 61 CACTGCCGGCTCATCTCTTGGCCATTTGGCAATTTAGATTTGATGAGCTGAAGAC 120
Qy 121 TGANTCAAGAATCCTATAGACAGTGAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180
Db 121 TGAATCAAGAATCCTATAGACAGTGAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180
Qy 181 CCTCATCAGCGTTCTCTCTGTGTCATCTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCAGCGTTCTCTCTGTGTCATCTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Qy 301 TGGCCAGAGCTCTATGACCCCTACCAACATCATGATGAGATGAGATGATGATGATGATG 360
Db 301 TGGCCAGAGCTCTATGACCCCTACCAACATCATGATGAGATGAGATGATGATGATGATG 360
Qy 361 GAAGGAAGATGGTCAAAATGAGCTTTTATCTCTTACATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGATGGTCAAAATGAGCTTTTATCTCTTACATTTTCTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAAGT 480
Qy 481 GCATGAAAAGCCACCAATGAGGATCTTATCCAGCAGATCTCTGTCGAAGAGTAGC 540
Db 481 GCATGAAAAGCCACCAATGAGGATCTTATCCAGCAGATCTCTGTCGAAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTTAAATGAGCTTTTAAATGAGCTTTTAAATGAGCTTTTAA 600
Db 541 CTGTGGAATCTGATCAGTTTAAATGAGCTTTTAAATGAGCTTTTAAATGAGCTTTTAA 600
Qy 601 TTTTCTTGTGGAAGAGCTTTTCAATGATTTATCTAGATGATGATGATGATGATGATG 660
Db 601 TTTTCTTGTGGAAGAGCTTTTCAATGATTTATCTAGATGATGATGATGATGATGATG 660
Qy 661 TACGTATAAATTAATATAAATGATGATGATGATGATGATGATGATGATGATGATGATG 720
Db 661 TACGTATAAATTAATATAAATGATGATGATGATGATGATGATGATGATGATGATGATG 720
Qy 721 TTAAGGAACAGCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 780
Db 721 TTAAGGAACAGCAATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 780
Qy 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTCATTTGATGATGATGATGAT 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTGGTTCATTTGATGATGATGATGAT 840
Qy 841 TTATAAATTAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
Db 841 TTATAAATTAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
Qy 901 TGGGAACCTTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACCTTCAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
Qy 961 AAAAATAAAGGGGAATTTCCCTGCTGATGATGATGATGATGATGATGATGATGATGAT 1020
Db 961 AAAAATAAAGGGGAATTTCCCTGCTGATGATGATGATGATGATGATGATGATGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCCATGAGTAAATATATCTGCTTTAAATTTTAAAGCATATA 1080
Db 1021 GAGAGATTTCCCATATTTCCCATGAGTAAATATATCTGCTTTAAATTTTAAAGCATATA 1080
Qy 1081 AGTAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATAGTGTGTTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1200
Db 1141 TTAATAGTGTGTTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1200

Qy 1201 TTCTAATCTGTTGTAAGGATTTCTTAAGATTTGAGGTTGAGGTTGAGGTTGAGGTTG 1260
Db 1201 TTCTAATCTGTTGTAAGGATTTCTTAAGATTTGAGGTTGAGGTTGAGGTTGAGGTTG 1260
Qy 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGCTTTTCTTTAGTGCATAAATAA 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGCTTTTCTTTAGTGCATAAATAA 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 197

US-10-013-919A-321
; Sequence 321, Application US/10013919A
; Publication No. US20040005657A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C85
; CURRENT APPLICATION NUMBER: US/10/013,919A
; CURRENT FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 624

```
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-013-919A-321

Query Match      100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCGTCACTCTCTCTGCGCATTTGGGCACATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGTCACTCTCTCTGCGCATTTGGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTGCTACCTCCAGAGTA 180
DB 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTGCTACCTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTCTGCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTCTGCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTCTGGCATATCATATTTGGAGGTATATGATGACCACTGATGAG 300
DB 241 TCTCAATATGCCCTCTCTGGCATATCATATTTGGAGGTATATGATGACCACTGATGAG 300

QY 301 TGGCCCAAGACTCTATGACCCCTAGAACCATCATGAATCAGATATTTAGCATATTTGCA 360
DB 301 TGGCCCAAGACTCTATGACCCCTAGAACCATCATGAATCAGATATTTAGCATATTTGCA 360

QY 361 GAAGAAGAGTGGTGCATAATAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
DB 361 GAAGAAGAGTGGTGCATAATAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAAGCCACCAATGAAGGGATTCTATCCAGCAAGATCCTCTCAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGGATTCTATCCAGCAAGATCCTCTCAAGAGTAGC 540

QY 541 CTGTGGAACTGATCAGTTACTTTAAATAAATGACCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAACTGATCAGTTACTTTAAATAAATGACCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATATAAATAGTATCCTCTGGTGGTTGACAGGTTTGAACCTGCACCTC 720
DB 661 TACGTATAAATTAATATAAATAGTATCCTCTGGTGGTTGACAGGTTTGAACCTGCACCTC 720

QY 721 TTAAGGAACAGCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780
DB 721 TTAAGGAACAGCCATATCTCTGATGATGATGATGATGATGATGATGATGATGATGATG 780

QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTTCATTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTTTCATTGAAACAGATATCTAA 840

QY 841 TTATAAATAGCTGTAGATATCAGTGGCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
DB 841 TTATAAATAGCTGTAGATATCAGTGGCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900

QY 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATGATGATGATGATGATGAT 960
```

RESULT 198
US-10-232-226-119
; Sequence 119, Application US/10232226
; Publication No. US20040006206A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C110
; CURRENT APPLICATION NUMBER: US/10/232,226
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246

QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCGATGAAT 1020
DB 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGTGAAGAAATGCAATTTAAAGCTATT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGTGAAGAAATGCAATTTAAAGCTATT 1080
QY 1081 AGTAAAAATGATATAAATAATATATCTTGTGAAGAAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAAAATGATATAAATAATATATCTTGTGAAGAAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTTTAAAGCTATT 1200
DB 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTTTAAAGCTATT 1200
QY 1201 TTCTAAATCTGCTGTAAGGTAATTTCTTAAAGAAATTTGAGGTAATTTTCAAAACT 1260
DB 1201 TTCTAAATCTGCTGTAAGGTAATTTCTTAAAGAAATTTGAGGTAATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
DB 1261 GAATGAGAGAAATTTGTATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

```
; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-232-226-119

Query Match      100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGCGTTCACGTTGCGGCCCTTCGCTACATGCTGGCGCTCGTCT 60
DB 1 GCCACGGCTCCGATGGCGTTCACGTTGCGGCCCTTCGCTACATGCTGGCGCTCGTCT 60

QY 61 CACTCGCGGCTCATCTTCTTCGCCATTGGGCACATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTCGCGGCTCATCTTCTTCGCCATTGGGCACATATAGCAATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAAATCCCTTGCTACTCCACAGATA 180
DB 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAAATCCCTTGCTACTCCACAGATA 180

QY 181 COTCATCCACGCTTCTTCTGCTGTCATGTTTCTTTGTGCGACAGAGTGGCTTACACTGG 240
DB 181 COTCATCCACGCTTCTTCTGCTGTCATGTTTCTTTGTGCGACAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGCA 360

QY 361 GAAGGAAGATGGTGGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGATGGTGGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCTGTCCAAAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATCAAGGATTTCTATCCAGCAAGATCTGTCCAAAGTAGC 540

QY 541 CTGTGGAACTGATCAAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAACTGATCAAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTC 720
DB 661 TAGCTATAAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGCACCTC 720

QY 721 TTAAGGAACAGCATTAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCATTAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTGTTTCAATGGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTGTTTCAATGGAACAGTATCTAA 840

QY 841 TTATAAATTAGCTGTAGATATACAGGTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATACAGGTCTCTGATGAAGTGAATAATGATATCTGACTAG 900

QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATTTAC 960

OY 961 AAAAATAAAAGCGGGAATTTTCCCTTGGCTTGAATATATATCCCTGTATATTTGATGAAT 1020
DB 961 AAAAATAAAAGCGGGAATTTTCCCTTGGCTTGAATATATATCCCTGTATATTTGATGAAT 1020

OY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTTGTAAATCTTAACTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTTGTAAATCTTAACTTAAGCATA 1080

OY 1081 AGTAAACATGATATAAAATATATGCTGAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAATATATGCTGAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140

OY 1141 TTAATGTTTGTATTTTGTGAAGACATTTATTTAGAAATTTGGTTATTTATGCTTACTG 1200
DB 1141 TTAATGTTTGTATTTTGTGAAGACATTTATTTAGAAATTTGGTTATTTATGCTTACTG 1200

OY 1201 TTCTAATCTGCTGTAAAGGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAATCTGCTGTAAAGGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260

OY 1261 GAATGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATAAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATAAATAAACTCT 1320

OY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 199
US-10-013-920A-321
; Sequence 321, Application US/10013920A
; Publication No. US20040906219A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kljavin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2630FIC78
; CURRENT APPLICATION NUMBER: US/10/013,920A
; CURRENT FILING DATE: 2001-10-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 624
; SEQ ID NO 321
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo sapiens
```


US-10-013-920A-321

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GCCACGGTCCGATGGCGTTACGTTCCGCGCCCTTCGCTACATGCTGGCGCTGCTGCT	60
Db	1	GCCACGGTCCGATGGCGTTACGTTCCGCGCCCTTCGCTACATGCTGGCGCTGCTGCT	60
Qy	61	CACGCGCGCTCATCTTCGCGCATTTGGCAATATAGCAATTTGAGTGAAGAC	120
Db	61	CACGCGCGCTCATCTTCGCGCATTTGGCAATATAGCAATTTGAGTGAAGAC	120
Qy	121	TGATTACAGAAATCCTATAGACCACTGTAACTCCCTGAATCCCTTGACTCCAGAGTA	180
Db	121	TGATTACAGAAATCCTATAGACCACTGTAACTCCCTGAATCCCTTGACTCCAGAGTA	180
Qy	181	CCTCATCCAGCTTCTTCGTCGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG	240
Db	181	CCTCATCCAGCTTCTTCGTCGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG	240
Qy	241	TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGACGACGATGAG	300
Db	241	TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGACGACGATGAG	300
Qy	301	TGGCCAGCACTCTATGACCTTACAACTCATGAATCAGATATTTCTAGCATATTTGCA	360
Db	301	TGGCCAGCACTCTATGACCTTACAACTCATGAATCAGATATTTCTAGCATATTTGCA	360
Qy	361	GAAGAAAGATGGTCAAAATAGCTTTTATCTTCTAGCAATTTTCTACTACCTATATGG	420
Db	361	GAAGAAAGATGGTCAAAATAGCTTTTATCTTCTAGCAATTTTCTACTACCTATATGG	420
Qy	421	CATGATCTATGTTTGGTGAAGTCTTTAGACAACAACAGAAATTTGGTCAAGTAAAT	480
Db	421	CATGATCTATGTTTGGTGAAGTCTTTAGACAACAACAGAAATTTGGTCAAGTAAAT	480
Qy	481	GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTCCAGAGTAGC	540
Db	481	GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTCCAGAGTAGC	540
Qy	541	CTGTGGAAATCTGATCAGTTATTTAAATAATGACTCTTTTAAATGTTTCCACAT	600
Db	541	CTGTGGAAATCTGATCAGTTATTTAAATAATGACTCTTTTAAATGTTTCCACAT	600
Qy	601	TTTTGCTTGTGAAGACTGTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT	660
Db	601	TTTTGCTTGTGAAGACTGTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT	660
Qy	661	TACGTATAAATTAATAAATAATGATTACTCTGTGTGTTGACAGGTTTGAACTTGCACTT	720
Db	661	TACGTATAAATTAATAAATAATGATTACTCTGTGTGTTGACAGGTTTGAACTTGCACTT	720
Qy	721	TTAAGGAACCCCAATATCTCTGAATGATGATTAATTAATTAATGTTTAAATGTTAT	780
Db	721	TTAAGGAACCCCAATATCTCTGAATGATGATTAATTAATTAATGTTTAAATGTTAT	780
Qy	781	GAAGCTTTGTTTATAGAACTTGTAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA	840
Db	781	GAAGCTTTGTTTATAGAACTTGTAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA	840
Qy	841	TTATAAATTAAGCTAGATATCAGTGTCTCTGATGAAGTGAAGTGAATGATATCTGACTAG	900
Db	841	TTATAAATTAAGCTAGATATCAGTGTCTCTGATGAAGTGAAGTGAATGATATCTGACTAG	900
Qy	901	TGGGAACCTTCATGGGTTTCTCTCATCTGTATGATGATTAATATATGATGATATCTAC	960
Db	901	TGGGAACCTTCATGGGTTTCTCTCATCTGTATGATGATTAATATATGATGATATCTAC	960
Qy	961	AAAAATAAAGCGGAAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTGATGAAT	1020
Db	961	AAAAATAAAGCGGAAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTGATGAAT	1020

Qy	1021	GAGAGATTTCCATATTTCCATCAGAGTAAATATATATCTTCTTAATCTTAAGCATATA	1080
Db	1021	GAGAGATTTCCATATTTCCATCAGAGTAAATATATATCTTCTTAATCTTAAGCATATA	1080
Qy	1081	AGTAAACATGATATAAATAATATATCTTCTTGAAGAATGCAATTTAAAGCTAAT	1140
Db	1081	AGTAAACATGATATAAATAATATATCTTCTTGAAGAATGCAATTTAAAGCTAAT	1140
Qy	1141	TTAAATGTTTATTTTATTTTGAAGACATTTATTAAGAAATGTTTATTAATGCTTACTG	1200
Db	1141	TTAAATGTTTATTTTATTTTGAAGACATTTATTAAGAAATGTTTATTAATGCTTACTG	1200
Qy	1201	TTCTAAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1260
Db	1201	TTCTAAATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1260
Qy	1261	GAATGAGAGAAATTTGTATACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1320
Db	1261	GAATGAGAGAAATTTGTATACCATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG	1320
Qy	1321	GAATTAAGACTC 1333	
Db	1321	GAATTAAGACTC 1333	

RESULT 200
US-10-230-130-119
; Sequence 119, Application US/10230130
; Publication No. US20040019183A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc
; APPLICANT: Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1C101
; CURRENT APPLICATION NUMBER: US/10/230,130
; CURRENT FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: 10/119,480
; PRIOR FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: 60/059113
; PRIOR FILING DATE: 1997-09-17
; PRIOR APPLICATION NUMBER: 60/062287
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/063549
; PRIOR FILING DATE: 1997-10-28
; PRIOR APPLICATION NUMBER: 60/064103
; PRIOR FILING DATE: 1997-10-31
; PRIOR APPLICATION NUMBER: 60/069873
; PRIOR FILING DATE: 1997-12-17
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/079294
; PRIOR FILING DATE: 1998-03-25
; PRIOR APPLICATION NUMBER: 60/079656
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: 60/079728
; PRIOR FILING DATE: 1998-03-27
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 246
; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien

US-10-230-130-119

Query Match 100.0%; Score 1333; DB 16; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTCTTGTGCGACGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTCTTGTGCGACGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAAGTATGAG 300

QY 301 TGGCCCGAGACTCTATGACCTTACACCATCATGATGAGTACAGATATCTAGCATATGTCA 360
Db 301 TGGCCCGAGACTCTATGACCTTACACCATCATGATGAGTACAGATATCTAGCATATGTCA 360

QY 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTCTATATGG 420
Db 361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTCTATATGG 420

QY 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACACACACACAGAGAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCGCAAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCGCAAGTAGC 540

QY 541 CTGTGGAATCTCATAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTCATAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTTGGAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTAAATGGTAT 660

QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTGCACTTC 720

QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATG 780

QY 781 GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840

QY 841 TTATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900
Db 841 TTATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900

QY 901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
Db 901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960

QY 961 AAAAATAAAGGGGAATTTCCCTTCGTTGAATATTTATCCCTGATATTTGATGAAT 1020
Db 961 AAAAATAAAGGGGAATTTCCCTTCGTTGAATATTTATCCCTGATATTTGATGAAT 1020
```

RESULT 201

US-10-119-480-119
; Sequence 119, Application US/10119480
; Publication No. US20040087769A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Desnoyers, Luc Gerritsen, Mary
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stephan, Jean-Philippe F.
; APPLICANT: Watanabe, Colin L.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3530P1
; CURRENT APPLICATION NUMBER: US/10/119,480
; CURRENT FILING DATE: 2002-04-09
; NUMBER OF SEQ ID NOS: 246
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 119
; LENGTH: 1333
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-119-480-119

Query Match 100.0%; Score 1333; DB 17; Length 1333;
Best Local Similarity 100.0%; Pred. No. 1.8e-303;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACCGAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTCTTGTGCGACGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTCTTCTGTCATGTTCTTCTTGTGCGACGAGTGGCTTACACTGG 240
```

QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
DB 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
QY 301 TGGCCAGGACTATATGACCCCTACAAACCATCATGAATGACAGATATTCATGATATTTGCA 360
DB 301 TGGCCAGGACTATATGACCCCTACAAACCATCATGAATGACAGATATTCATGATATTTGCA 360
QY 361 GAAGGAGGATGGTGCATATGATGATTTTATCTCTAGCATTTTCTACTACCTATATGG 420
DB 361 GAAGGAGGATGGTGCATATGATGATTTTATCTCTAGCATTTTCTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATGCTCCAGTTAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAAATGCTCCAGTTAGT 480
QY 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTGTCACAGATAGC 540
DB 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTGTCACAGATAGC 540
QY 541 CTGTGGATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATTAATTAATAAATGATTAATCTCTGGTGTGACAGGTTTGAATCTGCACTTC 720
DB 661 TACGTATTAATTAATAAATGATTAATCTCTGGTGTGACAGGTTTGAATCTGCACTTC 720
QY 721 TTAAGGAACAGCCATTAATCTCTGATGATGATTAATCTGATGATGATTAATCTGATGAT 780
DB 721 TTAAGGAACAGCCATTAATCTCTGATGATGATTAATCTGATGATGATTAATCTGATGAT 780
QY 781 GAAGCTTTGTTTATAGGAATCTTGTAGGGCTCAATTTGGTTTCAATGAACAGATATCTAA 840
DB 781 GAAGCTTTGTTTATAGGAATCTTGTAGGGCTCAATTTGGTTTCAATGAACAGATATCTAA 840
QY 841 TTTAATATGATCTGATGATATCAGGTGCTCTGATGATGATGATGATGATGATGATGATGAT 900
DB 841 TTTAATATGATCTGATGATATCAGGTGCTCTGATGATGATGATGATGATGATGATGATGAT 900
QY 901 TGGGAAACTTCATGAGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAAACTTCATGAGGTTTCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATATGATGATGAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGATATATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGTTTATTTCTTAAGCATAT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGTTTATTTCTTAAGCATAT 1080
QY 1081 AGTAAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGAT 1140
DB 1081 AGTAAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATGTTTATTTTGAAGCAATTAATTAATAAATGATGATGATGATGATGATGATGATGAT 1200
DB 1141 TTAATGTTTATTTTGAAGCAATTAATTAATAAATGATGATGATGATGATGATGATGATGAT 1200
QY 1201 TTTAATCTGTTGTTAAGGATTTCTTAAGATTTGACAGGATGATGATGATGATGATGATGAT 1260
DB 1201 TTTAATCTGTTGTTAAGGATTTCTTAAGATTTGACAGGATGATGATGATGATGATGATGAT 1260
QY 1261 GAATGAGAGAAATGATTAACCACTCTGCTGTTCTTTAGTGCATATCAATAAATCACTCT 1320
DB 1261 GAATGAGAGAAATGATTAACCACTCTGCTGTTCTTTAGTGCATATCAATAAATCACTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 202

US-09-822-846-396
; Sequence 396, Application US/09822846
; Publication No. US20030027139A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; APPLICANT: McCoy, John M.
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; APPLICANT: Evans, Cheryl
; APPLICANT: Merberg, David
; APPLICANT: Treacy, Maurice
; APPLICANT: Agostino, Michael J.
; APPLICANT: Steinger II, Robert J.
; APPLICANT: Bowman, Michael R.
; APPLICANT: Spaulding, Vikki
; APPLICANT: Wong, Gordon G.
; APPLICANT: Clark, Hilary
; APPLICANT: Fehnel, Kim
; APPLICANT: Howes, Steven H.
; APPLICANT: Resnick, Richard J.
; APPLICANT: Gulukota, Kamalakar
; APPLICANT: Graham, James R.
; APPLICANT: Genetics Institute, Inc.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING NOVEL SECRETED PROTEINS
; FILE REFERENCE: GIN 6400
; CURRENT APPLICATION NUMBER: US/09/822,846
; CURRENT FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195,605
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 396
; LENGTH: 1432
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-822-846-396

Query Match 99.1%; Score 1321.4; DB 10; Length 1432;
Best Local Similarity 99.5%; Pred. No. 1e-300;
Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 3 CCAGCGTCCGATGGCGTTACGTTCCGGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
DB 102 CCTCCCGAGCCATGGCGTTACGTTCCGGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 161
QY 63 CTGCGCGCTCATCTTCTTCCGCAATTTGGCACTATTAGCATTTGATGAGCTGAAGACTG 122
DB 162 CTGCGCGCTCATCTTCTTCCGCAATTTGGCACTATTAGCATTTGATGAGCTGAAGACTG 221
QY 123 ATTCAAGAATCTTATAGACCCAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTACC 182
DB 222 ATTCAAGAATCTTATAGACCCAGTGAATACCCCTGAATCCCTTGTACTCCAGAGTACC 281
QY 183 TCATCCAGCTTCTTCTGCTGATGTTCTTTGTCAGCAGAGTGGCTTACACTGGGTC 242
DB 282 TCATCCAGCTTCTTCTGCTGATGTTCTTTGTCAGCAGAGTGGCTTACACTGGGTC 341
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAGT 302
DB 342 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAGT 401
QY 303 GCCCAGGACTTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGAT 362
DB 402 GCCCAGGACTTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGAT 461
QY 363 AGGAGGATGGTGAATATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 422

Db 462 AGGAAGGATGGTGCATTAAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA 521
QY 423 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 482
Db 522 TGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGTGC 581
QY 483 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAGATCCCTGTCAGAGTAGCT 542
Db 582 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAGATCCCTGTCAGAGTAGCT 641
QY 543 GTGAATCTGATCAGTACTTTAAATAATGACTCCCTTATTTTAAATGTTTCCACATTT 602
Db 642 GTGAATCTGATCAGTACTTTAAATAATGACTCCCTTATTTTAAATGTTTCCACATTT 701
QY 603 TTGCTTGTGGAAGACTGTTTCAATGATGATCTCAGATAAAGATTTAAATGGTATTA 662
Db 702 TTGCTTGTGGAAGACTGTTTCAATGATGATCTCAGATAAAGATTTAAATGGTATTA 761
QY 663 CGTATAAATTTATATAAATGATTAATCTCTGCTGTTGACAGGTTTGAACCTTCACCTCTT 722
Db 762 CGTATAAATTTATATAAATGATTAATCTCTGCTGTTGACAGGTTTGAACCTTCACCTCTT 821
QY 723 AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGACTGTCCTAGTACATTTGA 782
Db 822 AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGACTGTCCTAGTACATTTGA 881
QY 783 AGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTTCATTTGAACAGTATCTAATT 842
Db 882 AGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTTCATTTGAACAGTATCTAATT 941
QY 843 ATAAATTTAGCTGATGATATCAGTGCTCTGATGATGATGATGATGATGATGATGATG 902
Db 942 ATAAATTTAGCTGATGATATCAGTGCTCTGATGATGATGATGATGATGATGATGATG 1001
QY 903 GGAATCTTCATGGTTTCCATGCTGATGATGATGATGATGATGATGATGATGATGATG 962
Db 1002 GGAATCTTCATGGTTTCCATGCTGATGATGATGATGATGATGATGATGATGATGATG 1061
QY 963 AAATAAAGCGGGAATTTTCCCTGCTGATGATGATGATGATGATGATGATGATGATG 1022
Db 1062 AAATAAAGCGGGAATTTTCCCTGCTGATGATGATGATGATGATGATGATGATGATG 1121
QY 1023 GAGATTTCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAAATCTTAAGCATAG 1082
Db 1122 GAGATTTCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAAATCTTAAGCATAG 1181
QY 1083 TAAACATGATATAAATAATATCTGATGATGATGATGATGATGATGATGATGATGATG 1142
Db 1182 TAAACATGATATAAATAATATCTGATGATGATGATGATGATGATGATGATGATGATG 1241
QY 1143 AAATGTTTATTTTATGTAAGACATTTATTTAAGAAATTTGTTTATTTATGCTTACTGTT 1202
Db 1242 AAATGTTTATTTTATGTAAGACATTTATTTAAGAAATTTGTTTATTTATGCTTACTGTT 1301
QY 1203 CTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATTCATGATGATGATGATGATG 1262
Db 1302 CTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATTCATGATGATGATGATGATG 1361
QY 1263 ATGAGAGAAATTTGATACCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1322
Db 1362 ATGAGAGAAATTTGATACCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1421
QY 1323 AATTAAGACTC 1333
Db 1422 AATTAAGACTC 1432

RESULT 203

US-10-044-477-2

; Sequence 2, Application US/10044477

; Publication No. US2002010342A1

; GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.

Corley, Neil C.
Shah, Purvi
TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
NUMBER OF SEQUENCES: 3
CORRESPONDENCE ADDRESS:
ADDRESSEE: Incyte Pharmaceuticals, Inc.
STREET: 3174 Porter Drive
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/044,477
FILING DATE: 10-Jan-2002
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US/09/365,705
FILING DATE: 02-Aug-1999
APPLICATION NUMBER: US/08/950,168
FILING DATE: 14-Oct-1997
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-845-0555
TELEFAX: 650-845-4166
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 1391 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-044-477-2

Query Match 98.8%; Score 1316.8; DB 14; Length 1391;
Best Local Similarity 99.5%; Pred. No. 1.2e-299;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 CCACGCGTCCGATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
Db 63 CTTCCCGAGCATGGCGTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCTCA 122
QY 63 CTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTATAGCATTTTATAGCTGAGACTG 122
Db 123 CTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTATAGCATTTTATAGCTGAGACTG 182
QY 123 ATTACAAAGTCCCTATAGACCAAGTGTATACCTGAAATCCCTTGTACTCCAGATACC 182
Db 183 ATTACAAAGTCCCTATAGACCAAGTGTATACCTGAAATCCCTTGTACTCCAGATACC 242
QY 183 TCATCCAGCTTCTTCTGCTCATGTTTCTTTGGCAGCAGAGTGGCTTACACTGGGTC 242
Db 243 TCATCCAGCTTCTTCTGCTCATGTTTCTTTGGCAGCAGAGTGGCTTACACTGGGTC 302
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 302
Db 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAGTG 362
QY 303 GCCCAGGACTCTATGACCCCTACCAACCATCATGATGAGATATTTCTAGCATATTTGTGCA 362
Db 363 GCCCAGGACTCTATGACCCCTACCAACCATCATGATGAGATATTTCTAGCATATTTGTGCA 422
QY 363 AGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGGCA 422

652	DB	TTGCTTGTGGAAAGACGTGTTTTCATATGTTATACCTCAGATAAAGATTTTAAATGGTATTA	711
663	QY	CGTATAAATTAATATAAAATGATTACCTCTGGTGTTCACAGGTTTGAACCTTGCACTTCCT	722
712	DB	CGTATAAATTAATATAAAATGATTACCTCTGGTGTTCACAGGTTTGAACCTTGCACTTCCT	771
723	QY	AAGGAAACAGCCCAATACCTCTGAATGATGATTAATTACTGACTGTCTCTAGTACATTGGA	782
772	DB	AAGGAAACAGCCCAATACCTCTGAATGATGATTAATTACTGACTGTCTCTAGTACATTGGA	831
783	QY	AGCTTTTGTGTTATAGGAACTTGTAGGCTCATTTTGGTTTCATTGAAACAGTATCTAAAT	842
832	DB	AGCTTTTGTGTTATAGGAACTTGTAGGCTCATTTTGGTTTCATTGAAACAGTATCTAAAT	891
843	QY	ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAAATGTAATCTCTGACTAGTG	902
892	DB	ATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAAATGTAATCTCTGACTAGTG	951
903	QY	GGAAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATGGAACATTTTACAA	962
952	DB	GGAAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATGGAACATTTTACAA	1011
963	QY	AAATATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTGCATGAATGA	1022
1012	DB	AAATATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATTGCATGAATGA	1071
1023	QY	GAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTCGCTTTAAATCTTCTTAAGCATAG	1082
1072	DB	GAGATTTCCCATATTTCCCATCAGAGTAATAAATACTTCGCTTTAAATCTTCTTAAGCATAG	1131
1083	QY	TAAACATGATATAAAATATATGCTGAATTACTTGTGAAGAATGCATTTAAAGCTATTTT	1142
1132	DB	TAAACATGATATAAAATATATGCTGAATTACTTGTGAAGAATGCATTTAAAGCTATTTT	1191
1143	QY	AAATGTGTTTTTATTTCTAAGACATTAATTAATTAAGAAATGGTATTATGCTTACTGTT	1202
1192	DB	AAATGTGTTTTTATTTCTAAGACATTAATTAATTAAGAAATGGTATTATGCTTACTGTT	1251
1203	QY	CTAATCTGTGTGTAAGGTTATCTTAAGAATTTGCAGGTACTACAGATTTTCAAACTGTA	1262
1252	DB	CTAATCTGTGTGTAAGGTTATCTTAAGAATTTGCAGGTACTACAGATTTTCAAACTGTA	1311
1263	QY	ATCAGAGAAAATTTGTATTAACCATCTGCTGTTTCTTTAGTGCAATACAAATAAACCTCTGA	1322
1312	DB	ATCAGAGAAAATTTGTATTAACCATCTGCTGTTTCTTTAGTGCAATACAAATAAACCTCTGA	1371
1323	QY	AAATTA 1328	
1372	DB	AAATTA 1377	

RESULT 205

```

1  US-10-373-809-34
2
3  / Sequence 34, Application US/10373809
4  / Publication No. US2004002360A1
5  /
6  / GENERAL INFORMATION:
7  /
8  / APPLICANT: Ruben et al.
9  /
10 / TITLE OF INVENTION: 29 Human Secreted Proteins
11 /
12 / FILE REFERENCE: P2015P1
13 /
14 / CURRENT APPLICATION NUMBER: US/10/373,809
15 /
16 / CURRENT FILING DATE: 2003-02-27
17 /
18 / PRIOR APPLICATION NUMBER: US/09/729,835
19 /
20 / PRIOR FILING DATE: 2000-12-06
21 /
22 / PRIOR APPLICATION NUMBER: 09/257,179
23 /
24 / PRIOR FILING DATE: 1999-02-25
25 /
26 / PRIOR APPLICATION NUMBER: 60/056,270
27 /
28 / PRIOR FILING DATE: 1997-08-29
29 /
30 / PRIOR APPLICATION NUMBER: 60/056,271
31 /
32 / PRIOR FILING DATE: 1997-08-29
33 /
34 / PRIOR APPLICATION NUMBER: 60/056,247
35 /
36 / PRIOR FILING DATE: 1997-08-29
37 /
38 / PRIOR APPLICATION NUMBER: 60/056,073
39 /
40 / PRIOR FILING DATE: 1997-08-29

```

Query Match	98.8%	Score 1316.4	DB 17	Length 1404
Best Local Similarity	99.5%	Pred. No. 1.5e-299		
Matches 1320	Conservative 0	Mismatches 6	Indels 0	Gaps 0
US-10-373-809-34				
3	CCACGCTCCGATGGCGTTACGTTCCGGCCTTCTGCTACATGCTGGCGCTGCTGCTCA	62		
52	CCTCCCGACCATGGCGTTACGTTCCGGCCTTCTGCTACATGCTGGCGCTGCTGCTCA	111		
53	CTGGCGGCTCATCTTCTTCCCATTTGGCCATTTAGCATTTGATGAGCTGAAGACTG	122		
112	CTGGCGGCTCATCTTCTTCCCATTTGGCCATTTAGCATTTGATGAGCTGAAGACTG	171		
123	ATTACAAAGAAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGTACTCCACAGTACC	182		
172	ATTACAGAAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGTACTCCACAGTACC	231		
183	TCATCCAGCTTTCTTCTGTCTCATGTTTCTTGTGACAGAGTGGCTTACATGGGTC	242		
232	TCATCCAGCTTTCTTCTGTCTCATGTTTCTTGTGACAGAGTGGCTTACATGGGTC	291		
243	TCATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAGTG	302		
292	TCATATGCCCCCTCTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAGTG	351		
303	GCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTCTAGCATATTTGTCA	362		
352	GCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTCTAGCATATTTGTCA	411		
363	AGGAGCATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA	422		
412	AGGAGCATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA	471		
423	TGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAAATGGTCCAGTTAAAGTGC	482		
472	TGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAAATGGTCCAGTTAAAGTGC	531		
483	ATGCAAAAGCCCAAAATGAGGGATTTCTATCCAGCAAGATCTGTCCAAAGATAGCCT	542		
532	ATGCAAAAGCCCAAAATGAGGGATTTCTATCCAGCAAGATCTGTCCAAAGATAGCCT	591		
543	GTGGAATCTGATCAGTTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTTCCACATTT	602		
592	GTGGAATCTGATCAGTTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTTCCACATTT	651		
603	TTGCTTGTGAAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTATTA	662		
652	TTGCTTGTGAAAGACGTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTATTA	711		
663	CGTATAAATTAATATAAAATGATTACCTCTGGTGTTCACAGGTTTGAATGCACTTCTTT	722		
712	CGTATAAATTAATATAAAATGATTACCTCTGGTGTTCACAGGTTTGAATGCACTTCTTT	771		
723	AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATCTGACTGTCTTAGTACATTTGGA	782		
772	AAGGAACAGCCATAATCTCTGAATGATGATTAATTAATCTGACTGTCTTAGTACATTTGGA	831		
783	AGCTTTTGTTTATAGGAACGTGTAGGGCTCAATTTTGGTTTTCATTGAAACAGTATCTAAT	842		
832	AGCTTTTGTTTATAGGAACGTGTAGGGCTCAATTTTGGTTTTCATTGAAACAGTATCTAAT	891		
843	ATAAAATAGCTGTAGATATACAGCTGTCTTCTGATGAAGTGAATAATGTATATCTGACTAGTG	902		

Db	181		CTGTGTCATGTTTTCTTTGTGCAGCAGAGTGGCTTACACTGGGTCTCAATATATGCCCTCTT	240
QY	259	GGCATA	TCATATTTGGAGGTATATGAGTAGAGCAGCTGATGAGTGGCCAGGACTCTATGA	318
Db	241	GGCATA	TCATATTTGGAGGTATATGAGTAGAGCAGCTGATGAGTGGCCAGGACTCTATGA	300
QY	319	CCCTAC	AACCATCATGATGATCAGATATTTCTAGCATATTTGTCAGAAAGGAGATGGTGC	378
Db	301	CCCTAC	AACCATCATGATGATCAGATATTTCTAGCATATTTGTCAGAAAGGAGATGGTGC	360
QY	379	ATTAGCT	TTTTTATCTTCTAGCATTTTTTTTACTACCTATATGSCATGATCTATGTTTTGGT	438
Db	361	ATTAGCT	TTTTTATCTTCTAGCATTTTTTTTACTACCTATATGSCATGATCTATGTTTTGGT	420
QY	439	GAGCTC	TTTAGAACACACACAGAGAATTTGTCAGTTTAAGTGCATGCAAAAGCCACCA	498
Db	421	GAGCTC	TTTAGAACACACACAGAGAATTTGTCAGTTTAAGTGCATGCAAAAGCCACCA	480
QY	499	AATGA	AGGGATTTCTATCCAGCAAGATCCTGTGCCAAGAGTAGCTGTGGAATCTGATCAGT	558
Db	481	AATGA	AGGGATTTCTATCCAGCAAGATCCTGTGCCAAGAGTAGCTGTGGAATCTGATCAGT	540
QY	559	TACTTT	AAAAAATGACTCCCTTATTTTTTAAATGTTTTCCACATTTTTTGTGTGGAAAGAC	618
Db	541	TACTTT	AAAAAATGACTCCCTTATTTTTTAAATGTTTTCCACATTTTTTGTGTGGAAAGAC	600
QY	619	TGTTTT	CATATGTTATCTCAGATAAGATTTTTAAATGGHTATACGTATAAATTAATATA	678
Db	601	TGTTTT	CATATGTTATCTCAGATAAGATTTTTAAATGGHTATACGTATAAATTAATATA	660
QY	679	AAATGA	TATCTCTGGTGTGACAGGTTTGAACCTTGACATTTGGAAGCTTTTTGTTTATAGG	738
Db	661	AAATGG	TATCTCTGGTGTGACAGGTTTGAACCTTGACATTTGGAAGCTTTTTGTTTATAGG	720
QY	739	CCCTGA	TGAATGATTAATTAATCTGACTGTCTTAGTACATTTGGAAGCTTTTTGTTTATAGG	798
Db	721	CCCTGA	TGAATGATTAATTAATCTGACTGTCTTAGTACATTTGGAAGCTTTTTGTTTATAGG	780
QY	799	AACTTG	PAGGGCTCATTTTCGTTTCATGAAACAGTATCTAATTTAATTTAGCTGTAGA	858
Db	781	AACTTG	PAGGGCTCATTTTCGTTTCATGAAACAGTATCTAATTTAATTTAGCTGTAGA	840
QY	859	TATCAG	TGCTCTGATGAGTGAATGTATATCTGACTAGTGGGAACTTCATGGGTT	918
Db	841	TATCAG	TGCTCTGATGAGTGAATGTATATCTGACTAGTGGGAACTTCATGGGTT	900
QY	919	TCCTCAT	CTCTCATGTATATATGGAATACATTTACAAAAATAAAAAGCGGAA	978
Db	901	TCCTCAT	CTCTCATGTATATATATGGAATACATTTACAAAAATAAAAAGCGGAA	960
QY	979	TTTTT	CCCTCGCTGATATATATCCCTGHTATATTCATGATGAGAGATTTCCCATATTT	1038
Db	961	TTTTT	CCCTCGCTGATATATATCCCTGHTATATTCATGATGAGAGATTTCCCATATTT	1020
QY	1039	CCATCAG	AGTAATAATACTTGCTTTAATCTTTAAGCATTAAGTAAACATGATATAAAA	1098
Db	1021	CCATCAG	AGTAATAATAATACTTGCTTTAATCTTTAAGCATTAAGTAAACATGATATAAAA	1080
QY	1099	ATATAT	GTCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATTTTAAATGTGTTTTATTT	1158
Db	1081	ATATAT	GTCTGAATTAATCTTGTGAAGATGCAATTTTAAAGCTATTTTAAATGTGTTTTATTT	1140
QY	1159	GTAA	GACATTTACTTTATTAAGAAATGCTTATATGCTTACTGTTCTTAATCTGGTGGTAAA	1218
Db	1141	GTAA	GACATTTACTTTATTAAGAAATGCTTATATGCTTACTGTTCTTAATCTGGTGGTAAA	1200
QY	1219	GGTATT	CTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACTGAATGAGAGAAATTTGTA	1278
Db	1201	GGTATT	CTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACTGAATGAGAGAAATTTGTA	1260
QY	1279	TAACCA	TCTGCTGTTTCTTTAGTGAATACAAATAAACTCTGAAATTAAGACTC	1333

```

RESULT 206
US-09-765-205-1
; Sequence 1, Application US/09765205
; Patent No. US20020034800A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Li
; TITLE OF INVENTION: BONE MARROW SECRETED PROTEINS AND POLYNUCLEOTIDES
; FILE REFERENCE: 1458.004/200130.449
; CURRENT APPLICATION NUMBER: US/09/765,205
; CURRENT FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: US/03/212,440
; PRIOR FILING DATE: 1998-12-16
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 1325
; TYPE: DNA
; ORGANISM: human
US-09-765-205-1

```

Query Match	98.5%	Score 1313.4	DB 9	Length 1325
Best Local Similarity	99.9%	Pred. No. 7.4e-299		
Matches 1314	Conservative 0	Mismatches 1	Indels 0	Gaps 0
QY	19	GTTTCAGCTTCGGGGCCTTCGTACATGCTGGCGCTGCTGCACATCGCGCTCATCTT	78	
Db	1	GTTTCAGTTCGGGCGCTTCGTACATGCTGGCGCTGCTGCACATCGCGCTCATCTT	60	
QY	79	CTTTCGGCATTTTGGCA CATTATAGCATTGATGAGCTTGAAGACTGATTACAAGAATCCTAT	138	
Db	61	CTTTCGGCATTTGGCACCATTATAGCAATTGATGAGCTTGAAGACTGATTACAAGAATCCTAT	120	
QY	139	AGACCAGTGTAAATACCTCGAATCCCTTGCTACTCCAGAGTACCTCATTCAGCTTTCTT	198	
Db	121	AGACCAGTGTAAATACCTCGAATCCCTTGCTACTCCAGAGTACCTCATTCAGCTTTCTT	180	
QY	199	CTGTGTCACTGTTCTTTGTGCACAGAGTGGCTTACACTGGGTTCTCAATATGCGCCTCTT	258	

Db 1261 TAACCATCTGCTGTTCTTCTTAGTGAATACATCAATAAACTCTGAATTAAGACTC 1315

RESULT 207
US-09-822-846-249
; Sequence 249, Application US/09822846
; Publication No. US20030027139A1
; GENERAL INFORMATION:
; APPLICANT: Jacobs, Kenneth
; APPLICANT: McCoy, John M.
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; APPLICANT: Evans, Cheryl
; APPLICANT: Merberg, David
; APPLICANT: Treacy, Maurice
; APPLICANT: Agostino, Michael J.
; APPLICANT: Steining II, Robert J.
; APPLICANT: Bowman, Michael R.
; APPLICANT: Spaulding, Vikki
; APPLICANT: Wong, Gordon G.
; APPLICANT: Clark, Hilary
; APPLICANT: Fechtel, Kim
; APPLICANT: Howes, Steven H.
; APPLICANT: Resnick, Richard J.
; APPLICANT: Gulukota, Kamalakara
; APPLICANT: Graham, James R.
; APPLICANT: Genetics Institute, Inc.
; TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING NOVEL SECRETED PROTEINS
; FILE REFERENCE: GIN 6400
; CURRENT APPLICATION NUMBER: US/09/822,846
; CURRENT FILING DATE: 2001-03-29
; PRIOR APPLICATION NUMBER: 60/195,605
; PRIOR FILING DATE: 2000-04-06
; NUMBER OF SEQ ID NOS: 629
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 249
; LENGTH: 2916
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-822-846-249

Query Match 97.6%; Score 1301.4; DB 10; Length 2916;
Best Local Similarity 99.8%; Pred. No. 8e-296;
Matches 1313; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 16 GCGCTTCAGTTCGCGGCTCTGCTACATGCTGGCGCTGCTCTCACTGCGCGCTCAT 75
Db 1 GCGCTTCAGTTCGCGGCTCTGCTACATGCTGGCGCTGCTCTCACTGCGCGCTCAT 60

QY 76 CTCTTCGGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGACTGATTAAGAATCC 135
Db 61 CTCTTCGGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGACTGATTAAGAATCC 120

QY 136 TATAGACAGTGTATACCTGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT 195
Db 121 TATAGACAGTGTATACCTGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTT 180

QY 196 CTCTGTGTGATGTTCTTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCCCT 255
Db 181 CTCTGTGTGATGTTCTTTTGTGACAGAGTGGCTTACACTGGGTCTCAATATGCCCT 240

QY 256 CTTCGATATCATATTTGGAGGTATATAGTAGACAGCTGATGAGTGGCCAGGACTCTA 315
Db 241 CTTCGATATCATATTTGGAGGTATATAGTAGAGACCGATGATGAGTGGCCAGGACTCTA 300

QY 316 TGACCTTCAACCATCATCAATGAGATATTTAGATATTTGTCAAGAGAGGATGGTG 375
Db 301 TGACCTTCAACCATCATCAATGAGATATTTAGATATTTGTCAAGAGAGGATGGTG 360

QY 376 CAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGGCATCATCTATGTTTT 435
Db 361 CAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGGCATCATCTATGTTTT 420

QY 436 GGTGAGCTCTTAGAACAACAACAAGAAATTTGGTCCAGTTAAGTGCATGCAAAAAGCCA 495
Db 421 GGTGAGCTCTTTAGAACCAACAACAAGAAATTTGGTCCAGTTAAGTGCATGCAAAAAGCCA 480

QY 496 CCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCRAAGATAGCTGCTGGAATCTGATC 555
Db 481 CCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCRAAGATAGCTGCTGGAATCTGATC 540

QY 556 AGTTACTTTAAAAAATGACTCTCTTATTTTTTAAATGTTTCCACATTTTGTCTGTGAAA 615
Db 541 AGTTACTTTAAAAAATGACTCTCTTATTTTTTAAATGTTTCCACATTTTGTCTGTGAAA 600

QY 616 GACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTATACGTATAAATTAAT 675
Db 601 GACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTATACGTATAAATTAAT 660

QY 676 ATAAATGATTTACCTCTGCTGTTGACAGTTTGAACCTTCTTAAGGAACAGCCAT 735
Db 661 ATAAATGATTTACCTCTGCTGTTGACAGTTTGAACCTTCTTAAGGAACAGCCAT 720

QY 736 AATCCTCTGAATGATGCAATTAATTACTGACTGTCTAGTACATGGAAGCTTTTCTTTAT 795
Db 721 AATCCTCTGAATGATGCAATTAATTACTGACTGTCTAGTACATGGAAGCTTTTCTTTAT 780

QY 796 AGGAACCTGTAGGCTCATTTTGGTTTCATTTGAACACAGTATCTAATTAATTAAGCTGT 855
Db 781 AGGAACCTGTAGGCTCATTTTGGTTTCATTTGAACACAGTATCTAATTAATTAAGCTGT 840

QY 856 AGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGGAACCTTCATGG 915
Db 841 AGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGGAACCTTCATGG 900

QY 916 GTTTCCTCATCTGCTGATGATGATTAATATATATGATACATTTACAAAATTAAGAGCG 975
Db 901 G-TTTCCTCATCTGCTGATGATGATTAATATATATGATACATTTACAAAATTAAGAGCG 959

QY 976 GAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGATGAGAGATTTCCCAT 1035
Db 960 GAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGATGAGAGATTTCCCAT 1019

QY 1036 TTTCCATCAGAGTAAATAATATACCTGCTTTAAATTTTAAAGCATAAGTAAACATGATATA 1095
Db 1020 TTTCCATCAGAGTAAATAATATACCTGCTTTAAATTTTAAAGCATAAGTAAACATGATATA 1079

QY 1096 AATAATATGCTGATTAATTTGTGAGAGTATGATGATTAATTTAAATGCTGTTTTTA 1155
Db 1080 AATAATATGCTGATTAATTTGTGAGAGTATGATGATTAATTTAAATGCTGTTTTTA 1139

QY 1156 TTTGTAAGACATTAATTAATTAAGAAATTTGTTTATATGCTTACTGTTCTTAATCTGCTGT 1215
Db 1140 TTTGTAAGACATTAATTAATTAAGAAATTTGTTTATATGCTTACTGTTCTTAATCTGCTGT 1199

QY 1216 AAGATATCTTAAGAAATTTGAGTACTACAGATTTTCAAACTGAATAGAGAAAAAT 1275
Db 1200 AAGATATCTTAAGAAATTTGAGTACTACAGATTTTCAAACTGAATAGAGAAAAAT 1259

QY 1276 GTATAACCATCTCTGCTGTTCTTTAGTGCATACATAAATACTCTGAAATTAAGA 1330
Db 1260 GTATAACCATCTCTGCTGTTCTTTAGTGCATACATAAATACTCTGAAATTAAGA 1314

RESULT 208
US-09-814-353-20379
; Sequence 20379, Application US/09814353
; Publication No. US20030165831A1
; GENERAL INFORMATION:
; APPLICANT: Thompson, Pamela
; APPLICANT: Lillie, James
; APPLICANT: Lee, John
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND
; TITLE OF INVENTION: THERAPY OF OVARIAN CANCER
; FILE REFERENCE: MRI-006B


```

; CURRENT APPLICATION NUMBER: US/09/814,353
; CURRENT FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: US 60/191,031
; PRIOR FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: US 60/207,124
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: US 60/211,940
; PRIOR FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: US 60/216,820
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 60/220,661
; PRIOR FILING DATE: 2000-07-25
; PRIOR APPLICATION NUMBER: US 60/257,672
; PRIOR FILING DATE: 2000-12-21
; NUMBER OF SEQ ID NOS: 2037
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20379
; LENGTH: 1640
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1, 1640
; OTHER INFORMATION: n = A,T,C or G
US-09-814-353-20379

```

Query Match	90.7%;	Score 1209.4;	DB 10;	Length 1640;	
Best Local Similarity	97.7%;	Pred. No. 2.7e-274;			
Matches 1301;	Conservative	0;	Mismatches 21;	Indels 9;	Gaps 7;
QY	3	CCACGGCTCCGATGGCGTTCACGTTTCGGGGCTTCTGCTACATGCTGGCGTGTGCTCA	62		
Db	127	CCTCCCAGCAGCATGGCTTCACGTTTCGGGGCTTCTGCTACATGCTGGCGTGTGCTCA	186		
QY	63	CTGGCGGCTCATCTTCTTCGCCATTTCGGCACTTATAGCATTTTCATGAGCTGAAGACTG	122		
Db	187	CTGGCGGCTCATCTTCTTCGCCATTTCGGCACTTATAGCATTTTCATGAGCTGAAGACTG	246		
QY	123	ATTACAAGAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGCTACTCCAGAGTACC	182		
Db	247	ATTACAAGAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGCTACTCCAGAGTACC	306		
QY	183	TCATCCAGGCTTCTTCGTGTCATGTTCTTTTGTGCAGCAGAGTGGCTTACCTGGGTC	242		
Db	307	TCATCCAGGCTTCTTCGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACCTGGGTC	366		
QY	243	TCAATATGCCCTCTTCGGCATATCATATTTGGAGGTATATGAGTAGACAGCTGATGATG	302		
Db	367	TCAATATGCCCTCTTCGGCATATCATATTTGGAGGTATATGAGTAGACAGCTGATGATG	426		
QY	303	GCCAGGACTCTATGACCTCAACACCATCATGAATGCAGATATTCTAGCATATTGTCCAGA	362		
Db	427	GCCAGGACTCTATGACCTCAACACCATCATGAATGCAGATATTCTAGCATATTGTCCAGA	486		
QY	363	AGGAAGGATGGTGAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA	422		
Db	487	AGGAAGGATGGTGAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA	546		
QY	423	TGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC	482		
Db	547	TGATCTATG-TTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGTGC	605		
QY	483	ATGCAAAAAGCCAAATGAAGGATTCATATCCAGCAAGATCCCTGTCCAAGAGTAGCCT	542		
Db	606	ATGCAAAAAGCCAAATGAAGGATTCATATCCAGCAAGATCCCTGTCCAAGAGTAGCCT	665		
QY	543	GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTTCCACATTT	602		
Db	666	GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTA-TTTTTTAAATGTTTCCACATTT	724		
QY	603	TTGCTTGTGAAGAGCTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATCGTATTA	662		
Db	725	TTGCTTGTGAAGAGCTGTTTTCCATATGTTTATATCTCAGATAAAGATTTTAAATCGTATTA	784		

Search completed: June 14, 2004, 20:34:02
Job time : 651 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 14, 2004, 16:06:22 ; Search time 3773 Seconds
(without alignments)
10550.301 Million cell updates/sec

Title: US-09-978-298A-321
Perfect score: 1333
Sequence: 1 gccacgcgtccgatggcgt.....aaactctgaattaagactc 1333

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 27513289 segs, 14931090276 residues

Total number of hits satisfying chosen parameters: 1

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%

Maximum Match 100%

Listing first 65000 summaries

Database :

EST:*

1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_estc:*
9: gb_est1:*
10: gb_est2:*
11: gb_est3:*
12: gb_est4:*
13: gb_est5:*
14: gb_est6:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_phg:*
27: em_gss_vrl:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	1290.4	96.8	1394	11	AF070654 Homo sapi

ALIGNMENTS

RESULT 1
AF070654

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

REFERENCE

AUTHORS

TITLE

JOURNAL

AF070654 1394 bp mRNA linear HTC 21-NOV-2002
Homo sapiens cornichon protein mRNA, complete cds.

AF070654.1 GI:4454683

HTC.

Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 1394)

Zhang, Q.H., Ye, M., Wu, X.Y., Ren, S.X., Zhao, M., Zhao, C.J., Fu, G., Shen, Y., Fan, H.Y., Lu, G., Zhong, M., Xu, X.R., Han, Z.G., Zhang, J.W., Tao, J., Huang, Q.H., Zhou, J., Hu, G.X., Gu, J., Chen, S.J. and Chen, Z. Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells

Genome Res. 10 (10), 1546-1560 (2000)

20499367

11042152

2 (bases 1 to 1394)

Fu, G., Ye, M., Zhang, Q., Zhou, J., Wu, J., Shen, Y., Kan, L., He, K., Gu, B., Chen, S., Mao, M. and Chen, Z. Human cornichon gene

Unpublished

3 (bases 1 to 1394)

Fu, G.

Direct Submission

Submitted (05-JUN-1998) Shanghai Institute of Hematology, Shanghai Second Medical University, Rui-Jin Hospital, 197 Rui-Jin Road II, Shanghai 200025, P. R. China

Location/Qualifiers

1. 1394

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

57..491

/codon_start=1

/product="cornichon protein"

/protein_id="AAD20960.1"

/db_xref="GI:4454684"

/translation="MAPTFAFCYMLALLTAALIFPAIWHIAFDLKTDPIDQ
CNTLNPLVLEPIHAFPCVFMFLGMLPLAYHINRYMSRPMYSGPGLYD
PTTMNADILAYCQKEGCKLAFYLLAFYLYGMIYLVSS"

ORIGIN

Query Match 96.8%; Score 1290.4; DB 11; Length 1394;

Best Local Similarity 99.0%; Pred. No. 9.1e-291;

Matches 1320; Conservative 0; Mismatches 11; Indels 3; Gaps 2;

Qy 3 CCACGCGTCGATGGCGTTCACGTTCCGCGCTTCTGTACATGCTGGCGTGTCTCA 62

Db 46 CTTCCCGAGCCATGGCGTTACGTTCCGCGCTTCTGTACATGCTGGCGTGTCTCA 105

Qy 63 CTGCGCGCTCATCTTCTTCGCGATTTGGCACATTAATGATTTGATGAGTGAAGACTG 122

Db 106 CTGCGCGCTCATCTTCTTCGCGATTTGGCACATTAATGATTTGATGAGTGAAGACTG 165

Qy 123 ATTACAGATCCCTATAGACAGTGTATACCTGATCCCTGTACTCCAGAGTACC 182

Db 166 ATTACAGATCCCTATAGACAGTGTATACCTGATCCCTGTACTCCAGAGTACC 225

Qy 183 TCATCCACGCTTTCTTCTGTGTATGTTCTTTGTGCGAGAGTGGCTTACATGGGTC 242

Db 226 TCATCCACGCTTTCTTCTGTGTATGTTCTTTGTGCGAGAGTGGCTTACATGGGTC 285

Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 302

Db 286 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAGTG 345

US-09-257-179-63

Query Match 100.0%; Score 784; DB 4; Length 145;
 Best Local Similarity 100.0%; Pred. No. 4.7e-79;
 Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MAFTFAAF	FCVNLAL	LTAA	LIFFAI	WHIIAF	DELKTD	YKNP	IDOC	NTIN	PLVLP	PEYLI	HA	60
DB	1	MAFTFAAF	FCVNLAL	LTAA	LIFFAI	WHIIAF	DELKTD	YKNP	IDOC	NTIN	PLVLP	PEYLI	HA	60
QY	61	FFCVN	FLCAE	WLT	GLN	WPL	LAYH	WYMS	RPVMS	GPGLY	DEPT	IMN	ADILAY	COKEGW
DB	61	FFCVN	FLCAE	WLT	GLN	WPL	LAYH	WYMS	RPVMS	GPGLY	DEPT	IMN	ADILAY	COKEGW
QY	121	CKLAF	YLLA	FFYY	LYG	MIY	VL	VSS	144					
DB	121	CKLAF	YLLA	FFYY	LYG	MIY	VL	VSS	144					

Search completed: June 14, 2004, 20:38:01
 Job time : 33 secs

RESULT 7
US-09-589-184-327
; TITLE OF INVENTION: DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 210121.478C9
; CURRENT APPLICATION NUMBER: US/09/614,124B
; CURRENT FILING DATE: 2001-07-11
; NUMBER OF SEQ ID NOS: 1668
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-614-124B-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 6
US-09-671-325-327
; TITLE OF INVENTION: DIAGNOSIS OF LUNG CANCER
; FILE REFERENCE: 210121.478C12
; CURRENT APPLICATION NUMBER: US/09/671,325
; CURRENT FILING DATE: 2000-09-26
; NUMBER OF SEQ ID NOS: 1825
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-671-325-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 8
US-09-257-179-63
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: P2015P1
; CURRENT APPLICATION NUMBER: US/09/257,179
; CURRENT FILING DATE: 1999-02-25
; EARLIER APPLICATION NUMBER: PCT/US98/17709
; EARLIER FILING DATE: 1998-08-27
; EARLIER APPLICATION NUMBER: 60/056,270
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,271
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,247
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,073
; EARLIER FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 63
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (145)
; OTHER INFORMATION: Xaa equals stop translation

RESULT 7
US-09-589-184-327
; Sequence 327, Application US/09589184
; Patent No. 6686447
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darriack
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND
; FILE REFERENCE: 210121.478C8
; CURRENT APPLICATION NUMBER: US/09/589,184
; CURRENT FILING DATE: 2000-06-05
; NUMBER OF SEQ ID NOS: 827
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-589-184-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
DB 1 MAFTFAAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTPNPLVPEYLIHA 60
QY 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNNPLLAYHIIWRYMSRPVMSGPGLYDPTTMMNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYLVSS 144

RESULT 8
US-09-257-179-63
; Sequence 63, Application US/09257179
; Patent No. 6410709
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: 29 Human Secreted Proteins
; FILE REFERENCE: P2015P1
; CURRENT APPLICATION NUMBER: US/09/257,179
; CURRENT FILING DATE: 1999-02-25
; EARLIER APPLICATION NUMBER: PCT/US98/17709
; EARLIER FILING DATE: 1998-08-27
; EARLIER APPLICATION NUMBER: 60/056,270
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,271
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,247
; EARLIER FILING DATE: 1997-08-29
; EARLIER APPLICATION NUMBER: 60/056,073
; EARLIER FILING DATE: 1997-08-29
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 63
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE
; LOCATION: (145)
; OTHER INFORMATION: Xaa equals stop translation

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/365,705
FILING DATE: 02-Aug-1999
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/950,168
FILING DATE: 14-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PP-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-365-705-1

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
DB 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYVLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYVLVSS 144

RESULT 3
US-09-702-705-327

; Sequence 327, Application US/09702705
; Patent No. 6504010
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C14
; CURRENT APPLICATION NUMBER: US/09/702,705
; CURRENT FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 1833
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-702-705-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
DB 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYVLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYVLVSS 144

RESULT 4

US-09-736-457-327
; Sequence 327, Application US/09736457
; Patent No. 6509448
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; APPLICANT: Fan, Liqun
; APPLICANT: Wang, AiJun
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE THERAPY AND
; FILE REFERENCE: 210121.478C15
; CURRENT APPLICATION NUMBER: US/09/736,457
; CURRENT FILING DATE: 2000-12-13
; NUMBER OF SEQ ID NOS: 1864
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 144
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-736-457-327

Query Match 100.0%; Score 784; DB 4; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
DB 1 MAFTFAFCYMLALLTLTAALFFAIWHIIAFDELKTDYKNPIDQCNLTNPLVPEYLIHA 60
QY 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
DB 61 FFCVMFLCAAEWLTLGLNMPLLAYHIWYMRPVMGPGLYDPTTIMNADILAYCQKEGW 120
QY 121 CKLAFYLLAFFYLYGMIYVLVSS 144
DB 121 CKLAFYLLAFFYLYGMIYVLVSS 144

RESULT 5

US-09-614-124B-327
; Sequence 327, Application US/09614124B
; Patent No. 6630574
; GENERAL INFORMATION:
; APPLICANT: Wang, Tongtong
; APPLICANT: Bangur, Chaitanya S.
; APPLICANT: Lodes, Michael A.
; APPLICANT: Fanger, Gary
; APPLICANT: Vedwick, Tom
; APPLICANT: Carter, Darrick
; APPLICANT: Retter, Marc
; APPLICANT: Mannion, Jane
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THERAPY AND

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 14, 2004, 20:34:06 ; Search time 31 Seconds
(without alignments)
239.811 Million cell updates/sec

Title: US-09-978-298A-322
Perfect score: 784
Sequence: 1 MAFTFAFCYMLALLTAAL.....FYLLAFFYLYGMIVLVSS 144

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database :
1: /cgn2_6/ptodata/2/iaa/5A COMB.pep.*
2: /cgn2_6/ptodata/2/iaa/5B COMB.pep.*
3: /cgn2_6/ptodata/2/iaa/6A COMB.pep.*
4: /cgn2_6/ptodata/2/iaa/6B COMB.pep.*
5: /cgn2_6/ptodata/2/iaa/PTUS COMB.pep.*
6: /cgn2_6/ptodata/2/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	784	100.0	144	2	US-08-950-168-1
2	784	100.0	144	4	US-09-365-705-1
3	784	100.0	144	4	US-09-702-705-327
4	784	100.0	144	4	US-09-736-457-327
5	784	100.0	144	4	US-09-614-124B-327
6	784	100.0	144	4	US-09-671-325-327
7	784	100.0	144	4	US-09-589-184-327
8	784	100.0	145	4	US-09-257-179-63

ALIGNMENTS

RESULT 1
US-08-950-168-1
; Sequence 1, Application US/08950168
; Patent No. 5968744
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Corley, Neil C.
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto

STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSEQ for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/950,168
FILING DATE: Herewith
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Billings, Lucy J.
REGISTRATION NUMBER: 36,749
REFERENCE/DOCKET NUMBER: PF-0401 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-855-0555
TELEFAX: 650-845-4166
TELEX:
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 144 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
LIBRARY: BLADNOT04
CLONE: 1318847
US-08-950-168-1
Query Match 100.0%; Score 784; DB 2; Length 144;
Best Local Similarity 100.0%; Pred. No. 4.7e-79;
Matches 144; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MAFTFAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTLNPLVLYLHA 60
DB 1 MAFTFAFCYMLALLTAALIFFAIWHIIAFDELKTDYKNPIDQCNTLNPLVLYLHA 60
QY 61 FFCVMFLCAEWLTGLNMPLLAYHWYMSRPMVSGPLYDPTTNADILAYCOKEGW 120
DB 61 FFCVMFLCAEWLTGLNMPLLAYHWYMSRPMVSGPLYDPTTNADILAYCOKEGW 120
QY 121 CKLAFYLLAFFYLYGMIVLVSS 144
DB 121 CKLAFYLLAFFYLYGMIVLVSS 144
RESULT 2
US-09-365-705-1
; Sequence 1, Application US/09365705
; Patent No. 6348576
; GENERAL INFORMATION:
; APPLICANT: Hillman, Jennifer L.
; APPLICANT: Corley, Neil C.
; APPLICANT: Shah, Purvi
; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Drive
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0

Db 181 CCTCATCCACGGCTTCTCTGTCATGTTCTTTTGTGACGACAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Qy 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Db 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Qy 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATATTTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATATTTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC 540
Qy 541 CTGTGAATCTGATCAGTCTTAAATAATGACTCTTAAATAATGTTTAAATGTTCCACAT 600
Db 541 CTGTGAATCTGATCAGTCTTAAATAATGACTCTTAAATAATGTTTAAATGTTCCACAT 600
Qy 601 TTTTGTCTGGAAGACTGTTTTCATGTTTATCTAGTATGATGATGATGATGATGATGAT 660
Db 601 TTTTGTCTGGAAGACTGTTTTCATGTTTATCTAGTATGATGATGATGATGATGATGAT 660
Qy 661 TAGGTATAATTAATAAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 720
Db 661 TAGGTATAATTAATAAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 720
Qy 721 TTAAGGAAAGCAGCATATCTCTGAATGATGATGATGATGATGATGATGATGATGATG 780
Db 721 TTAAGGAAAGCAGCATATCTCTGAATGATGATGATGATGATGATGATGATGATGATG 780
Qy 781 GAAGCTTTTGTATAGGAACTGTGAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACTGTGAGGCTCATTTTGGTTCATTTGATGAAACAGTATCTAA 840
Qy 841 TTATAAATTAGCTGATAGATCAGGCTCTCTGATGATGATGATGATGATGATGATGATG 900
Db 841 TTATAAATTAGCTGATAGATCAGGCTCTCTGATGATGATGATGATGATGATGATGATG 900
Qy 901 TGGGAACTTCATGGGTTTCTCATCTGTCATGTCATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACTTCATGGGTTTCTCATCTGTCATGTCATGATGATGATGATGATGATGATGAT 960
Qy 961 AAAAAATAAAGCGGAAATTTCCCTTGGTGAATATATCCCTGATATATGCAATGAAT 1020
Db 961 AAAAAATAAAGCGGAAATTTCCCTTGGTGAATATATCCCTGATATATGCAATGAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATTTCTTAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATGCTGATATCTGTTGAGAGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATATCTGTTGAGAGATGATGATGATGATGAT 1140
Qy 1141 TTAATCTGTTTATTTATTTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1200
Db 1141 TTAATCTGTTTATTTATTTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1200
Qy 1201 TTCTAATCTGTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1260
Db 1201 TTCTAATCTGTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1260
Qy 1261 GAATGAGAGAAATTTGATTAACCATCTCTGTTTCTTTAGTGAATGATGATGATGATGAT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTCTGTTTCTTTAGTGAATGATGATGATGATGAT 1320

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 2
AX362359 1333 bp DNA linear PAT 15-FEB-2002
LOCUS Sequence 119 from Patent WO0208288.
DEFINITION
ACCESSION AX362359
VERSION AX362359.1 GI:18694637
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Baker, K.P., Desnoyers, L., Gerritsen, M.E., Goddard, A.,
Godowski, P.J., Grimaldi, J.C., Gurney, A.L., Smith, V., Stephan, J.P.,
Watanabe, C.K. and Wood, W.I.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0208288-A 119 31-JAN-2002;
Genentech, Inc. (US)
FEATURES
source location/Qualifiers
1..1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCCAGCGTCCGATGGGTTCCACGTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGGGTTCCACGTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGATTAAGAATCTATAGACAGCTGAATACCTGATACCTGATCCCTGTTACTCCAGATA 180
Db 121 TGATTAAGAATCTATAGACAGCTGAATACCTGATACCTGATCCCTGTTACTCCAGATA 180
Qy 181 CCTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGACGAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGCTTTCTTCTGTCATGTTCTTTGTGACGAGAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Qy 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Db 301 TGGCCACGAGACTCTATGACCCCTACACCATCATGATGATGAGTATCTAGCATATGTCA 360
Qy 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATATTTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTCTAGCATATTTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTGTCCAGAGTAGC 540
Qy 541 CTGTGAATCTGATCAGTCTTAAATAATGACTCTTAAATAATGTTTAAATGTTCCACAT 600

Db 541 CTGTGGAATCGATCAGTACTTAAATAAGTACTCTTATTTTAAATGTTTCCAT 600
QY 601 TTTTGTCTGTGGAAGAACTGTTTCAATGATGTTATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAACTGTTTCAATGATGTTATCTCAGATAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATAAGATTAACCTCTGGTGTGACAGGTTTGAACCTTC 720
Db 661 TAGCTATAAATTAATAAATAAGATTAACCTCTGGTGTGACAGGTTTGAACCTTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTAGCTCTCTAGTACATTTG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTAGCTCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTTCATTGAAACAGTATCTAA 840
QY 841 TTAATAAATTAGCTAGATATCAGTGTCTCTGATGAGTGAATGAAATGATATCTGACTAG 900
Db 841 TTAATAAATTAGCTAGATATCAGTGTCTCTGATGAGTGAATGAAATGATATCTGACTAG 900
QY 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATATCTTAC 960
Db 901 TGGAAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATATCTTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGCTTAAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTGTTTATTTGTAAGACATTAATTAATGAAGATTTGGTATTAATGCTTACTG 1200
Db 1141 TTAATGTGTTTATTTGTAAGACATTAATTAATGAAGATTTGGTATTAATGCTTACTG 1200
QY 1201 TTCTAAATCTGTGTAAAGATTAATCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAAATCTGTGTAAAGATTAATCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATGATATAACCATCCTGCTGTTCTTTAGTGAATACATAAATACTCT 1320
Db 1261 GAATGAGAGAAAATGATATAACCATCCTGCTGTTCTTTAGTGAATACATAAATACTCT 1320
QY 1321 GAATTAAGACTC 1333
Db 1321 GAATTAAGACTC 1333

RESULT 3
AX454416
LOCUS AX454416 1333 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 1 from Patent WO0208284.
ACCESSION AX454416
VERSION AX454416.1 GI:21713832
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Baker K.P., Ferrara N., Gerber H., Gerritsen M.E., Goddard A.,
Goddard P.J., Gurney A.L., Hillan K.J., Marsters S.A., Pan J.,
Paoni N.F., Stephan J.P., Watanabe C.K., Williams P.M., Wood W.I.
and Ye W.

TITLE Compositions and methods for the diagnosis and treatment of

JOURNAL

disorders involving angiogenesis
Patent: WO 0208284-A 1 31-JAN-2002;
Genentech, Inc. (US); Baker, Kevin P. (US); Ferrara, Napoleone
(US); Gerber, Hanspeter (US); Gerritsen, Mary E. (US); Goddard,
Audrey (US); Godowski, Paul J. (US); Gurney, Austin L. (US);
Hillan, Kenneth J. (US); Marsters, Scot A. (US); Pan, James (US);
Paoni, Nicholas F. (US); Stephan, Jean-Philippe F. (US);
Watanabe, Colin K. (US); Williams, P. Mickey (US); Wood, William
I. (US)

FEATURES
source

Location/Qualifiers
1. .1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGTGTGCT 60
Db 1 GCCACGCGTCCGATGCGTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGTGTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTGCGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTGCGCAATTTGGCAATATATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGAATTAACAAGATCCTATAGACCAAGTGTATACCTGAATCCCTCTGTATCTCCAGAGTA 180
Db 121 TGAATTAACAAGATCCTATAGACCAAGTGTATACCTGAATCCCTCTGTATCTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTCTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTCTTCTGTGTCTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCAATATATTTGGAGGTATATAGTAGAGCAAGTGAAGTGA 300
Db 241 TCTCAATATGCCCTCTTGGCAATATATTTGGAGGTATATAGTAGAGCAAGTGAAGTGA 300
QY 301 TGGCCCAAGGACTCTATGACCTCAACCAATCAATGAATGTCAGATATTTAGCATATTTGTC 360
Db 301 TGGCCCAAGGACTCTATGACCTCAACCAATCAATGAATGTCAGATATTTAGCATATTTGTC 360
QY 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTTTCTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTTTCTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGTGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGAGAGATCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGAGAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTCTTAAATAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTCTTAAATAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTTATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAGCTGTTTTTATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTCCTC 720
Db 661 TACGTATAAATTAATAAATAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTCCTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTAGCTCTCTAGTACATTTG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTAGCTCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTGGTTTTCATTGAAACAGTATCTAA 840

1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAAGAAATGGTTATATGCTTACTG 1200
1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAAGAAATGGTTATATGCTTACTG 1200
1201 TTCTAAATCTGCTGTAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAC 1260
1201 TTCTAAATCTGCTGTAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAC 1260
1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGTGAATACATAAACTCT 1320
1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGTGAATACATAAACTCT 1320
1321 GAAATTAAGACTC 1333
1321 GAAATTAAGACTC 1333

RESULT 5
AX538136
LOCUS AX538136 1333 bp DNA linear PAT 23-NOV-2002
DEFINITION Sequence 321 from Patent EP1241179.
ACCESSION AX538136
VERSION AX538136.1 GI:25270261
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Wood, W. I., Goddard, A., Gurney, A., Yuan, J., Baker, K. P. and Chen, J.
TITLE Human cornichon-like protein and nucleic acids encoding it
JOURNAL Patent: EP 1241179-A 321 18-SEP-2002;
Genentech, Inc. (US)
FEATURES
source 1. .1333
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 100.0%; Score 1333; DB 6; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GCCACGCGTCCGATGGCGTTCAAGTTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
1 GCCACGCGTCCGATGGCGTTCAAGTTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
61 CACTGCCGCGCTCATCTTCTTGGCCATTTGGCCATTTAGCATTTGATGAGCTGAGAC 120
61 CACTGCCGCGCTCATCTTCTTGGCCATTTGGCCATTTAGCATTTGATGAGCTGAGAC 120
121 TGATTACAAGAAATCCTATAGACAGTGTAAATCCCTGAATCCCTTGTTACTCCAGAGTA 180
121 TGATTACAAGAAATCCTATAGACAGTGTAAATCCCTGAATCCCTTGTTACTCCAGAGTA 180
181 CCTCATCCAGGTTCTTCTGTCGTCATGTTCTTCTGTCAGAGAGTGGCTTACACTGGG 240
181 CCTCATCCAGGTTCTTCTGTCGTCATGTTCTTCTGTCAGAGAGTGGCTTACACTGGG 240
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACAGTGTATGAG 300
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACAGTGTATGAG 300
301 TGGCCAGGACTCTATGACCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
301 TGGCCAGGACTCTATGACCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
361 GAAGGAAGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGGCTCTTAGAACAACACACAGAAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGGCTCTTAGAACAACACACAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTAATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTAATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGTGGAAGAGTCTGTTTTCATATGTTACTCAGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTTGTGGAAGAGTCTGTTTTCATATGTTACTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATATAAATATGATTAACCTCTGGTGTGACAGGTTTGAACCTTC 720
Db 661 TAGCTATAAATTAATATAAATATGATTAACCTCTGGTGTGACAGGTTTGAACCTTC 720
QY 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATG 780
QY 781 GAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTCGAAAACAGTATCTAA 840
Db 781 GAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTTCGAAAACAGTATCTAA 840
QY 841 TTATAAATTAAGTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
Db 841 TTATAAATTAAGTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATATCTGACTAG 900
QY 901 TGGAAAATCTCATGGGTTTCTCATCTGATGCGATGATATATATGATGATATATAC 960
Db 901 TGGAAAATCTCATGGGTTTCTCATCTGATGCGATGATATATATGATGATATATAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATATAAATAATATCTGCTTTAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGATATAAATAATATCTGCTTTAATTTCTTAAGCAT 1080
QY 1081 AGTAAAATCATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAAATCATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATGTTTATTTTAAAGACATTAATTAAGAAATTTGGTATTTATGCTTACTG 1200
Db 1141 TTAATGTTTATTTTAAAGACATTAATTAAGAAATTTGGTATTTATGCTTACTG 1200
QY 1201 TTCTAAATCTGCTGTAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAC 1260
Db 1201 TTCTAAATCTGCTGTAAGGTTATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAAC 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGTGAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGTGAATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 6
AX538635
LOCUS AX538635 1333 bp mRNA linear PRI 03-OCT-2003
DEFINITION Homo sapiens clone DN23330 CNIL (UNQ155) mRNA, complete cds.
ACCESSION AX538635
VERSION AX538635.1 GI:37182391
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1333)
Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J.,
Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B.,
Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E.,
Heidens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S.,
Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C.,
Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V.,
Stinson, J., Vagts, A., Vanden, R., Watanabe, C., Wiewand, D., Woods, K.,
Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z.,
Goddard, A., Wood, W.I. and Godowski, P.
The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
Genome Res. 13 (10), 2265-2270 (2003)
12975309
2 (bases 1 to 1333)
Clark, H.F.
Direct Submission
Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA
Location/Qualifiers
1. 1333
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="DNA2330"
1. 1333
/locus_tag="UNQ155"
14..448
/locus_tag="UNQ155"
/note="PRO181"
/codon_start=1
/product="CNIL"
/protein_id="AAO88998.1"
/db_xref="GI:37182392"
/translation="MAFTPAFCYMLALLTAAALFFAIWHIIADEFUKTYKNPIDQ
CNTLPLVPEYLHAFVCFMFLCAEWLTLGNLPLLAYHWRVMSRPVMSGPLGYD
PTTINMADILAYCQEGWCKLAFYLLAFYLYLGMIVLVSS"
ORIGIN
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-283; Mismatches 0; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGGCGTCACTCTTCTGCGCAATTTGGCACTATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGGCGTCACTCTTCTGCGCAATTTGGCACTATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGAATACAGAACTCTATAGACAGAGTAATCCCTGAATCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGAATACAGAACTCTATAGACAGAGTAATCCCTGAATCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CTTCAATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
DB 181 CTTCAATCCAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
QY 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCTCAACCATCATGATGAGATATCTAGCATATTTGTC 360
DB 301 TGGCCAGGACTCTATGACCTCAACCATCATGATGAGATATCTAGCATATTTGTC 360
QY 361 GAAGGAGGATGGTGAATATAGCTTTTATCTTCTAGCAATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGATGGTGAATATAGCTTTTATCTTCTAGCAATTTTCTTACTACCTATATGG 420

DB 361 GAAGGAGGATGGTGAATATAGCTTTTATCTTCTAGCAATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGAGATCCCTGCTCCAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGAGATCCCTGCTCCAGAGTAGC 540
QY 541 CTGTGGATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGATTAATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGATTAATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATTAATTAATTAATGAATGATTAATCTGCTGGTGTGACAGGTTTGAACTTGCACTTC 720
DB 661 TACGTATTAATTAATTAATGAATGATTAATCTGCTGGTGTGACAGGTTTGAACTTGCACTTC 720
QY 721 TTAAGGAAACAGCCATAATCCCTCTGAATGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 780
DB 721 TTAAGGAAACAGCCATAATCCCTCTGAATGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTGGAACAGATATCAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTGGAACAGATATCAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 900
QY 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 960
DB 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGATGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 960
QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 1020
DB 961 AAAAATAAAGCGGGAATTTCCCTTCGCTGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 1020
QY 1021 GAGGATTTCCCATATTTCCATCAGATAAATAATATCTGCTTTAATTTCTTAAGCATATA 1080
DB 1021 GAGGATTTCCCATATTTCCATCAGATAAATAATATCTGCTTTAATTTCTTAAGCATATA 1080
QY 1081 AGTAAACATGATATAAATAATATCTGCTGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 1140
DB 1081 AGTAAACATGATATAAATAATATCTGCTGATTAATCTGCTGGTGTGACAGGTTTGAACTTG 1140
QY 1141 TTAATGTTTATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAAT 1200
DB 1141 TTAATGTTTATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAAT 1200
QY 1201 TTTCAATCTGCTGGTGTGAAAGTATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAAT 1260
DB 1201 TTTCAATCTGCTGGTGTGAAAGTATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAATTTTAAAGCAAT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
DB 1261 GAATGAGAGAAATTTGATTAACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 7
BD194411
LOCUS
DEFINITION
Secretory proteins and polynucleotides encoding the same.
ACCESSION
BD194411
VERSION
BD194411.1 GI:33004152

1378 bp DNA linear PAT 17-JUL-2003

KEYWORDS JP 2002509722-A/6.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1378)
 AUTHORS Jacobs, K., McCoy, J. M., Lavallie, E. R., Racie, L. A. C., Evans, C., Merberg, D., Treacy, M., Agostino, M. J., and II, R. J. S.
 TITLE Secretory proteins and polynucleotides encoding the same
 JOURNAL Patent: JP 2002509722-A 6 02-APR-2002;
 GENETICS INSTITUTE INC
 COMMENT OS Homo sapiens (human)
 PN JP 2002509722-A/6
 PD 02-APR-2002
 PF 30-MAR-1999 JP 2000541293
 PR 31-MAR-1998 US 60/080110, 29-MAR-1999 US 09/280591 PI
 KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A COLLINS PI
 RACIE,
 PI CHERYL EVANS, DAVID MERBERG, MAURICE TREACY, MICHAEL J AGOSTINO,
 PI ROBERT J STEININGER II
 PC C12N15/09, C07K14/00, C07K14/435, C12N5/10, C12N15/00, PC
 C12N5/00
 CC Secretory proteins and polynucleotides encoding the same PH
 Key Location/Qualifiers
 FT source 1..1378
 FT /organism="Homo sapiens (human)".
 FEATURES source
 Location/Qualifiers
 1..1378
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 ORIGIN
 Query Match 99.1%; Score 1321.4; DB 6; Length 1378;
 Best Local Similarity 99.5%; Pred. No. 3.4e-280;
 Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 3 CCACGCGTCCGATGCGGTTGAGTTCAGTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTCA 62
 DB 33 CTTCCCGAGCGATGCGGTTGAGTTCAGTTCGGCGCTTCTGCTACATGCTGGCGTCTGCTCA 92
 QY 63 CTGCGCGCTCATCTCTTCTGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGACTG 122
 DB 93 CTGCGCGCTCATCTCTTCTGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGACTG 152
 QY 123 ATTCAAGAACTCTATAGACCGATGATACCTGAATCCCTTCTGCTACCTCCAGAGTACC 182
 DB 153 ATTCAAGAACTCTATAGACCGATGATACCTGAATCCCTTCTGCTACCTCCAGAGTACC 212
 QY 183 TCATCCAGCTTCTCTGTCATGTTCTGTCATGTTCTGTCAGAGTGGCTTACACTGGGTC 242
 DB 213 TCATCCAGCTTCTCTGTCATGTTCTGTCATGTTCTGTCAGAGTGGCTTACACTGGGTC 272
 QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGATAGACCAAGTATGAGT 302
 DB 273 TCAATATGCCCTCTTGGCATATCATATTTGGAGTATATGATAGACCAAGTATGAGT 332
 QY 303 GCCCAGGACTCTATGACCTCAACCAATCAATGCAATGTCAGATATTCAGATATGTCAGA 362
 DB 333 GCCCAGGACTCTATGACCTCAACCAATCAATGCAATGTCAGATATTCAGATATGTCAGA 392
 QY 363 AGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACCTATATGCA 422
 DB 393 AGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACCTATATGCA 452
 QY 423 TGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 482
 DB 453 TGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 512
 QY 483 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAGATCTGTCACAGAGTACCT 542
 DB 513 ATGCAAAAGCCACCAATGAGGATTTCTATCCAGCAGATCTGTCACAGAGTACCT 572

543 GTGGAATCTGATCAGTTACGTTTAAATAATGACTCCTTATATTTTAAATGTTTCCACATTT 602
 DB 573 GTGGAATCTGATCAGTTTACGTTTAAATAATGACTCCTTATATTTTAAATGTTTCCACATTT 632
 QY 603 TTGCTCTGGAAGACGCTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGTTTAA 662
 DB 633 TTGCTCTGGAAGACGCTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGTTTAA 692
 QY 663 CGTATAAATTAATAATAAAAGATTACCTCTGCTGTTGACAGGTTTGAACCTTGGCACTTCTT 722
 DB 693 CGTATAAATTAATAATAAAAGATTACCTCTGCTGTTGACAGGTTTGAACCTTGGCACTTCTT 752
 QY 723 AAGGAACGACCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 782
 DB 753 AAGGAACGACCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTAATTA 812
 QY 783 AGCTTTTGTGTTATAGGAACCTTGTAGGGCTCAATTTTGGTTCATTTGAAACAGTATCTAAT 842
 DB 813 AGCTTTTGTGTTATAGGAACCTTGTAGGGCTCAATTTTGGTTCATTTGAAACAGTATCTAAT 872
 QY 843 ATAAATAGCTGTAGATATCAGGTGCTCTCATGAGAGTGAATAATGATATCTGACTAGT 902
 DB 873 ATAAATAGCTGTAGATATCAGGTGCTCTCATGAGAGTGAATAATGATATCTGACTAGT 932
 QY 903 GGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTA 962
 DB 933 GGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTA 992
 QY 963 AAATAAAAGCGGAAATTTTCCCTTCGCTTGAATAATTAATTCCTGCTGATATTCGATGAATGA 1022
 DB 993 AAATAAAAGCGGAAATTTTCCCTTCGCTTGAATAATTAATTCCTGCTGATATTCGATGAATGA 1052
 QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAATTAATTAATTAATTAATTA 1082
 DB 1053 GAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAATTAATTAATTAATTAATTA 1112
 QY 1083 TAAACATCATATAAAATATATGCTGAATTAATTTGTTGAAGAAATGCAATTAAGAGCTATTTT 1142
 DB 1113 TAACATGATTAATAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1172
 QY 1143 AAATGTGTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1202
 DB 1173 AAATGTGTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1232
 QY 1203 CTAATCTGCTGTAAGAGTATTTCTTAAGAAATTCAGAGTACTACAGATTTTCAAAACTGA 1262
 DB 1233 CTAATCTGCTGTAAGAGTATTTCTTAAGAAATTCAGAGTACTACAGATTTTCAAAACTGA 1292
 QY 1263 ATGAGAGAAATTTGTATAAACCATCTGCTGTTTCCCTTTAGTCAATACATATAAACTCTGA 1322
 DB 1293 ATGAGAGAAATTTGTATAAACCATCTGCTGTTTCCCTTTAGTCAATACATATAAACTCTGA 1352
 QY 1323 AATTAAGACTC 1333
 DB 1353 AATTAAGACTC 1363

RESULT 8
 AR080257
 LOCUS 1391 bp DNA linear PAT 31-AUG-2000
 DEFINITION Sequence 2 from patent US 5968744.
 ACCESSION AR080257
 VERSION AR080257.1 GI:10006992
 KEYWORDS Unknown.
 SOURCE Unclasseified.
 ORGANISM Unclasseified.
 REFERENCE 1 (bases 1 to 1391)
 AUTHORS Hillman, J. L., Corley, N. C. and Shah, P.
 TITLE Human cornichon molecule
 JOURNAL Patent: US 5968744-A 2 19-OCT-1999;
 FEATURES Location/Qualifiers
 1..1391 source


```

Db 363 GCCCAGGACTCTATGACCCCTACACCATCATGATGACATATCTAGCATATGTCAGA 422
Qy 363 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTATCTACCTATATGGCA 422
Db 423 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTATCTACCTATATGGCA 482
Qy 423 TGATCTATGTTTGTGTAGCTCTTAGAACACACACAGAGAATGTTGTCAGTAAAGTC 482
Db 483 TGATCTATGTTTGTGTAGCTCTTAGAACACACACAGAGAATGTTGTCAGTAAAGTC 542
Qy 483 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCACAGATAGCT 542
Db 543 ATGCAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCACAGATAGCT 602
Qy 543 GTGGGAATCTGATCAGTCTTAAATAAAGATGATCTTATTTTAAATGTTTCCACATTT 602
Db 603 GTGGGAATCTGATCAGTCTTAAATAAAGATGATCTTATTTTAAATGTTTCCACATTT 662
Qy 603 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTACAGATAAGATTTTAAATGTTTAA 662
Db 663 TTGCTTGTGGAAGACTGTTTCAATATGTTATCTACAGATAAGATTTTAAATGTTTAA 722
Qy 663 CGTATAAATTAATAAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTGCATCTTT 722
Db 723 CGTATAAATTAATAAAGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTGCATCTTT 782
Qy 723 AAGGAACAGCCATATCTCTCAATGATGATTAATCTGATCTGCTGCTGCTGCTGCTGCT 782
Db 783 AAGGAACAGCCATATCTCTCAATGATGATTAATCTGATCTGCTGCTGCTGCTGCTGCT 842
Qy 783 AGCTTTTGTATAGGAAGCTGTAGGCTCATTTTGGTTTCAATCAACAGATCTCAATT 842
Db 843 AGCTTTTGTATAGGAAGCTGTAGGCTCATTTTGGTTTCAATCAACAGATCTCAATT 902
Qy 843 ATAAATAGCTGTAGATACAGTCTCTGATGAAGTGAATATATATCTGACTAGTG 902
Db 903 ATAAATAGCTGTAGATACAGTCTCTGATGAAGTGAATATATATCTGACTAGTG 962
Qy 903 GGAACCTTCATGGGTTTCTCATCTGCTGATGATGATTAATATATGATGATTAATA 962
Db 963 GGAACCTTCATGGGTTTCTCATCTGCTGATGATGATTAATATATGATGATTAATA 1022
Qy 963 AAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATATATATATATGATGATTA 1022
Db 1023 AAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATATATATATATGATGATTA 1082
Qy 1023 GAGATTTCCCATATTTCCATCAGATTAATAATATATATATATATATATATGATTA 1082
Db 1083 GAGATTTCCCATATTTCCATCAGATTAATAATATATATATATATATATATGATTA 1142
Qy 1083 TAAACATGATATAAATAATATATATATATATATATATATATATATATATATATAT 1142
Db 1143 TAAACATGATATAAATAATATATATATATATATATATATATATATATATATATAT 1202
Qy 1143 AAATGTGTTTATTTGTAAGACATTAATATATATATATATATATATATATATATAT 1202
Db 1203 AAATGTGTTTATTTGTAAGACATTAATATATATATATATATATATATATATATAT 1262
Qy 1203 CTAATCTGGTGAAGTATTTTAAAGATTTTAAAGATTTTAAAGATTTTAAAGATTTT 1262
Db 1263 CTAATCTGGTGAAGTATTTTAAAGATTTTAAAGATTTTAAAGATTTTAAAGATTTT 1322
Qy 1263 ATGAGAGAAATTTGTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1322
Db 1323 ATGAGAGAAATTTGTAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1382
Qy 1323 AATTAAAG 1330
Db 1383 AATTAAAA 1390

```

RESULT 10

BD266710
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BD266710
29 human secreted proteins.
BD266710
BD266710.1 GI:33076478
JP 2002532054-A/33.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS
TITLE
JOURNAL

1 (bases 1 to 1404)
Ruben, S.M., Rosen, C.A., Fan, P., Kyaw, H. and Wei, Y.F.
29 human secreted proteins
Patent: JP 2002532054-A 33 02-OCT-2002;
HUMAN GENOME SCIENCES INC
OS Homo sapiens (human)
PN JP 2002532054-A/33
PD 02-OCT-2002

COMMENT

PF 27-AUG-1998 JP 2000507689
PR 29-AUG-1997 US 60/056073, 29-AUG-1997 US 60/056271 PR
29-AUG-1997 US 60/056270, 29-AUG-1997 US 60/056247 PI STEVEN
M RUBEN, CRAIG A ROSEN, PING FAN, HLA KYAW, YING FEI WEI PC
C12N15/09, A61K38/00, A61K48/00, A61P15/00, A61P17/00, A61P37/00, PC
C07K14/52,
PC C07K16/24, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12P21/08 PC
, C12Q1/68, G01N33/15,
PC G01N33/50, C12N15/00, A61K37/02, C12N5/00
CC n equals a,t,g, or c
FH Key Location/Qualifiers
FT source 1..1404
/organism="Homo sapiens (human)".

FEATURES
source

1..1404
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 98.8%; Score 1316.4; DB 6; Length 1404;
Best Local Similarity 99.5%; Pred. No. 4.3e-279;
Matches 1320; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Qy 3 CCACGGTCCGATCGGTTACGTTCCGCGCTTCTGCTACATGCTGGCGTGGCTCA 62
Db 52 CTTCCAGCATCGGTTACGTTCCGCGCTTCTGCTACATGCTGGCGTGGCTCA 111
Qy 63 CTGCGGCGCTCATCTTCTCGCCATTGGCACATTATAGCATTTGATGAGTGAAGCTG 122
Db 112 CTGCGGCGCTCATCTTCTCGCCATTGGCACATTATAGCATTTGATGAGTGAAGCTG 171
Qy 123 ATTCAAGAATCTTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCAGATACC 182
Db 172 ATTCAAGAATCTTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCAGATACC 231
Qy 183 TCATCCAGCTTCTTCTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGTC 242
Db 232 TCATCCAGCTTCTTCTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGTC 291
Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAAGTG 302
Db 292 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAAGTG 351
Qy 303 GCCCAGAGCTTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATG 362
Db 352 GCCCAGAGCTTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATG 411
Qy 363 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTATATATGCA 422
Db 412 AGGAGGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTATATATGCA 471
Qy 423 TGATCTATGTTTGTGGTGGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 482
Db 472 TGATCTATGTTTGTGGTGGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGTGC 531


```

QY 1099 ATATATGCTGAATTACTCTGGAAGAAATGCAATTTAAAGCTATTTTAAATGCTTTTATTT 1158
Db 1081 ATATATGCTGAATTACTCTGGAAGAAATGCAATTTAAAGCTATTTTAAATGCTTTTATTT 1140
QY 1159 GTAAGACATTAATTAAAGAAATGGTTATTATGCTTACTGTTCTTAATCTGGTGTAAA 1218
Db 1141 GTAAGACATTAATTAAAGAAATGGTTATTATGCTTACTGTTCTTAATCTGGTGTAAA 1200
QY 1219 GGTATTTCTTAAGAAATTCAGCTACTACAGATTTTCAGAACTGAATGAGAGAAATTTGA 1278
Db 1201 GGTATTTCTTAAGAAATTCAGCTACTACAGATTTTCAGAACTGAATGAGAGAAATTTGA 1260
QY 1279 TAACCATCTGCTGTTCTCTTTAGTGAACAATAAATCTCTGAATTAAGACTC 1333
Db 1261 TAACCATCTGCTGTTCTCTTTAGTGAACAATAAATCTCTGAATTAAGACTC 1315

RESULT 13
LOCUS BD127279
DEFINITION Primer for synthesizing full-length cDNA and use thereof.
ACCESSION BD127279
VERSION BD127279.1 GI:23222224
KEYWORDS JP 2002017375-A/2710.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1321)
Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
Primer for synthesizing full-length cDNA and use thereof
Patent: JP 2002017375-A 2710 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017375-A/2710
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA,TETSUO NISHIKAWA,TAKAO ISOGAI,KOJI HAYASHI,SHIZUKO
PI TSHII,
PI YURI KAWAI,AI WAKAMATSU,TOMOYASU SUGIYAMA,KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI,HISASHI KOGA
PC
C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10,
C12P21/02,C12Q1/68//C12P21/08,G06F17/30,C12N15/00,C12N5/00 CC
Primer for synthesizing full-length cDNA and use thereof FH Key
Location/Qualifiers
(9)..(440).
FT CDS
Source
1..1321
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 98.4%; Score 1311.8; DB 6; Length 1321;
Best Local Similarity 99.8%; Pred. No. 4.4e-278;
Matches 1313; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 12 CGATGGCGTTCACGTTCCGGCTTCTGCTACATGCTGGCGCTGCTGCTACTGCCGCGC 71
Db 7 CCATGGCGTTCACGTTCCGGCTTCTGCTACATGCTGGCGCTGCTGCTACTGCCGCGC 66

QY 72 TCATCTTCTTCCCAATTTGGCACATTATAGCAATTTGATGAGCTGAAGACTGATTACAAGA 131
Db 67 TCATCTTCTTCCCAATTTGGCACATTATAGCAATTTGATGAGCTGAAGACTGATTACAAGA 126

QY 132 ATCCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCCGAGTACCTCCACG 191
Db 127 ATCCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCCGAGTACCTCCACG 186

```

```

QY 192 CTTTCTTCTGCTGCTAATGTTCTTTGTGAGAGAGTGGCTTACACTGGGCTCTCAATATGC 251
Db 187 CTTTCTTCTGCTGCTAATGTTCTTTGTGAGAGAGTGGCTTACACTGGGCTCTCAATATGC 246
QY 252 CCGCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAGTGTGCCCCAGGAC 311
Db 247 CCGCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAGTGTGCCCCAGGAC 306
QY 312 TCTATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATTTGTGAGAGGAGGAT 371
Db 307 TCTATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATTTGTGAGAGGAGGAT 366
QY 372 GGTCAAAATAGCTTTTATCTTCTAGCAATTTTCTACCTATATGCGCATGATCTATG 431
Db 367 GGTCAAAATAGCTTTTATCTTCTAGCAATTTTCTACCTATATGCGCATGATCTATG 426
QY 432 TTTTGGTGGAGCTCTTAGAACCAACACAGAGAGATTTGGTCCAGTTAAAGTGCATGCAAAA 491
Db 427 TTTTGGTGGAGCTCTTAGAACCAACACAGAGAGATTTGGTCCAGTTAAAGTGCATGCAAAA 486
QY 492 GCCACCAATGAAGGAGTTCTTATCCAGCAAGATCCTGTCCAAGAGTAGCCTGTGGAATCT 551
Db 487 GCCACCAATGAAGGAGTTCTTATCCAGCAAGATCCTGTCCAAGAGTAGCCTGTGGAATCT 546
QY 552 GATCAGTTACTTTTAAAAAAGACCTCTTATTTTAAAGTTTCCACATTTTGTCTTGTG 611
Db 547 GATCAGTTACTTTTAAAAAAGACCTCTTATTTTAAATGTTTCCACATTTTGTCTTGTG 606
QY 612 GAAAGACCTGTTTTCATATGTTATATCTCAGATAAGATTTTAAAGTGTATACGTATTAAT 671
Db 607 GAAAGACCTGTTTTCATATGTTATATCTCAGATAAGATTTTAAAGTGTATACGTATTAAT 666
QY 672 TAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGACCTCTTTAAGGAAACAG 731
Db 667 TAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGACCTCTTTAAGGAAACAG 726
QY 732 CCATATCTCTCTGAATGATGATTAATTTACTGACCTGCTCTAGTACATTTGGAAGCTTTGT 791
Db 727 CCATATCTCTCTGAATGATGATTAATTTACTGACCTGCTCTAGTACATTTGGAAGCTTTGT 786
QY 792 TTATAGGAACCTGTAGGGCTCATTTTGGTTTCATTGTAACACAGATATCTAATTTATAATTTAG 851
Db 787 CTATAGGAACCTGTAGGGCTCATTTTGGTTTCATTGTAACACAGATATCTAATTTATAATTTAG 846
QY 852 CTGTAGATATCAGGTGCTTCTGTGAAGTGAAGTGAATATATCTGACTAGTGGGAACTTC 911
Db 847 CTGTAGATATCAGGTGCTTCTGTGAAGTGAAGTGAATATATCTGACTAGTGGGAACTTC 906
QY 912 ATGGGTTTCCCTCATCTCTCATGTCGATGATATATATGATATGATATTTACAAAAATAAAA 971
Db 907 ATGGGTTTCCCTCATCTCTCATGTCGATGATATATATGATATGATATTTACAAAAATAAAA 966
QY 972 GCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGTATATTTGCAATGATGAGATTTCC 1031
Db 967 GCGGGAATTTTCCCTTCCCTTGAATATATATCCCTGTATATTTGCAATGATGAGATTTCC 1026
QY 1032 CATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTTAAGCAATGAATAACATGA 1091
Db 1027 CATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTTAAGCAATGAATAACATGA 1086
QY 1092 TATAAAATATATCTCTGAAATTTACTTTGGAAGATGCAATTTAAAGCTATTTTAAATGTTT 1151
Db 1087 TATAAAATATATCTCTGAAATTTACTTTGGAAGATGCAATTTAAAGCTATTTTAAATGTTT 1146
QY 1152 TTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTATTTATGCTTACTGTTCTAATCTGG 1211
Db 1147 TTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTATTTATGCTTACTGTTCTAATCTGG 1206
QY 1212 TGGTAAAGGTATTTCTTAAGAAATTTGAGGTAATTAAGGTAATTAAGGTAATTAAGGTAAT 1271
Db 1207 TGGTAAAGGTATTTCTTAAGAAATTTGAGGTAATTAAGGTAATTAAGGTAATTAAGGTAAT 1266

```

QY 1272 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAAATT 1326
 Db |||||||
 1267 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAAATT 1321
 |||||||

RESULT 14
 AK074781
 LOCUS
 DEFINITION Homo sapiens cDNA FLJ90300 fis, clone NT2RP2000533, highly similar to Homo sapiens cornichon protein mRNA.
 ACCESSION AK074781
 VERSION AK074781.1 GI:22760452
 KEYWORDS oligo capping; fis (full insert sequence).
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Isogai,T., Ota,T., Nishikawa,T., Hayashi,K., Otsuki,T., Sugiyama,T., Suzuki,Y., Nagai,K., Sugano,S., Ishii,S., Kawai-Hio,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y., Kojima,S., Nagahari,K., Masuho,Y., Ono,T., Okano,K., Yoshikawa,Y., Aotsuka,S., Sasaki,N., Hattori,A., Okumura,K., Iwayanagi,T. and Niomiya,K.
 TITLE NEDO human cDNA sequencing project
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 1321)
 AUTHORS Isogai,T. and Otsuki,T.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-2002) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
 COMMENT NEDO human cDNA sequencing project supported by Ministry of Economy, Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction: Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure, Human Genome Center; cDNA 5'- & 3'-end one pass sequencing and clone selection: Helix Research Institute (supported by Japan Key Technology Center etc.).
 FEATURES
 source
 1. 1321
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="NT2RP2000533"
 /cell_line="NT2"
 /cell_type="teratocarcinoma"
 /clone_lib="NT2RP2"
 /note="cloning vector: pME18SFL3-mRNA from NT2 neuronal precursor cells after 2-weeks retinoic acid (RA) induction"

ORIGIN
 Query Match 98.4%; Score 1311.8; DB 9; Length 1321;
 Best Local Similarity 99.8%; Pred. No. 4.4e-278;
 Matches 1313; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 12 CGATGGCGTTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGTGTGCTGCTACTGCGGCG 71
 Db |||||||
 7 CCATGGCGTTTCACGTTCCGGCGCTTCTGCTACATGCTGGCGTGTGCTGCTACTGCGGCG 66
 |||||||
 72 TCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGACTGATTACAGA 131
 Db |||||||
 67 TCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGACTGATTACAGA 126
 |||||||
 132 ATCTCTATAGACGAGTGATACCTGATCCCTTGTTACTCCAGAGTACCTCATCCACG 191
 QY |||||||
 127 ATCTCTATAGACGAGTGATACCTGATCCCTTGTTACTCCAGAGTACCTCATCCACG 186
 Db |||||||
 192 CTTTCTTCTGTTGTCATGTTCTTTGTCAGCAGAGTGGCTTACATGCTGGTCTCAATATGC 251
 QY |||||||
 187 CTTTCTTCTGTTGTCATGTTCTTTGTCAGCAGAGTGGCTTACATGCTGGTCTCAATATGC 246
 Db |||||||

QY 252 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAGTGGCCCGAGAC 311
 Db |||||||
 247 CCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAGTGGCCCGAGAC 306
 |||||||

QY 312 TCTATGACCCCTACAAACCATCATGAATGCAGATATTTCTAGCATATTTGTTCAGAGGAGGAT 371
 Db |||||||
 307 TCTATGACCCCTACAAACCATCATGAATGCAGATATTTCTAGCATATTTGTTCAGAGGAGGAT 366
 |||||||

QY 372 GGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTACTTACCTATATATGCGCATGCTATG 431
 Db |||||||
 367 GGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTACTTACCTATATATGCGCATGCTATG 426
 |||||||

QY 432 TTTTGTGAGCTCTTAGACACACACAGAGAATTTGTTCAGTTAAGTGCATGCAAAA 491
 Db |||||||
 427 TTTTGTGAGCTCTTAGACACACACAGAGAATTTGTTCAGTTAAGTGCATGCAAAA 486
 |||||||

QY 492 GCCACCAATGAAGGAGTCTATCCAGCAAGATCTCTCCAAAGAGTAGGCTCTGGAATCT 551
 Db |||||||
 487 GCCACCAATGAAGGAGTCTATCCAGCAAGATCTCTCCAAAGAGTAGGCTCTGGAATCT 546
 |||||||

QY 552 GATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTTTTTGTCTGTG 611
 Db |||||||
 547 GATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTTTTTGTCTGTG 606
 |||||||

QY 612 GAAACACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTATACGTATAAT 671
 Db |||||||
 607 GAAACACTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTATACGTATAAT 666
 |||||||

QY 672 TAAATAAATAAGTATACCTCTGGTTCACAGTTTGAACCTTGCACTTCTTAAAGAACAG 731
 Db |||||||
 667 TAAATAAATAAGTATACCTCTGGTTCACAGTTTGAACCTTGCACTTCTTAAAGAACAG 726
 |||||||

QY 732 CCATTAATCTCTGAATGATGATTAATTAATCTGACGTCTAGTACATTTGGAGCTTTGT 791
 Db |||||||
 727 CCATTAATCTCTGAATGATGATTAATTAATCTGACGTCTAGTACATTTGGAGCTTTGT 786
 |||||||

QY 792 TTATAGGAACCTGTAGGCTCATTTGTTTTCATTGAAACAGATCTAATATAAATTAG 851
 Db |||||||
 787 CTATAGGAACCTGTAGGCTCATTTTGGTTTCATTGAAACAGATCTAATATAAATTAG 846
 |||||||

QY 852 CTGTAGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGAACTTC 911
 Db |||||||
 847 CTGTAGATATCAGGTGCTTCTGATGAAGTAAATGTATATCTGACTAGTGGAACTTC 906
 |||||||

QY 912 ATGGGTTTCCCTCATCTGTCATGTCGATTAATATATATGGAATCAATTAACAAAATAAAA 971
 Db |||||||
 907 ATGGGTTTCCCTCATCTGTCATGTCGATTAATATATATGGAATCAATTAACAAAATAAAA 966
 |||||||

QY 972 GCGGAATTTTCCCTTCGTTGAATATTTATCCCTGTATATGCGTATATGAGATGAGATTTCC 1031
 Db |||||||
 967 GCGGAATTTTCCCTTCGTTGAATATTTATCCCTGTATATGCGTATATGAGATGAGATTTCC 1026
 |||||||

QY 1032 CATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATCTTTAAGCATAACTAAACATGA 1091
 Db |||||||
 1027 CATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATCTTTAAGCATAACTAAACATGA 1086
 |||||||

QY 1092 TATAAATAATATCTGAAATTTACTTGTGAAGATGCAATTAAGCTATTTTAAATGTGTT 1151
 Db |||||||
 1087 TATAAATAATATCTGAAATTTACTTGTGAAGATGCAATTTAAAGCTATTTTAAATGTGTT 1146
 |||||||

QY 1152 TTTATTTGTAAGACATTTACTTATTAAGAAATGGTTATATGCTTACTGTTCTAATCTGG 1211
 Db |||||||
 1147 TTTATTTGTAAGACATTTACTTATTAAGAAATGGTTATATGCTTACTGTTCTAATCTGG 1206
 |||||||

QY 1212 TGGTAAAGGTATTTCTTAAGATTTTGCAGGTACTACAGATTTTCAAACTGAATGAGAGAA 1271
 Db |||||||
 1207 TGGTAAAGGTATTTCTTAAGATTTTGCAGGTACTACAGATTTTCAAACTGAATGAGAGAA 1266
 |||||||

QY 1272 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAAATT 1326
 Db |||||||
 1267 AATTGTATACCACTCTGCTGTTCTTTAGTGCATACATAAATACTGAAATT 1321
 |||||||

REFERENCE 1 (bases 1 to 1398)
 AUTHORS Plisov,S.Y., Ivanov,S.V., Lerman,M. and Perantoni,A.O.
 TITLE Direct Submission
 JOURNAL Submitted (04-NOV-1998) Laboratory of Comparative Carcinogenesis,
 National Cancer Institute, FCRC, Bldg 538, Room 221, Frederick, MD
 21702, USA

FEATURES source

Location/Qualifiers
 1..1398
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="dbSTS:G38596"
 /db_xref="taxon:9606"
 /chromosome="14"
 /cell_line="786-0"
 /tissue type="clear cell carcinoma"
 57..491
 /note="expression elevated in dividing 786-0 cells
 compared with confluent 786-0 cells"
 /codon_start=1
 /product="cornichon"
 /protein_id="AAC98388.1"
 /db_xref="GI:4063709"
 /translation="MAFPAFCYMLALLLTAALIFPAIWHIIAFDELKDYKPIDQ
 CNTLNPLVPLYLHAFPCVNFCLCAEWLTLGLNPLLHAYHWRMSRPVMSGPLXD
 PTTINADILAYCOREGWCKLAFYLLAFYLYLGMIVLVSS"

CDS

Query Match 96.0%; Score 1279.4; DB 9; Length 1398;
 Best Local Similarity 98.9%; Pred. No. 5.9e-271;
 Matches 1320; Conservative 0; Mismatches 8; Indels 7; Gaps 3;
 Qy 3 CCACGGTCGATGCGGTTCAGTTCGGGCTTCTGTACATGCTGGCGTGTGCTCA 62
 Db 46 CTTCCCGAGCATGGCGTTCAGTTCGGGCTTCTGTACATGCTGGCGTGTGCTCA 105
 Qy 63 CTGCGGCTCATCTTCTTCCGATTTGGACATATAGCATTTGATGAGCTGAAGCTG 122
 Db 106 CTGCGGCTCATCTTCTTCCGATTTGGACATATAGCATTTGATGAGCTGAAGCTG 165
 Qy 123 ATTACAGAACTCTATAGACAGTGTATACCTGAATCCCTGTACTCCCGAGTACC 182
 Db 166 ATTACAGAACTCTATAGACAGTGTATACCTGAATCCCTGTACTCCCGAGTACC 225
 Qy 183 TCATCCAGCTTCTTCTGTCATGTTCTTGTGACGAGTGGCTTACACTGGGTC 242
 Db 226 TCATCCAGCTTCTTCTGTCATGTTCTTGTGACGAGTGGCTTACACTGGGTC 285
 Qy 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 302
 Db 286 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGTG 345
 Qy 303 GCCCAGGACTCTATGACCTTACACCATCATGATGAGTATCTAGCATTTGTGAGA 362
 Db 346 GCCCAGGACTCTATGACCTTACACCATCATGATGAGTATCTAGCATTTGTGAGA 405
 Qy 363 AGGAAGATGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATGGCA 422
 Db 406 AGGAAGATGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATGGCA 465
 Qy 423 TGATCTATGTTTGTGAGCTCTAGACACACACAGAGAATTTGTCAGTTAAGTGC 482
 Db 466 TGATCTATGTTTGTGAGCTCTAGACACACACAGAGAATTTGTCAGTTAAGTGC 525
 Qy 483 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGCCT 542
 Db 526 ATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGCCT 585
 Qy 543 GTGGAATCTGATGAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 602
 Db 586 GTGGAATCTGATGAGTTACTTTAAATAAGTCTCTTATTTTAAATGTTTCCACATTT 645
 Qy 603 TTGCTTGTGGAAGACTGTTT-CATATGTTATATCAGATAAGATTTAAATGGTATT 661

Db 646 TTGCTTGTGGAAGACTGTTTCCATATGTTATCTACTCAGATAAAGATTTTAAATGGTATT 705
 Qy 662 ACGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGTCTCT 721
 Db 706 ACGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGTCTCT 765
 Qy 722 TAAGGACAGCCATAAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 781
 Db 766 TAAGGACAGCCATAAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 825
 Qy 782 AAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAGACAGTATCTAAT 841
 Db 826 AAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAGACAGTATCTAAT 885
 Qy 842 TATATAATAGCTGATGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 901
 Db 886 TATATAATAGCTGATGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 945
 Qy 902 GGGAAACCTTCATGAGTTCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAAT 961
 Db 946 GGGAAACCTTCATGAGTTCCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAATTAAT 1005
 Qy 962 AAAAT-----AAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGATATTTGCAT 1016
 Db 1006 AAAATAAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGATATTTGCAT 1065
 Qy 1017 GAATGAGAGATTTCCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA 1075
 Db 1066 GAATGAGAGATTTCCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA 1125
 Qy 1076 GCATAAGTAAACATGATATAAATAATATATGCTGAATTAATTTGTAAGAATGCATTTAAAG 1135
 Db 1126 GCATAAGTAAACATGATATAAATAATATATGCTGAATTAATTTGTAAGAATGCATTTAAAG 1185
 Qy 1136 CTATTTAAATGCTTTTTTATTTTCTAAGACATTAATTAATAAGAAATTTGTTATATGCT 1195
 Db 1186 CTATTTAAATGCTTTTTTATTTTCTAAGACATTAATTAATAAGAAATTTGTTATATGCT 1245
 Qy 1196 TACTGTTCTAATCTGGTGTAAAGGATTTCTTAAGAATTTGTCAGGTACTACAGATTTTCA 1255
 Db 1246 TACTGTTCTAATCTGGTGTAAAGGATTTCTTAAGAATTTGTCAGGTACTACAGATTTTCA 1305
 Qy 1256 AAACCTGAATGAGAAAATTTGATAACCATCTCTGTTCTCTTTAGTGAATACATAA 1315
 Db 1306 AAACCTGAATGAGAAAATTTGATAACCATCTCTGTTCTCTTTAGTGAATACATAA 1365
 Qy 1316 ACTCTGAATTTAAGA 1330
 Db 1366 ACTNTGAATTTAAGA 1380

Search completed: June 14, 2004, 17:53:03
 Job time : 5333 secs

Result No.	Score	Query		Length	DB	ID	Description
		Match	%				
1	1333	100.0	1333	2	AAZ34164		Aaz34164 Human PRO
2	1333	100.0	1333	3	AA884339		Aaa88439 Anticoum
3	1333	100.0	1333	3	AAAC78538		Aac78538 Human PRQ
4	1333	100.0	1333	6	ABK33595		Abk33595 cDNA enco
5	1333	100.0	1333	6	AB188072		Ab188072 Human PRO
6	1333	100.0	1333	6	AB195561		Ab195561 Human ang
7	1333	100.0	1333	7	ACA66900		Acac66900 cDNA enco
8	1333	100.0	1333	7	ACD42697		Accd42697 Novel hum
9	1333	100.0	1333	7	ACD68652		Acde68652 Novel hum
10	1333	100.0	1333	7	ACA63732		Acde63732 Novel hum
11	1333	100.0	1333	7	ACA71896		Acac71896 Human sec
12	1333	100.0	1333	7	ACX92536		Abx92536 cDNA enco
13	1333	100.0	1333	7	ACA66277		Acac66277 Human cDN
14	1333	100.0	1333	7	ACA68556		Acac68556 Novel hum
15	1333	100.0	1333	8	ABT44285		Abt44285 Human PRO
16	1333	100.0	1333	8	ADA24860		Ada24860 Novel hum
17	1333	100.0	1333	8	ACD29878		Accd29878 Novel hum
18	1333	100.0	1333	8	ADA12521		Ada12521 Human cDN
19	1333	100.0	1333	8	ABT44568		Abt44568 Human PRO
20	1333	100.0	1333	8	ACD82235		Acde82235 Human sec
21	1333	100.0	1333	8	ACD29293		Accd29293 Novel hum
22	1333	100.0	1333	8	ABT43941		Abt43941 Human mem
23	1333	100.0	1333	8	ADB83609		Adb83609 Novel hum

97 1333 100.0 1333 10 ADE89756 Human cDN
 98 1333 100.0 1333 10 ADD77600 Novel hum
 99 1333 100.0 1333 10 ADD77846 Novel hum
 100 1333 100.0 1333 10 ADD85304 Novel hum
 101 1333 100.0 1333 10 ADD73836 Human PRO
 102 1333 100.0 1333 10 ADD74574 Human PRO
 103 1333 100.0 1333 10 ADD77102 Novel hum
 104 1333 100.0 1333 10 ADD85796 Novel hum
 105 1333 100.0 1333 10 ADE05345 Human PRO
 106 1333 100.0 1333 10 ADD74820 Human PRO
 107 1321.4 99.1 1378 2 AAX90853 cDNA clon
 108 1321.4 99.1 1432 6 ABK36005 cDNA sequ
 109 1316.8 98.8 1391 2 AAX30544 Human cor
 110 1316.8 98.8 1391 6 AAX31079 Human cor
 111 1316.8 98.8 1391 6 ABK91098 cDNA enco
 112 1316.4 98.8 1404 2 AAX30168 Human sec
 113 1313.4 98.5 1320 3 AAX36228 cDNA enco
 114 1311.8 98.4 1321 4 AAK94250 Human ful
 115 1301.4 97.6 2316 6 ABK35858 cDNA sequ
 116 1277.8 95.9 1398 7 ABX10419 DNA enco
 117 1195.4 89.7 1360 9 ADD78291 Human CGD

ALIGNMENTS

RESULT 1
 AAZ34164
 ID AAZ34164 standard; cDNA; 1333 BP.

XX AC AAZ34164;

XX DT 07-DEC-1999 (first entry)

XX DE Human PRO181 nucleotide sequence.

XX KW Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
 KW probe; blood coagulation disorder; cancer; cellular adhesion disorder;
 KW secreted protein; transmembrane protein; ss.

XX OS Homo sapiens.

XX PN WO9946281-A2.

XX PD 16-SEP-1999.

XX PF 08-MAR-1999; 99WO-U5005028.

XX PR 10-MAR-1998; 98US-0077450P.

XX PR 11-MAR-1998; 98US-0077632P.

XX PR 11-MAR-1998; 98US-0077641P.

XX PR 11-MAR-1998; 98US-0077649P.

XX PR 12-MAR-1998; 98US-0077791P.

XX PR 13-MAR-1998; 98US-0078004P.

XX PR 17-MAR-1998; 98US-00040220.

XX PR 20-MAR-1998; 98US-0078886P.

XX PR 20-MAR-1998; 98US-0078910P.

XX PR 20-MAR-1998; 98US-0078936P.

XX PR 20-MAR-1998; 98US-0078939P.

XX PR 25-MAR-1998; 98US-0079294P.

XX PR 26-MAR-1998; 98US-0079656P.

XX PR 27-MAR-1998; 98US-0079663P.

XX PR 27-MAR-1998; 98US-0079664P.

XX PR 27-MAR-1998; 98US-0079689P.

PR 01-APR-1998; 98US-0080328P.
 PR 01-APR-1998; 98US-0080333P.
 PR 01-APR-1998; 98US-0080334P.
 PR 08-APR-1998; 98US-0081049P.
 PR 08-APR-1998; 98US-0081070P.
 PR 08-APR-1998; 98US-0081071P.
 PR 09-APR-1998; 98US-0081195P.
 PR 09-APR-1998; 98US-0081203P.
 PR 09-APR-1998; 98US-0081229P.
 PR 15-APR-1998; 98US-0081817P.
 PR 15-APR-1998; 98US-0081838P.
 PR 15-APR-1998; 98US-0081952P.
 PR 15-APR-1998; 98US-0081953P.
 PR 21-APR-1998; 98US-0082568P.
 PR 21-APR-1998; 98US-0082569P.
 PR 22-APR-1998; 98US-0082700P.
 PR 22-APR-1998; 98US-0082704P.
 PR 22-APR-1998; 98US-0082804P.
 PR 23-APR-1998; 98US-0082767P.
 PR 23-APR-1998; 98US-0082796P.
 PR 27-APR-1998; 98US-0083336P.
 PR 28-APR-1998; 98US-0083322P.
 PR 29-APR-1998; 98US-0083392P.
 PR 29-APR-1998; 98US-0083495P.
 PR 29-APR-1998; 98US-0083496P.
 PR 29-APR-1998; 98US-0083499P.
 PR 29-APR-1998; 98US-0083500P.
 PR 29-APR-1998; 98US-0083545P.
 PR 29-APR-1998; 98US-0083554P.
 PR 29-APR-1998; 98US-0083558P.
 PR 29-APR-1998; 98US-0083559P.
 PR 30-APR-1998; 98US-0083742P.
 PR 05-MAY-1998; 98US-0084366P.
 PR 06-MAY-1998; 98US-0084414P.
 PR 07-MAY-1998; 98US-0084441P.
 PR 07-MAY-1998; 98US-0084598P.
 PR 07-MAY-1998; 98US-0084600P.
 PR 07-MAY-1998; 98US-0084627P.
 PR 07-MAY-1998; 98US-0084637P.
 PR 07-MAY-1998; 98US-0084639P.
 PR 07-MAY-1998; 98US-0084640P.
 PR 07-MAY-1998; 98US-0084643P.
 PR 13-MAY-1998; 98US-0085323P.
 PR 13-MAY-1998; 98US-0085338P.
 PR 13-MAY-1998; 98US-0085339P.
 PR 15-MAY-1998; 98US-0085573P.
 PR 15-MAY-1998; 98US-0085579P.
 PR 15-MAY-1998; 98US-0085808P.
 PR 15-MAY-1998; 98US-0085828P.
 PR 15-MAY-1998; 98US-0085689P.
 PR 15-MAY-1998; 98US-0085697P.
 PR 15-MAY-1998; 98US-0085700P.
 PR 18-MAY-1998; 98US-0086023P.
 PR 22-MAY-1998; 98US-0086392P.
 PR 22-MAY-1998; 98US-0086414P.
 PR 22-MAY-1998; 98US-0086430P.
 PR 22-MAY-1998; 98US-0086486P.
 PR 28-MAY-1998; 98US-0087098P.
 PR 28-MAY-1998; 98US-0087106P.
 PR 28-MAY-1998; 98US-0087208P.
 PR 30-JUL-1998; 98US-0094651P.
 PR 11-SEP-1998; 98US-0100038P.

(GETH) GENENTECH INC.

Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;

WPI; 1999-551358/46.

P-PSDB; AAY41732.

New secreted and transmembrane polypeptides and their polynucleotides,
 useful for treating blood coagulation disorders, cancers and cellular

adhesion disorders.

Claim 2; Fig 128; 530pp; English.

The present invention describes secreted and transmembrane polypeptides and their polynucleotides. The nucleotide sequences are useful as sources of probes, primers, for chromosome mapping, and for generation of antisense sequences. They can also be used to create transgenic animals. The proteins can be used to treat a variety of diseases and disorders, depending on their function. Diseases that may be treated include blood coagulation disorders, cancers and cellular adhesion disorders. They may also be used to raise antibodies. AA33891 to AA33438, and AA41685 to AA41774 represent polynucleotide and polypeptide sequence given in the exemplification of the present invention

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 2; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9,6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCGATGGCGCTTACGTTCCGGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCCAGCGTCGATGGCGCTTACGTTCCGGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTCGCGGCTCATCTTCTCGCCATTTGGCAGCATTTAGCATTTTGATGAGCTGAAGAC 120
 DB 61 CACTCGCGGCTCATCTTCTCGCCATTTGGCAGCATTTAGCATTTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACAGGTGTAATACCCCTGTAATCCCTTGTACTCCCGAGAT 180
 DB 121 TGATTACAGAAATCCTATAGACAGGTGTAATACCCCTGTAATCCCTTGTACTCCCGAGAT 180
 QY 181 CTTCTATCCAGCTTCTTCTGTCGATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 DB 181 CTTCTATCCAGCTTCTTCTGTCGATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 QY 241 TCTCATATGCCCCCTTCCGATATCATATTTGGAGGTATATGAGTACAGTACAGTGTAG 300
 DB 241 TCTCATATGCCCCCTTCCGATATCATATTTGGAGGTATATGAGTACAGTACAGTGTAG 300
 QY 301 TGGCCCGAGCTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGAT 360
 DB 301 TGGCCCGAGCTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGAT 360
 QY 361 GAAGGAGAGATGCTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCT 420
 DB 361 GAAGGAGAGATGCTGCAATTTAGCTTTTATCTTCTTCTTCTTCTTCTTCTTCTTCT 420
 QY 421 CATGATCTATGTTTGTGTCAGCTCTTGAACACACACAGAGATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGTGTCAGCTCTTGAACACACACAGAGATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
 DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
 QY 541 CTGTGGAATCTGATGAGTACCTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATGAGTACCTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTCTGTGGAAGACGTTTTCATGTTTATCTTACTCAGATAAAGATTTTAAATGTTAT 660
 DB 601 TTTTGTCTGTGGAAGACGTTTTCATGTTTATCTTACTCAGATAAAGATTTTAAATGTTAT 660
 QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
 DB 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
 QY 721 TTAAGGAAACAGCATTATCTCTGAATGATGCAATTAATTTACTGACTGTCTTAGTACATTG 780
 DB 721 TTAAGGAAACAGCATTATCTCTGAATGATGCAATTAATTTACTGACTGTCTTAGTACATTG 780

QY 781 GAAGCTTTTGTATTAGGAATTCTTGTAGGGCTCATTTTGGTTTCAATTTGAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATTAGGAATTCTTGTAGGGCTCATTTTGGTTTCAATTTGAACAGTATCTAA 840
 QY 841 TTATAAAATTAGCTGTAGATATCAGGTGCTTCTGTAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 DB 841 TTATAAAATTAGCTGTAGATATCAGGTGCTTCTGTAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 QY 901 TGGGAAACTTCATGGGTTTCCATCTCATCTGTCATGTCATGATGATGATGATGATGATGATGAT 960
 DB 901 TGGGAAACTTCATGGGTTTCCCTCATCTGTCATGTCATGATGATGATGATGATGATGATGATGAT 960
 QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTGCAATGAAT 1020
 DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTGCAATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTTAAATTTCTTAAGCAT 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTTAAATTTCTTAAGCAT 1080
 QY 1081 AGTAAACATGATATAAAATATATATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 1140
 DB 1081 AGTAAACATGATATAAAATATATATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 1140
 QY 1141 TTAATATGTTTATTTTGAAGACATTTTAAAGAAATTTGGTATTATGCTTACTG 1200
 DB 1141 TTAATATGTTTATTTTGAAGACATTTTAAAGAAATTTGGTATTATGCTTACTG 1200
 QY 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 DB 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGCTTCTTCTTAGTGAATGCAATTAAGTCT 1320
 DB 1261 GAATGAGAGAAATTTGTAACCATCTGCTGCTTCTTCTTAGTGAATGCAATTAAGTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 RESULT 2
 AAA88439
 ID AAA88439 standard; cdna; 1333 BP.
 XX
 AC AAA88439;
 XX
 DT 09-JAN-2001 (first entry)
 XX
 DE Antitumour PRO181 cdna clone DNA23330-1390.
 XX
 KW PRO181; antitumour; antiproliferative; human; cancer; therapy;
 KW drug screening; ss.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 14..448
 FT sig_peptide /*tag= a
 FT mat_peptide /*tag= b
 FT 74..445
 FT /*tag= c
 XX
 PN WO200053751-A1.
 XX
 PD 14-SEP-2000.
 XX
 PF 30-DEC-1999; 99WO-US031243.
 XX
 PR 08-MAR-1999; 99WO-US005028.
 PR 29-MAR-1999; 99US-0126773P.
 PR 20-JUL-1999; 99US-0144758P.

PR 08-SEP-1999; 99WO-US020594.
 PR 20-DEC-1999; 99WO-US030999.
 XX
 PA (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Napier MA, Wood WI;
 XX WPI; 2000-594321/56.
 DR P-PSDB; AAB19524.
 XX
 XX Novel PRO181 and PRO237 polypeptides useful for treating tumors including
 PT cancers of breast, prostate, lung, leukemia in humans and for identifying
 PT compounds capable of inhibiting growth of neoplastic cells.
 PT
 PS Claim 20; Fig 1; 107pp; English.
 XX
 CC The present sequence is that of cDNA clone DNR23330-1390 (ATCC 209775),
 CC which includes an open reading frame coding for human PRO181 (see
 CC AAB19524), a novel inhibitor of neoplastic cell growth. The cDNA was
 CC isolated from a placenta cDNA library. The library was cloned into vector
 CC pSST-AMY.0, a plasmid that has the yeast alcohol dehydrogenase (ADH)
 CC promoter preceding the cDNA cloning sites and the mouse amylase sequence
 CC (without the secretion signal). Yeast clones secreting amylase were
 CC selected, and insert cDNA was amplified by PCR using primers (see
 CC AAA88441-42) based on yeast ADH promoter and mouse amylase sequences. The
 CC encoded protein shows significant sequence homology to cornichon protein.
 CC The invention provides PRO181 and PRO237 (see AAB19525) polypeptides and
 CC polynucleotides, vectors, host cells, methods for their production,
 CC chimeric molecules and antibodies. Also claimed is a composition
 CC comprising PRO181 or PRO237, or their agonists, useful for the treatment
 CC of a tumour, especially breast cancer, ovarian cancer, renal cancer,
 CC colorectal cancer, uterine cancer, prostate cancer, lung cancer, bladder
 CC cancer, central nervous system cancer, melanoma and leukaemia. PRO181 and
 CC PRO237 are also useful for treating neuronal, glial, astrocytal,
 CC hypothalamic and other glandular, macrophagal, epithelial, stromal, and
 CC blastocoele disorders and inflammatory, angiogenic and immunologic
 CC disorders. They are useful for identifying agonists to PRO181 or PRO237
 CC in drug screening and rational drug design
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 3; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGAATTTCTATCCAGCAAGATCCTGTGCCAAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAAAATGAAGGGAATTTCTATCCAGCAAGATCCTGTGCCAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTCTTTAAAAAATGACCTCTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTCTTTAAAAAATGACCTCTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTCTGTGGAAGAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGCTAT 660
 DB 601 TTTTCTCTGTGGAAGAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGCTAT 660
 QY 661 TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
 DB 661 TACGTATAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
 QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
 QY 781 GAAGCTTTTGTATTATAGGAACCTTTAGGGCTCATTTTGGCTTTCAATTGAAACAGATATCTAA 840
 DB 781 GAAGCTTTTGTATTATAGGAACCTTTAGGGCTCATTTTGGCTTTCAATTGAAACAGATATCTAA 840
 QY 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
 DB 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
 QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
 DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
 QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAAT 1020
 DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTAAT 1020
 QY 1021 GAGAGATTTCCCAATATTTCCCATCAGAGTAATAAATACTTGTCTTTAAATTTCTTAAGCATA 1080
 DB 1021 GAGAGATTTCCCAATATTTCCCATCAGAGTAATAAATACTTGTCTTTAAATTTCTTAAGCATA 1080
 QY 1081 AGTAACAATGATATAAATAATATATATGCTGAATTAATTAATTAATTAATTAATTAATTAAT 1140
 DB 1081 AGTAACAATGATATAAATAATATATATGCTGAATTAATTAATTAATTAATTAATTAATTAAT 1140
 QY 1141 TTAATGCTGTTTTTATTTCTTAAGACATTAATTAATTAAGAAATTTGGTTATTAATGCTTACTG 1200
 DB 1141 TTAATGCTGTTTTTATTTCTTAAGACATTAATTAATTAAGAAATTTGGTTATTAATGCTTACTG 1200
 QY 1201 TTCTATCTGGTGTAAAGTATTTCTTAAGAAATTTGACAGTACTCAGATTTTCAAACT 1260
 DB 1201 TTCTATCTGGTGTAAAGTATTTCTTAAGAAATTTGACAGTACTCAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAAATTTGTATAAACCCTCCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320
 DB 1261 GAATGAGAGAAAATTTGTATAAACCCTCCTGCTGTTCTTTAGTGAATACATAAATAAATCTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 3
 AAC78538
 ID AAC78538 standard; cDNA; 1333 BP.
 XX
 AC AAC78538;
 XX 08-FEB-2001 (first entry)
 XX

DE Human PR0181 (UNQ155) nucleotide sequence SEQ ID NO:321.
 XX
 KW Human; secreted protein; transmembrane protein; PRO; EST; cytosolic;
 KW expressed sequence tag; detection; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200053756-A2.
 XX
 PD 14-SEP-2000.
 XX
 PF 18-FEB-2000; 2000WO-US004341.
 XX
 PR 08-MAR-1999; 99WO-US005028.
 PR 12-MAR-1999; 99US-0123957P.
 PR 29-MAR-1999; 99US-0126773P.
 PR 21-APR-1999; 99US-0130232P.
 PR 28-APR-1999; 99US-0131445P.
 PR 14-MAY-1999; 99US-0134287P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX WPI; 2000-611443/58.
 DR P-PSDB; AAB44288.
 XX
 XX Novel PRO polypeptides and polynucleotides used in detection methods, to
 PT target bioactive molecules to specific cells, and to modulate cellular
 PT activities.
 XX
 PS Claim 2; Fig 128; 636pp; English.
 XX
 CC AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence
 CC tag) sequences which encode secreted or transmembrane PRO polypeptides.
 CC The PRO polynucleotides and polypeptides have cytosolic activity. The
 CC polynucleotides and polypeptides can be used for detecting the presence
 CC of PRO polypeptides in samples, for linking bioactive molecules to cells
 CC and for modulating biological activities of cells, using the polypeptides
 CC for specific targeting. The polypeptide targeting can be used to kill the
 CC target cells, e.g. for the treatment of cancers. The polypeptide pairs
 CC provide specific targeting of bioactive molecules to cells. AAC78600 to
 CC AAC78987 represent PCR primers and probes used in the isolation of the
 CC PRO polynucleotide sequences
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 3; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGGCTCGATGGCGTTCACGTTGCGGCTCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGGCTCGATGGCGTTCACGTTGCGGCTCTTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTCCGCGCTCATCTTCTTCGCCATTATAGCAATTTGATGAGCTGAAGAC 120
 121 TGATTACAAGATCCCTATAGACCAAGTGTATATACCTGAATCCCTTGTACTCCAGAGTA 180
 121 TGATTACAAGATCCCTATAGACCAAGTGTATATACCTGAATCCCTTGTACTCCAGAGTA 180
 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGAGCAAGTATGAG 300
 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGAGCAAGTATGAG 300
 301 TGGCCAGAGACTATAGACCCCTACACCATCATGATGCAGATATTTAGCAATTTGTCA 360
 301 TGGCCAGAGACTATAGACCCCTACACCATCATGATGCAGATATTTAGCAATTTGTCA 360
 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACCAACACAGAGAAGATTTGGTCCAGTTAAGT 480
 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACCAACACAGAGAAGATTTGGTCCAGTTAAGT 480
 481 GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAGAGATCTGTCCAGAGTAGC 540
 481 GCATGCAAAAGACCAACCAATGAAGGATTTCTATCCAGCAGAGATCTGTCCAGAGTAGC 540
 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCCAT 600
 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCCAT 600
 601 TTTTGTGTGGAAAGACTGTTTTCATATGTTATATCATAGATAAAGATTTTAAATGGTAT 660
 601 TTTTGTGTGGAAAGACTGTTTTCATATGTTATATCATAGATAAAGATTTTAAATGGTAT 660
 661 TACGTATAAATATATATAAATGATTAATCTCTGCTGTGTGACAGGTTTGAACCTGCACATC 720
 661 TACGTATAAATATATATAAATGATTAATCTCTGCTGTGTGACAGGTTTGAACCTGCACATC 720
 721 TTAAGGAACACCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 780
 721 TTAAGGAACACCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 780
 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAITTTGGTTTCAITGAAAACAGTATCTAA 840
 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAITTTGGTTTCAITGAAAACAGTATCTAA 840
 841 TTATAAATAGCTCTAGATATACAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 841 TTATAAATAGCTCTAGATATACAGTGTCTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATATGATATCATTTAC 960
 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATATGATATCATTTAC 960
 961 AAAAATAAAGAGCGGAATTTTCCCTGCTGCTGAATATATCCCTGTATATATGATGATGAT 1020
 961 AAAAATAAAGAGCGGAATTTTCCCTGCTGCTGAATATATATCCCTGTATATATGATGATGAT 1020
 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATAATCTTGTCTTAAATCTTAAAGATA 1080
 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATAATCTTGTCTTAAATCTTAAAGATA 1080
 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGAATGCAATTTAAAGCTATT 1140
 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGAATGCAATTTAAAGCTATT 1140
 1141 TTAATATGTTTTTATTTGTAAGACATTAATTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200
 1141 TTAATATGTTTTTATTTGTAAGACATTAATTTATTAAGAAATTTGGTTATTTATGCTTACTG 1200

QY 1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGCTCTTTAGTGCATACATATAAACTCT 1320
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGCTCTTTAGTGCATACATATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1321 GAAATTAAGACTC 1333

RESULT 4

ABK33595

ID ABK33595 standard; cDNA; 1333 BP.

XX

AC ABK33595;

XX

DT 08-MAY-2002 (first entry)

XX

DE cDNA encoding human PRO protein, Seq ID No 119.

XX

KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;

XX

KW breast cancer; prostate tumour; rectal tumour; liver tumour;

XX

KW pericyte cell proliferation; chondrocyte cell proliferation;

XX

KW tumour necrosis factor-alpha; gene; ss.

XX

OS Homo sapiens.

XX

PN WO200208288-A2.

XX

ED 31-JAN-2002.

XX

XX 29-JUN-2001; 2001WO-US021066.

XX

PR 20-JUL-2000; 2000US-0219556P.

XX

PR 25-JUL-2000; 2000US-0220585P.

XX

PR 25-JUL-2000; 2000US-0220605P.

XX

PR 25-JUL-2000; 2000US-0220607P.

XX

PR 25-JUL-2000; 2000US-0220624P.

XX

PR 25-JUL-2000; 2000US-0220638P.

XX

PR 25-JUL-2000; 2000US-0220654P.

XX

PR 25-JUL-2000; 2000US-0220666P.

XX

PR 26-JUL-2000; 2000US-0220893P.

XX

PR 28-JUL-2000; 2000WO-US020710.

XX

PR 01-AUG-2000; 2000US-0227133P.

XX

PR 22-AUG-2000; 2000US-0227133P.

XX

PR 23-AUG-2000; 2000WO-US023522.

XX

PR 24-AUG-2000; 2000WO-US023328.

XX

PR 10-NOV-2000; 2000WO-US030873.

XX

PR 28-NOV-2000; 2000US-0253646P.

XX

PR 01-DEC-2000; 2000WO-US032678.

XX

PR 20-DEC-2000; 2000US-00747259.

XX

PR 20-DEC-2000; 2000WO-US034956.

XX

PR 28-FEB-2001; 2001WO-US006520.

XX

PR 01-MAR-2001; 2001WO-US006666.

XX

PR 22-MAR-2001; 2001US-00816744.

XX

PR 10-MAY-2001; 2001US-00854208.

XX

PR 10-MAY-2001; 2001US-00854280.

XX

PR 25-MAY-2001; 2001WO-US017092.

XX

PA (GETH) GENENTECH INC.

XX

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

PI

XX WPI; 2002-172001/22.

XX P-PSDB; AAU83651.

XX

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,

PT useful for treating a PRO related disorder and for diagnosing tumors such

PT

PT as lung cancer, colon cancer, breast tumor, prostate tumor, rectal tumor
 PT or liver tumor.

XX Claim 2; Fig 119; 359pp; English.

XX The invention relates to one hundred and twenty two nucleic acids
 CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
 CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
 CC agonists and antagonists are useful for treating a PRO related disorder.
 CC The PRO polypeptides are useful for diagnosing tumours, especially lung
 CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. The PRO polypeptides are useful for stimulating the
 CC proliferation of, or gene expression, in pericyte cells, for stimulating
 CC the proliferation or differentiation of chondrocyte cells, for
 CC stimulating the release of tumour necrosis factor-alpha from human blood,
 CC for stimulating or inhibiting the proliferation of normal human dermal
 CC fibroblast cells. The PRO polypeptide may also be used as molecular
 CC weight markers and for tissue typing. The PRO nucleic acids have
 CC applications in molecular biology, including use as hybridisation probes,
 CC and in chromosome and gene mapping. ABK33536-ABK33657 represent human PRO
 CC protein coding sequences of the invention

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 6; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCGATGGGTTACGTTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 1 GCCACGCGTCGATGGGTTACGTTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCT 60

QY 61 GACTGCGGCGCTCATCTTCTGCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 61 GACTGCGGCGCTCATCTTCTGCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACCAAGATCCTATAGACCACTGAATACCTCGAATCCCTTTGACTCCCCAGAGTA 180
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 121 TGATTACCAAGATCCTATAGACCACTGAATACCTCGAATCCCTTTGACTCCCCAGAGTA 180

QY 181 COTCATCCACGCTTTCTTCTGCTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 181 COTCATCCACGCTTTCTTCTGCTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300

QY 301 TGGCCCGAGACTCTATGACCTTACCAACCATCATGAATGCAGATATTTCTAGCATATTGTCA 360
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 301 TGGCCCGAGACTCTATGACCTTACCAACCATCATGAATGCAGATATTTCTAGCATATTGTCA 360

QY 361 GAAGAGAGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 361 GAAGAGAGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGCTCCAGTTAAGT 480
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGCTCCAGTTAAGT 480

QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTCTATCAGCAAGATCCTGTCCAAGAGTAGC 540
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTCTATCAGCAAGATCCTGTCCAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTTACCTTTTAAAAAATGATCTCTTTTAAATGTTTCCACAT 600
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 541 CTGTGGAATCTGATCAGTTTACCTTTTAAAAAATGATCTCTTTTAAATGTTTCCACAT 600

QY 601 TTTTGGCTTGTGGAAGACCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 601 TTTTGGCTTGTGGAAGACCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGGTATAAATTAATATAAAATGATTTACCTCTGGTGTGACAGGTTTGAAGCTTGCACTTC 720

QY 1 GCCCAGCGGTCGATGGGCTTCACTGTCGGGCTTCTGCTACATGCTGGGCGCTGCTGCT 60
Db 1 GCCCAGCGGTCGATGGGCTTCACTGTCGGGCTTCTGCTACATGCTGGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACAATATAGACATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTCGCCATTTGGCACAATATAGACATTTGATGAGCTGAAGAC 120
QY 121 TGATTAAGAATCTCTATAGACAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
Db 121 TGATTAAGAATCTCTATAGACAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CTTCAATCCAGCGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
Db 181 CTTCAATCCAGCGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240
QY 241 TCTCAATATGCCCTCTTGGCATATCAATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCAATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
QY 301 TGGCCAGAGCTCTATGACCTTACAACTATGATGAATGAGATGAGATGAGATGAGATGAGAT 360
Db 301 TGGCCAGAGCTCTATGACCTTACAACTATGATGAATGAGATGAGATGAGATGAGATGAGAT 360
QY 361 GAAGGAAGGATGGTCAATATGAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
Db 361 GAAGGAAGGATGGTCAATATGAGCTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCCAATGAGGATTTCTATCCAGCAAGATCTGTCGAGAGTAGC 540
Db 481 GCATGCAAAAGCCCAATGAGGATTTCTATCCAGCAAGATCTGTCGAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTTCTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGGCTGTGGAAGACAGCTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGGCTGTGGAAGACAGCTGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGACCTTC 720
Db 661 TAGCTATAAATTAATAAATGATTTACCTCTGGTGTTCACAGGTTTGAACCTTGACCTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTGTTTCATGAAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTCCTTCTGATGAGTGAATGATGATGATGATGATGAT 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTCCTTCTGATGAGTGAATGATGATGATGATGATGAT 900
QY 901 TGGGAACTTTCATGGGTTTCTTCTCATCTGTCATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACTTTCATGGGTTTCTTCTCATCTGTCATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGAAATTTCCCTTCGCTGAATATTAATCCCTGATATTAATGATGATGAT 1020
Db 961 AAAAATAAAGCGGAAATTTCCCTTCGCTGAATATTAATCCCTGATATTAATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTAAATTTCTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAAATATATGCTGAATTTCTGTTGAAGAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAAATATATGCTGAATTTCTGTTGAAGAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTATTTTGAAGACATTTACTTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
Db 1141 TTAATGTTGTTTATTTTGAAGACATTTACTTTATTAAGAAATTTGTTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGTTGTTGAAGATTTCTTTAAGAAATTTGAGGACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGTTGTTGAAGATTTCTTTAAGAAATTTGAGGACTACAGATTTTCAAAACT 1260
QY 1261 GAACTGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATACAATAAAACTCT 1320
Db 1261 GAACTGAGAGAAATTTGTATTAACCATCTGCTGTTCTTTAGTGAATACAATAAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 6
ABL95561
ID ABL95561 standard; cDNA; 1333 BP.
XX ABL95561;
AC ABL95561;
XX 19-JUL-2002 (first entry)
XX Human angiogenesis related cDNA PRO181 SEQ ID NO: 1.
DE Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiac; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic; gene; ss.
XX Homo sapiens.
XX WO200208284-A2.
XX 31-JAN-2002.
XX 09-JUL-2001; 2001WO-US021735.
XX 20-JUL-2000; 2000US-0219556P.
XX 25-JUL-2000; 2000US-0220624P.
XX 25-JUL-2000; 2000US-0220664P.
XX 28-JUL-2000; 2000WO-US020710.
XX 02-AUG-2000; 2000US-0222695P.
XX 17-AUG-2000; 2000US-00643657.
XX 23-AUG-2000; 2000WO-US023522.
XX 24-AUG-2000; 2000WO-US023328.
XX 07-SEP-2000; 2000US-0230978P.
XX 18-SEP-2000; 2000US-00664610.
XX 18-SEP-2000; 2000US-00665350.
XX 24-OCT-2000; 2000US-0242922P.
XX 08-NOV-2000; 2000US-00709238.
XX 08-NOV-2000; 2000WO-US030952.
XX 10-NOV-2000; 2000WO-US030873.
XX 01-DEC-2000; 2000WO-US032678.
XX 20-DEC-2000; 2000US-00747259.
XX 20-DEC-2000; 2000WO-US034956.
XX 22-JAN-2001; 2001US-00767609.
XX 28-FEB-2001; 2001US-00796498.
XX 28-FEB-2001; 2001WO-US006520.
XX 01-MAR-2001; 2001WO-US006666.
XX 09-MAR-2001; 2001US-00802706.
XX 14-MAR-2001; 2001US-00808689.
XX 22-MAR-2001; 2001US-00816744.
XX 05-APR-2001; 2001US-00828366.
XX 10-MAY-2001; 2001US-00854208.
XX 10-MAY-2001; 2001US-00854280.
XX 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 30-MAY-2001; 2001US-00870574.
 PR 30-MAY-2001; 2001WO-US017443.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 XX (GETH) GENENTECH INC.
 PA (BAKE/) BAKER K P.
 PA (FERR/) FERRARA N.
 PA (GERB/) GERBER H.
 PA (GERR/) GERRITSEN M E.
 PA (GODD/) GODDARD A.
 PA (GODO/) GODOFSKI P J.
 PA (GURN/) GURNEY A L.
 PA (HILL/) HILLAN K J.
 PA (MARS/) MARSTERS S A.
 PA (PANJ/) PAN J.
 PA (PAON/) PAONI N F.
 PA (STEP/) STEPHAN J F.
 PA (WATA/) WATANABE C K.
 PA (WILL/) WILLIAMS P M.
 PA (WOOD/) WOOD W I.
 XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
 PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
 XX WPI; 2002-171999/22.
 DR P-PSDB; ABB95423.
 XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
 PT infarction), endothelial or angiogenic disorders in a mammal.
 XX Claim 1; Fig 1; 567bp; English.
 PS The present invention provides the protein and coding sequences of human
 CC PRO proteins. These are useful for treating or diagnosing a
 CC cardiovascular, endothelial or angiogenic disorder, including cardiac
 CC hypertrophy, trauma, cancer, age-related macular degeneration,
 CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
 CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
 CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
 CC healing. The present sequence is a coding sequence of the invention
 XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 SQ
 Query Match 100.0%; Score 1333; DB 6; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGGCTCGATGGGTTACGTTTCGGCGCTTCGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGGCTCGATGGGTTACGTTTCGGCGCTTCGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCCGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCCGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACCACTGTAATACCCCTGAATCCCTTGACTCCCAAGATA 180
 DB 121 TGATTACAGAAATCCTATAGACCACTGTAATACCCCTGAATCCCTTGACTCCCAAGATA 180
 QY 181 CCTCATCAGCTTCTTCTGTCATGTTCTTCTTCTGTCAGAGTGGCTTACCTGGG 240
 DB 181 CCTCATCAGCTTCTTCTGTCATGTTCTTCTTCTGTCAGAGTGGCTTACCTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGGATATCATATTTGGAGGTATATGATAGCAGTGTATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGGATATCATATTTGGAGGTATATGATAGCAGTGTATGAG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGAGATATTCAGCATATTTGTCA 360
 DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGAGATATTCAGCATATTTGTCA 360
 QY 361 GAAGGAAGATGGTGCATAATAGCTTTTATCTCTAGCAATTTTTTACCTATATGG 420
 DB 361 GAAGGAAGATGGTGCATAATAGCTTTTATCTCTAGCAATTTTTTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTAAAT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTAAAT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATCTTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTCCCAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTTTAAATGTTCCCAT 600
 QY 601 TTTTGTCTGTGGAAGAGTCTTTTTTATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
 DB 601 TTTTGTCTGTGGAAGAGTCTTTTTTATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
 QY 661 TACGTATAAATTAATATAAATAATGATTACCTCTGCTGTGTGACAGTTTGAACCTTGCAT 720
 DB 661 TACGTATAAATTAATATAAATAATGATTACCTCTGCTGTGTGACAGTTTGAACCTTGCAT 720
 QY 721 TTAAGGAACGACCAATTAATCCTGAATGATGATTAATTAATGATGATTAATGATGAT 780
 DB 721 TTAAGGAACGACCAATTAATCCTGAATGATGATTAATTAATGATGATTAATGATGAT 780
 QY 781 GAAGCTTTGTTTATAGGAATCTCTAGGCTCAATTTGGTGTTCATTTGAACAGATATCTAA 840
 DB 781 GAAGCTTTGTTTATAGGAATCTCTAGGCTCAATTTGGTGTTCATTTGAACAGATATCTAA 840
 QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTCTCTGATGAAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTCTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAATCTCATGGTTCCTCATCTGTCATGTCGATGATGATATATATGATGATATAC 960
 DB 901 TGGGAATCTCATGGTTCCTCATCTGTCATGTCGATGATGATATATATGATGATATAC 960
 QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020
 DB 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAATCTTAAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAATCTTAAAGCATA 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGGAAGATGCAATTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGGAAGATGCAATTTAAAGCTATT 1140
 QY 1141 TTAATGTTTATTTTATTTGTAAGACATTTATTTAAAGAAATGCTTTATTTATGCTTACTG 1200
 DB 1141 TTAATGTTTATTTTATTTGTAAGACATTTATTTAAAGAAATGCTTTATTTATGCTTACTG 1200
 QY 1201 TTTCAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAAACT 1260
 DB 1201 TTTCAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGGAAATTTGTATACCATCTGCTGTTTCTTTTGTAGTGAATATACATAAACTCT 1320
 DB 1261 GAATGAGGAAATTTGTATACCATCTGCTGTTTCTTTTGTAGTGAATATACATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 RESULT 7

ACA66900
ID ACA66900 standard; cDNA; 1333 BP.
XX AC
XX ACA66900;
XX AC
XX 23-JUN-2003 (first entry)
XX
XX cDNA encoding human PRO polypeptide #60.
XX
XX Human; PRO polypeptide; secreted and transmembrane protein;
KW anti-PRO antibody; diagnostic assay; gene expression; tumour; cytostatic;
KW gene; ss.
XX
XX
OS Homo sapiens.
XX
XX US2003036635-A1.
XX
XX 20-FEB-2003.
XX
XX 28-AUG-2002; 2002US-00230163.
XX
XX 25-JUL-2000; 2000US-0220638P.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX
XX 29-JUN-2001; 2001WO-US021066.
XX
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KF, Desnoyers L, Geritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI
XX
XX WPI: 2003-342045/32.
XX
XX P-PSDB; AB080798.
XX
XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for the manufacture of a medicament for diagnosing or treating
PT tumor.
XX
XX Claim 2; Fig 119; 314pp; English.
XX
XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the diagnosis and treatment of tumours. Anti-PRO antibodies are
CC useful in diagnostic assays for PRO, by detecting its expression in
CC specific cells, tissues or serum, and for affinity purification of PRO
CC from recombinant cell culture or natural sources. ACA66841-ACA66962
CC represent cDNA sequences encoding the human PRO polypeptides of the
CC invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ
Query March 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCTTCTGCTACATGCGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCTTCTGCTACATGCGCGCTGCTGCT 60
QY 61 CACTGCGGCGCTCATCTTCTCCCATTTGGACATTATAGCATTTGATCAGCTGAAGAC 120
DB 61 CACTGCGGCGCTCATCTTCTTCCGCAATTGGACATTATAGCATTTGATCAGCTGAAGAC 120
QY 121 TGATTACAGATCCCTATAGACAGGTGTAATACCTGAACTCCCTGTACTCCACAGTA 180
DB 121 TGATTACAGATCCCTATAGACAGGTGTAATACCTGAACTCCCTGTACTCCACAGTA 180
QY 181 CCTCATCCACGCTTCTCTGTGTCATGTTCTTTGTGACGAGAGTGGCTTACACTGGG 240

Db 181 CCTCATCCACGCTTCTCTGTGTGTCATGTTCTTTGTGACGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGTGCAATATCATATTTGGAGGTATATGATAGACCGAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGTGCAATATCATATTTGGAGGTATATGATAGACCGAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATTTCTAGCATATTTGTCA 360
DB 301 TGGCCAGGACTCTATGACCTCAACCATCATGAATGCAGATATTTCTAGCATATTTGTCA 360
QY 361 GAAGAAAGGATGGTGCATAATAGCTTTTATCTTTCTAGCATATTTTCTACTACCTATATGG 420
DB 361 GAAGAAAGGATGGTGCATAATAGCTTTTATCTTTCTAGCATATTTTCTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTAACT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTAACT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCGAAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCGAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAAATTAATAAAATGATTAACCTCTGTGTTTGCACAGGTTTGAACCTTGCACATC 720
DB 661 TACGTATAAAATTAATAAAATGATTAACCTCTGTGTTTGCACAGGTTTGAACCTTGCACATC 720
QY 721 TTAAGAAACAGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATGAT 780
DB 721 TTAAGAAACAGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATGAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTGTTTTCATTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTGTTTTCATTGAAACAGATATCTAA 840
QY 841 TTATAAATTAGCTGATGATATACAGTGTCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
DB 841 TTATAAATTAGCTGATGATATACAGTGTCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAAACCTTCTATGCTTCT 960
DB 901 TGGGAAACCTTCTATGCTTCT 960
QY 961 AAAAAATAAAAGCGGGAATTTTCCCTCTGCTGAATATATCCCTGATATATTCATGATGAT 1020
DB 961 AAAAAATAAAAGCGGGAATTTTCCCTCTGCTGAATATATCCCTGATATATTCATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTTAATTTCTTAAGCATATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTTAATTTCTTAAGCATATA 1080
QY 1081 AGTAACATGATATAAAATATATCTGCTGAATATATCTGCTGAAGTGAAGTGAAGTGAAGTGAAG 1140
DB 1081 AGTAACATGATATAAAATATATCTGCTGAATATATCTGCTGAAGTGAAGTGAAGTGAAGTGAAG 1140
QY 1141 TTAATATGTTTTTATTTTGAAGCATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
DB 1141 TTAATATGTTTTTATTTTGAAGCATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
QY 1201 TTTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTTCTAATCTGGTGAAGGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATAACCATCTGCTCTCTTTTGTAGTGAAGTGAAGTGAAGTGAAGTGAAG 1320
DB 1261 GAATGAGAGAAATTTGATAACCATCTGCTCTCTTTTGTAGTGAAGTGAAGTGAAGTGAAGTGAAG 1320

Qy 1321 GAAATTAAGACTC 1333
| | | | | | | | | |
Db 1321 GAAATTAAGACTC 1333

RESULT 8
ACD42697
ID ACD42697 standard; cDNA; 1333 BP.
XX
AC ACD42697;
XX
XX 09-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; virucide; gene therapy;
KW cell death; growth induction cascade; blood coagulation cascade;
KW viral infection; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003050239-A1.
XX
PD 13-MAR-2003.
XX
PF 15-OCT-2001; 2001US-00978191.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077633P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080103P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081836P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.

22-APR-1998; 98US-0082700P.
22-APR-1998; 98US-0082704P.
22-APR-1998; 98US-0082797P.
22-APR-1998; 98US-0082804P.
23-APR-1998; 98US-0082796P.
27-APR-1998; 98US-0083336P.
28-APR-1998; 98US-0083322P.
29-APR-1998; 98US-0083329P.
29-APR-1998; 98US-0083455P.
29-APR-1998; 98US-0083496P.
29-APR-1998; 98US-0083500P.
29-APR-1998; 98US-0083545P.
29-APR-1998; 98US-0083554P.
29-APR-1998; 98US-0083558P.
29-APR-1998; 98US-0083559P.
30-APR-1998; 98US-0083742P.
05-MAY-1998; 98US-0084366P.
06-MAY-1998; 98US-0084414P.
06-MAY-1998; 98US-0084441P.
07-MAY-1998; 98US-0084588P.
07-MAY-1998; 98US-0084600P.
07-MAY-1998; 98US-0084627P.
07-MAY-1998; 98US-0084637P.
07-MAY-1998; 98US-0084639P.
07-MAY-1998; 98US-0084640P.
07-MAY-1998; 98US-0084643P.
13-MAY-1998; 98US-0085323P.
13-MAY-1998; 98US-0085338P.
13-MAY-1998; 98US-0085339P.
15-MAY-1998; 98US-0085573P.
15-MAY-1998; 98US-0085579P.
15-MAY-1998; 98US-0085580P.
15-MAY-1998; 98US-0085582P.
15-MAY-1998; 98US-0085689P.
15-MAY-1998; 98US-0085700P.
15-MAY-1998; 98US-0085704P.
18-MAY-1998; 98US-0086023P.
22-MAY-1998; 98US-0086392P.
22-MAY-1998; 98US-0086414P.
22-MAY-1998; 98US-0086430P.
22-MAY-1998; 98US-0086486P.
28-MAY-1998; 98US-0087098P.
28-MAY-1998; 98US-0087106P.
28-MAY-1998; 98US-0087208P.
26-JUN-1998; 98US-00105413.
26-JUN-1998; 98US-0090863P.
26-JUN-1998; 98US-0091010P.
01-JUL-1998; 98US-0091359P.
30-JUL-1998; 98US-0094651P.
11-SEP-1998; 98US-0100038P.
07-OCT-1998; 98US-00168978.
07-OCT-1998; 98WO-US021141.
02-NOV-1998; 98US-00184216.
06-NOV-1998; 98US-00187368.
20-NOV-1998; 98US-0109304P.
20-NOV-1998; 98WO-US024855.
07-DEC-1998; 98US-00202054.
22-DEC-1998; 98US-00218517.
22-DEC-1998; 98US-0113296P.
23-DEC-1998; 98US-0113621P.
05-JAN-1999; 98WO-US000106.
05-MAR-1999; 98US-00254465.
08-MAR-1999; 98WO-US005028.
10-MAR-1999; 98US-00265686.
10-MAR-1999; 98WO-US005190.
12-MAR-1999; 98US-00267213.
12-MAR-1999; 98US-0123957P.
29-MAR-1999; 98US-0126773P.
12-APR-1999; 98US-00284291.
21-APR-1999; 98US-0130232P.
26-APR-1999; 98US-0131022P.


```
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 12-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH ) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCGATGCGCTTACGTTTCGGGCTTCTGTACATGCTGCGCTGCTGCT 60
Db 1 GCCACGCGTCGATGCGCTTACGTTTCGGGCTTCTGTACATGCTGCGCTGCTGCT 60
QY 61 CACTGCCGGCTCATCTTCTTCCGCAATTAGCAATTATAGCAATTGATGAGCTGAAGAC 120
```

```
Db 61 CACTGCCGGCTCATCTTCTTCCGCAATTATAGCAATTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACCAAGTGTATAACCTCGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACCAAGTGTATAACCTCGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTTGTGTCAATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCAGCTTCTTCTTGTGTCAATGTTCTTTGTCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATAGTAGACAGATGATGAG 300
Db 241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATAGTAGACAGATGATGAG 300
QY 301 TGGCCGAGGACTATGACCCCTAGCAATCAATCAATGCAGATATTCAGCAATATTCGA 360
Db 301 TGGCCGAGGACTATGACCCCTAGCAATCAATCAATGCAGATATTCAGCAATATTCGA 360
QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGCTCAAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGCTCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGAATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTTCGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTTAC 660
Db 601 TTTTCTTTCGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTTAC 660
QY 661 TAGCTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACCTC 720
Db 661 TAGCTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACCTC 720
QY 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAACTTTGAGGCTCATTTGGTTCATGAGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACTTTGAGGCTCATTTGGTTCATGAGAAACAGATATCTAA 840
QY 841 TTATAAATTAGCTGATAGATATCAGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATTAGCTGATAGATATCAGTGCTTCTGATGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGCTCATGCTGATGATATATATGATATAC 960
Db 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGCTCATGCTGATGATATATATGATATAC 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCTGATGAATATATATCCCTGATATGATGAAT 1020
Db 961 AAAAATAAAAGCGGGAATTTTCCCTTCTGATGAATATATATCCCTGATATGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCCATCAGATAAATAATATATCTGCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCCATCAGATAAATAATATATCTGCTTAAATCTTAAAGCATA 1080
QY 1081 AGTAACATGATATAAATAATATATCTGCTGAAATTTACTTGTGAAGATGCTATTAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATATCTGCTGAAATTTACTTGTGAAGATGCTATTAAGCTATT 1140
QY 1141 TTAATATGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGGTATATGCTTACTG 1200
Db 1141 TTAATATGTTTTTATTTGTAAGACATTTACTTATTAAGAAATGGTATATGCTTACTG 1200
```

QY 1201 TTCTAATCTGGTGAAGGATATCTTAAGATTTGAGGACTACAGATTTTCAAAACT 1260
 Db 1201 TTCTAATCTGGTGAAGGATATCTTAAGATTTGAGGACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAAATGTATACCACTCCCTGCTGTTCTTTAGTGCAATACAAATAAACTCT 1320
 Db 1261 GAATGAGAGAAAATGTATACCACTCCCTGCTGTTCTTTAGTGCAATACAAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 9

ACD68652
 ID ACD68652 standard; cDNA; 1333 BP.

XX ACD68652;

DT 17-SEP-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX Human; secreted and transmembrane protein; PRO; cytostatic;
 KW antiarthritic; osteopathic; gene therapy; TNF-Agonist-Alpha;
 KW chondrocyte stimulator; pericyte stimulator; fibroblast modulator;
 KW pharmaceutical; diagnostic; biosensor; bioindicator; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; bone disorder; cartilage disorder; sports injury;
 KW arthritis; wound; gene; ss.

XX Homo sapiens.

XX US2003045687-A1.

XX 06-MAR-2003.

XX 12-AUG-2002; 2002US-00218631.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX P-PSDB; ABO33764.

XX New genes, and its encoded secreted and transmembrane polypeptides,
 PT useful for stimulating Tumor Necrosis Factor alpha, or chondrocyte or
 PT pericyte proliferation, especially for treating lung tumors, arthritis or
 PT wounds in a mammal.

XX Claim 2; Fig 119; 314pp; English.

XX The invention describes an isolated nucleic acid molecule comprising a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 122 PRO (secreted and transmembrane) polypeptides whose sequences are
 CC fully defined in the specification; or (b) any of 122 nucleotide
 CC sequences having e.g. 4834, 2504 or 1759 bp fully defined in the
 CC specification; or the full length coding sequence of any these 122
 CC nucleotide sequences. The PRO polypeptides or polynucleotides are useful
 CC as pharmaceuticals, diagnostics, biosensors or bioeffectors. These are
 CC particularly useful for detecting tumours (e.g. lung tumour, colon
 CC tumour, breast tumour, prostate tumour, rectal tumour, or liver tumour)
 CC in a mammal, for stimulating the release of TNF-alpha from human blood,
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells, for stimulating proliferation of pericyte cells, or for modulating
 CC normal human dermal fibroblast proliferation. The PRO nucleic acid or

CC polypeptide is also useful for treating tumours or various bone and/or
 CC cartilage disorders (e.g. sports injuries or arthritis), or wounds. The
 CC PRO polypeptides are useful in drug screening, particularly as targets
 CC for therapeutic intervention in these diseases, and in the diagnostic
 CC determination of the presence of these diseases. The PRO polypeptides are
 CC also useful as molecular weight markers, or for chromosome
 CC identification. The PRO genes are useful as hybridisation probes, or for
 CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
 CC also be used in gene therapy, particularly for replacing a defective
 CC gene. This sequence encodes a novel human secreted and transmembrane PRO
 CC polypeptide

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGCGCTCTCTGTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGCGCTCTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCCATATATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCCATATATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGAAATCCCTGTACTCCAGAGTA 180
 Db 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGAAATCCCTGTACTCCAGAGTA 180
 QY 181 CCTCATCCAGCTTCTTCTGTGTCACTGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
 Db 181 CCTCATCCAGCTTCTTCTGTGTCACTGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
 QY 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
 Db 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACCAATCATGATGATGATGATGATGATGATGATGATG 360
 Db 301 TGGCCAGGACTCTATGACCCCTACCAATCATGATGATGATGATGATGATGATGATGATG 360
 QY 361 GAAGGAGGATGGTGCATAATTTAGCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCTT 420
 Db 361 GAAGGAGGATGGTGCATAATTTAGCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCT 420
 QY 421 CATGATCATGTTTGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db 421 CATGATCATGTTTGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGCCAAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGCCAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTGTTGGAAGACTGTTTTTCAATGTTATATCTAGTAAAGATTTTAAATGGTAT 660
 Db 601 TTTTGTGTTGGAAGACTGTTTTTCAATGTTATATCTAGTAAAGATTTTAAATGGTAT 660
 QY 661 TACCTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGCTTTGAACCTGCATTC 720
 Db 661 TACCTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGCTTTGAACCTGCATTC 720
 QY 721 TTAAGGAAACGCCATAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
 Db 721 TTAAGGAAACGCCATAATCTCTGAATGATGATTAATTAATCTGCTGCTAGTACATTTG 780
 QY 781 GAAGCTTTTGTGTTATAGAACTTTAGGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840
 Db 781 GAAGCTTTTGTGTTATAGAACTTTAGGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840

DE Human secreted and transmembrane polypeptide PRO181 cDNA.
XX
KW Human; ss; gene; thrombolytic agent; interferon; interleukin; cytokine;
KW erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;
KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;
KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;
KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;
KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;
KW glomerulonephritis; lung disease; pulmonary hypertension; preclampsia;
KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;
KW inflammatory bowel disease; reproductive disorder; premature labour.
XX
OS Homo sapiens.
XX
PN US2002177553-A1.
XX
PD 28-NOV-2002.
XX
XX 15-OCT-2001; 2001US-00978192.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079932P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US013252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Shelton DL;
PI Kljavan IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Stewart TA, Williams PM, Wood WI;
XX
XX WPI: 2003-328499/31.
DR P-PSDB; AB084920.
XX
XX New isolated PRO polypeptides e.g. PRO213, PRO274 and PRO300, for use as
PT pharmaceuticals, diagnostics, biosensors and bioreactors, for identifying
PT modulators of receptor-ligand interactions.
XX
XX Claim 2; SEQ ID NO 321; 55pp; English.
PS
XX The invention relates to an isolated secreted and transmembrane
XX polypeptide, designated as PRO polypeptide. The PRO polypeptide is useful
CC in PRO polypeptide detection methods. The PRO polypeptide is useful for
CC linking a bioactive molecule to a cell. The PRO polypeptide or an
CC antibody against it is useful for modulating a biological activity of a
CC cell. The PRO polypeptide is useful in industrial applications including
CC pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO
CC polypeptide is also useful as a thrombolytic agent, interferon,
CC interleukin, erythropoietin, colony stimulating factor and other
CC cytokines. The PRO polypeptide is useful for treating disease such as
CC cancer e.g. colorectal carcinoma; apoptosis related conditions e.g. AIDS,
CC amyotrophic lateral sclerosis; inflammatory disease e.g. asthma,
CC atherosclerosis; neurodegenerative disease e.g. Alzheimer's disease,
CC Parkinson's disease; cardiovascular disease e.g. hypertension and
CC myocardial ischaemia; kidney disease e.g. renal failure and
CC glomerulonephritis; lung disease e.g. pulmonary hypertension, bronchial
CC asthma; gastrointestinal disorders e.g. gastric ulcer and inflammatory
CC bowel disease; reproductive disorders e.g. premature labour and
CC preclampsia; carcinogenesis. The present sequence represents a cDNA
CC encoding a PRO polypeptide of the invention. Note: The sequence data for

CC this patent did not form part of the printed specification but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?docid=20020177553

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;

QY 1 GCCACGCGTCGATGGCGTTCCACGTTTCGCGCCCTCTCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCGATGGCGTTCCACGTTTCGCGCCCTCTCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTCCCGGCTCATCTTCTTCCGCAATTTGGCAATTTAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTCCCGGCTCATCTTCTTCCGCAATTTGGCAATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCCAAGATTA 180
DB 121 TGATTACAGAAATCCTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCCAAGATTA 180
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGAGAGTGGCTTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
QY 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATGAGATATTTAGCATATTTGTCA 360
DB 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATGAGATATTTAGCATATTTGTCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTAGCTCTTAGAACACACACACAGAGAATTTGTCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTAGCTCTTAGAACACACACACAGAGAATTTGTCAGTTAAGT 480
QY 481 GCATGCAAAAGCCAAATGAAGGATCTTATCCAGCAAGATCTCTGTCGAAGTAGC 540
DB 481 GCATGCAAAAGCCAAATGAAGGATCTTATCCAGCAAGATCTCTGTCGAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAAGATCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAAGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGCTGGAAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTCTGCTGGAAAGACTGTTTTCATATGTTATATCTCAGATAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGACTTC 720
DB 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTTGCACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGGAACAGCATAATCTCTGAATGATGCAATTAATTAATGATGATGATGATGATG 780
DB 721 TTAAGGAACAGCATAATCTCTGAATGATGCAATTAATTAATGATGATGATGATGATG 780
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTTCATTTGAAACAGATCTCAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGTTCATTTGAAACAGATCTCAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGCTCTCTGATGAAGTGAATAATGATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960

QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATACTTGTGCTTTAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATATTTCCATCAGAGTAATAAATACTTGTGCTTTAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATCTGTGAAGAAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTTGTGAAGCAATTAATTAAGAAATGCTTATATGCTTACTG 1200
DB 1141 TTAATGCTGTTTATTTTGTGAAGCAATTAATTAAGAAATGCTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTTAAAGGTAATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGCTGTTAAAGGTAATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGCTTCTTGTAGTGAATTAATAAACTCT 1320
DB 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGCTTCTTGTAGTGAATTAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 12
ABX92536
ID ABX92536 standard; cDNA; 1333 BP.
XX AC ABX92536;
XX DT 08-MAY-2003 (first entry)
XX DE cDNA encoding human PRO181 polypeptide.
XX KW Human; PRO polypeptide; secreted and transmembrane protein; immune disorder; diabetes; hyper-insulinaemia; hypo-insulinaemia; cardiac insufficiency; nervous system disorder; kidney disorder; bone disorder; cartilage disorder; arthritis; tumour; wound healing; genetic disorder; cytosolic; antidiabetic; anti-inflammatory; antithrombotic; anti-tumour; vulnery; antianaemic; dermatological; cardiant; gene; ss.
XX OS Homo sapiens.
XX PN US2002169284-A1.
XX PD 14-NOV-2002.
XX PF 16-OCT-2001; 2001US-00978697.
XX PR 26-MAY-1981; 81US-00267213.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077719P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-0080402P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.

```
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00818920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001US-00886342.
PR 29-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021066.
PR 30-JUL-2001; 2001WO-US021735.
XX XX (GETH ) GENENTECH INC.

XX 88US-0079656P.
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WT;
XX WPI. 2003-288163/28.
DR P-PSDB; ABU61118.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating cancer, kidney diseases, bone,
PT cartilage disorders and immune deficiencies.
XX
PS Claim 2; Fig 128; 459pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for
CC identifying agonists or antagonists. The bioactive molecule maybe a
CC toxin, radiolabel or antibody, and causes apoptosis or death of the cell.
CC The PRO polypeptides are useful for treating immune disorders, diabetes
CC or hyper- or hypo-insulinaemia, cardiac insufficiency, nervous system
CC disorders, kidney disorders, bone and cartilage disorders or arthritis,
CC tumours, and wound healing. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and gene
CC mapping, in the generation of antisense RNA and DNA, in the preparation
CC of PRO polypeptides, for generating transgenic animals or knockout
CC animals, for the genetic analysis of individuals with genetic disorders,
CC and in gene therapy. The present sequence encodes a human PRO polypeptide
CC of the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC segdata.uspto.gov/psipsideEntry.html
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGGGTCCGATCGGCTTCAACGCTCGCGGCTTCTGTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGGGTCCGATCGGCTTCAACGCTCGCGGCTTCTGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGGGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGGGCTCATCTTCTTCGCCATTGGGCACATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGAATTACAGAAATCCTATAGACACGAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCC 180
Db 121 TGAATTACAGAAATCCTATAGACACGAGTGAATACCTGTAATCCCTGTAATCCCTGTAATCC 180
QY 181 CCTCATCCACGGCTTTCTTCTGTGTATGTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGGCTTTCTTCTGTGTATGTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGTATTTAGCTATTGTCA 360
Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGATGAGTATTTAGCTATTGTCA 360
QY 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTGGTCCAGTTAAGT 480
```

Db 421 CATGATCTATGTTTGGTAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAAGTAGC 540
Qy 541 CTGTGGAAATCTGATCAGTACTTTTAAAAAATGATCCCTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAAATCTGATCAGTACTTTTAAAAAATGATCCCTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTCAATGTTTACTACAGATAAAGATTTTAAATGCTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCAATGTTTACTACAGATAAAGATTTTAAATGCTAT 660
Qy 661 TACGTATAAAATTAATAAATAAGTATTACCTCTGGTGTGACAGATTTGAACTTCCACATC 720
Db 661 TACGTATAAAATTAATAAATAAGTATTACCTCTGGTGTGACAGATTTGAACTTCCACATC 720
Qy 721 TTAAGGACACGCCAATATCCCTCTGAATGATGCATTAATCTGACTGTCCTAGTACATTG 780
Db 721 TTAAGGACACGCCAATATCCCTCTGAATGATGCATTAATCTGACTGTCCTAGTACATTG 780
Qy 781 GAAGCTTTGTTTATAGAACTTGTAGGGCTCAATTTGGTTCATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTGTTTATAGAACTTGTAGGGCTCAATTTGGTTCATTTGAAACAGATATCTAA 840
Qy 841 TTATAAATAGCTGTAGATATCAGGTGCTTCGATGAAGTGAAGTGAATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCGATGAAGTGAAGTGAATATATCTGACTAG 900
Qy 901 TGGGAAATCTCATGGTTCCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAAATCTCATGGTTCCTCTCATCTGATGATGATGATGATGATGATGATGATGATGAT 960
Qy 961 AAAAATAAAAGCGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATATGATGAAT 1020
Db 961 AAAAATAAAAGCGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATATGATGAAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGATTAATAAATATATATCTGCTTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGATTAATAAATATATATCTGCTTTAATTTCTTAAGCATA 1080
Qy 1081 AGTAAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATGTTGTTTTATTTTGAAGACATTTACTTATTAAGAAATTTGGTATTATGCTTACTG 1200
Db 1141 TTAATGTTGTTTTATTTTGAAGACATTTACTTATTAAGAAATTTGGTATTATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCTCTGCTGTTCTTTAGTGCATTAACAATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 13

ACA66277
ID ACA66277 standard; cdna; 1333 BP.XX
AC ACA66277;

XX 24-JUN-2003 (first entry)

XX Human cDNA encoding secreted/transmembrane protein PRO181.

Human; ss; gene; secreted protein; transmembrane protein; PRO;
malignancy; cancer; ovarian cancer; colorectal cancer; sarcoma;
leukemia; lymphoma; inflammatory disease; necrosis; atherosclerosis;
infertility; premature aging; psoriasis; inflammatory disease;
renal disease; arthritis; immune-mediated alopecia; stroke; encephalitis;
hepatitis; multiple sclerosis; gene therapy.

XX Homo sapiens.

OS US2003004102-A1.

XX 02-JAN-2003.

XX 15-OCT-2001; 2001US-00978189.

XX 17-OCT-1997; 97US-0062250P.

XX 03-NOV-1997; 97US-0064249P.

XX 13-NOV-1997; 97US-0065311P.

XX 21-NOV-1997; 97US-0066364P.

XX 10-MAR-1998; 98US-0077450P.

XX 11-MAR-1998; 98US-0077632P.

XX 11-MAR-1998; 98US-0077641P.

XX 11-MAR-1998; 98US-0077649P.

XX 12-MAR-1998; 98US-0077791P.

XX 13-MAR-1998; 98US-0078004P.

XX 17-MAR-1998; 98US-00040220.

XX 20-MAR-1998; 98US-0078886P.

XX 20-MAR-1998; 98US-0078910P.

XX 20-MAR-1998; 98US-0078936P.

XX 20-MAR-1998; 98US-0078939P.

XX 25-MAR-1998; 98US-0079294P.

XX 26-MAR-1998; 98US-0079656P.

XX 27-MAR-1998; 98US-0079663P.

XX 27-MAR-1998; 98US-0079664P.

XX 27-MAR-1998; 98US-0079689P.

XX 27-MAR-1998; 98US-0079728P.

XX 27-MAR-1998; 98US-0079786P.

XX 30-MAR-1998; 98US-0079920P.

XX 30-MAR-1998; 98US-0079923P.

XX 26-JUN-1998; 98US-00105413.

XX 07-OCT-1998; 98US-00168978.

XX 07-OCT-1998; 98WO-US021141.

XX 02-NOV-1998; 98US-00184216.

XX 06-NOV-1998; 98US-00187368.

XX 20-NOV-1998; 98WO-US024855.

XX 07-DEC-1998; 98US-00202054.

XX 22-DEC-1998; 98US-00218517.

XX 05-JAN-1999; 99WO-US000106.

XX 05-MAR-1999; 99US-00254465.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99US-00265686.

XX 10-MAR-1999; 99WO-US005190.

XX 12-MAR-1999; 99US-00267213.

XX 12-APR-1999; 99US-00284291.

XX 14-MAY-1999; 99WO-US0311832.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 25-AUG-1999; 99US-00380138.

XX 25-AUG-1999; 99US-00380142.

XX 30-NOV-1999; 99WO-US028313.

XX 02-DEC-1999; 99WO-US028551.

XX 16-DEC-1999; 99WO-US030095.

XX 30-DEC-1999; 99WO-US031243.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

PR 10-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000US-00709238.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 27-NOV-2000; 2000US-00723749.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001US-00816744.
 PR 22-MAR-2001; 2001US-00816920.
 PR 10-MAY-2001; 2001WO-US009552.
 PR 10-MAY-2001; 2001US-00854208.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashtenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hallan KJ;
 PI Kljavin IG, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX
 DR WPI: 2003-341189/32.
 DR P-PSDB; ABU80387.
 XX
 PT New genes and secreted and transmembrane polypeptides (e.g. PRO337 or
 PT PRO1559), useful for treating or diagnosing e.g. cancers,
 PT atherosclerosis, infertility, stroke, encephalitis, hepatitis or multiple
 PT sclerosis in mammals.
 XX
 PS Claim 2; Fig 128; 460pp; English.
 XX
 CC The invention relates to a new isolated nucleic acid molecule comprises a
 CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
 CC 94 PRO polypeptides whose sequences are fully defined in the
 CC specification; or (b) any of 94 nucleotide sequences fully defined in the
 CC specification; or the full length coding sequence of any these 94
 CC nucleotide sequences. Also included are an isolated PRO polypeptide
 CC scoring at least 80% positives when compared to any of the PRO
 CC polypeptide sequences cited above (or an isolated PRO polypeptide having
 CC at least 80% amino acid sequence identity to: (a) an amino acid sequence
 CC encoded by the nucleotide deposited with ATCC numbers listed in the
 CC specification; (b) the PRO polypeptide, lacking its associated signal
 CC peptide; or (c) an extracellular domain of the PRO polypeptide, with or
 CC lacking its associated signal peptide), a vector comprising the nucleic
 CC acid molecule, a host cell comprising the vector (and producing a PRO
 CC polypeptide), a chimeric molecule comprising the PRO polypeptide fused
 CC to a heterologous amino acid sequence and an anti-PRO antibody. The PRO
 CC polypeptides or polynucleotides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. These are particularly useful for
 CC detecting or treating e.g. malignancies or cancers (e.g. ovarian cancer,
 CC colorectal cancer, sarcoma, leukaemia or lymphoma), inflammatory disease,
 CC necrosis, atherosclerosis, infertility, premature aging, psoriasis,
 CC inflammatory disease, renal disease, arthritis, immune-mediated alopecia,
 CC

CC stroke, encephalitis, hepatitis, or multiple sclerosis in mammals. The
 CC PRO polypeptides are useful in drug screening, particularly as targets
 CC for therapeutic intervention in these diseases, and in the diagnostic
 CC determination of the presence of these diseases. The PRO polypeptides are
 CC also useful as molecular weight markers, or for chromosome
 CC identification. The PRO genes are useful as hybridisation probes, or for
 CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
 CC also be used in gene therapy, particularly for replacing a defective
 CC gene. The present sequence encodes a PRO polypeptide
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 7; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCCAGCGTCCGATGGGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCCAGCGTCCGATGGGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCCGCTCATCTTCTTGGCCATTTGGCACAATNAGCATTGATGAGCTGAAGAC 120
 DB 61 CACTGCCCGCTCATCTTCTTGGCCATTTGGCACAATNAGCATTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTTGTAATCCCAAGATA 180
 DB 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTTGTAATCCCAAGATA 180
 QY 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTTCTGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCCTCTTGGCATATCATTTGGAGGTATATGATAGACCACTGATGAG 300
 DB 241 TCTCAATATGCCCCTCTTGGCATATCATTTGGAGGTATATGATAGACCACTGATGAG 300
 QY 301 TGGCCCCAGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTGTCA 360
 DB 301 TGGCCCCAGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTGTCA 360
 QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTCTACTTATATGG 420
 DB 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTCTACTTATATGG 420
 QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCACCAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCACCAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGCTGTGAAAGAGCTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTGCTGTGAAAGAGCTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
 DB 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
 QY 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATTAATCTCTAGTCTAGTCAATG 780
 DB 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATTAATCTCTAGTCTAGTCAATG 780
 QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGTAACAGAGTATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGTAACAGAGTATCTAA 840
 QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTCTGATGAGTGAAGTAAATGTATATCTGACTAG 900

Db 841 TTTAAATTAAGCTGTAGATATACAGTGTCTCTGATGAAGTGAATGATATCTGACTAG 900
Qy TGGGAACTTCATGGGTTTCCTCATCTGTCATGTCGATGATTATATATGATATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCCTCATCTGTCATGTCGATGATTATATATGATATTTAC 960
Qy 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATCTGCTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATCTGCTTTAAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATGATATATAAATATATGCTGAATTAATCTTTGGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATATAAATATATGCTGAATTAATCTTTGGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATGCTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATATGCTTACTG 1200
Db 1141 TTAATGCTTTTATTTTGAAGACATTTACTTATTAAGAAATGCTTATATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGGTAAAGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGGTAAAGTATTTCTTAAGAAATTTGAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATAACCATCTGCTGCTCTTTAGTGAATACAAATPAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATAACCATCTGCTGCTCTTTAGTGAATACAAATPAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 14

ID ACA68556 standard; cDNA; 1333 BP.
XX ACA68556;
AC ACA68556;
DT 25-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX Human; secreted and transmembrane protein; PRO; cardiant; cytostatic;
KW antiangiogenic; hypotensive; vulnery; antiarteriosclerotic;
KW gene therapy; cardiovascular disorder; endothelial disorder;
KW angiogenic disorder; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; atherosclerosis; hypertension;
KW arterial restenosis; rheumatoid arthritis; angina; myocardial infarction;
KW thrombophlebitis; lymphangitis; tumour angiogenesis; breast carcinoma;
KW liver carcinoma; wound healing; chromosome mapping; gene mapping; gene;
XX ss.
XX Homo sapiens.
XX
XX US2003088063-AL.
XX
XX 08-MAY-2003.
XX
XX 12-AUG-2002; 2002US-00219003.
XX
XX 25-JUL-2000; 2000US-0220664P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-393229/37.
DR P-PSDB; ABU82107.
XX One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.
XX Claim 2; Fig 119; 314pp; English.
XX The invention describes one hundred and eighty seven nucleic acids
CC encoding novel human secreted and transmembrane (PRO) polypeptides. The
CC PRO nucleic acids, polypeptides, agonists and antagonists are useful for
CC treating or diagnosing a cardiovascular, endothelial or angiogenic
CC disorder in a mammal, e.g. cardiac hypertrophy, trauma, cancer, age-
CC related macular degeneration, atherosclerosis, hypertension, arterial
CC restenosis, rheumatoid arthritis, angina, myocardial infarctions,
CC thrombophlebitis, lymphangitis, tumour angiogenesis (such as breast
CC carcinoma and liver carcinoma) and wound healing. The PRO nucleic acids
CC have applications in molecular biology, including use as hybridisation
CC probes, and in chromosome and gene mapping. This sequence encodes a novel
CC human secreted and transmembrane PRO polypeptide
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 7; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCACGCGTCCGATGGCGTTCACTTCGCGGCCCTTCTGTACATGCTGGCGCTGCTGT 60
Db 1 GCCACGCGTCCGATGGCGTTCACTTCGCGGCCCTTCTGTACATGCTGGCGCTGCTGT 60
Qy 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTCGCCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
Qy 121 TGATTACAGAAATCCCTATAGACAGCTGTAATACCTGTAATCCCTTGTACTCCCCAGATTA 180
Db 121 TGATTACAGAAATCCCTATAGACAGCTGTAATACCTGTAATCCCTTGTACTCCCCAGATTA 180
Qy 181 CCTCATCCACGCTTTCTTCTGTGTATGTTCTTTGTGCGAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGCTTTCTTCTGTGTATGTTCTTTGTGCGAGAGTGGCTTACACTGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATATATTTGGAGGTATATGATGACCACTGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATATATTTGGAGGTATATGATGACCACTGATGAG 300
Qy 301 TGGCCCGAGACTCTATGACCTTACCAACCATCATGATGCAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCGAGACTCTATGACCTTACCAACCATCATGATGCAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAAGATGGTCAAAATTTAGCTTTTATCTTCTAGCATTTTTTACTACTATATGG 420
Db 361 GAAGGAAGATGGTCAAAATTTAGCTTTTATCTTCTAGCATTTTTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATTTGCTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATTTGCTCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTATTTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCTTTATTTTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATCTAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660

Db 541 CTGTGGAATCTGATCAGTACTCTTTAAATAAGTACTCCTTATTTTAAAGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TACGTATAAATTATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATATCTCTGAATGATGCATTAATTAATCTGACTGTCTCTAGTACATTC 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGCATTAATTAATCTGACTGTCTCTAGTACATTC 780
QY 781 GAAGCTTTTGTGTTTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGATCTAA 840
Db 781 GAAGCTTTTGTGTTTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGTATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAGTGAATGTATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGATGATACATTTAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATTCCTGTATATTCGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATTCCTGTATATTCGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTAAATCTTTAAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGATTAATAATATATCTGCTTAAATCTTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTAATCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGGTGTATATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATTAATTAAGAAATGGTGTATATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATGTATACCATCTGCTGTTTCTTTAGTGAATACATAAATAAATCT 1320
Db 1261 GAATGAGAGAAAATGTATACCATCTGCTGTTTCTTTAGTGAATACATAAATAAATCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 16
ADA24860
ID ADA24860 standard; cDNA; 1333 BP.
XX
AC ADA24860;
DT 20-NOV-2003 (first entry)
DE
XX Novel human secreted and transmembrane protein PRO181 cDNA.
KW Human; secreted and transmembrane protein; PRO; Gene; ss; tissue typing;
KW chromosome identification; vaccine; cancer; retinal disorder;
KW sports-related joint disorder; osteoarthritis; rheumatoid arthritis;
KW wound healing; obesity; diabetes; hearing loss;
KW cardiac insufficiency disorder; kidney disorder; nervous system disorder;
KW haemoglobin associated disorder.
XX Homo sapiens.

XX US2003050241-A1.
PN 13-MAR-2003.
XX 16-OCT-2001; 2001US-00978564.
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077751P.
PR 13-MAR-1998; 98US-0078004P.
XX 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
XX 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
XX 28-APR-1998; 98US-0083332P.
PR 29-APR-1998; 98US-0083332P.
XX 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
XX 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
XX 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
XX 05-MAY-1998; 98US-0083742P.
PR 06-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.

```
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085682P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98WO-US010304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
XX Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX MPI; 2003-521814/49.
XX P-PSDB; ADA24861.
XX
XX New isolated PRO polypeptides for example extracellular, secreted and
XX membrane bound proteins, useful for modulating the biological activities
XX of cells and for treating, for example diabetes, cancer, rheumatoid
XX arthritis, and hearing loss.
XX
XX Claim 2; Fig 128; 461pp; English.
XX
XX The invention describes an isolated secreted and transmembrane (PRO)
XX polypeptide (I). PRO337 polypeptide is useful for detecting PRO4993
XX polypeptide in a sample, and vice versa. PRO725, PRO700 and PRO739 are
XX useful for detecting PRO1559 polypeptide in a sample, and PRO1559 is
XX useful for detecting PRO725, PRO700 and PRO739 in a sample. PRO4993 is
XX useful for linking a bioactive molecule to a cell expressing a PRO337
XX polypeptide, and PRO337 is useful for linking a bioactive molecule to a
XX cell expressing a PRO4993 polypeptide. PRO1559 is useful for linking a
XX bioactive molecule to a cell expressing a PRO735, PRO700 and PRO739
XX

Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;

QY 1 GCCACGCGTCCGATGGGTTTCAGGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
|
|
|
Db 1 GCCACGCGTCCGATGGGTTTCAGGTTCCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
|
|
|
QY 61 CACTGCCGCGTCACTTCTTCTGTCATGTTTCTTGTGTCAGACAGTCCCTTGTACTCCAGAGTA 120
|
|
|
Db 61 CACTGCCGCGTCACTTCTTCTGTCATGTTTCTTGTGTCAGACAGTCCCTTGTACTCCAGAGTA 120
|
|
|
QY 121 TGATTACAGAAATCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCAGAGTA 180
|
|
|
Db 121 TGATTACAGAAATCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCAGAGTA 180
|
|
|
QY 181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTGTGTCAGACAGTGGCTTACACTGGG 240
|
|
|
Db 181 CCTCATCCAGCTTCTTCTGTCATGTTTCTTGTGTCAGACAGTGGCTTACACTGGG 240
|
|
|
QY 241 TCTCAATATGCCCCCTTGGCATATCATATTTGGAGGTATATGATAGACAGTATGATGAG 300
|
|
|
Db 241 TCTCAATATGCCCCCTTGGCATATCATATTTGGAGGTATATGATAGACAGTATGATGAG 300
|
|
|
QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
|
|
|
Db 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCAGATATTTCTAGCATATTTGCA 360
|
|
|
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
|
|
|
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
|
|
|
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACAGAGAATTTGGTCCAGTTAAGT 480
|
|
|
```

Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAATTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTATCCAGCAAGATCTGTCCAAAGATAGC 540
Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTATCCAGCAAGATCTGTCCAAAGATAGC 540
QY 541 CTGTGAATCTGATCAGTACTTATAAAGATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGAATCTGATCAGTACTTATAAAGATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATAAATAAGATTAACCTCTGCTGTTGATGACAGTTTGAACCTTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATAAGATTAACCTCTGCTGTTGATGACAGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTTCATTGGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTTCATTGGAACAGATATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCATGATGAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCATGATGAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATATGATACATTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATATGATACATTAC 960
QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATTTATCCCTGTATATGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATTTATCCCTGTATATGATGAAT 1020
QY 1021 GAGAGATTCCTATATTTCCATCAGATTAATAATATATCTGCTTTAATCTTAAAGCATA 1080
Db 1021 GAGAGATTCCTATATTTCCATCAGATTAATAATATATCTGCTTTAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTCTGTTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTTCTGTTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGTTTATGCTTACTG 1200
Db 1141 TTAATGTGTTTATTTTGAAGACATTTACTTATTAAGAAATTTGTTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAGAAATTTGAGGATCTACACATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGTAAAGGATTTCTTAAGAAATTTGAGGATCTACACATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACATCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACATCTGCTGTTCTTTAGTGCATACATAAACTCT 1320
QY 1321 GAATTAAGACTC 1333
Db 1321 GAATTAAGACTC 1333

RESULT 17

ACD29878

ID ACD29878 standard; cdna; 1333 BP.

XX

AC ACD29878;

XX

DT 08-SEP-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO181 cdna.

XX

KW Human; secreted and transmembrane protein; PRO; cell death; neuropathy;
peripheral neuropathy; diabetic peripheral neuropathy;
Kw AIDS-associated neuropathy; Charcot-Marie-Tooth disease;
Kw Refsum's disease; Abetalipoproteinemia; Tangier disease;
Kw Krabbe's disease; Metachromatic leukodystrophy; Fabry's disease;
Kw Dejerine-Sottas syndrome; chromosome mapping; gene mapping; gene therapy;
gene; ss.

XX Homo sapiens.

OS US2003050240-A1.

XX 13-MAR-2003.

XX 16-OCT-2001; 2001US-00978403.

XX 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 11-MAR-1998; 98US-0077649P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 20-MAR-1998; 98US-0078939P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.

PR 27-MAR-1998; 98US-0079786P.

PR 30-MAR-1998; 98US-0079920P.

PR 30-MAR-1998; 98US-0079923P.

PR 31-MAR-1998; 98US-0080105P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080165P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080328P.

PR 01-APR-1998; 98US-0080333P.

PR 01-APR-1998; 98US-0080334P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 08-APR-1998; 98US-0081071P.

PR 09-APR-1998; 98US-0081195P.

PR 09-APR-1998; 98US-0081203P.

PR 09-APR-1998; 98US-0081229P.

PR 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081838P.

PR 15-APR-1998; 98US-0081952P.

PR 15-APR-1998; 98US-0081955P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082700P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082966P.

PR 27-APR-1998; 98US-0083336P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083392P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083500P.

PR 29-APR-1998; 98US-0083545P.

```
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98WO-US028313.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US0000219.
PR 06-JAN-2000; 2000WO-US0000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004341.
PR 24-FEB-2000; 2000WO-US0005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier WA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WL;
XX
XX WPI; 2003-503575/47.
XX P-PSDB; ABO19689.
DR
DR
XX
XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
XX Claim 2; Fig 128; 459pp; English.
XX
XX The invention describes an isolated, secreted and transmembrane
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting
CC PRO4993, PRO337, PRO1559, PRO725, PRO700 or PRO739 polypeptide, and for
CC linking a bioactive molecule to a cell expressing the above polypeptides.
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes
CC cell death. (I) is useful as therapeutic agent, in medical and industrial
CC applications e.g. for treating neuropathy, especially peripheral
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,
CC Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinaemia,
CC
Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGGTTACCGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGCGGTTACCGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTGTCGCACATTATAGCATTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCGCCATTGTCGCACATTATAGCATTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGGTAAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGATTACAGAAATCCTATAGACAGGTAAATACCTGTAATCCCTGTAATCCCTGTAATCCCTGTA 180
QY 181 CCTCATCCAGCGCTTCTTCTGCTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCGCTTCTTCTGCTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTAGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTAGATGAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGATGAT 360
DB 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATGATGATGATGAT 360
```

Db 301 TGGCCAGGACTATGACCCCTACAAACCATCATGAATGAGATATTTAGCATATTTGTCA 360
Qy |||||
Db 361 GAAGAGGATGGTGCATATGCTTTTATCTCTAGCATTTTCTTACTATATGG 420
Qy |||||
Db 361 GAAGAGGATGGTGCATATGCTTTTATCTCTAGCATTTTCTTACTATATGG 420
Qy |||||
Db 421 CATGATCTATCTTTTGGTGGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTAAAT 480
Qy |||||
Db 421 CATGATCTATCTTTTGGTGGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTAAAT 480
Qy |||||
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCAGAGTAGC 540
Qy |||||
Db 541 CTGTGGATCTGATCAGTATCTTTAAATAAGTCTCTTATTTTAAATGTTTCCCAT 600
Db 541 CTGTGGATCTGATCAGTATCTTTAAATAAGTCTCTTATTTTAAATGTTTCCCAT 600
Qy |||||
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Qy |||||
Db 661 TACGATATAAATAAATAAATGATTAATCTCTGGTGGTGAAGTTCGAACTGCACTTC 720
Db 661 TACGATATAAATAAATAAATGATTAATCTCTGGTGGTGAAGTTCGAACTGCACTTC 720
Qy |||||
Db 721 TTAAGGACAGCATAATCCTCTGAATGATGATTAATCTCTGCTGCTAGTCCCTAGTACATG 780
Db 721 TTAAGGACAGCATAATCCTCTGAATGATGATTAATCTCTGCTGCTAGTCCCTAGTACATG 780
Qy |||||
Db 781 GAAGCTTTTGTATPAGGAACCTGTPAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATPAGGAACCTGTPAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
Qy |||||
Db 841 TTATAAATAGCTGATGATATCAGTCTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTGATGATATCAGTCTCTGATGAAGTGAATGATATATCTGACTAG 900
Qy |||||
Db 901 TGGGAACTTCATGGTTCCTCATCTCATGTCGATGATTAATATATGGAATACATTTAC 960
Db 901 TGGGAACTTCATGGTTCCTCATCTCATGTCGATGATTAATATATGGAATACATTTAC 960
Qy |||||
Db 961 AAAAATAAAGCGGGAATTTTCCCTCGCTTGAATATTTATCCCTGCTATATGCAATGAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTCGCTTGAATATTTATCCCTGCTATATGCAATGAT 1020
Qy |||||
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATTTCTTAAGCAT 1080
Qy |||||
Db 1081 AGTAACATGATATAAATAATATCTGCTGATTTCTGTAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATCTGCTGATTTCTGTAAGATGCAATTTAAAGCTATT 1140
Qy |||||
Db 1141 TTAATGTTTTTATTTTGAAGACATTTATTTAAGAAATGGTATTATGCTTACTG 1200
Db 1141 TTAATGTTTTTATTTTGAAGACATTTATTTAAGAAATGGTATTATGCTTACTG 1200
Qy |||||
Db 1201 TTTAATCTGTTGTTAAGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTTAATCTGTTGTTAAGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy |||||
Db 1261 GAATGAGAGAAATTTGTAACATCTGCTGCTCTTCTTTAGTGCATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACATCTGCTGCTCTTCTTTAGTGCATACAAATAAACTCT 1320
Qy |||||
Db 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 18
ADA12521

ID AC
XX AC
XX AC
DT 06-NOV-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane polypeptide PRO181.
XX
KW ss: gene; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;
XX diabetic complication; tissue typing; human.
OS Homo sapiens.
XX
PN US2003055216-A1.
XX
PD 20-MAR-2003.
XX
PF 17-OCT-2001; 2001US-00978824.
XX
PR 21-MAY-1996; 96US-0018049P.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077751P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.

181 CCTCATCCAGCGTTCTCTGTGTCATGTTTCTTTGTGACGAGAGTGGCTTACACTGGG 240
Db
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300
Qy
241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300
Db
301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATCTAGCATATTTGTCA 360
Qy
301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATCTAGCATATTTGTCA 360
Db
361 GAAGGAGGATGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy
361 GAAGGAGGATGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db
421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGTCAGTTAAGT 480
Qy
421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGTCAGTTAAGT 480
Db
481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
Qy
481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
Db
541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT 600
Qy
541 CTGTGGAATCTGATCAGTACTTTTAAAAAATGACTCTTATTTTAAAAATGTTTCCACAT 600
Db
601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
Qy
601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db
661 TAGTATAAATTAATAAAGATTAAGTACTCTGTTGTTGACAGGTTTGAACCTGCATTC 720
Qy
661 TAGTATAAATTAATAAAGATTAAGTACTCTGTTGTTGACAGGTTTGAACCTGCATTC 720
Db
721 TTAAGGAACGCCATAATCTCTCAATGATGATTAATTAATGATGCTCTCTAGTACATTTG 780
Qy
721 TTAAGGAACGCCATAATCTCTCAATGATGATTAATTAATGATGCTCTCTAGTACATTTG 780
Db
781 GAAGCTTTTGTATAGGAATCTTAGGGCTCAATTTGGTTTCAATGAAACAGATCTAA 840
Qy
781 GAAGCTTTTGTATAGGAATCTTAGGGCTCAATTTGGTTTCAATGAAACAGATCTAA 840
Db
841 TTAATAATAGCTAGATATCAGGCTCTCTGATGAAGTGAATGATATCTGACTAG 900
Qy
841 TTAATAATAGCTAGATATCAGGCTCTCTGATGAAGTGAATGATATCTGACTAG 900
Db
901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATATGATATAC 960
Qy
901 TGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATATGATATAC 960
Db
961 AAAAATAAAGCGGGAATTTTCCCTTGGCTGGAATATATATCCCTGATATATGATGAAT 1020
Qy
961 AAAAATAAAGCGGGAATTTTCCCTTGGCTGGAATATATATATCCCTGATATATGATGAAT 1020
Db
1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGTTTAACTTCTTAAGGATA 1080
Qy
1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATATCTGTTTAACTTCTTAAGGATA 1080
Db
1081 AGTAAACATGATATAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
Qy
1081 AGTAAACATGATATAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
Db
1141 TTAATATGTTTTTATTTGTAAGACATTAATTTATTAAGAAATGTTGTTATGCTTACTG 1200
Qy
1141 TTAATATGTTTTTATTTGTAAGACATTAATTTATTAAGAAATGTTGTTATGCTTACTG 1200
Db
1201 TTCTAACTCTGTTGTAAGGATTTCTTAAGAAATTTGCAAGGACTACACATTTTCAAAACT 1260
Qy
1201 TTCTAACTCTGTTGTAAGGATTTCTTAAGAAATTTGCAAGGACTACACATTTTCAAAACT 1260
Db
1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGTTCTTCTTGTAGTGAATACAAATAAACTCT 1320
Qy
1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGTTCTTCTTGTAGTGAATACAAATAAACTCT 1320
Db

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 19

ABT44568
ID ABT44568 standard; cDNA; 1333 BP.

XX
AC ABT44568;
XX
DT 06-NOV-2003 (first entry)

XX Human PRO181 cDNA.

XX PRO; proliferation; gene; pericyte cell; TNF alpha; chondrocyte; blood;
KW tumour necrosis factor; proliferation; differentiation; gene therapy;
KW dermal fibroblast; ss.

XX Homo sapiens.

XX US2003027988-A1.

XX 06-FEB-2003.

XX 26-AUG-2002; 2002US-00227884.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-503301/47.

XX P-PSDB; ABJ72415.

XX New PRO protein encoding nucleic acid, useful for preparing PRO
PT polypeptides and anti-PRO antibodies for detecting the presence of a
PT tumor in a mammal.

XX Claim 2; Fig 119; 324pp; English.

XX The invention relates to a novel isolated PRO protein encoding nucleic
CC acid. The nucleic acid of the invention may be useful for preparing PRO
CC polypeptides and anti-PRO antibodies for detecting the presence of a
CC tumour in a mammal. Furthermore, the molecules of the invention may be
CC useful for stimulating proliferation or gene expression in pericyte
CC cells, the release of tumour necrosis factor (TNF)-alpha from human
CC blood, the proliferation or differentiation of chondrocyte cells and for
CC inhibiting the proliferation of normal human dermal fibroblast cells.
CC Finally, the molecules may be utilised during gene therapy. The current
CC sequence is that of the human PRO cDNA of the invention

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 8; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCACGCGTCCGATGCGGTTACGTTGCGGCTTCTGCTACATGCTGGCGTCTGCT 60

Db 1 GCCCACGCGTCCGATGCGGTTACGTTGCGGCTTCTGCTACATGCTGGCGTCTGCT 60

Qy 61 CACTGCGCGCTCATCTTCTGCGCATTTGCGCATTTAGCATTTAGCTGGAAGAC 120

Db 61 CACTGCGCGCTCATCTTCTGCGCATTTGCGCATTTAGCATTTAGCTGGAAGAC 120

Qy 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCTCCCTGTAATCCCTTGTCTCCAGAGTA 180

Db 121 TGATTACAAGAAATCCTATAGACCACTGTAATACCTCCCTGTAATCCCTTGTCTCCAGAGTA 180

121	DB	121	TGATTA	CAAGAA	TCC	TATAG	ACC	AGTGTAA	ACCCTGAA	TCCCTTG	TACTCC	CAGAGTA	180
181	QY	181	CCTCAT	CCACGC	TTTCTT	CTGTGTCAT	GTGTTCTTTGTG	CACAGTGG	CTTAC	CTGGG	240		
181	DB	181	CCTCAT	CCACGC	TTTCTT	CTGTGTCAT	GTGTTCTTTGTG	CACAGTGG	CTTAC	CTGGG	240		
241	QY	241	TCTCA	TATG	CCCTCTT	TGGCATAT	CATATTTG	AGGTATAT	GAGTATAG	ACAGTATG	300		
241	DB	241	TCTCA	TATG	CCCTCTT	TGGCATAT	CATATTTG	AGGTATAT	GAGTATAG	ACAGTATG	300		
301	QY	301	TGGCC	CAGGACT	CTAT	CAC	CCCTCA	CAACCAT	CATGAAT	TCGAGATAT	CTTAGCATAT	TCGCA	360
301	DB	301	TGGCC	CAGGACT	CTAT	CAC	CCCTCA	CAACCAT	CATGAAT	TCGAGATAT	CTTAGCATAT	TCGCA	360
361	QY	361	GAGGA	AGGAT	GTGG	CAAA	TAGCTTTT	TATCTT	CTAGCAT	TTTTTTT	TACTAC	CTATATG	420
361	DB	361	GAGGA	AGGAT	GTGG	CAAA	TAGCTTTT	TATCTT	CTAGCAT	TTTTTTT	TACTAC	CTATATG	420
421	QY	421	CATGAT	CTAT	TTTTT	TG	TGAGCTT	TAGAAC	CAACAC	CACAGAGAAT	TGGTCC	AGTAA	480
421	DB	421	CATGAT	CTAT	TTTTT	TG	TGAGCTT	TAGAAC	CAACAC	CACAGAGAAT	TGGTCC	AGTAA	480
481	QY	481	GCAT	G	CAAA	AGC	CAACCAAT	GAAGGAT	TCTAT	CCAGCAAGAT	CTCTGT	CCAGAGTATG	540
481	DB	481	GCAT	G	CAAA	AGC	CAACCAAT	GAAGGAT	TCTAT	CCAGCAAGAT	CTCTGT	CCAGAGTATG	540
541	QY	541	CTG	TGG	AATCTG	ATCAGT	TACTTT	AAAAATG	ACTCCTT	ATTTT	AAAA	TGTTTCC	600
541	DB	541	CTG	TGG	AATCTG	ATCAGT	TACTTT	AAAAATG	ACTCCTT	ATTTT	AAAA	TGTTTCC	600
601	QY	601	TTTTG	CTGTG	G	AAAG	ACTGTTTT	TCATATG	TATATCT	CAGATAAG	AATTTT	AAATG	660
601	DB	601	TTTTG	CTGTG	G	AAAG	ACTGTTTT	TCATATG	TATATCT	CAGATAAG	AATTTT	AAATG	660
661	QY	661	TAC	GTATA	AAATTA	TATA	AAAA	TGATTT	ACCTCTG	TGTGTGA	CAGGTTT	GAACTTGC	720
661	DB	661	TAC	GTATA	AAATTA	TATA	AAAA	TGATTT	ACCTCTG	TGTGTGA	CAGGTTT	GAACTTGC	720
721	QY	721	TTA	AGG	AA	CAG	CCATAAT	CTCTG	GAATG	TGCATTAAT	TACTG	ACTGCTCCT	780
721	DB	721	TTA	AGG	AA	CAG	CCATAAT	CTCTG	GAATG	TGCATTAAT	TACTG	ACTGCTCCT	780
781	QY	781	GA	AGCTTT	TGTTTAT	AG	AACTTGT	GAGGCTCAT	TTTTG	TTTCA	TGAAACAG	TATCTAA	840
781	DB	781	GA	AGCTTT	TGTTTAT	AG	AACTTGT	GAGGCTCAT	TTTTG	TTTCA	TGAAACAG	TATCTAA	840
841	QY	841	TTA	AAAT	TAGCT	TAGATAT	CAGTGTCT	CTGATGA	AGTGAA	AAATGTAT	CTG	ACTAG	900
841	DB	841	TTA	AAAT	TAGCT	TAGATAT	CAGTGTCT	CTGATGA	AGTGAA	AAATGTAT	CTG	ACTAG	900
901	QY	901	TGG	AAA	CTTCA	TGG	TTTCT	CACTGT	CA	TGTCGATG	ATATATAT	TGGATAC	960
901	DB	901	TGG	AAA	CTTCA	TGG	TTTCT	CACTGT	CA	TGTCGATG	ATATATAT	TGGATAC	960
961	QY	961	AAA	AA	TAA	AG	CGGAA	TTTTCC	CTT	CGGTTG	AAATAT	TCCCTGTAT	1020
961	DB	961	AAA	AA	TAA	AG	CGGAA	TTTTCC	CTT	CGGTTG	AAATAT	TCCCTGTAT	1020
1021	QY	1021	GAG	AGAT	TTCC	CA	TATTTCC	ATCAG	AGTA	TAAATAT	ACTTGC	TTTTAA	1080
1021	DB	1021	GAG	AGAT	TTCC	CA	TATTTCC	ATCAG	AGTA	TAAATAT	ACTTGC	TTTTAA	1080
1081	QY	1081	AG	TAA	CA	TG	ATATA	AAAA	TATATCT	TG	GAAGA	ATGCA	1140
1081	DB	1081	AG	TAA	CA	TG	ATATA	AAAA	TATATCT	TG	GAAGA	ATGCA	1140
1141	QY	1141	TTA	AA	TG	TTTTAT	TG	TAA	GA	CA	TATTTA	TAA	1200
1141	DB	1141	TTA	AA	TG	TTTTAT	TG	TAA	GA	CA	TATTTA	TAA	1200
1201	QY	1201	TT	C	TAA	TCTG	TG	TAA	AG	AATTTT	TG	CAG	1260
1201	DB	1201	TT	C	TAA	TCTG	TG	TAA	AG	AATTTT	TG	CAG	1260

QY	1361	GAATGAGAGAAAATGTGATTAACCAATCCTGCTGTCTTTCCTTTAGTGCAATACAAATAAACTCT	1320
Db	1361	GAATGAGAGAAAATGTGATTAACCAATCCTGCTGTCTTTCCTTTAGTGCAATACAAATAAACTCT	1320
QY	1321	GAATTTAAGACTC	1333
Db	1321	GAATTTAAGACTC	1333

RESULT 20

ACD82235
ID ACD82235 standard; cDNA; 1333 BP.

AC ACD82235:

DT 19-SEP-2003 (first entry)

Human secreted/transmembrane polypeptide PRO 181 cDNA.

AA Human; ss; chondrocyte stimulation; TNF-alpha stimulation; gene therapy; gene
KW KW
KW human dermal fibroblast stimulation; tumour; tissue typing; gene;
KW affinity purification.

XX Homo sapiens. OS

XX
PN
US200304934-A1.XX
PD
06-MAR-2003.

28-AUG-2002; 2002US-00230338.

PR 01-JUN-2001; 2001WO-US017800,

23-JUN-2001; 2001WC-USVZ1088
09-APR-2002; 2002US-00119480.

PA (GETH) GENENTECH INC.

PI Baker KP, Desnoyers L

XX
DR WPI; 2003-492274/46.
DR P-FSDB; ABO34310.

PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.

PS Claim 2: Fig 119: 315pp: English.

The invention relates to an isolated nucleic acid encoding a PRO polypeptide. Nucleic acids that encode PRO can be used to generate either transgenic animals or knock-out animals useful in developing and screening of therapeutically useful reagents. The nucleic acids may also be used in gene therapy for replacing defective gene, in chromosome identification, as chromosome markers, or in generating probes to isolate full length PRO cDNA. The PRO polypeptides are useful for chondrocyte stimulation, TNF-alpha stimulation, human dermal fibroblasts stimulation and for detecting the presence of tumour in an mammal. The PRO polypeptides are useful as molecular markers for protein electrophoresis and the isolated nucleic acids may be used for recombinantly expressing those markers. The PRO polypeptides and nucleic acids may also be used in tissue typing. Anti-PRO antibodies are useful in diagnostic assays for PRO and in affinity purification of PRO from recombinant cell culture or natural sources. The present sequence represents cDNA encoding a human secreted/transmembrane PRO polypeptide

Sequence 1333 BP: 394 A: 240 C: 247 G: 452 T: 0 U: 0 Other: 0

Query Match	100.0%	Score 1333;	DB 8;	Length 1333;
Best Local Similarity	100.0%	Pred. No. 9.6e-308;		
Matches 1333;	Conservative	0;	Mismatches 0;	Indels 0;
Gaps 0				

Best local similarity 100.0%; Freq: NO: 3.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db	1081	AGTAAACATGATATAAAATATATATGCTGAATTACTTGTGAAGATGCAATTTAAAGCTATT	1144
Qy	1141	TTAAATGCTGTTTTATTGTTAAGACATTACTTATTAAAGAAATGGTTATTATGCTTACTG	1200
Db	1141	TTAAATGCTGTTTTATTGTTAAGACATTACTTATTAAAGAAATGGTTATTATGCTTACTG	1200
Qy	1201	TTCTAAATCTGCTGTTAAAGCTATTCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAACCT	1260
Db	1201	TTCTAAATCTGCTGTTAAAGCTATTCTTTAAGAAATTTGCAGGTACTACAGATTTTCAAACCT	1260
Qy	1261	GAATGAGAGAAAAATTTGATATACCATCTGCTGTTCTTTAGTGCATACATATAAACTCT	1320
Db	1261	GAATGAGAGAAAAATTTGATATACCATCTGCTGTTCTTTAGTGCATACATATAAACTCT	1320
Qy	1321	GAATTTAAGACTC 1333	
Db	1321	GAATTTAAGACTC 1333	
RESULT 21			
ACD29293			
ID	ACD29293 standard; cDNA; 1333 BP.		
XX	AC	ACD29293;	
XX	AC	ACD29293;	
XX	DT	27-AUG-2003 (first entry)	
XX	DE	Novel human secreted and transmembrane polypeptide cDNA #81.	
XX	KW	Human; secreted and transmembrane protein; PRO; viral infection;	
XX	KW	tumour growth; retinal disorder; injury; sight loss;	
XX	KW	retinitis pigmentosa; age-related macular degeneration;	
XX	KW	sport-related joint problem; articular cartilage defect; osteoarthritis;	
XX	KW	rheumatoid arthritis; wound healing; obesity; diabetes; insulinaemia;	
XX	KW	kidney disorder; mesangial cell function; Berger disease; nephropathy;	
XX	KW	celiac disease; dermatitis; Crohn disease; neuropathy;	
XX	KW	cardiac insufficiency disorder; peripheral neuropathy;	
XX	KW	diabetic peripheral neuropathy; autonomic neuropathy;	
XX	KW	reduced motility of the gastrointestinal tract;	
XX	KW	atony of the urinary bladder; post polio syndrome; Krabbe's disease;	
XX	KW	Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;	
XX	KW	Refsun's disease; gene; ss.	
XX	OS	Homo sapiens.	
XX	PN	US2003049633-A1.	
XX	PN	13-MAR-2003.	
XX	PD	13-MAR-2003.	
XX	PF	16-OCT-2001; 2001US-00978585.	
XX	PR	17-OCT-1997; 97US-0062250P.	
XX	PR	03-NOV-1997; 97US-0064249P.	
XX	PR	13-NOV-1997; 97US-0065311P.	
XX	PR	21-NOV-1997; 97US-0066366P.	
XX	PR	10-MAR-1998; 98US-0077450P.	
XX	PR	11-MAR-1998; 98US-0077632P.	
XX	PR	11-MAR-1998; 98US-0077641P.	
XX	PR	11-MAR-1998; 98US-0077649P.	
XX	PR	12-MAR-1998; 98US-0077791P.	
XX	PR	13-MAR-1998; 98US-0078004P.	
XX	PR	17-MAR-1998; 98US-00040220.	
XX	PR	20-MAR-1998; 98US-0078886P.	
XX	PR	20-MAR-1998; 98US-0078910P.	
XX	PR	20-MAR-1998; 98US-0078936P.	
XX	PR	20-MAR-1998; 98US-0078939P.	
XX	PR	25-MAR-1998; 98US-0079294P.	
XX	PR	26-MAR-1998; 98US-0079656P.	
XX	PR	27-MAR-1998; 98US-0079663P.	
XX	PR	27-MAR-1998; 98US-0079664P.	
XX	PR	27-MAR-1998; 98US-0079689P.	
XX	PR	27-MAR-1998; 98US-0079728P.	

PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081171P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0082796P.
PR 28-APR-1998; 98US-0083336P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0083742P.
PR 06-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 13-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086142P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 26-JUN-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0030863P.
PR 26-JUN-1998; 98US-0031010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003376.
PR 18-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US004341.
PR 02-MAR-2000; 2000WO-US005004.
PR 10-MAR-2000; 2000WO-US005841.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.

This invention relates to one hundred and twenty two novel nucleic acids encoding human PRO membrane bound proteins or receptors. Extracellular proteins play important roles in the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells (for example proliferation, migration or differentiation) is typically governed by information received from other cells and the immediate environment. The information is often transmitted by secreted polypeptides (for example mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neurotrophic factors and hormones) which are received and interpreted by diverse cell receptors or membrane bound proteins. These membrane bound proteins and receptors may be of use as pharmaceutical and diagnostic agents, such as in the blocking of receptor-ligand interactions. The current invention provides the amino acid sequences of novel human membrane bound receptors and proteins, along with the cDNA sequences encoding them. The novel proteins of the invention may have cytostatic activities through the stimulation of chondrocytes. The nucleic acids of the invention may be useful for the manufacture of a medicament for diagnosing or treating a tumour in a mammal. In addition, they may be useful for measuring or detecting the expression of a tumour associated gene. The present sequence is the cDNA sequence encoding a human PRO protein of the invention

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGCTTACGTTGGGGCTTCTGCTACATGCTGGGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGCTTACGTTGGGGCTTCTGCTACATGCTGGGCTGCTGCT 60

QY 61 CACTGCGGGCTCATCTTCTGCCATTTGGACATTTAGCATTTGATGAGTGAAGAC 120
DB 61 CACTGCGGGCTCATCTTCTGCCATTTGGACATTTAGCATTTGATGAGTGAAGAC 120

QY 121 TGATTAACAAGATCTTATAGACAGTGTAAATCCCTGTAATCCCTGTAATCCCTGTA 180
DB 121 TGATTAACAAGATCTTATAGACAGTGTAAATCCCTGTAATCCCTGTAATCCCTGTA 180

QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTTGCGATATCATATTTGGAGTATATGAGTACCATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGCGATATCATATTTGGAGTATATGAGTACCATGATGAG 300

QY 301 TGGCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATGTC 360
DB 301 TGGCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATGTC 360

QY 361 GAAGGAAGTATGTCATATGCTTTTATCTTCTAGCATTTTCTACTATATGG 420
DB 361 GAAGGAAGTATGTCATATGCTTTTATCTTCTAGCATTTTCTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATCCAAAGCCCAATGAGGATCTATCCAGCAAGATCTGTCGAAGATGAG 540
DB 481 GCATCCAAAGCCCAATGAGGATCTATCCAGCAAGATCTGTCGAAGATGAG 540

QY 541 CTGTGGAATCTCATGTTTAAATGACCTTTTAAATGATGTTTAAATGATGTTTAAATG 600
DB 541 CTGTGGAATCTCATGTTTAAATGACCTTTTAAATGATGTTTAAATGATGTTTAAATG 600

QY 601 TTTTCTGTTGGAAGACTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTTGGAAGACTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACCTTGCCTTC 720

DB 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGACAGTTTGAACCTTGCCTTC 720
QY 721 TTAAGGAACAGCCATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780
DB 721 TTAAGGAACAGCCATATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTA 780
QY 781 GAAGCTTTTGTATATAGGAACCTTTAGGGCTCATTTTGGTTCATTTGATTAATTAATTAATTA 840
DB 781 GAAGCTTTTGTATATAGGAACCTTTAGGGCTCATTTTGGTTCATTTGATTAATTAATTAATTA 840
QY 841 TTATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900
DB 841 TTATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900
QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATTAATTAATTAATTAATTAATTA 960
DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATTAATTAATTAATTAATTAATTA 960
QY 961 AAAAAATAAAGCGGGAAATTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCT 1020
DB 961 AAAAAATAAAGCGGGAAATTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1080
QY 1081 AGTAAACATGATTAATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1140
DB 1081 AGTAAACATGATTAATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1140
QY 1141 TTAATATGTTTATATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
DB 1141 TTAATATGTTTATATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
QY 1201 TTCTAATCTGGTGTAAAGTATTTCTTAAGATTTGAGATTTGAGATTTGAGATTTGAGATTTGAGATTT 1260
DB 1201 TTCTAATCTGGTGTAAAGTATTTCTTAAGATTTGAGATTTGAGATTTGAGATTTGAGATTTGAGATTT 1260
QY 1261 GAATGAGAGAAATTTGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1320
DB 1261 GAATGAGAGAAATTTGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 23
ADB83609
ID ADB83609 standard; cDNA; 1333 BP.
XX
AC ADB83609;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX
OS Homo sapiens.
XX
FN US2003073814-A1.
XX
PD 17-APR-2003.

Qy	1261	GAATGAGAGAAAAATTGTATTAACCATCCTGCTGTTCTTTAGTGCATATACAATAAAACTCT	1320
Db <th>1261</th> <th>GAATGAGAGAAAAATTGTATTAACCATCCTGCTGTTCTTTAGTGCATATACAATAAAACTCT</th> <th>1320</th>	1261	GAATGAGAGAAAAATTGTATTAACCATCCTGCTGTTCTTTAGTGCATATACAATAAAACTCT	1320

QY 1321 GAAATTAAGACTC 1333
|||
Db 1321 GAAATTAAGACTC 1333

RESULT 24

ADB80715
ID ADB80715 standard; cDNA; 1333 BP.

AC ADB80715:

DT 04-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PR0181 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic; vulnary; antiarthritic; pericyte cell proliferation; pericyte cell differentiation; chondrocyte cell proliferation; chondrocyte cell differentiation; tumour necrosis factor alpha release; (TNF)-alpha release; dermal fibroblast cell proliferation; dermal fibroblast cell differentiation inhibitor; tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; liver tumour; tissue typing; chromosome mapping; gene mapping; gene therapy.

OS Homo sapiens.

XX
PN
US2003088068-A1

08-MAY-2003

13-AUG-2002: 2002US-00219481

01-JUN-2001 - 2001W0-115017800
XX
PR

PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00118480

XX
DA (GENTH) GENTENECU INC

XX
PT

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

DR WPI; 2003-657982/62.

XX
E

PT useful in gene th

XX
PS Claim 2; Fig 119; 305pp; English.

CC The invention describes an isolat

useful for stimulating the proliferation of gene expression in pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF) α from human blood. PRO982, PRO357, PRO723, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1334, PRO826, PRO357, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322, PRO3940, PRO6079, PRO8936 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408.

```
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATTG 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGACTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGAACTCTGAGGGCTCAATTTGGTTTCAATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTCTGAGGGCTCAATTTGGTTTCAATTTGAAACAGATATCTAA 840
QY 841 TTATAAATTAGCTCTAGATATACAGGTGCTTCTGATGAAGTGAATGAAATCTATATCTGACTAG 900
Db 841 TTATAAATTAGCTCTAGATATACAGGTGCTTCTGATGAAGTGAATGAAATCTATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGCTTTCTCATCTCTGATGTCATGTCGATGATATATATGATATGATATAC 960
Db 901 TGGGAACCTTCATGGCTTTCTCATCTCTGATGTCATGTCGATGATATATATGATATGATATAC 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATCAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATGATCAAT 1020
QY 1021 GAGAGATTCCCATATTTCCATCCAGAGTAATAAATATATATATATATATATATATATATAT 1080
Db 1021 GAGAGATTCCCATATTTCCATCCAGAGTAATAAATATATATATATATATATATATATATAT 1080
QY 1081 AGTAACATGATATAAATAATATATGCTGATATATATATATATATATATATATATATATATAT 1140
Db 1081 AGTAACATGATATAAATAATATATGCTGATATATATATATATATATATATATATATATATAT 1140
QY 1141 TTAATGCTGTTTTTATTTGTAAGACATATATATATATATATATATATATATATATATATATAT 1200
Db 1141 TTAATGCTGTTTTTATTTGTAAGACATATATATATATATATATATATATATATATATATATAT 1200
QY 1201 TTCTAATCTGTTGTAAGATATATATATATATATATATATATATATATATATATATATATATAT 1260
Db 1201 TTCTAATCTGTTGTAAGATATATATATATATATATATATATATATATATATATATATATATAT 1260
QY 1261 GAATGAGAGAAATGATATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAATGATATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 25
ADB73256
ID ADB73256 standard; cDNA; 1333 BP.
AC
XX ADB73256;
XX
DT 04-DEC-2003 (first entry)
DE
XX
XX Novel human secreted and transmembrane protein PRO181 cDNA.
KW human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW chondrocyte cell differentiation; chondrocyte cell proliferation;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003096968-A1.
XX
XX 22-MAY-2003.
XX
XX 29-AUG-2002; 2002US-00232223.
XX
```

```
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-765525/72.
DR P-PSDB; ADB73257.
XX
XX New isolated PRO polypeptides useful as molecular weight markers in
PT protein electrophoresis, useful for tissue typing, and for treating
PT arthritis and tumors.
XX
XX Claim 2; Fig 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, (TNF)-
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1818, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
```

```
Query Match 100.0%; Score 1333; DB 8; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACACGCTCCGATGCGCTTCAGTTTCGGGGCTTCTGCTACATGCTGGGGCTGCTGCT 60
Db 1 GCCACACGCTCCGATGCGCTTCAGTTTCGGGGCTTCTGCTACATGCTGGGGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTTCGCCATTTCGCCCATATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTTCGCCATTTCGCCCATATATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACAGTGTATATACCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAAATCCTATAGACAGTGTATATACCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTTCTGTCATGTTCTTGTGTGACAGAGTGGCTTACACTGGG 240
```

Db 191 ||||| CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCAATTTGGAGGTATATGAGTAGACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCAATTTGGAGGTATATGAGTAGACAGTATGAG 300
QY 301 TGGCCAGAGCTCTATGAGCCCTACAAACATCATGAAATGAGATATCTAGCATATTTGTCA 360
Db 301 TGGCCAGAGCTCTATGAGCCCTACAAACATCATGAAATGAGATATCTAGCATATTTGTCA 360
QY 361 GAAGGAAGATGCTGCAATATGAGCTTTTATCTCTAGCATTTTCTACTACTATATGG 420
Db 361 GAAGGAAGATGCTGCAATATGAGCTTTTATCTCTAGCATTTTCTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAAAGATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCAGCAAGATCTGTGCCAAGATGAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCAGCAAGATCTGTGCCAAGATGAGC 540
QY 541 CTGTGAATCTCATGAGTTTAAATGACCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGAATCTCATGAGTTTAAATGACCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGTGAAAGAGCTGTTTTCATATGTTTATCTCAGATPAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTGTGAAAGAGCTGTTTTCATATGTTTATCTCAGATPAAAGATTTTAAATGGTAT 660
QY 661 TACGATTAATTAATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGATTAATTAATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATCTAGTCTGTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATCTAGTCTGTCTAGTACATG 780
QY 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTGGTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTGGTTCATTGAAACAGTATCTAA 840
QY 841 TTAATAATTTAGCTGTAGATATCAGGCTCTTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTAATAATTTAGCTGTAGATATCAGGCTCTTCTGATGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATACATTTAC 960
QY 961 AAAAATAAAGGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATGATGAT 1020
Db 961 AAAAATAAAGGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAAATATCTGCTTTAATCTTAAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAAATATCTGCTTTAATCTTAAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGATTTCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGATTTCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTATGTAAGACATTTATTTAAGAAATGGTATTTATGCTTACG 1200
Db 1141 TTAATATGTTTATTTATGTAAGACATTTATTTAAGAAATGGTATTTATGCTTACG 1200
QY 1201 TTTCAATCTGGTGAAGATTTCTTAAAGATTTTCAGATCTACAGATTTTCAAACT 1260
Db 1201 TTTCAATCTGGTGAAGATTTCTTAAAGATTTTCAGATCTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTCTCTTTAGTGCAATACAAATAAACTCT 1320

Db 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTCTCTTTAGTGCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 26
ADB78338
ID ADB78338 standard; cDNA; 1333 BP.
XX
AC ADB78338;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003092889-A1.
XX
PD 15-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219478.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI: 2003-765495/72.
DR P-PSDB; ADB78339.
XX
PT New isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX
PS Claim 2; Fig 119; 308pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1336,
CC PRO1343, PRO1376, PRO1387, PRO1403, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO1801, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,

are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (III) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sports injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 8; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACCGCTCCGATGGCGTTCAAGTTCGCGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACCGCTCCGATGGCGTTCAAGTTCGCGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCCGCTCATCTCTTCCGCAATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCCGCTCATCTCTTCCGCAATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGAATTACAAGAACTCTATAGACCAAGTGAATAACCTCGAATCCCTTGTACTCCAGAGTA 180
 DB 121 TGAATTACAAGAACTCTATAGACCAAGTGAATAACCTCGAATCCCTTGTACTCCAGAGTA 180
 QY 181 CCTCATCCACGCTTTCTTCTGTCGATGTTCTTTGTCGACAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTTCTTCTGTCGATGTTCTTTGTCGACAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTGAAGAC 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTGAAGAC 300
 QY 301 TGGCCCGAGACTCTATGACCCCTTACCAACCATCATGAATGAGATATTCAGCATATTTGCA 360
 DB 301 TGGCCCGAGACTCTATGACCCCTTACCAACCATCATGAATGAGATATTCAGCATATTTGCA 360
 QY 361 GAAGGAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
 DB 361 GAAGGAGGATGGTGCAGAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACAGAGAAATTCGTCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACAGAGAAATTCGTCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCGAAGTAGC 540
 QY 541 CTGTGGAAATCTGATCAGTACTCTTTAAAATAAGTACCTCTATTTTTTAATGTTTCCCAT 600
 DB 541 CTGTGGAAATCTGATCAGTACTCTTTAAAATAAGTACCTCTATTTTTTAATGTTTCCCAT 600
 QY 601 TTTTCTCTGTGGAAGAGCTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTCTGTGGAAGAGCTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATTAATGATGCTGCTAGTACATTG 780
 DB 721 TTAAGGAACAGCCATAAATCTCTGAATGATGATTAATTAATGATGCTGCTAGTACATTG 780

QY 781 GAAGCTTTTGTATATAGAACTTTAGGGCTCATTTTGGTTTCAATTGAAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATATAGAACTTTAGGGCTCATTTTGGTTTCAATTGAAACAGTATCTAA 840
 QY 841 TTATAAATTAAGCTAGCTAGATATCAGTCTCTCTGATGAAGTGAAATGCTATATCTGACTAG 900
 DB 841 TTATAAATTAAGCTAGCTAGATATCAGTCTCTCTGATGAAGTGAAATGCTATATCTGACTAG 900
 QY 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATGAGATACATTAC 960
 DB 901 TGGGAAACTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATGAGATACATTAC 960
 QY 961 AAAAATAAAAAGCGGGAAATTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAAT 1020
 DB 961 AAAAATAAAAAGCGGGAAATTTCCCTTCGCTTGAATATATATCCCTGTATATGTCATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATATCTTAAATCTTAAAGCATA 1080
 DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAATAATATATCTTAAATCTTAAAGCATA 1080
 QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTGTGAAGAAATGCAATTAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTGTGAAGAAATGCAATTAAGCTATT 1140
 QY 1141 TTAATCTGTTTATTTTGTAAAGACATTAATTAAGAAATGCTGTTATATGCTTACTG 1200
 DB 1141 TTAATCTGTTTATTTTGTAAAGACATTAATTAAGAAATGCTGTTATATGCTTACTG 1200
 QY 1201 TTCTAAATCTGTGTAAGGTAATTTCTTAAAGAAATTCGAGGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAAATCTGTGTAAGGTAATTTCTTAAAGAAATTCGAGGTACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTTCTTTAGTGCATTAACAATAAACTCT 1320
 DB 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTTCTTTAGTGCATTAACAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 RESULT 27
 ADB84986
 ID ADB84986 standard; cDNA; 1333 BP.
 XX
 AC ADB84986;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 XX Human PRO polynucleotide #60.
 DE Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 KW arthritis; sports injury; cytostatic; antiarthritic.
 XX
 OS Homo sapiens.
 XX
 XX US2003073817-A1.
 XX
 XX 17-APR-2003.
 XX
 XX 26-AUG-2002; 2002US-00227883.
 XX
 XX 01-AUG-2000; 2000US-0222425P.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-730024/69.
DR P-PSDB; ADB84987.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT e.g. in gene therapy, disease diagnosis, chromosome identification and
PT tissue typing.
XX
PS Claim 2; Fig 119; 314pp; English.
XX
CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGCTTACGTTTCGGGCTTCTGCTACATGTCGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGCTTACGTTTCGGGCTTCTGCTACATGTCGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGCAGCTATATACCTGAAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGAACTCTATAGCAGCTATATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTTGTCAGCAGAGTGGCTTACCTGGG 240
DB 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTTCTTTGTCAGCAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCGCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300
DB 241 TCTCAATATGCGCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300
QY 301 TGGCCACGAGTCTTATGACCCCTCAACCATCATGAATGCAGATATTTCTAGCATTTCTCA 360
DB 301 TGGCCACGAGTCTTATGACCCCTCAACCATCATGAATGCAGATATTTCTAGCATTTCTCA 360
QY 361 GAAGGAGGATGTCGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGATGTCGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACACAGAAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACACAGAAATTTGGTCCAGTTAAGT 480

DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACACAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGATCTGATCAGTTTCTTAAATAAGTACCTCTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGATCTGATCAGTTTCTTAAATAAGTACCTCTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGAAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGAAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAAATTAATATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
DB 661 TACGATATAAATTAATATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATGATTAATTTACGATCTCTAGTACATTCG 780
DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATGATTAATTTACGATCTCTAGTACATTCG 780
QY 781 GAAGCTTTTGTATATAGGAACCTTGTAGGCTCATTTTGGTTTCAATTTGAACAGATTAATA 840
DB 781 GAAGCTTTTGTATATAGGAACCTTGTAGGCTCATTTTGGTTTCAATTTGAACAGATTAATA 840
QY 841 TTATATAATAGCTGTAGATATCAGGCTTCTGATGAGTGAAGTGAATGATATATCTGACTAG 900
DB 841 TTATATAATAGCTGTAGATATCAGGCTTCTGATGAGTGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAAACCTTCAATGCTTCTCATCTGATGATGATTAATTTATGATGATGATTAATTTAC 960
DB 901 TGGGAAACCTTCAATGCTTCTCATCTGATGATGATTAATTTATGATGATGATTAATTTAC 960
QY 961 AAAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGATATATGATGATGAT 1020
DB 961 AAAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGATATATGATGATGAT 1020
QY 1021 GAGAGATTTTCCCATATTTCCATCAGAGTAATAATAATACTTCTGTTTAAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTTCCCATATTTCCATCAGAGTAATAATAATACTTCTGTTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATGCTGAAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTATATGCTTACTG 1200
DB 1141 TTAATGCTGTTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGAATACAAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 28
ADB78092
ID ADB78092 standard; cDNA; 1333 BP.
XX
AC ADB78092;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX

XX	Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW	vulnerary; antiarthritic; pericyte cell proliferation;
KW	pericyte cell differentiation; chondrocyte cell proliferation;
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;
XX	gene therapy.
XX	
OS	Homo sapiens.
PN	US2003092886-A1.
XX	
PD	15-MAY-2003.
XX	
XX	09-AUG-2002; 2002US-00216165.
XX	
PR	25-JUL-2000; 2000US-0220607P.
XX	
PR	01-JUN-2001; 2001WO-US017800.
PR	29-JUN-2001; 2001WO-US021086.
PR	09-APR-2002; 2002US-00119480.
XX	
PA	(GETH) GENENTECH INC.
XX	
XX	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI	WPI; 2003-765494/72.
DR	P-PSDB; ADB78093.
DR	
PT	Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT	molecular weight markers in protein electrophoresis, for treating
PT	arthritis, tumor.
XX	
PS	Claim 2; Fig 119; 308pp; English.
XX	
CC	The invention describes an isolated PRO (secreted and transmembrane)
CC	polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC	useful for stimulating the proliferation of or gene expression in
CC	pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are
CC	for stimulating the proliferation or differentiation of chondrocyte
CC	cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC	are useful for stimulating the release of tumour necrosis factor (TNF)-
CC	alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC	PRO247, PRO337, PRO536, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC	PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC	PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC	PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC	PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC	PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC	PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC	stimulating the proliferation of normal human dermal fibroblasts cells.
CC	PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC	PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC	inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC	polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC	are useful for detecting the presence of tumour in a mammal which
CC	involves comparing the level of expression of the above PRO polypeptides
CC	in a test sample of cells taken from the mammal, and a control sample of
CC	normal cells of the same cell type, where a higher level of expression of
CC	the PRO polypeptides in the test sample as compared to the control sample
CC	is indicative of the presence of tumour in the mammal. The tumour is lung
CC	tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC	liver tumour. (I) is useful as molecular weight markers, for tissue
CC	typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC	useful for chromosome and gene mapping or gene therapy. (II) is useful
CC	for generating transgenic animals or knock-out animals which are useful
CC	screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC	is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC	sport injuries). This sequence encodes a human secreted and transmembrane
CC	PRO polypeptide.
XX	

[illegible]

QY 901 TGGGAAACTTCATGGGTTTCCTCATCTGTGATGATTAATATATGGATACATTTAC 960
 DB |||||||
 QY 901 TGGGAAACTTCATGGGTTTCCTCATCTGTGATGATTAATATATGGATACATTTAC 960
 DB |||||||
 QY 961 AAAAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGATATGATGAT 1020
 DB |||||||
 QY 961 AAAAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGATATGATGAT 1020
 DB |||||||
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATCTTAAGCAT 1080
 DB |||||||
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATCTTAAGCAT 1080
 DB |||||||
 QY 1081 AGTAACATGATATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 1140
 DB |||||||
 QY 1081 AGTAACATGATATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA 1140
 DB |||||||
 QY 1141 TTAATATGCTGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGGTATATGCTTACTG 1200
 DB |||||||
 QY 1141 TTAATATGCTGTTTTTATTTGTAAGACATTAATCTTATTAAGAAATGGTATATGCTTACTG 1200
 DB |||||||
 QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
 DB |||||||
 QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
 DB |||||||
 QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATAAATAAACTCT 1320
 DB |||||||
 QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATAAATAAACTCT 1320
 DB |||||||
 QY 1321 GAAATTAAGACTC 1333
 DB |||||||
 QY 1321 GAAATTAAGACTC 1333
 DB |||||||

RESULT 30
 ADB87158
 ID ADB87158 standard; cDNA; 1333 BP.

AC ADB87158;

XX 04-DEC-2003 (first entry)

XX Human PRO polynucleotide #60.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
 KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
 KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
 KW arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003088067-A1.

XX 08-MAY-2003.

XX 13-AUG-2002; 2002US-00219479.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen WB, Goddard A, Godowski PI;
 FI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX WPI; 2003-657981/62.

XX P-PSDB; ADB87159.

XX One hundred and twenty two nucleic acids encoding PRO polypeptides,
 PT useful in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.

XX Claim 2; Fig 119; 314pp; English.
 PS The invention relates to human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
 CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. They are particularly useful for
 CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
 CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
 CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, for stimulating the proliferation or differentiation of
 CC chondrocyte cells, for stimulating the proliferation of or gene
 CC expression in pericyte cells or for stimulating the proliferation of
 CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
 CC hybridisation probes in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
 CC technology, in generating transgenic animals or knock-out animals which
 CC may be used in the development and screening of therapeutically useful
 CC reagents, in gene therapy, in chromosome identification, as chromosome
 CC markers and in generating probes. The PRO polypeptides, or anti-PRO
 CC antibodies, are useful for preparing a medicament for treating a
 CC condition which is responsive to the PRO polypeptides or anti-PRO
 CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
 CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
 CC differentiation of chondrocytes. The PRO polypeptides are useful as
 CC molecular markers for protein electrophoresis, and in tissue typing. This
 CC sequence represents a human PRO polynucleotide of the invention.
 XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCCGATGGCGTTTCAGGTTCCGCGCCTTCTCTACATGCTGGCGTCTGCT 60
 DB |||||||
 QY 1 GCCCAGCGTCCGATGGCGTTTCAGGTTCCGCGCCTTCTCTACATGCTGGCGTCTGCT 60
 DB |||||||
 QY 61 CACTGCCGCGCTCATCTTCTCGCCATTGCGCACATTATAGCATTTGATGAGCTGAAGAC 120
 DB |||||||
 QY 61 CACTGCCGCGCTCATCTTCTCGCCATTGCGCACATTATAGCATTTGATGAGCTGAAGAC 120
 DB |||||||
 QY 121 TGATTACAAAGATTCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTTATCTCCAGAT 180
 DB |||||||
 QY 121 TGATTACAAAGATTCCTATAGACCAAGTGAATACCCCTGAATCCCTTGTTATCTCCAGAT 180
 DB |||||||
 QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTCTGTCAGCAGAGTGGCTTACACTGG 240
 DB |||||||
 QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
 DB |||||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
 DB |||||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTATGAG 300
 DB |||||||
 QY 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAATGACAGATATCTAGCATATTTG 360
 DB |||||||
 QY 301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAATGACAGATATCTAGCATATTTG 360
 DB |||||||
 QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATATTTTCTTACCTATATGG 420
 DB |||||||
 QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTCTAGCATATTTTCTTACCTATATGG 420
 DB |||||||
 QY 421 CATGATCTATGTTTTTGGTGAGCTCTTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAG 480
 DB |||||||
 QY 421 CATGATCTATGTTTTTGGTGAGCTCTTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAG 480
 DB |||||||
 QY 481 GGTATGCAAAAGCCCAATGAAGGATCTTATCCAGCAAGATCTCTGTCAGAGTAGC 540
 DB |||||||
 QY 481 GGTATGCAAAAGCCCAATGAAGGATCTTATCCAGCAAGATCTCTGTCAGAGTAGC 540
 DB |||||||
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
 DB |||||||
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
 DB |||||||

QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATCTTATCTACATTAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAAGACTGTTTTCATATCTTATCTACATTAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAATAAATGATTAACCTCTGTGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TAGCTATAAATTAATAATAAATGATTAACCTCTGTGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTAGTACATTTG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTCTCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTGCAATTTGGTTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTGCAATTTGGTTTCATTTGAACAGATATCTAA 840
QY 841 TTATAAATAGCTAGATATCAGGTCCTCTGATGAAGTGAATGATAATCTATCTGACTAG 900
Db 841 TTATAAATAGCTAGATATCAGGTCCTCTGATGAAGTGAATGATAATCTATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCCATCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAACCTTCATGGGTTTCCATCTGATGATGATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATAATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATAATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGATATCTGTAATATCTGTAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATATCTGTAATATCTGTAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTGTAAGACATATCTTATTAAGAAATGCTTATTAATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATATCTTATTAAGAAATGCTTATTAATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGATTTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA 1260
Db 1201 TTCTAATCTGCTGTAAGATTTTCCATCAGAGTAATAATAATAATAATAATAATAATAATAATA 1260
QY 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAATTTGTAATACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 31
ADB84740
ID ADB84740 standard; cDNA; 1333 BP.
XX AC ADB84740;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polynucleotide #60.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX PN US2003092890-A1.

XX PD 15-MAY-2003.
XX PF 14-AUG-2002; 2002US-00219536.
XX PR 28-JUL-1999; 99US-0146222P.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-JUN-2001; 2001WO-US017800.
PR 23-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR WPI; 2003-777259/73.
DR DR P-PSDB; ADB84741.
XX PT New isolated PRO polypeptides, useful for tissue typing, gene therapy, as
PT molecular weight markers in protein electrophoresis, and for treating
PT arthritis and tumors.
XX PS Claim 2; Fig 119; 308pp; English.
XX CC The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumour, rectal tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACAGGCTCCGATGGCGTTTACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACAGGCTCCGATGGCGTTTACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCCGGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCCGGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAGAAATCCCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCCAAGATA 180
QY 181 CCTCATCCAGCGCTTCTTCTGCTGCTCATCTTTCTTGTGTCAGCAGAGTGGCTTACCTGG 240
Db 181 CCTCATCCAGCGCTTCTTCTGCTGCTCATCTTTCTTGTGTCAGCAGAGTGGCTTACCTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCAAGTATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATAGACCAAGTATGAG 300
Db |||||
QY 301 TGGCCCCAGGACTCTATGACCCCTCAACCATCATGAATGACAGATATCTAGCATATTTGCA 360
Db |||||
QY 301 TGGCCCCAGGACTCTATGACCCCTCAACCATCATGAATGACAGATATCTAGCATATTTGCA 360
Db |||||
QY 361 GAAGGAAGGATGGTGAATAGCTTTTATCTCTAGCAATTTTCTACCTATATGG 420
Db |||||
QY 361 GAAGGAAGGATGGTGAATAGCTTTTATCTCTAGCAATTTTCTACCTATATGG 420
Db |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 481 GCATGCAAAAGCCCAACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCOAAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAGCCCAACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCOAAGAGTAGC 540
Db |||||
QY 541 CTGTGGAACTGATCAGTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAACTGATCAGTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGGCTGTGGAAGACTGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGGCTGTGGAAGACTGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TACGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
Db |||||
QY 661 TACGTATAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATTC 720
Db |||||
QY 721 TTAAGGAACGCCATATCTCTGCAAGATGCAATTAATTAAGTCTGCTCTAGTACATTC 780
Db |||||
QY 721 TTAAGGAACGCCATATCTCTGCAAGATGCAATTAATTAAGTCTGCTCTAGTACATTC 780
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db |||||
QY 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db |||||
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTGATGAAGTGAATATATATATGATATTCAT 900
Db |||||
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTGATGAAGTGAATATATATATGATATTCAT 900
Db |||||
QY 901 TGGGAACCTCATGGTTTCTCATCTGTCATGTCGATGATATATATATGATATTCAT 960
Db |||||
QY 901 TGGGAACCTCATGGTTTCTCATCTGTCATGTCGATGATATATATATGATATTCAT 960
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
Db |||||
QY 1021 GAGGATTTCCCATATTTCCATCAGATATATATATATATCTGCTTTTAAATCTTAAAGCATA 1080
Db |||||
QY 1021 GAGGATTTCCCATATTTCCATCAGATATATATATATATCTGCTTTTAAATCTTAAAGCATA 1080
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGTAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATATGTTTATTTTATTTAGACATATCTATTTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db |||||
QY 1141 TTAATATGTTTATTTTATTTAGACATATCTATTTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGTGTGTAAGGATTTTAAAGATTTTGAAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1201 TTCTAATCTGTGTGTAAGGATTTTAAAGATTTTGAAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGATATACCATCTGCTGTTTCTTTAGTCAATACAAATAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGATATACCATCTGCTGTTTCTTTAGTCAATACAAATAAACTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333

Db 1321 GAAATTAAGACTC 1333

RESULT 32

ADB83855

ID ADB83855 standard; cDNA; 1333 BP.

XX ADB83855;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
vulnary; antithratic; pericyte cell proliferation;
XX KW pericyte cell differentiation; chondrocyte cell proliferation;
XX KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
(TNF)-alpha release; dermal fibroblast cell proliferation;
XX KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX KW colon tumour; breast tumour; prostate tumour; rectal tumour;
XX KW liver tumour; tissue typing; chromosome mapping; gene mapping;
gene therapy.

XX OS Homo sapiens.

XX PN US2003069397-A1.

XX PD 10-APR-2003.

XX PF 09-AUG-2002; 2002US-00216159.

XX PR 25-JUL-2000; 2000US-0220607P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2003-657584/62.

XX DR P-PSDB; ADB83856.

XX PT New isolated polypeptides designated PRO polypeptides including
polypeptides useful for stimulating the proliferation or differentiation
of specific cell types, and for diagnosing cancer.

XX PS Claim 2; Fig 119; 314pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO3422,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (III) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	GCCACGGCTCGATGGCGCTCACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT	60
DB	1	GCCACGGCTCGATGGCGCTCACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT	60
QY	61	CACTGCGGCGCTCATCTTCTTGCCATTTGGCAGATTTGATGAGCTGAAGAC	120
DB	61	CACTGCGGCGCTCATCTTCTTGCCATTTGGCAGATTTGATGAGCTGAAGAC	120
QY	121	TGATTAACAAGATCTTATAGACAGTGTAATACCCCTGAATCCCTTGTAATCCAGAGTA	180
DB	121	TGATTAACAAGATCTTATAGACAGTGTAATACCCCTGAATCCCTTGTAATCCAGAGTA	180
QY	181	CTTCATCCAGCTTCTTCTGCTCATGTTCTTCTGTCAGCAGAGTGCTTACACTGGG	240
DB	181	CTTCATCCAGCTTCTTCTGCTCATGTTCTTCTGTCAGCAGAGTGCTTACACTGGG	240
QY	241	TCCTAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGCCAGTATGAG	300
DB	241	TCCTAATATGCCCTCTTGCCATATCATATTTGGAGGTATATGAGTAGCCAGTATGAG	300
QY	301	TGSCCCAGAGCTCTATGACCTCAACCATCATGATGCGAGATTTCTAGCATATTTGTC	360
DB	301	TGSCCCAGAGCTCTATGACCTCAACCATCATGATGCGAGATTTCTAGCATATTTGTC	360
QY	361	GAAGGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATG	420
DB	361	GAAGGAAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATG	420
QY	421	CATGATCTATGTTTTGGTGAGCTTTAGAACACACACAGAGAATGGTCCAGTTAAGT	480
DB	421	CATGATCTATGTTTTGGTGAGCTTTAGAACACACACAGAGAATGGTCCAGTTAAGT	480
QY	481	GCATGCAAAAGCCCAATGAGGATTTATCCAGCAAGATCTGTCCTGCAAGATGAG	540
DB	481	GCATGCAAAAGCCCAATGAGGATTTATCCAGCAAGATCTGTCCTGCAAGATGAG	540
QY	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCAC	600
DB	541	CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCAC	600
QY	601	TTTTGCTGTGGAAAGACTGTTTTTCATATGTTTATCTCAGATAAAGATTTAAATGG	660
DB	601	TTTTGCTGTGGAAAGACTGTTTTTCATATGTTTATCTCAGATAAAGATTTAAATGG	660
QY	661	TACGTATAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAATTTGCACTT	720
DB	661	TACGTATAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAATTTGCACTT	720
QY	721	TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT	780
DB	721	TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT	780
QY	781	GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTCATTGAAACAGTATCTAA	840

DB	781	GAAGCTTTTGTATAGGAATCTGTAGGGCTCATTTTGGTTCATTGAAACAGTATCTAA	840
QY	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCGATGAAGTGAAGATGATATCTGAC	900
DB	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCGATGAAGTGAAGATGATATCTGAC	900
QY	901	TGGGAACTTCATGAGGTTTCCCTCATCTGTCATGTCGATGATATATATGATACAT	960
DB	901	TGGGAACTTCATGAGGTTTCCCTCATCTGTCATGTCGATGATATATATGATACAT	960
QY	961	AAAAATAAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATG	1020
DB	961	AAAAATAAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATG	1020
QY	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATATATATCTGCTTAAATCTTAAAG	1080
DB	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATATATATCTGCTTAAATCTTAAAG	1080
QY	1081	AGTAAACATGATATATAAATATATCTGCTGATGATGATGATGATGATGATGAT	1140
DB	1081	AGTAAACATGATATATAAATATATCTGCTGATGATGATGATGATGATGATGAT	1140
QY	1141	TTAAATGCTTTTATTTTAAAGACATCTTATTAAGAAATTTGCTTATTTATCTG	1200
DB	1141	TTAAATGCTTTTATTTTAAAGACATCTTATTAAGAAATTTGCTTATTTATCTG	1200
QY	1201	TTCTAATCTGCTGCTTAAAGATTTTAAAGATTTTGCAGTACTACAGATTTTCA	1260
DB	1201	TTCTAATCTGCTGCTTAAAGATTTTAAAGATTTTGCAGTACTACAGATTTTCA	1260
QY	1261	GAATCAGAGAAAATTTGTATACCATCTGCTGCTTCTTCTTGTAGTGCATACAA	1320
DB	1261	GAATCAGAGAAAATTTGTATACCATCTGCTGCTTCTTCTTGTAGTGCATACAA	1320
QY	1321	GAATTTAAAGACTC 1333	
DB	1321	GAATTTAAAGACTC 1333	

RESULT 33
ADB73010
ID ADB73010 standard; cDNA; 1333 BP.
XX
AC ADB73010;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003092887-A1.
XX
PD 15-MAY-2003.
XX
PF 12-AUG-2002; 2002US-00218956.
XX
PR 29-JUN-2001; 2001WO-US021066.
XX
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX P-PSDB; ADB73011.
XX WPI; 2003-777258/73.
XX DR P-PSDB; ADB73011.
XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
PT molecular weight markers, for treating arthritis, tumor.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO382, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1476, PRO1567,
CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO1543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGGCTCCGATCGGCTTCACTGTCGGCGCTTCTGCTACATCGTCGGCTGCTGCT 60
Db 1 GCCACGGCTCCGATCGGCTTCACTGTCGGCGCTTCTGCTACATCGTCGGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTCTTCCGCAATTTGGCAATATAGCATTTGATGAGCTGAGAC 120
Db 61 CACTGCGCGCTCATCTCTTCCGCAATTTGGCAATATAGCATTTGATGAGCTGAGAC 120
QY 121 TGATTACAAGATCCCTATAGACCAAGTGTAATACCTCGAATCCCTTGTAATCCCAAGTA 180
Db 121 TGATTACAAGATCCCTATAGACCAAGTGTAATACCTCGAATCCCTTGTAATCCCAAGTA 180
QY 181 CCTCATCCAGCTTCTCTTCTGTCATGTTCTTCTGTCGAGCAGAGTGGCTTACATGGG 240
Db 181 CCTCATCCAGCTTCTCTTCTGTCATGTTCTTCTGTCGAGCAGAGTGGCTTACATGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATAGTAGCCAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATAGTAGCCAGTATGAG 300

QY 301 TGGCCCGAGGACTTATGACCCCTAGCAACCATCATGAATGCAGATATTTCTAGCATATTGTCA 360
Db 301 TGGCCCGAGGACTTATGACCCCTAGCAACCATCATGAATGCAGATATTTCTAGCATATTGTCA 360
QY 361 GAAGGAGGATGGTGCAGAAATTTAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTGCAGAAATTTAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAAACAACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCTATCTTTTGGTGGAGCTCTTAGAAACAACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGAATTTCTATCCAGCAAGATCCCTGCAAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGGAATTTCTATCCAGCAAGATCCCTGCAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATATAATTAATATAAATGATTACTCTGTGTTTGCAGAGTTTGCACATTC 720
Db 661 TACGTATATAATTAATATAAATGATTACTCTGTGTTTGCAGAGTTTGCACATTC 720
QY 721 TTAAGGAACGCCATAAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
Db 721 TTAAGGAACGCCATAAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
QY 781 GAGGCTTTTGTATAGAACTTTAGGCTCATTTGGTTCATTTGTTTCAATGAAAGATTTCTAA 840
Db 781 GAGGCTTTTGTATAGAACTTTAGGCTCATTTGGTTCATTTGTTTCAATGAAAGATTTCTAA 840
QY 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATATATATCTGACTAG 900
Db 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATATATATCTGACTAG 900
QY 901 TGGGAAACTTCATGCGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATTTAC 960
Db 901 TGGGAAACTTCATGCGGTTTCCCTCATCTGTCATGTCGATGATATATATGATATTTAC 960
QY 961 AAAAAATTAAGGCGGGAATTTTCCCTGCTGGAATATATCCCTGATATTTGCAATGAAT 1020
Db 961 AAAAAATTAAGGCGGGAATTTTCCCTGCTGGAATATATCCCTGATATTTGCAATGAAT 1020
QY 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATTTCTTAAGCATA 1080
Db 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTGCTTTAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTTGAAGACATTTACTTTATTAAGAAATTTGTTTATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGAAGACATTTACTTTATTAAGAAATTTGTTTATGCTTACTG 1200
QY 1201 TTTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAGGTTACTACAGATTTTCAAACT 1260
Db 1201 TTTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAGGTTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTATACCATCTGCTGTTCTTTAGTGAATATACATAAATACCT 1320
Db 1261 GAATGAGAGAAATTTGTATACCATCTGCTGTTCTTTAGTGAATATACATAAATACCT 1320
QY 1321 GAAATTTAAGACTC 1333
Db 1321 GAAATTTAAGACTC 1333

RESULT 34
ADB76543
ID ADB76543 standard; cDNA; 1333 BP.
XX AC
XX ADB76543;
XX DT 04-DEC-2003 (first entry)
XX DE Human PRO polynucleotide sequence #81.
XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX OS Homo sapiens.
XX PN US2003083248-A1.
XX PD 01-MAY-2003.
XX PF 16-OCT-2001; 2001US-00978757.
XX PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077633P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 01-APR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US000356.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUN-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001WO-US009552.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AV, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Filvaroff E, Gong S, Gao W, Gerber H, Gerritsen MB;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX WPI; 2003-755118/71.
 DR P-PSDB; ADB76544.
 XX
 PT New PRO polypeptides useful for treating peripheral neuropathy,
 PT neuropathies associated with systemic disease such as post-polio syndrome
 PT or AIDS-associated syndrome.
 XX
 PS Claim 2; Fig 128; 425pp; English.
 XX
 CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for linking
 CC bioactive molecules to cells expressing PRO polypeptides, for modulating
 CC biological activities of cells expressing PRO polypeptides, and for
 CC identifying agonists or antagonists. The bioactive molecule maybe a
 CC toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides
 CC are useful for treating neuropathy and neuropathy related diseases such
 CC as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCCAGCGGCCGATGGCGTTTCACGTTTCGGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 DB 1 GCCCAGCGGCCGATGGCGTTTCACGTTTCGGGGCTTCTGCTACATGCTGGCGTGTGCT 60
 QY 61 CACTGGCGCGCTCATCTCTTCGCGATTTCGGCAATPATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGGCGCGCTCATCTCTTCGCGATTTCGGCAATPATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCCTATAGACAGCTGAATACCCCTGAATCCCTGTACTCCAGAGTA 180
 DB 121 TGATTACAGAAATCCCTATAGACAGCTGAATACCCCTGAATCCCTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTCTCTGTGCTAATGTTTCTTTGTGACAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTCTGTGCTAATGTTTCTTTGTGACAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCCCTCTGTGCAATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
 DB 241 TCTCAATATGCCCCCTCTGTGCAATATCATATTTGGAGGTATATGAGTAGACAGTGAATGAG 300
 QY 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTCTAGCATATTTGTC 360
 DB 301 TGGCCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTCTAGCATATTTGTC 360
 QY 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTACCTATATGG 420
 DB 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTACCTATATGG 420
 QY 421 CATGATCTATGTTTGTGCTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGTGCTGAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTTATTTTAAAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCTTTATTTTAAAAATGTTTCCACAT 600
 QY 601 TTTTGTCTTGTGGAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTTGTGGAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TAGCTATAAATTAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 DB 661 TAGCTATAAATTAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTTC 720
 QY 721 TTAAGGAACAGCCATATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
 DB 721 TTAAGGAACAGCCATATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
 QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCATTTTGGTTCATTTGAAACAGTATCTAA 840
 QY 841 TTATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900
 DB 841 TTATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 900
 QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATCATATATATATGATGATGATGAT 960
 DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATCATATATATATGATGATGATGAT 960
 QY 961 AAAAAATAAAGGCGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATATAT 1020
 DB 961 AAAAAATAAAGGCGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATATATAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATATATATATATATATATATATAT 1080
 DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATATATATATATATATATATATAT 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGTAAGAAATGCAATTTAAAGCTAT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGTAAGAAATGCAATTTAAAGCTAT 1140
 QY 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
 DB 1141 TTAATATGCTTTTATTTGTAAGACATTAATTTAAGAAATTTGGTATTTATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACAGTACTACAGATTTTCAAACT 1260
 DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGACAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAAATTTGATATACCACTCTGCTCTCTTTAGTGAATACAAATAAAACTCT 1320

1261 GAATGAGAGAAAATTGTATACCATCTGCTGTTCTTTATGTCGAATACAATAAACTCT 1320

PR	29-MAR-1999;	99US-0126773P.	QY	61	CACTGCCGCTCATCTTCTTCCCATTTGGCACATTAAGCATTTGATGAGCTGAAGAC	120
PR	12-APR-1999;	99US-00284291.	Db	61	CACTGCCGCTCATCTTCTTCCCATTTGGCACATTAAGCATTTGATGAGCTGAAGAC	120
PR	21-APR-1999;	99US-0130232P.	QY	121	TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGTA	180
PR	26-APR-1999;	99US-0131022P.	Db	121	TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCACAGTA	180
PR	28-APR-1999;	99US-0131445P.	QY	181	CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGG	240
PR	14-MAY-1999;	99US-00311832.	Db	181	CCTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGG	240
PR	14-MAY-1999;	99US-0134287P.	QY	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATG	300
PR	14-MAY-1999;	99WO-US010733.	Db	241	TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGAATG	300
PR	02-JUN-1999;	99WO-US012252.	QY	301	TGCCCCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATTTG	360
PR	16-JUN-1999;	99US-0139557P.	Db	301	TGCCCCCAGGACTCTATGACCTTACACCATCATGAATGAGATATTTCTAGCATATTTG	360
PR	23-JUN-1999;	99US-0141037P.	QY	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTTAGCATTTTCTTACTACTATATGG	420
PR	07-JUL-1999;	99US-0142680P.	Db	361	GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTTTAGCATTTTCTTACTACTATATGG	420
PR	26-JUL-1999;	99US-0145698P.	QY	421	CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTA	480
PR	28-JUL-1999;	99US-0146222P.	Db	421	CATGATCTATGTTTGGTGAGCTCTTAGAACCAACACACAGAGAAATTTGGTCCAGTTA	480
PR	25-AUG-1999;	99US-00380137.	QY	481	GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540
PR	25-AUG-1999;	99US-00380142.	Db	481	GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC	540
PR	29-OCT-1999;	99US-0162506P.	QY	541	CTGTGGAATCTGATCAGTTACTTTTAAATAAGTGCCTCTTATTTTAAATGTTTCCACAT	600
PR	30-DEC-1999;	99WO-US031243.	Db	541	CTGTGGAATCTGATCAGTTACTTTTAAATAAGTGCCTCTTATTTTAAATGTTTCCACAT	600
PR	02-DEC-1999;	99WO-US030095.	QY	601	TTTTTGTCTGGAAGACGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGTTT	660
PR	30-DEC-1999;	99WO-US031274.	Db	601	TTTTTGTCTGGAAGACGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGTTT	660
PR	05-JAN-2000;	2000WO-US000219.	QY	661	TACGTATAAATTAATAAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGC	720
PR	06-JAN-2000;	2000WO-US000277.	Db	661	TACGTATAAATTAATAAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGC	720
PR	11-FEB-2000;	2000WO-US003565.	QY	721	TTAAGGAACAGCCATTAATCTCTGATGATGATTAATTTACTGACGTCTCTAGTAC	780
PR	18-FEB-2000;	2000WO-US004341.	Db	721	TTAAGGAACAGCCATTAATCTCTGATGATGATTAATTTACTGACGTCTCTAGTAC	780
PR	24-FEB-2000;	2000WO-US005004.	QY	781	GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTGAAACAGATATCT	840
PR	02-MAR-2000;	2000WO-US005841.	Db	781	GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTCATTTGAAACAGATATCT	840
PR	10-MAR-2000;	2000WO-US006319.	QY	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTG	900
PR	21-MAR-2000;	2000WO-US007532.	Db	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTG	900
PR	30-MAR-2000;	2000WO-US008439.	QY	901	TGGGAACTTCTATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGGAATAC	960
PR	17-MAY-2000;	2000WO-US013705.	Db	901	TGGGAACTTCTATGGGTTTCTCATCTGTCATGTCGATGATTAATATATGGAATAC	960
PR	30-MAY-2000;	2000WO-US014941.	QY	961	AAAAATAAAAGCGGAAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCGAT	1020
PR	02-JUN-2000;	2000WO-US015264.	Db	961	AAAAATAAAAGCGGAAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTCGAT	1020
PR	28-JUL-2000;	2000WO-US020710.	QY	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTTCTGCTTTAAATCTTAAG	1080
PR	24-AUG-2000;	2000WO-US023328.	Db	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTTCTGCTTTAAATCTTAAG	1080
PR	08-NOV-2000;	2000US-00709238.	QY	1081	AGTAAACATGATATAAATAATATCTGTAATTTACTTGTGAAGATGCAATTTAAAG	1140
PR	21-NOV-2000;	2000US-00727749.	Db	1081	AGTAAACATGATATAAATAATATCTGTAATTTACTTGTGAAGATGCAATTTAAAG	1140
PR	01-DEC-2000;	2000WO-US032678.	QY	1141	TTAAATGCTTTTATTTTGTAAAGACATTTACTTTTAAAGAAATTTGGTTATTATG	1200
PR	20-DEC-2000;	2000WO-US0347259.	Db			
PR	28-DEC-2000;	2000WO-US034956.	QY			
PR	28-FEB-2001;	2001WO-US006520.	Db			
PR	22-MAR-2001;	2001US-00816744.	QY			
PR	22-MAR-2001;	2001US-00816920.	Db			
PR	22-MAR-2001;	2001WO-US009552.	QY			
PR	10-MAY-2001;	2001US-00854208.	Db			
PR	25-MAY-2001;	2001WO-US017092.	QY			
PR	01-JUN-2001;	2001US-00872035.	Db			
PR	01-JUN-2001;	2001WO-US017800.	QY			
PR	08-JUN-2001;	2001US-00874503.	Db			
PR	14-JUN-2001;	2001US-00882636.	QY			
PR	19-JUN-2001;	2001US-00886342.	Db			
PR	20-JUN-2001;	2001WO-US019692.	QY			
PR	29-JUN-2001;	2001WO-US021066.	Db			
PR	09-JUL-2001;	2001WO-US021735.	QY			
PR	30-JUL-2001;	2001US-00918585.	Db			
XX			QY			
XX			Db			

(GETH) GENENTECH INC.

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGCTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGCGGCTTACGTTCCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

```
Db 1141 TTAATGCTGTTTATTTATTTGTAAGACATTACTTATTAAAGAAATGGTTATTATGCTTACTG 1200
QY 1201 TTCTTAATCTGGTGAAGAGTATTTCTTAAGAATTTGCAGGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTTAATCTGGTGAAGAGTATTTCTTAAGAATTTGCAGGTACTACAGATTTTCAAACT 1260
QY 1261 GAATCAGAGAGAAATTTGTAACCATCTGCTCTTCTTTAGTGCATACAAATAAACTCT 1320
Db 1261 GAATCAGAGAGAAATTTGTAACCATCTGCTCTTCTTTAGTGCATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 36
ADC61729
ID ADC61729 standard; cDNA; 1333 BP.
XX
AC ADC61729;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003049684-A1.
XX
PD 13-MAR-2003.
XX
PF 24-OCT-2001; 2001US-00017081.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 21-NOV-1997; 97US-0065311P.
PR 11-MAR-1998; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077643P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083559P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0080863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-010038P.
PR 07-OCT-1998; 98US-00168978.
PR 02-NOV-1998; 98US-00184214.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-00204855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
```

```
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99US-00265686.
PR 12-MAR-1999; 99WO-US0005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-MAR-1999; 99US-0126773P.
PR 12-MAR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 28-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 200WO-US000219.
PR 06-JAN-2000; 200WO-US000277.
PR 06-JAN-2000; 200WO-US000376.
PR 11-FEB-2000; 200WO-US003565.
PR 18-FEB-2000; 200WO-US004341.
PR 24-FEB-2000; 200WO-US005004.
PR 02-MAR-2000; 200WO-US005841.
PR 10-MAR-2000; 200WO-US006319.
PR 21-MAR-2000; 200WO-US007532.
PR 30-MAR-2000; 200WO-US008439.
PR 17-MAY-2000; 200WO-US013705.
PR 22-MAY-2000; 200WO-US014042.
PR 30-MAY-2000; 200WO-US014941.
PR 02-JUN-2000; 200WO-US015264.
PR 28-JUL-2000; 200WO-US020710.
PR 28-AUG-2000; 200WO-US023328.
PR 08-NOV-2000; 200US-00709238.
PR 27-NOV-2000; 200US-00723749.
PR 01-DEC-2000; 200WO-US032678.
PR 20-DEC-2000; 200US-00747259.
PR 20-DEC-2000; 200WO-US034956.
PR 28-FEB-2001; 200WO-US006520.
PR 22-MAR-2001; 200US-00816744.
PR 22-MAR-2001; 200US-00816920.
PR 22-MAR-2001; 200WO-US009552.
PR 10-MAY-2001; 200US-00854208.
PR 19-MAY-2001; 200US-00854280.
PR 25-MAY-2001; 200US-00817092.
PR 01-JUN-2001; 200US-00872035.
PR 01-JUN-2001; 200WO-US017800.
PR 05-JUN-2001; 200US-00874503.
PR 14-JUN-2001; 200US-00882636.
PR 19-JUN-2001; 200US-00886342.
PR 20-JUN-2001; 200WO-US019692.
PR 28-JUN-2001; 200WO-US021066.
PR 09-JUL-2001; 200WO-US021735.
PR 30-JUL-2001; 200US-00918585.
XX (GETH ) GENENTECH INC.
PA
XX
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
```

```
Db      1021 GAGAGATTCCCATATTTCCATCAGAGTAATAAATATATCTTGCTTTAAATCTTAAGCATA 1080
Qy      1081 AGTAAACATGATATAAAAATATATCTGTAATTAATCTTGGAAGAAATGCAATTTAAAGCTATT 1140
Db      1081 AGTAAACATGATATAAAAATATATCTGTAATTAATCTTGGAAGAAATGCAATTTAAAGCTATT 1140
Qy      1141 TTAATGTTGTTTATTTTGAAGACATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db      1141 TTAATGTTGTTTATTTTGAAGACATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Qy      1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db      1201 TTCTAATCTGGTGGTAAAGGTAATCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Qy      1261 GAATCAGAGAAATTTGTAATACCATCTGCTGCTTTCTTTAGTGCATACATAAAACTCT 1320
Db      1261 GAATCAGAGAAATTTGTAATACCATCTGCTGCTTTCTTTAGTGCATACATAAAACTCT 1320
Qy      1321 GAAATTAAGACTC 1333
Db      1321 GAAATTAAGACTC 1333

RESULT 37
ID      ADC63693
XX      ADC63693 standard; cDNA; 1333 BP.
AC      ADC63693;
XX
DT      18-DEC-2003 (first entry)
XX
DE      Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
KW      Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW      cytosolic; ophthalmological; antirheumatic; osteopathic; antirheumatic;
KW      vulnery; auditory; tumour growth; retinal disorder;
KW      sports-related joint problem; articular cartilage defects;
KW      osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS      Homo sapiens.
XX
FN      US2003054405-A1.
XX
PD      20-MAR-2003.
XX
PF      24-OCT-2001; 2001US-00998833.
XX
PR      17-OCT-1997; 97US-0062250P.
PR      03-NOV-1997; 97US-0064249P.
PR      13-NOV-1997; 97US-0065311P.
PR      21-NOV-1997; 97US-0066364P.
PR      10-MAR-1998; 98US-0077450P.
PR      11-MAR-1998; 98US-0077632P.
PR      11-MAR-1998; 98US-0077641P.
PR      11-MAR-1998; 98US-0077649P.
PR      12-MAR-1998; 98US-0077791P.
PR      13-MAR-1998; 98US-0078004P.
PR      17-MAR-1998; 98US-00040220.
PR      20-MAR-1998; 98US-0078886P.
PR      20-MAR-1998; 98US-0078910P.
PR      20-MAR-1998; 98US-0078936P.
PR      20-MAR-1998; 98US-0078939P.
PR      25-MAR-1998; 98US-0079294P.
PR      26-MAR-1998; 98US-0079656P.
PR      27-MAR-1998; 98US-0079663P.
PR      27-MAR-1998; 98US-0079664P.
PR      27-MAR-1998; 98US-0079689P.
PR      27-MAR-1998; 98US-0079728P.
PR      27-MAR-1998; 98US-0079786P.
PR      30-MAR-1998; 98US-0079920P.
PR      30-MAR-1998; 98US-0079923P.
PR      31-MAR-1998; 98US-0080105P.
PR      31-MAR-1998; 98US-0080107P.
PR      31-MAR-1998; 98US-0080165P.
PR      01-APR-1998; 98US-0080194P.
PR      01-APR-1998; 98US-0080327P.
PR      01-APR-1998; 98US-0080328P.
PR      01-APR-1998; 98US-0080333P.
PR      01-APR-1998; 98US-0080334P.
PR      08-APR-1998; 98US-0081049P.
PR      08-APR-1998; 98US-0081070P.
PR      08-APR-1998; 98US-0081071P.
PR      09-APR-1998; 98US-0081195P.
PR      09-APR-1998; 98US-0081203P.
PR      09-APR-1998; 98US-0081229P.
PR      15-APR-1998; 98US-0081817P.
PR      15-APR-1998; 98US-0081819P.
PR      15-APR-1998; 98US-0081838P.
PR      15-APR-1998; 98US-0081952P.
PR      15-APR-1998; 98US-0081955P.
PR      21-APR-1998; 98US-0082568P.
PR      21-APR-1998; 98US-0082569P.
PR      22-APR-1998; 98US-0082700P.
PR      22-APR-1998; 98US-0082704P.
PR      22-APR-1998; 98US-0082797P.
PR      23-APR-1998; 98US-0082804P.
PR      27-APR-1998; 98US-0083336P.
PR      28-APR-1998; 98US-0083322P.
PR      29-APR-1998; 98US-0083392P.
PR      29-APR-1998; 98US-0083495P.
PR      29-APR-1998; 98US-0083496P.
PR      29-APR-1998; 98US-0083499P.
PR      29-APR-1998; 98US-0083500P.
PR      29-APR-1998; 98US-0083545P.
PR      29-APR-1998; 98US-0083554P.
PR      29-APR-1998; 98US-0083558P.
PR      30-APR-1998; 98US-0083559P.
PR      30-APR-1998; 98US-0083742P.
PR      05-MAY-1998; 98US-0084366P.
PR      06-MAY-1998; 98US-0084414P.
PR      06-MAY-1998; 98US-0084441P.
PR      07-MAY-1998; 98US-0084598P.
PR      07-MAY-1998; 98US-0084600P.
PR      07-MAY-1998; 98US-0084627P.
PR      07-MAY-1998; 98US-0084637P.
PR      07-MAY-1998; 98US-0084639P.
PR      07-MAY-1998; 98US-0084640P.
PR      07-MAY-1998; 98US-0084643P.
PR      13-MAY-1998; 98US-0085323P.
PR      13-MAY-1998; 98US-0085338P.
PR      13-MAY-1998; 98US-0085339P.
PR      15-MAY-1998; 98US-0085573P.
PR      15-MAY-1998; 98US-0085579P.
PR      15-MAY-1998; 98US-0085580P.
PR      15-MAY-1998; 98US-0085582P.
PR      15-MAY-1998; 98US-0085689P.
PR      15-MAY-1998; 98US-0085697P.
PR      15-MAY-1998; 98US-0085700P.
PR      15-MAY-1998; 98US-0085704P.
PR      18-MAY-1998; 98US-0086023P.
PR      22-MAY-1998; 98US-0086392P.
PR      22-MAY-1998; 98US-0086414P.
PR      22-MAY-1998; 98US-0086430P.
PR      22-MAY-1998; 98US-0086486P.
PR      28-MAY-1998; 98US-0087086P.
PR      28-MAY-1998; 98US-0087106P.
PR      28-MAY-1998; 98US-0087208P.
PR      26-JUN-1998; 98US-00105413.
PR      26-JUN-1998; 98US-0090863P.
PR      01-JUL-1998; 98US-0091010P.
PR      30-JUL-1998; 98US-0091359P.
PR      11-SEP-1998; 98US-0094651P.
PR      07-OCT-1998; 98US-0100038P.
PR      98US-00168978.
```

PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187366.
PR 20-NOV-1998; 98US-0103304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-0017092.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-008866342.

PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
XX
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTCACTTCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGTTCACTTCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCCTGGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCCTGGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGAATTAAGAATCCTATAGACAGTGAATACCTGAATCCCTGTTACTCCCGAGTGA 180
DB 121 TGAATTAAGAATCCTATAGACAGTGAATACCTGAATCCCTGTTACTCCCGAGTGA 180
QY 181 CCTCATCCAGCTTCTCTGTGTCACTTTCTTGTGCAGCAGAGTGGCTTACACTGG 240
DB 181 CCTCATCCAGCTTCTCTGTGTCACTTTCTTGTGCAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCCCTTTGGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGA 300
DB 241 TCTCAATATGCCCCCTTTGGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGA 300
QY 301 TGGCCCCAGGCTCTATGACCCCTACCAACCATCATGAATCAGATATTCAGCATATGTCA 360
DB 301 TGGCCCCAGGCTCTATGACCCCTACCAACCATCATGAATCAGATATTCAGCATATGTCA 360
QY 361 GAAAGGAAGGTGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAAGGAAGGTGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAAGAGGATCTATCCAGCAGATCCTGTCGAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCCAAAAGAGGATCTATCCAGCAGATCCTGTCGAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAAGACTCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAAGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGGCTTGTGAAAGACCTGTTTTCATATGTTATATCTGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGGCTTGTGAAAGACCTGTTTTCATATGTTTATATCTGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTACCTCTGGTGTGTGACAGGTTTGCACTTTC 720
DB 661 TACGTATAAATTAATAAATGATTACCTCTGGTGTGTGACAGGTTTGCACTTTC 720
QY 721 TTAAGGAACAGCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATG 780
DB 721 TTAAGGAACAGCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCAATTTGGTTCATTTCAATGAAACAGATATCAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCAATTTGGTTCATTTCAATGAAACAGATATCAA 840
QY 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGTGAGTGAAGTGAATATATATCTGACTAG 900
DB 841 TTATATAATTAGCTGTAGATATCAGGTGCTTCTGTGAGTGAAGTGAATATATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCTCTCATCTGTCTGATCGATGATATATATATGATACATTTAC 960

XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NP, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX WPI; 2003-596568/56.
DR P-PSDB; ADC66794.
XX
PT Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them, useful for treating wound healing, tissue growth and
PT muscle generation and regeneration, amiotrophic lateral sclerosis or
PT neuropathy.
XX
PS Claim 2; SEQ ID NO 321; 472pp; English.
XX
CC The invention describes an isolated secreted and transmembrane PRO
CC polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various
CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating
CC amiotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
CC diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
CC useful for generating transgenic animals or knockout animals which are
CC useful in the development and screening of therapeutically useful
CC reagents, as probes for generating a pool of sequences for identifying
CC related PRO coding sequences, and to construct hybridisation probes for
CC mapping the gene which encodes the PRO and for the genetic analysis of
CC individuals with genetic disorders, for recombinantly expressing (I) and
CC for chromosome identification. (II) is useful as molecular marker for
CC protein electrophoresis purposes, and as therapeutic agents. (I) is also
CC useful for screening compounds to identify those that mimic the PRO
CC polypeptide (agonists) or prevent the effect of the PRO polypeptide
CC (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
CC are useful for immunohistochemical staining and/or assay of sample
CC fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a human secreted and transmembrane PRO
CC protein.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTCAAGTTCGCGGCTTCTGTACATGCTGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTCAAGTTCGCGGCTTCTGTACATGCTGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCTATAGACAGCTGTAATACCTCAATCCCTGCTTACTCCACAGATTA 180
DB 121 TGATTACAAGATCCTATAGACAGCTGTAATACCTGGAATCCCTTGTTACTCCACAGATTA 180
QY 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGAG 300

QY 301 TGGCCGAGGACTCTATGACCCCTACAAACNATCATGATGCGATATTTCTAGCATATTGTCA 360
DB 301 TGGCCGAGGACTCTATGACCCCTACAAACNATCATGATGCGATATTTCTAGCATATTGTCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAT 480
DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACCAACACACAGAGAATTTGGTCCAGTTAAT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGG 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGG 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACTTC 720
DB 661 TAGCTATAAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTGCACTTC 720
QY 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCCATTAATCCTCTGAATGATGATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTAGGGCTCATTTTGGTTCATTTGAAACAGATATCTAA 840
QY 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
DB 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
QY 901 TGGGAACCTTCAATGCTTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATG 960
DB 901 TGGGAACCTTCAATGCTTCTCATCTGTCATGTCATGTCATGTCATGTCATGTCATGTCATG 960
QY 961 AAAATAAAGCGGGAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCC 1020
DB 961 AAAATAAAGCGGGAATTTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCCCTTCC 1020
QY 1021 GAGAGATTTCCCATATTTCCCATGAGTAATAAATACTTCTGCTTTAAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCCATGAGTAATAAATACTTCTGCTTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATGCTGAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTAATGCTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGCTTTTATTTTGTGAAGATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
DB 1141 TTAATATGCTTTTATTTTGTGAAGATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAATCTGGTGAAGATTTCTTAAAGATTTTGCAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGATAAACAATCTGCTGTTCTTCTAGTGAATTAAGTAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATAAACAATCTGCTGTTCTTCTAGTGAATTAAGTAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 39
ADC68917
ID ADC68917 standard; cDNA; 1333 BP.
XX AC
XX AC
XX AC
DT 18-DEC-2003 (first entry)
XX
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
XX
PN US2003064407-A1.
XX
XX 03-APR-2003.
XX
XX 24-OCT-2001; 2001US-00999834.
XX
XX 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083498P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-00202054.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-00000106.
PR 05-JAN-1999; 99US-00254465.
PR 08-MAR-1999; 99US-0005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130212P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.


```
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-007093238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA
XX
PI (GETH ) GENENTECH INC.
Ashkenazi AJ, Baker KP, Botstein D, Desnovers L, Eaton DL;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGTCCGATGGCGTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGGTGGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTCACGTTCCGGGCTTCTGCTACATGCTGGCGTGGTGGCT 60
QY 61 CACTGGCGGCTCATCTTCTTCCGCAATTTGGSCAATPATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGGCGGCTCATCTTCTTCCGCAATTTGGSCAATPATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGAGTGTATACCTGAATCCCGTTGTACTCCAGATTA 180
DB 121 TGATTACAGAAATCCTATAGACAGAGTGTATACCTGAATCCCGTTGTACTCCAGATTA 180
```

```
QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCAGAGAGTGCTTACATGGG 240
DB CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCAGAGAGTGCTTACATGGG 240
QY 241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGATGACAGATGATGAG 300
DB TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGATGACAGATGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCCAGATATTTAGCATATTTGCA 360
DB TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATCCAGATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGAGTGGTGAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB GAAGGAAGAGTGGTGAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTTTAGAACAAACACACAGAGAAATTCGTCAGTAAAGT 480
DB CATGATCTATGTTTGGTGAGCTTTAGAACAAACACACAGAGAAATTCGTCAGTAAAGT 480
QY 481 GCATGCAAAAAGGCCCAATGAAGGATTTCTATCCAGAAAGATCCTGTCCAGAGTAGC 540
DB GCATGCAAAAAGGCCCAATGAAGGATTTCTATCCAGAAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
DB CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGAAAGACTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
DB TTTTCTTGTGAAAGACTGTTTTCATATGTTTATCTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
DB TACGTATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
DB TTAAGGAACAGCCATAATCTCTGATGATTAATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTGGTGTTCATTTGAACAGATTAATA 840
DB GAAGCTTTTGTATAGGAACCTTGAGGCTCATTTGGTGTTCATTTGAACAGATTAATA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAAGTGAATGATATCTGACTAG 900
DB TTATAAATTAGCTGTAGATATCAGGTCTTCTGATGAGTGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATACATTTAC 960
DB TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATACATTTAC 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAT 1020
DB AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTCTGCTTTAATTTCTTAAGCAATA 1080
DB GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTCTGCTTTAATTTCTTAAGCAATA 1080
QY 1081 AGTAAACATGATATATAAATAATATGCTGAATTTACTTTGGAAGATGCAATTTAAGCAAT 1140
DB AGTAAACATGATATATAAATAATATGCTGAATTTACTTTGGAAGATGCAATTTAAGCAAT 1140
QY 1141 TTAATATGTTTTTATTTGTAAGACATTTACTTTAAGAAATTTGTTTATTTATGCTTACTG 1200
DB TTAATATGTTTTTATTTGTAAGACATTTACTTTAAGAAATTTGTTTATTTATGCTTACTG 1200
QY 1201 TTTCTAATCTGGTGAAGGATTTCTTAAGATTTTCCAGGTACTACAGATTTTCAAACT 1260
DB TTTCTAATCTGGTGAAGGATTTCTTAAGATTTTCCAGGTACTACAGATTTTCAAACT 1260
```

```
QY 1261 GAATGAGAGAAATTTATACCACTCTGCTGTTCTTTACTGCAATACATAAACTCT 1320
Db |||||||
QY 1261 GAATGAGAGAAATTTATACCACTCTGCTGTTCTTTACTGCAATACATAAACTCT 1320
Db |||||||
QY 1321 GAAATTAAAGACTC 1333
Db |||||||
QY 1321 GAAATTAAAGACTC 1333
Db |||||||

RESULT 40
ADC62977
ID ADC62977 standard; cdna; 1333 BP.
AC ADC62977;
XX
XX
XX 18-DEC-2003 (first entry)
XX Human cDNA encoding secreted/transmembrane protein, PRO181.
XX
XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
XX Homo sapiens.
XX
XX US2003068648-A1.
XX
XX 10-APR-2003.
XX
XX 25-OCT-2001; 2001US-00013921.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077649P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 20-MAR-1998; 98US-0078886P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 31-MAR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081193P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081223P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081838P.
XX
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 22-APR-1998; 98US-0082804P.
XX 23-APR-1998; 98US-0082796P.
XX 27-APR-1998; 98US-0083322P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083392P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083500P.
XX 29-APR-1998; 98US-0083545P.
XX 29-APR-1998; 98US-0083554P.
XX 29-APR-1998; 98US-0083558P.
XX 29-APR-1998; 98US-0083559P.
XX 30-APR-1998; 98US-0083742P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 06-MAY-1998; 98US-0084441P.
XX 07-MAY-1998; 98US-0084598P.
XX 07-MAY-1998; 98US-0084600P.
XX 07-MAY-1998; 98US-0084627P.
XX 07-MAY-1998; 98US-0084637P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 13-MAY-1998; 98US-0085323P.
XX 13-MAY-1998; 98US-0085339P.
XX 15-MAY-1998; 98US-0085573P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085689P.
XX 15-MAY-1998; 98US-0085697P.
XX 15-MAY-1998; 98US-0085700P.
XX 18-MAY-1998; 98US-0085704P.
XX 22-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086414P.
XX 22-MAY-1998; 98US-0086430P.
XX 22-MAY-1998; 98US-0086486P.
XX 28-MAY-1998; 98US-0087098P.
XX 28-MAY-1998; 98US-0087106P.
XX 28-MAY-1998; 98US-0087208P.
XX 26-JUN-1998; 98US-0090863P.
XX 26-JUN-1998; 98US-0091010P.
XX 01-JUL-1998; 98US-0091359P.
XX 30-JUL-1998; 98US-0094651P.
XX 11-SEP-1998; 98US-0100038P.
XX 07-OCT-1998; 98WO-US021141.
XX 20-NOV-1998; 98US-0109304P.
XX 22-DEC-1998; 98WO-US024855.
XX 22-DEC-1998; 98US-0113296P.
XX 05-JAN-1999; 99WO-US000106.
XX 08-MAR-1999; 99WO-US005028.
XX 10-MAR-1999; 99WO-US005190.
XX 12-MAR-1999; 99US-0123957P.
XX 29-MAR-1999; 99US-0126773P.
XX 21-APR-1999; 99US-0130232P.
XX 26-APR-1999; 99US-0131022P.
XX 28-APR-1999; 99US-0131445P.
XX 14-MAY-1999; 99US-0134287P.
XX 14-MAY-1999; 99WO-US010723.
XX 02-JUN-1999; 99WO-US012252.
XX 16-JUN-1999; 99US-0139557P.
XX 30-NOV-1999; 99WO-US028313.
XX 02-DEC-1999; 99WO-US028551.
```

PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 30-DEC-1999; 99WO-US031295.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 22-MAR-2001; 2001WO-US009552.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 30-JUL-2001; 2001US-00918585.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Baton DL;
 PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
 PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
 PI Stewart TA, Tumas D, Williams PM, Wood WI;
 XX
 DR WPI: 2003-695924/66.
 DR P-PSDB; AD62978.
 XX
 PT New isolated secreted and transmembrane PRO polypeptides, useful in the
 PT preparation of a medicament for treating a condition responsive to the
 PT polypeptide, and as therapeutic agents e.g. vaccines.
 XX
 PS Claim 2; SEQ ID NO 321; 467pp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 94 fully defined sequences as given
 CC in the specification (including PRO lacking its associated signal
 CC peptide, a PRO extracellular domain with or without its associated signal
 CC peptide). Also included are nucleic acids encoding the PRO proteins
 CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
 CC comprising the vector and producing PRO, a chimeric molecule comprising
 CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
 CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
 CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
 CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
 CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
 CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
 CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
 CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
 CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCGATGGCGTTCCAGCTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGGCTCGATGGCGTTCCAGCTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTAGCAATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCAATTTAGCAATTTGATGAGCTGAAGAC 120
 QY 121 TGATTTACAGAAATCCTATAGACCACTGTAATACCTCGAATCCCTTGTACTCCCAAGATA 180
 DB 121 TGATTTACAGAAATCCTATAGACCACTGTAATACCTCGAATCCCTTGTACTCCCAAGATA 180
 QY 181 CCTCATCCACGGCTTCTTCTGTGTCATGTTCTTTGTGCGACAGAGTGGCTTACATGGG 240
 DB 181 CCTCATCCACGGCTTCTTCTGTGTCATGTTCTTTGTGCGACAGAGTGGCTTACATGGG 240
 QY 241 TCTCAATATGCCCTTCTTGGCAATTTAGCTTTTATCTTCTAGCAATTTTACTACTATGG 300
 DB 241 TCTCAATATGCCCTTCTTGGCAATTTAGCTTTTATCTTCTAGCAATTTTACTACTATGG 300
 QY 301 TGGCCCGAGGACTCTATGATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATATTTGCA 360
 DB 301 TGGCCCGAGGACTCTATGATGACCCCTACCAACCATCATGAATGAGATATTTCTAGCATATTTGCA 360
 QY 361 GAAGGAAGATGGTGCAAAATTTAGCTTTTATCTTCTAGCAATTTTACTACTATGG 420
 DB 361 GAAGGAAGATGGTGCAAAATTTAGCTTTTATCTTCTAGCAATTTTACTACTATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAGAGAAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACAACAGAGAAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACCTTTAAAAAAGACTCCCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACCTTTAAAAAAGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGTTGGAAAGAGCTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTGTTGGAAAGAGCTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATCTGACTGCTCTAGTACATG 780
 DB 721 TTAAGGAACAGCCATAATCCTCTGATGATGATTAATCTGACTGCTCTAGTACATG 780
 QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAAACAGATCTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAAACAGATCTAA 840
 QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAACTTCAATGCGTTTCTCTCATCTGATGCGATGATATATATGATGATTTAC 960
 DB 901 TGGGAACTTCAATGCGTTTCTCTCATCTGATGCGATGATATATATGATGATTTAC 960
 QY 961 AAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 DB 961 AAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 QY 1021 GAGAGATTTCCCAATTTTCCATCAGAGTAATAAATATATCTTGCCTTAAATTTTAAAGCATA 1080
 DB 1021 GAGAGATTTCCCAATTTTCCATCAGAGTAATAAATATATCTTGCCTTAAATTTTAAAGCATA 1080
 QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGCAATTTTAAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTGTGAAGATGCAATTTTAAAGCTATT 1140

```
QY 1141 TTAATGCTGTTTATTGTTAAGACATTAAGACATTAAGAAATGGTTATTATGCTTACTG 1200
Db |||||
QY 1141 TTAATGCTGTTTATTGTTAAGACATTAAGACATTAAGAAATGGTTATTATGCTTACTG 1200
Db |||||
QY 1201 TTCTAAATCTGGTGTGAAGGTATTCTTAAGAAATTCAGAGTACTACAGATTTTCAAAACT 1260
Db |||||
QY 1201 TTCTAAATCTGGTGTGAAGGTATTCTTAAGAAATTCAGAGTACTACAGATTTTCAAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATGTTATTAACCAATCCCTGCTGTTTCTTTAGTGCATTAATAAACTCT 1320
Db |||||
QY 1321 GAATTAAGACTC 1333
Db |||||
QY 1321 GAATTAAGACTC 1333
Db |||||

RESULT 41
ADC68042
ID ADC68042 standard; cDNA; 1333 BP.
XX AC
XX AC
XX 18-DEC-2003 (first entry)
XX DE
XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX KW
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
XX KW cystostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
XX KW vulnary; auditory; tumour growth; retinal disorder;
XX KW sports-related joint problem; articular cartilage defects;
XX KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS
XX OS Homo sapiens.
XX PN
XX PN US2003069178-A1.
XX PD
XX PD 10-APR-2003.
XX PF
XX PF 16-OCT-2001; 2001US-00978423.
XX PR
XX PR 17-OCT-1997; 97US-0062250P.
XX PR 13-NOV-1997; 97US-0064249P.
XX PR 13-NOV-1997; 97US-0065311P.
XX PR 21-NOV-1997; 97US-0066364P.
XX PR 10-MAR-1998; 98US-0077450P.
XX PR 11-MAR-1998; 98US-0077632P.
XX PR 11-MAR-1998; 98US-0077641P.
XX PR 11-MAR-1998; 98US-0077649P.
XX PR 12-MAR-1998; 98US-0077791P.
XX PR 13-MAR-1998; 98US-0078004P.
XX PR 20-MAR-1998; 98US-0078886P.
XX PR 20-MAR-1998; 98US-0078910P.
XX PR 20-MAR-1998; 98US-0078936P.
XX PR 20-MAR-1998; 98US-0078939P.
XX PR 25-MAR-1998; 98US-0079294P.
XX PR 26-MAR-1998; 98US-0079565P.
XX PR 27-MAR-1998; 98US-0079663P.
XX PR 27-MAR-1998; 98US-0079664P.
XX PR 27-MAR-1998; 98US-0079689P.
XX PR 27-MAR-1998; 98US-0079726P.
XX PR 27-MAR-1998; 98US-0079786P.
XX PR 30-MAR-1998; 98US-0079920P.
XX PR 30-MAR-1998; 98US-0079923P.
XX PR 31-MAR-1998; 98US-0080105P.
XX PR 31-MAR-1998; 98US-0080194P.
XX PR 01-APR-1998; 98US-0080327P.
XX PR 01-APR-1998; 98US-0080328P.
XX PR 01-APR-1998; 98US-0080333P.
XX PR 01-APR-1998; 98US-0080334P.
XX PR 08-APR-1998; 98US-0081049P.
XX PR 08-APR-1998; 98US-0081070P.
XX PR 08-APR-1998; 98US-0081071P.
XX PR 09-APR-1998; 98US-0081195P.
XX PR 09-APR-1998; 98US-0081203P.
XX PR 09-APR-1998; 98US-0081229P.
XX PR 15-APR-1998; 98US-0081817P.
XX PR 15-APR-1998; 98US-0081819P.
XX PR 15-APR-1998; 98US-0081838P.
XX PR 15-APR-1998; 98US-0081952P.
XX PR 15-APR-1998; 98US-0081955P.
XX PR 21-APR-1998; 98US-0082568P.
XX PR 21-APR-1998; 98US-0082569P.
XX PR 22-APR-1998; 98US-0082700P.
XX PR 22-APR-1998; 98US-0082704P.
XX PR 22-APR-1998; 98US-0082797P.
XX PR 22-APR-1998; 98US-0082804P.
XX PR 23-APR-1998; 98US-0082966P.
XX PR 27-APR-1998; 98US-0083332P.
XX PR 28-APR-1998; 98US-0083322P.
XX PR 29-APR-1998; 98US-0083495P.
XX PR 29-APR-1998; 98US-0083496P.
XX PR 29-APR-1998; 98US-0083496P.
XX PR 29-APR-1998; 98US-0083499P.
XX PR 29-APR-1998; 98US-0083500P.
XX PR 29-APR-1998; 98US-0083545P.
XX PR 29-APR-1998; 98US-0083554P.
XX PR 29-APR-1998; 98US-0083558P.
XX PR 30-APR-1998; 98US-0083559P.
XX PR 05-MAY-1998; 98US-0084366P.
XX PR 06-MAY-1998; 98US-0084414P.
XX PR 06-MAY-1998; 98US-0084441P.
XX PR 07-MAY-1998; 98US-0084598P.
XX PR 07-MAY-1998; 98US-0084600P.
XX PR 07-MAY-1998; 98US-0084627P.
XX PR 07-MAY-1998; 98US-0084637P.
XX PR 07-MAY-1998; 98US-0084639P.
XX PR 07-MAY-1998; 98US-0084640P.
XX PR 07-MAY-1998; 98US-0084643P.
XX PR 13-MAY-1998; 98US-0085323P.
XX PR 13-MAY-1998; 98US-0085338P.
XX PR 13-MAY-1998; 98US-0085339P.
XX PR 15-MAY-1998; 98US-0085573P.
XX PR 15-MAY-1998; 98US-0085579P.
XX PR 15-MAY-1998; 98US-0085580P.
XX PR 15-MAY-1998; 98US-0085582P.
XX PR 15-MAY-1998; 98US-0085689P.
XX PR 15-MAY-1998; 98US-0085697P.
XX PR 15-MAY-1998; 98US-0085700P.
XX PR 18-MAY-1998; 98US-0086023P.
XX PR 22-MAY-1998; 98US-0086392P.
XX PR 22-MAY-1998; 98US-0086414P.
XX PR 22-MAY-1998; 98US-0086430P.
XX PR 22-MAY-1998; 98US-0086486P.
XX PR 28-MAY-1998; 98US-0087098P.
XX PR 28-MAY-1998; 98US-0087106P.
XX PR 28-MAY-1998; 98US-0087208P.
XX PR 26-JUN-1998; 98US-0090863P.
XX PR 26-JUN-1998; 98US-0091010P.
XX PR 01-JUL-1998; 98US-0091359P.
XX PR 30-JUL-1998; 98US-0094651P.
XX PR 11-SEP-1998; 98US-0100038P.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 22-DEC-1998; 98US-0113296P.
XX PR 23-DEC-1998; 98US-0113621P.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 12-MAR-1999; 99US-0123957P.
XX PR 29-MAR-1999; 99US-0126773P.
XX PR 21-APR-1999; 99US-0130232P.
XX PR 26-APR-1999; 99US-0131022P.
```

PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021086.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-657582/62.
DR P-FSDB; ADC68043.
XX
PT Novel secreted and transmembrane polypeptides, designated PRO
PT polypeptides, and polynucleotides encoding them useful for treating
PT kidney diseases, bone, cartilage and retinal disorders.
XX
PS Claim 2; SEQ ID NO 321; 469pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCACGCGCCGATGCGGTTACGTTGCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCACGCGCCGATGCGGTTACGTTGCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTGGCCATTGCGCAATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTGGCCATTGCGCAATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAAGAATCCTATAGACAGCTGTAATACCTGAAATCCCTGTGATCTCCAGAGTA 180
DB 121 TGATTAAGAATCCTATAGACAGCTGTAATACCTGAAATCCCTGTGATCTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGCTGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGCTGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTCAGCATATTGTCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTCAGCATATTGTCA 360
QY 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAAAATTAGCTTTTATCTCTTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAGAATTGGTCCAGTAAAT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACCAACACACAGAGAATTGGTCCAGTAAAT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTACTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTACTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTATCTAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTGCACCTTC 720
DB 661 TACGTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTGCACCTTC 720
QY 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGATCTGCTAGTACATTTG 780
DB 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGATCTGCTAGTACATTTG 780
QY 781 GAAGCTTTGTTTATAGGAATCTGAGGCTCATTTTGGTTTCAATGGAACAGATCTAA 840
DB 781 GAAGCTTTGTTTATAGGAATCTGAGGCTCATTTTGGTTTCAATGGAACAGATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATGATATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATATGGAATACATTTAC 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCTGATGCGATGATTAATATATGGAATACATTTAC 960
QY 961 AAAAATAAAGCGGGGAATTTTCCCTTCGCTTGAATATATTCCTCTGATATATGATGAAT 1020
DB 961 AAAAATAAAGCGGGGAATTTTCCCTTCGCTTGAATATATTCCTCTGATATATGATGAAT 1020


```
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATCTCGATGATATATATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATCTCGATGATATATATGATACATTTAC 960
QY 961 AAAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATTATCCCTGTATATTGCAATGAAT 1020
Db 961 AAAAAATAAAAGCGGAAATTTCCCTTCGCTTGAATATTATCCCTGTATATTGCAATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCCAGAGTAAATAATATCTGCTTTAAATCTTTAAGCAATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCCAGAGTAAATAATATCTGCTTTAAATCTTTAAGCAATA 1080
QY 1081 AGTAACATCATATAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTAAGCTATT 1140
Db 1081 AGTAACATCATATAAAATATATGCTGAATTAATCTTGTGAAGAAATGCAATTAAGCTATT 1140
QY 1141 TTAATATGTTTATTTTGTGAAGACATTAATCTTAAAGAAATTTGGTTATATATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGTGAAGACATTAATCTTAAAGAAATTTGGTTATATATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACCT 1260
Db 1201 TTCTAATCTGCTGTTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACCT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTGCATATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTGCATATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 43
ADc67417
ID ADC67417 standard; cdna; 1333 BP.
XX
AC ADC67417;
XX
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cdna encoding secreted/transmembrane protein, PRO181.
XX
XX vulnary; virucide; neuroprotective; cytostatic; gene therapy;
XX tumour cell proliferation inhibitor;
XX secreted and transmembrane protein; PRO; viral infection; wound healing;
XX tissue growth; muscle generation; muscle regeneration;
XX amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
XX diabetic peripheral neuropathy; chromosome identification; antagonist;
XX tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003073131-A1.
XX
XX 17-APR-2003.
XX
XX 25-OCT-2001; 2001US-00016177.
XX
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
XX 13-NOV-1997; 97US-0065311P.
XX 21-NOV-1997; 97US-0066364P.
XX 10-MAR-1998; 98US-0077450P.
XX 11-MAR-1998; 98US-0077632P.
XX 11-MAR-1998; 98US-0077641P.
XX 12-MAR-1998; 98US-0077791P.
XX 13-MAR-1998; 98US-0078004P.
XX 20-MAR-1998; 98US-0078888P.
XX 20-MAR-1998; 98US-0078910P.
XX 20-MAR-1998; 98US-0078936P.
XX 20-MAR-1998; 98US-0078939P.
XX
XX 25-MAR-1998; 98US-0079294P.
XX 26-MAR-1998; 98US-0079656P.
XX 27-MAR-1998; 98US-0079663P.
XX 27-MAR-1998; 98US-0079664P.
XX 27-MAR-1998; 98US-0079689P.
XX 27-MAR-1998; 98US-0079728P.
XX 27-MAR-1998; 98US-0079786P.
XX 30-MAR-1998; 98US-0079920P.
XX 30-MAR-1998; 98US-0079923P.
XX 31-MAR-1998; 98US-0080105P.
XX 31-MAR-1998; 98US-0080107P.
XX 31-MAR-1998; 98US-0080165P.
XX 01-APR-1998; 98US-0080194P.
XX 01-APR-1998; 98US-0080327P.
XX 01-APR-1998; 98US-0080328P.
XX 01-APR-1998; 98US-0080333P.
XX 01-APR-1998; 98US-0080334P.
XX 08-APR-1998; 98US-0081049P.
XX 08-APR-1998; 98US-0081070P.
XX 08-APR-1998; 98US-0081071P.
XX 09-APR-1998; 98US-0081195P.
XX 09-APR-1998; 98US-0081203P.
XX 09-APR-1998; 98US-0081229P.
XX 15-APR-1998; 98US-0081817P.
XX 15-APR-1998; 98US-0081819P.
XX 15-APR-1998; 98US-0081838P.
XX 15-APR-1998; 98US-0081952P.
XX 15-APR-1998; 98US-0081955P.
XX 21-APR-1998; 98US-0082568P.
XX 21-APR-1998; 98US-0082569P.
XX 22-APR-1998; 98US-0082700P.
XX 22-APR-1998; 98US-0082704P.
XX 22-APR-1998; 98US-0082797P.
XX 23-APR-1998; 98US-0082804P.
XX 23-APR-1998; 98US-0082796P.
XX 27-APR-1998; 98US-0083336P.
XX 28-APR-1998; 98US-0083322P.
XX 29-APR-1998; 98US-0083392P.
XX 29-APR-1998; 98US-0083495P.
XX 29-APR-1998; 98US-0083496P.
XX 29-APR-1998; 98US-0083499P.
XX 29-APR-1998; 98US-0083500P.
XX 29-APR-1998; 98US-0083545P.
XX 29-APR-1998; 98US-0083554P.
XX 29-APR-1998; 98US-0083558P.
XX 30-APR-1998; 98US-0083559P.
XX 30-APR-1998; 98US-0083742P.
XX 05-MAY-1998; 98US-0084366P.
XX 06-MAY-1998; 98US-0084414P.
XX 07-MAY-1998; 98US-0084598P.
XX 07-MAY-1998; 98US-0084600P.
XX 07-MAY-1998; 98US-0084627P.
XX 07-MAY-1998; 98US-0084637P.
XX 07-MAY-1998; 98US-0084639P.
XX 07-MAY-1998; 98US-0084640P.
XX 07-MAY-1998; 98US-0084643P.
XX 13-MAY-1998; 98US-0085323P.
XX 13-MAY-1998; 98US-0085338P.
XX 13-MAY-1998; 98US-0085339P.
XX 15-MAY-1998; 98US-0085573P.
XX 15-MAY-1998; 98US-0085579P.
XX 15-MAY-1998; 98US-0085580P.
XX 15-MAY-1998; 98US-0085582P.
XX 15-MAY-1998; 98US-0085689P.
XX 15-MAY-1998; 98US-0085697P.
XX 15-MAY-1998; 98US-0085700P.
XX 15-MAY-1998; 98US-0085704P.
XX 18-MAY-1998; 98US-0086023P.
XX 22-MAY-1998; 98US-0086392P.
XX 22-MAY-1998; 98US-0086414P.
XX 22-MAY-1998; 98US-0086430P.
XX 22-MAY-1998; 98US-0086486P.
```



```

PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-0102114P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-01000106.
PR 08-MAR-1999; 98US-010005028.
PR 10-MAR-1999; 98US-010005190.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-0134287P.
PR 02-JUN-1999; 98US-01010733.
PR 02-JUN-1999; 98US-01012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-028313.
PR 02-DEC-1999; 98US-028551.
PR 02-DEC-1999; 98US-028565.
PR 16-DEC-1999; 98US-0300095.
PR 30-DEC-1999; 98US-0301243.
PR 05-JAN-2000; 98US-0301274.
PR 06-JAN-2000; 98US-03000219.
PR 06-JAN-2000; 98US-03000277.
PR 11-FEB-2000; 98US-03000376.
PR 18-FEB-2000; 98US-03004341.
PR 24-FEB-2000; 98US-03005004.
PR 02-MAR-2000; 98US-03005841.
PR 10-MAR-2000; 98US-03006319.
PR 21-MAR-2000; 98US-03007532.
PR 30-MAR-2000; 98US-03008439.
PR 17-MAY-2000; 98US-03013705.
PR 22-MAY-2000; 98US-03014042.
PR 30-MAY-2000; 98US-03014941.
PR 02-JUN-2000; 98US-03015264.
PR 24-JUL-2000; 98US-03020710.
PR 01-DEC-2000; 98US-03032678.
PR 20-DEC-2000; 98US-03034956.
PR 28-FEB-2001; 98US-03006520.
PR 22-MAR-2001; 98US-03009552.
PR 25-MAY-2001; 98US-03017092.
PR 01-JUN-2001; 98US-03017800.
PR 20-JUN-2001; 98US-03019692.
PR 29-JUN-2001; 98US-03021066.
PR 09-JUL-2001; 98US-03021735.
PR 30-JUL-2001; 98US-03021855.
PR
PR (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini IU, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
PR WPI; 2003-743810/70.
DR P-PSDB; ADC67418.
DR

```

XX Novel isolated secreted and transmembrane PRO polypeptides, useful in the preparation of a medicament for treating a condition responsive to the polypeptide, and as therapeutic agents e.g. vaccines.

XX Claim 2; SEQ ID NO 321; 464pp; English.

XX The invention describes an isolated secreted and transmembrane PRO polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615 is useful in biotechnological and medical research, as well as in various industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703, PRO708, PRO351, PRO381, PRO615, PRO618, PRO772, PRO853, PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful therapeutically in vivo for lessening the effects of viral infection. PRO200 is useful for the treatment of wound healing, tissue growth and muscle generation and regeneration. PRO37 is useful for treating

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTCAGTTCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGCGTTCAGTTCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGAAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGATCTCCAGAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACAGAGTGAATACCCCTGAATCCCTTGATCTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTTCTGTCGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCGTCATGTTTCTTGTGTCAGCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATAGACAGTATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATAGACAGTATGATGAG 300

QY 301 TGGCCCGAGCTCTATGACCCCTACCAACCATCATGAATCAGATATCTAGCATATTTGCA 360
DB 301 TGGCCCGAGCTCTATGACCCCTACCAACCATCATGAATCAGATATCTAGCATATTTGCA 360

QY 361 GAAGGAAGATGGTGCATATTTAGCTTTTCTCTAGCATTTTCTTCTAGCATTTTCTAGCTATATGG 420
DB 361 GAAGGAAGATGGTGCATATTTAGCTTTTCTCTAGCATTTTCTTCTAGCATTTTCTAGCTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCACCAAAATGAAGGATTTATCAGCAAGATCTCTGTCAGAGTAGC 540
DB 481 GCATGCAAAAGCCACCAAAATGAAGGATTTATCAGCAAGATCTCTGTCAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TAGGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGACCTTGCCTTC 720
DB 661 TAGGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGGTTTGACCTTGCCTTC 720

QY 721 TTAAGGAACAGCATAATCTCTGATGATGATTAATTAATCTGACTGTCTAGTACATTG 780
DB 721 TTAAGGAACAGCATAATCTCTGATGATGATTAATTAATCTGACTGTCTAGTACATTG 780


```
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086332P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-00211141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0187368.
PR 20-NOV-1998; 98US-0024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 14-FEB-2000; 2000US-0180165P.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 03-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;

Qy 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCGTGTACATGCTGGCGTGTGCT 60
Db 1 GCCCAGCGCTCCGATGGCGTTACGTTGCGGGCTTCGTGTACATGCTGGCGTGTGCT 60
Qy 61 CACTGCCGCGCTCATCTTCTTCCGCAATTGGCAGATTGATGAGCTGGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTCCGCAATTGGCAGATTGATGAGCTGGAAGAC 120
Qy 121 TGATTACAAGAACTCTATAGACAGTGTAACTCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAACTCTATAGACAGTGTAACTCCCTGAATCCCTTGTACTCCAGAGTA 180
Qy 181 CCTCATCCAGCGTTTCTTCTGTGTCAATGTTTGTGTCAGAGAGTGGCTTACCTGGG 240
Db 181 CCTCATCCAGCGTTTCTTCTGTGTCAATGTTTGTGTCAGAGAGTGGCTTACCTGGG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTGG 300
Qy 301 TGGCCAGGAGTCTATCAACCTTACCAACCATCATGAATGCAGATATTTAGCATATTGCA 360
Db 301 TGGCCAGGAGTCTATGACCTTACCAACCATCATGAATGCAGATATTTAGCATATTGCA 360
Qy 361 GAAGGAAGATGGTGCAGAAATTAGCTTTTATCTTGTAGCATTTTTTTTACTACCTATGG 420
Db 361 GAAGGAAGATGGTGCAGAAATTAGCTTTTATCTTGTAGCATTTTTTTTACTACCTATGG 420
Qy 421 CATGATCTATGTTTGTGCTTGTAGAGCTTTAGACACACACAGAGAAATGCTCCAGTAA 480
Db 421 CATGATCTATGTTTGTGCTTGTAGAGCTTTAGACACACACAGAGAAATGCTCCAGTAA 480
Qy 481 GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Db 481 GCATCAAAAAGCCACCAAAATGAAGGATCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCACTTCTTAAATAAATGACTCCTTATTTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCACTTCTTAAATAAATGACTCCTTATTTTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTGTTGGAAGAGTCTTTTTCATATGTTATCTACATGAAGATTTTAAATGTTAT 660
Db 601 TTTTGTGTTGGAAGAGTCTTTTTCATATGTTATCTACATGAAGATTTTAAATGTTAT 660
```

QY 661 TACGTATAAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGACATTC 720
Db |||||
QY 661 TACGTATAAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGACATTC 720
Db |||||
QY 721 TTAAGGAACAGCCATATCCCTCTGAATGATCATTAATTAATCTGCTGCTGACATTC 780
Db |||||
QY 721 TTAAGGAACAGCCATATCCCTCTGAATGATCATTAATTAATCTGCTGCTGACATTC 780
Db |||||
QY 781 GAAGCTTTTGTATTAGGAATCTCTAGGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
Db |||||
QY 781 GAAGCTTTTGTATTAGGAATCTCTAGGGCTCATTTTGGTTTCAATGAAACAGATATCTAA 840
Db |||||
QY 841 TTATAAATAGCTAGATATCAGGTGCTCTCGATGAAGTGAATATGATATCTGACTAG 900
Db |||||
QY 841 TTATAAATAGCTAGATATCAGGTGCTCTCGATGAAGTGAATATGATATCTGACTAG 900
Db |||||
QY 901 TGGGAACCTCATGGTTTCTCATCTCTGATGCTGATGATATATATGATGATATGATAT 960
Db |||||
QY 901 TGGGAACCTCATGGTTTCTCATCTCTGATGCTGATGATATATATGATGATATGATAT 960
Db |||||
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATCCCTGATATATGATGATAT 1020
Db |||||
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTGGCTTGAATATATCCCTGATATATGATGATAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCCATGAGTAATAATATATATCTTAAATCTTAAAGCAT 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCCATGAGTAATAATATATATCTTAAATCTTAAAGCAT 1080
Db |||||
QY 1081 AGTAACATCATATAAATAATATATGCTGATTAATCTTGAAGTGAATGATGATGAT 1140
Db |||||
QY 1081 AGTAACATCATATAAATAATATATGCTGATTAATCTTGAAGTGAATGATGATGAT 1140
Db |||||
QY 1141 TTAATATGCTGTTTATTTGTAAGACATATCTTAAAGTGAATGATGATGATGATGAT 1200
Db |||||
QY 1141 TTAATATGCTGTTTATTTGTAAGACATATCTTAAAGTGAATGATGATGATGATGAT 1200
Db |||||
QY 1201 TTCTATCTGCTGTTTAAAGTATCTTAAAGTGAATGATGATGATGATGATGATGAT 1260
Db |||||
QY 1201 TTCTATCTGCTGTTTAAAGTATCTTAAAGTGAATGATGATGATGATGATGATGAT 1260
Db |||||
QY 1261 GAATGAGAGAAATCTGATAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db |||||
QY 1261 GAATGAGAGAAATCTGATAACCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 45

ADC36848
ID ADC36848 standard; cDNA; 1333 BP.

XX AC
XX ADC36848;

XX DT
XX 18-DEC-2003 (first entry)

XX DE
XX Human PRO polynucleotide #60.

XX KW
XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX arthritis; sports injury; cytostatic; antiarthritic.

XX OS
XX Homo sapiens.

XX PN
XX US2003088065-A1.

XX PD
XX 08-MAY-2003.

XX PF
XX 14-AUG-2002; 2002US-00219464.

XX XX

PR

01-JUN-2001; 2001WO-US017800.

29-JUN-2001; 2001WO-US021066.

09-APR-2002; 2002US-00119480.

XX PA
XX (GETH) GENENTECH INC.

XX XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;

XX WPI; 2003-657979/62.

DR P-PSDB; ADC36849.

XX XX

PT One hundred and twenty two nucleic acids encoding PRO polypeptides,

PT useful in gene therapy, or for preparing a medicament for treating

PT cancer.

XX XX

XX Claim 2; Fig 119; 315pp; English.

CC The invention relates to human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

CC diagnostics, biosensors or bioreactors. They are particularly useful for

CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for

CC stimulating the release of tumour necrosis factor (TNF)-alpha from human

CC blood, for stimulating the proliferation or differentiation of

CC chondrocyte cells, for stimulating the proliferation of or gene

CC expression in pericyte cells or for stimulating the proliferation of

CC normal human dermal fibroblasts. The PRO nucleic acids are useful as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant

CC technology, in generating transgenic animals or knock-out animals which

CC may be used in the development and screening of therapeutically useful

CC reagents, in gene therapy, in chromosome identification, as chromosome

CC markers and in generating probes. The PRO polypeptides, or anti-PRO

CC antibodies, are useful for preparing a medicament for treating a

CC condition which is responsive to the PRO polypeptides or anti-PRO

CC antibodies, such as pericyte-associated tumours and bone and/or cartilage

CC disorders (e.g. arthritis, sports injuries), involving inducing the re-

CC differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This

CC sequence represents a human PRO polynucleotide of the invention.

XX SQ

Sequence 1333 BP; 394 A; 247 G; 452 T; 0 U; 0 Other;

Query Match

Best Local Similarity 100.0%; Score 1333; DB 9; Length 1333;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGTTTCACGTTCCGCGCCCTTCTGCTACATGCTGGCGCTGCT 60

Db 1 GCCACGCGTCCGATGGGTTTCACGTTCCGCGCCCTTCTGCTACATGCTGGCGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCAGATTTAGCATTTGATGAGCTGAGAC 120

Db 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCAGATTTAGCATTTGATGAGCTGAGAC 120

QY 121 TGATTAAGAATCCTATAGACAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180

Db 121 TGATTAAGAATCCTATAGACAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCAGCTTCTTCTGTGTCATGTTTCTTGTGTCAGAGAGTGGCTTACACTGG 240

Db 181 CCTCATCCAGCTTCTTCTGTGTCATGTTTCTTGTGTCAGAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTTCTTGGCATATCATTTTGGGGTATATGATGAGTACAGTATGAG 300

Db 241 TCTCAATATGCCCTTCTTGGCATATCATTTTGGGGTATATGATGAGTACAGTATGAG 300

QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGATGACAGATATTTCTAGCATATTGTCA 360

Db 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGATGACAGATATTTCTAGCATATTGTCA 360


```
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 07-OCT-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00285686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.

PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001US-00854280.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH ) GENENTECH INC.
XX

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCCGATGGCGTTCACGTTGCGCGCCTTCGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGTCCGATGGCGTTCACGTTGCGCGCCTTCGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCCGCGCTCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCCGCGCTCATCTTCTTCGCCATTGGGCACATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAAGAAATCCTATAGACCCAGTGTAATACCTGTAATCCCTTGACTCCCGAGTA 180
DB 121 TGATTACAAGAAATCCTATAGACCCAGTGTAATACCTGTAATCCCTTGACTCCCGAGTA 180

QY 181 CCTCATCCACGCTTCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTTCTTCTGTCATGTTCTTTGTCAGCAGAGTGCTTACACTGGG 240
```

Qy	241	TCTCAATATGCCCCTCTGGCATATCATATTTGGAGGTATATGATAGACCACTGATGAG	300
Db	241	TCTCAATATGCCCCTCTGGCATATCATATTTGGAGGTATATGATAGACCACTGATGAG	300
Qy	301	TGGCCCAAGACTCTATGACCCCTTACAAACCATCATGAATGCAGATATCTTAGCATATTGTCA	360
Db	301	TGGCCCAAGACTCTATGACCCCTTACAAACCATCATGAATGCAGATATCTTAGCATATTGTCA	360
Qy	361	GAAGGAAGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTATCTACCTATATGG	420
Db	361	GAAGGAAGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTATCTACCTATATGG	420
Qy	421	CATGATCTATGTTTTGGTGAGCTCTTTAGAACCAACACACAGAAGAAATGGTCCAGTTAAAGT	480
Db	421	CAATGATCTATGTTTTGGTGAGCTCTTTAGAACCAACACACAGAAGAAATGGTCCAGTTAAAGT	480
Qy	481	GCATGCAAAAAGCCCAATGAAGGATTCATATCCAGGAAGATTCCTGTCCAAAGATGAG	540
Db	481	GCATGCAAAAAGCCCAATGAAGGATTCATATCCAGGAAGATTCCTGTCCAAAGATGAG	540
Qy	541	CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
Db	541	CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTTTAAATGTTTTCCACAT	600
Qy	601	TTTTGCTCTGGGAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTTAAATGGTAT	660
Db	601	TTTTGCTCTGGGAAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTTAAATGGTAT	660
Qy	661	TAGCTATAAATTAATATAAATGANTACCTCTGGTGTTGACAGGTTTGAATTCGACTTC	720
Db	661	TAGCTATAAATTAATATAAATGANTACCTCTGGTGTTGACAGGTTTGAATTCGACTTC	720
Qy	721	TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGACTGTCCTAGTACATTTG	780
Db	721	TTAAGGAACAGCCATAATCTCTGAATGATGCATTAATTAATCTGACTGTCCTAGTACATTTG	780
Qy	781	GAAGCTTTTCTTTATAGGAACTCTGAGGGCTCATTTTTGGTTTCAATGAAACAGTATCTAA	840
Db	781	GAAGCTTTTCTTTATAGGAACTCTGAGGGCTCATTTTTGGTTTCAATGAAACAGTATCTAA	840
Qy	841	TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGTATATCTGACTAG	900
Db	841	TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGTATATCTGACTAG	900
Qy	901	TGGGAACCTTCATGGGTTTCTCATCTCTCATGTCGATGATTAATATATATGGAATCTTAC	960
Db	901	TGGGAACCTTCATGGGTTTCTCATCTCTCATGTCGATGATTAATATATATGGAATCTTAC	960
Qy	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAT	1020
Db	961	AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAT	1020
Qy	1021	GAGAGATTTCCGATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTCTTAAGCAT	1080
Db	1021	GAGAGATTTCCGATATTTCCATCAGAGTAATAAATATATCTGCTTTAAATTTCTTAAGCAT	1080
Qy	1081	AGTAACATGATATAAATAATATATGCTGAAATTAATCTGTGAAGAAATGCATTTAAAGCTATT	1140
Db	1081	AGTAACATGATATAAATAATATATGCTGAAATTAATCTGTGAAGAAATGCATTTAAAGCTATT	1140
Qy	1141	TTAAATGTGTTTTTATTTCTAGACATATCTTATTAAGAAATTTGGTTATATATGCTTACTG	1200
Db	1141	TTAAATGTGTTTTTATTTCTAGACATATCTTATTAAGAAATTTGGTTATATATGCTTACTG	1200
Qy	1201	TTTCTAATCTGGTGGAAGGATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAGCT	1260
Db	1201	TTTCTAATCTGGTGGAAGGATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAAGCT	1260
Qy	1261	GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGCATATCAATAAAACTCT	1320
Db	1261	GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGCATATCAATAAAACTCT	1320
Qy	1321	GAATTTAAGACTC	1333

Db	1321	GAATTAGACTC 1333
RESULT 47		
ADC21838		
ID	ADC21838	standard; cDNA; 1333 BP.
XX	AC	
XX	ADC21838;	
XX		
DT	18-DEC-2003	(first entry)
XX		
DE	Human PRO polynucleotide #60.	
XX		
XX	Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;	
KW	tumour; cancer; lung; colon; breast; prostate; rectum; liver;	
KW	tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;	
KW	pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;	
KW	arthritis; sports injury; cytostatic; antiarthritic.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003096969-A1.	
XX		
PD	22-MAY-2003.	
XX		
PF	29-AUG-2002; 2002US-00232225.	
XX		
XX	02-JUN-2000; 2000WO-US015264.	
PR	05-JUN-2000; 2000US-0209832P.	
PR	20-JUN-2000; 2000US-0212901P.	
PR	22-JUN-2000; 2000US-0213807P.	
PR	20-JUL-2000; 2000US-0219556P.	
PR	25-JUL-2000; 2000US-0220585P.	
PR	25-JUL-2000; 2000US-0220605P.	
PR	25-JUL-2000; 2000US-0220607P.	
PR	25-JUL-2000; 2000US-0220624P.	
PR	25-JUL-2000; 2000US-0220638P.	
PR	25-JUL-2000; 2000US-0220664P.	
PR	25-JUL-2000; 2000US-0220666P.	
PR	26-JUL-2000; 2000US-0220893P.	
PR	01-AUG-2000; 2000US-0222425P.	
PR	22-AUG-2000; 2000US-0227133P.	
PR	23-AUG-2000; 2000WO-US023522.	
PR	24-AUG-2000; 2000WO-US030873.	
PR	10-NOV-2000; 2000US-0253646P.	
PR	28-NOV-2000; 2000WO-US032678.	
PR	01-DEC-2000; 2000US-00747259.	
PR	20-DEC-2000; 2000WO-US034956.	
PR	20-DEC-2000; 2000WO-US006520.	
PR	28-FEB-2001; 2001WO-US017092.	
PR	25-MAY-2001; 2001WO-US017800.	
PR	01-JUN-2001; 2001WO-US021066.	
PR	29-JUN-2001; 2001WO-US021066.	
PR	09-APR-2002; 2002US-00119480.	
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;	
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood	
XX		
XX	WPI; 2003-765526/72.	
DR	P-PSDB; ADC21839.	
DR		
XX		
PT	Novel isolated PRO polypeptide useful for tissue typing, as molecular	
PT	weight markers in protein electrophoresis, for treating arthritis, t	
XX		
PS	Claim 2; Fig 119; 308pp; English.	
XX		
CC	The invention relates to human PRO polypeptides (secreted and	
CC	transmembrane polypeptides) and the PRO polynucleotides encoding them	
CC	The PRO polypeptides and polynucleotides are useful as pharmaceutical	
CC	diagnostics, biosensors or bioreactors. They are particularly useful	

The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for

661	TACGCTATTAATTAATATAAATGATTACCTCTGGGTGTGACAGGTTTGAACCTTGACCTTC	780	
721	TTAAGGAACAGCCATAAATCCCTGGAATCATGCAATTAATTAATCTGACTGCTCTAGTACATTG	780	
721	TTAAGGAACAGCCATAAATCCCTGGAATCATGCAATTAATTAATCTGACTGCTCTAGTACATTG	780	
781	GAAGCTTTTGTATTATAGGAACCTTGAGGGCTCAATTTGGTTTTCATATGGAACAGTATCTAA	840	
781	GAAGCTTTTGTATTATAGGAACCTTGAGGGCTCAATTTGGTTTTCATATGGAACAGTATCTAA	840	
841	TTATATAATTAGCTGTAGATATCAGCTGCTTCTGATGAACTGAAATGATATATCTGACTAG	900	
841	TTATATAATTAGCTGTAGATATCAGCTGCTTCTGATGAACTGAAATGATATATCTGACTAG	900	
901	TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATATGGAATACATTTAC	960	
901	TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTATATATGGAATACATTTAC	960	
961	AAAAATAAAGCGGGAATTTCCCTTCGTTGAATATATCCCTGATATATGCGATGAAT	1020	
961	AAAAATAAAGCGGGAATTTCCCTTCGTTGAATATATCCCTGATATATGCGATGAAT	1020	
1021	GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAAATTTCTTAAGCATA	1080	
1021	GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTGCTTTAAATTTCTTAAGCATA	1080	
1081	AGTAACCATGATATAAAAAATATATGTCGAAATTAATCTTGTGGAAGAAATGCAATTTAAAGCTATT	1140	
1081	AGTAACCATGATATAAAAAATATATGTCGAAATTAATCTTGTGGAAGAAATGCAATTTAAAGCTATT	1140	
1141	TTAAATGCTGTTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTTATATGCTTACTG	1200	
1141	TTAAATGCTGTTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTTATATGCTTACTG	1200	
1201	TTCTAAATCTCGTGTAAAGCTATTCTTTAAGAAATTTGCAGTACTACAGATTTTCAAACCT	1260	
1201	TTCTAAATCTCGTGTAAAGCTATTCTTTAAGAAATTTGCAGTACTACAGATTTTCAAACCT	1260	
1261	GAATGAGAGAAAATGTATTAACCATCTGCTGCTTCTTTAGTGCATACATAAACTCT	1320	
1261	GAATGAGAGAAAATGTATTAACCATCTGCTGCTTCTTTAGTGCATACATAAACTCT	1320	
QY	1321	GAATTAAGACTC	1333
DB	1321	GAATTAAGACTC	1333
RESULT 48			
ADC49869			
ID	ADC49869 standard; cDNA; 1333 BP.		
XX	ADC49869;		
AC	AC		
XX	AC		
DT	18-DEC-2003 (first entry)		
XX	18-DEC-2003 (first entry)		
DE	Novel human secreted and transmembrane protein PRO181 cDNA.		
XX	human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;		
KW	vulnerary; antiarthritic; pericyte cell proliferation;		
KW	pericyte cell differentiation; chondrocyte cell proliferation;		
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;		
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;		
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;		
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;		
XX	gene therapy.		
OS	Homo sapiens.		
XX	US2003088064-A1.		
PN	08-MAY-2003.		
XX			
PD			
XX			

XX	RESULT 48
XX	ADC49869
XX	ID ADC49869 standard; cDNA; 1333 BP.
XX	AC
XX	ADC49869;
XX	AC
XX	18-DEC-2003 (first entry)
XX	DE
XX	Novel human secreted and transmembrane protein PR0181 cDNA.
XX	human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW	vulnery; antiarthritic; pericyte cell proliferation;
KW	pericyte cell differentiation; chondrocyte cell proliferation;
KW	chondrocyte cell differentiation; tumor necrosis factor alpha release;
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;
KW	gene therapy.
XX	OS
XX	Homo sapiens.
XX	US2003088064-A1.
XX	PD
XX	08-MAY-2003.
XX	PD
XX	XX

PF	14-AUG-2002; 2002US-00219075.	121	TGATTACAGAACTCTATAGACCACTGTAATACCTGATCCCTTGTACTCCAGAGTA	180
XX				
PR	25-JUL-2000; 2000US-0220605P.	181	CCTCATCCAGCTTTCTTCTGTCTGTCATGTTCTTTGTGACAGAGTGGCTTACATGGG	240
PR	01-JUN-2001; 2001MO-US017800.	181	CTTCATCCAGCTTTCTTCTGTCTGTCATGTTCTTTGTGACAGAGTGGCTTACATGGG	240
PR	29-JUN-2001; 2001MO-US021066.	241	TCTCAATATGCTCTTCTTGTGATATATATTTGGAGGTATATGATAGACAGTGTATGAG	300
XX	09-APR-2002; 2002US-00119480.	241	TCTCAATATGCTCTTCTTGTGATATATATTTGGAGGTATATGATAGACAGTGTATGAG	300
PA	(GETH) GENENTECH INC.			
XX				
PI	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,	301	TGCCCCAGGACTCTATGACCCCTACACCAATCATGAATGCAGATATTTAGCATATTTCTCA	360
PI	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;	301	TGCCCCAGGACTCTATGACCCCTACACCAATCATGAATGCAGATATTTAGCATATTTCTCA	360
XX				
DR	WPI; 2003-801154/75.	361	GAAGGAAGTGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATATGG	420
XX				
PT	New secreted and transmembrane PRO polypeptide useful for preparing a	361	GAAGGAAGTGGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACCTATATATGG	420
PT	medicament for treating a condition that is responsive to the PRO			
PT	polypeptide or anti-PRO antibody, e.g. cancer.			
XX				
PS	Claim 2; SEQ ID NO 119; 314pp; English.			
XX				
CC	The invention describes an isolated PRO (secreted and transmembrane)	481	GCATGCAAAAAGCCACCAAAATGAAGGGAATCTATCCAGCAAGATCCTGTCCAGAGTAGC	540
CC	polypeptide (I). PRO82, PRO1160, PRO1187 or PRO1329 polypeptide are	481	GCATGCAAAAAGCCACCAAAATGAAGGGAATCTATCCAGCAAGATCCTGTCCAGAGTAGC	540
CC	useful for stimulating the proliferation of or gene expression in			
CC	pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are	541	CTGTGGAATCTGATCAGTACTTAAATAAATGACTCCCTTATTTTAAATGTTTCCACAT	600
CC	for stimulating the proliferation or differentiation of chondrocyte	541	CTGTGGAATCTGATCAGTACTTAAATAAATGACTCCCTTATTTTAAATGTTTCCACAT	600
CC	cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide			
CC	are useful for stimulating the release of tumour necrosis factor (TNF)-			
CC	alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,			
CC	PRO347, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,	601	TTTTGCTTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660
CC	PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,	601	TTTTGCTTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT	660
CC	PRO1025, PRO1181, PRO1126, PRO1186, PRO1293, PRO1244, PRO1274, PRO1412,			
CC	PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,	661	TACGTATATAATATAATAAATGATTAATCTCTGCTGTTGACAGGTTTGAACCTTGACATTC	720
CC	PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,			
CC	PRO1887, PRO1928, PRO341, PRO1801, PRO4333, PRO1543, PRO3444, PRO4322,	661	TACGTATATAATATAATAAATGATTAATCTCTGCTGTTGACAGGTTTGAACCTTGACATTC	720
CC	PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for			
CC	stimulating the proliferation of normal human dermal fibroblasts cells.	721	TTAAGCAACGCAATTAATCTCTGCTGTTGACAGGTTTGAACCTTGACATTC	780
CC	PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,	721	TTAAGCAACGCAATTAATCTCTGCTGTTGACAGGTTTGAACCTTGACATTC	780
CC	PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for			
CC	inhibiting the proliferation of normal human dermal fibroblast cells. PRO			
CC	polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,	781	GAAGCTTTTGTGTTATAGGAACCTTGTAGGCTCATTTTGGTTTCATGTAAGCAAGTATCTAA	840
CC	are useful for detecting the presence of tumour in a mammal which	781	GAAGCTTTTGTGTTATAGGAACCTTGTAGGCTCATTTTGGTTTCATGTAAGCAAGTATCTAA	840
CC	involves comparing the level of expression of the above PRO polypeptides			
CC	in a test sample of cells taken from the mammal, and a control sample of	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT	900
CC	normal cells of the same cell type, where a higher level of expression of	841	TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT	900
CC	the PRO polypeptides in the test sample as compared to the control sample			
CC	is indicative of the presence of tumour in the mammal. The tumour is lung	901	TGSGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTTATATATGATGATATTTAC	960
CC	tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or	901	TGSGAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTTATATATGATGATATTTAC	960
CC	liver tumour. (i) is useful as molecular weight markers, for tissue			
CC	typing, or as therapeutic agents. A polynucleotide (ii) encoding (i) is	961	AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATTAATATCCCTGATATATGATGATAT	1020
CC	useful for chromosome and gene mapping or gene therapy. (ii) is useful	961	AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATTAATATCCCTGATATATGATGATAT	1020
CC	for generating transgenic animals or knock-out animals which are useful			
CC	screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide	1021	GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTTGCTTTAAATTTCTTAAGCATTA	1080
CC	is useful for treating bone and/or cartilage disorders (e.g., arthritis,	1021	GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTTGCTTTAAATTTCTTAAGCATTA	1080
CC	sport injuries). This sequence encodes a human secreted and transmembrane			
CC	PRO polypeptide.			
XX				
SQ	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;			
	Query Match 100.0%; Score 1333; DB 9; Length 1333;			
	Best Local Similarity 100.0%; Pred. No. 9.6e-306;			
	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1 GCCCACGGCTCCGATGGCGTTACAGTTTCGGGCTTCTGCTACATGTCGGCGTGTGCT 60			
DB	1 GCCCACGGCTCCGATGGCGTTACAGTTTCGGGCTTCTGCTACATGTCGGCGTGTGCT 60			
QY	61 CACTGCGCGCTGATCTTCTTGGCAATTTGGCAATTTAGCATTTGATGAGCTGAAGAC 120			
DB	61 CACTGCGCGCTGATCTTCTTGGCAATTTGGCAATTTAGCATTTGATGAGCTGAAGAC 120			
QY	121 TGATTACAGAACTCTATAGACCACTGTAATACCTGATCCCTTGTACTCCAGAGTA 180			

QY 1261 GAATGAGAGAAAATTGTATACCATCTCGCTGTTCTTCTTAGTGCATACATATAAACTCT 1320
 DB 1261 GAATGAGAGAAAATTGTATACCATCTCGCTGTTCTTCTTAGTGCATACATATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 49
 ADC49068
 ID ADC49068 standard; cDNA; 1333 BP.
 XX
 AD 49068;
 XX
 18-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulvar; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 US2003088070-Al.
 XX
 PD 08-MAY-2003.
 XX
 PF 28-AUG-2002; 2002US-00230260.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR P-PSDB; ADC49069.
 XX
 PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
 PT in gene therapy, chromosome identification, tissue typing, or as
 PT hybridization probes in chromosome and gene mapping.
 XX
 PS Claim 2; SEQ ID NO 119; 315pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (III) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGTTTCAGCTTCGCGCCCTCTGTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGGTTTCAGCTTCGCGCCCTCTGTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTTCTGGCCATTGGCCATTATAGCATTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGCTCATCTTTCTGGCCATTGGCCATTATAGCATTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTGTAATCCCTGTAATCCCAAGAT 180
 DB 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTGTAATCCCAAGAT 180

QY 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240
 DB 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240

QY 241 TCTCAATATGCCCCCTCTTGGCCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300
 DB 241 TCTCAATATGCCCCCTCTTGGCCATATCATATTTGGAGGTATATGAGTAGACCACTGATGAG 300

QY 301 TGGCCCGAGACTCTATGACCCCTACCAACCAATCAATGATGAGATATTTCTAGCATATTTGTC 360
 DB 301 TGGCCCGAGACTCTATGACCCCTACCAACCAATCAATGATGAGATATTTCTAGCATATTTGTC 360

QY 361 GAAGGAAGGATGGTGCATATTTAGTCTTTTATCTTCTAGCATTTTCTTCTTCTTCTTCTTCT 420
 DB 361 GAAGGAAGGATGGTGCATATTTAGTCTTTTATCTTCTTCTAGCATTTTCTTCTTCTTCTTCT 420

QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAACT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAACT 480

QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540
 DB 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTTACCTTTTAAATAAATGACTCTTTTAAATGTTTAAATGTTTCC 600
 DB 541 CTGTGGAATCTGATCAGTTTACCTTTTAAATAAATGACTCTTTTAAATGTTTAAATGTTTCC 600

QY 601 TTTTGTCTTGGAAAGACTCTTTTCTATGTTTATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
 DB 601 TTTTGTCTTGGAAAGACTCTTTTCTATGTTTATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660

QY 661 TAGGTATAATTAATAATAAATGATTTACCTCTGGTGTCTGCACAGGTTTGAACCTTGCACTTTC 720
 DB 661 TAGGTATAATTAATAATAAATGATTTACCTCTGGTGTCTGCACAGGTTTGAACCTTGCACTTTC 720

```
QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATGATTAATTAATGATGCTGCTAGTACATG 780
DB 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATGATTAATTAATGATGCTGCTAGTACATG 780
QY 781 GAAGCTTTTGTATTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAAACAGATATCAA 840
DB 781 GAAGCTTTTGTATTATAGGAACCTTGTAGGCTCATTTTGTGTTTCAATGAAACAGATATCAA 840
QY 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
DB 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAAACTTCAATGGTTTCCCTCACTGTCATGTCATGTCATGTCATGTCATGTCATGTCATG 960
DB 901 TGGGAAACTTCAATGGTTTCCCTCACTGTCATGTCATGTCATGTCATGTCATGTCATGTCATG 960
QY 961 AAAAAATAAAAAGCGGAATTTCCCTTCCCTTGAATATATCCCTGATATATGATATGATAT 1020
DB 961 AAAAAATAAAAAGCGGAATTTCCCTTCCCTTGAATATATCCCTGATATATGATATGATAT 1020
QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAAATAATACTGTTTAATTTCTTAAGCATTA 1080
DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAAATAATACTGTTTAATTTCTTAAGCATTA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTAATGCTGAAGTGAAGTGAAGTGAAGTGAAT 1140
DB 1081 AGTAAACATGATATAAATAATATGCTGAATTAATGCTGAAGTGAAGTGAAGTGAAGTGAAT 1140
QY 1141 TTAATATGCTTTTATTTTGAAGACATTAATTAATGAAGTGAAGTGAAGTGAAGTGAAGTGA 1200
DB 1141 TTAATATGCTTTTATTTTGAAGACATTAATTAATGAAGTGAAGTGAAGTGAAGTGAAGTGA 1200
QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1260
DB 1201 TTCTAATCTGGTGAAGTATTTCTTAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTGTAGTGAAGTGAAGTGAAGTGAAG 1320
DB 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTGTAGTGAAGTGAAGTGAAGTGAAG 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333
RESULT 50
ID ADC49585 standard; cDNA; 1333 BP.
XX
AC ADC49585;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003088071-A1.
XX
PD 08-MAY-2003.
XX
PF 29-AUG-2002; 2002US-00232231.
XX
```

```
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH ) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI,
XX WPI; 2003-801156/75.
DR P-PSDB; ADC49586.
XX
PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; SEQ ID NO 119; 315pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO226, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO3431, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO3940, PRO6079, PRO9836 or PRO1096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1774, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGCTTCACGTTCCGGGCTTCTGCTACATGCTGCGGTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGCTTCACGTTCCGGGCTTCTGCTACATGCTGCGGTGCTGCT 60
QY 61 CACTGCGGCGCTCATCTTCTTCCCATTTGGGCACATTATAGCATTTGATGAGCTGAGAC 120
DB 61 CACTGCGGCGCTCATCTTCTTCCCATTTGGGCACATTATAGCATTTGATGAGCTGAGAC 120
QY 121 TGATTACAGAAATCCCTATAGACCAGTGAATCCCTGAAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAGAAATCCCTATAGACCAGTGAATCCCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTTCTTCTGTCATGTTTCTTGTGACAGAGTGGCTTACACTGGG 240
```


polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO329, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

D	b	721	TTAAGGAACAGCCATAAACUUCCTGTAATGATGATTAATTAATCTGACGTGCTCTAGTACATG	780
Q	y	781	GAAGCTTTTGTGTTTATAGGAACTTTGAGGCTCATTTGGTGTTCATTGGAACAGTACTTAA	840
D	b	781	GAAGCTTTTGTGTTTATAGGAACTTTGAGGCTCATTTGGTGTTCATTGGAACAGTACTTAA	840
Q	y	841	TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGATGATATATCTGACTAG	900
D	b	841	TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGATGATATATCTGACTAG	900
Q	y	901	TGGGAAACTTCATGGGTTTCCTCATCTGTCATGTCGATGATATATATATGATGATATTTAC	960
D	b	901	TGGGAAACTTCATGGGTTTCCTCATCTGTCATGTCGATGATATATATATGATGATATTTAC	960
Q	y	961	AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAT	1020
D	b	961	AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCAATGAT	1020
Q	y	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTGCTTTAAATCTTTAAGCATAT	1080
D	b	1021	GAGAGATTTCCCATATTTCCATCAGAGTAATAAATACTGCTTTAAATCTTTAAGCATAT	1080
Q	y	1081	AGTAACATGATATAAAAAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAGCTATT	1140
D	b	1081	AGTAACATGATATAAAAAATATATGCTGAATTAATCTGTGAAGATGCAATTTAAGCTATT	1140
Q	y	1141	TTAAATGTGTTTATTTGTAAGACATTAATCTTATTAAGAAATGGTTATATGCTTACTG	1200
D	b	1141	TTAAATGTGTTTATTTGTAAGACATTAATCTTATTAAGAAATGGTTATATGCTTACTG	1200
Q	y	1201	TTCTAATCTGGTGAAGGTAATCTTTAAGAAATTCGAGTACTACAGATTTTCAAAACT	1260
D	b	1201	TTCTAATCTGGTGAAGGTAATCTTTAAGAAATTCGAGTACTACAGATTTTCAAAACT	1260
Q	y	1261	GAATGAGAGAAAATTTGATTAACCATCCTGCTGTCTTCTTTAGTGAATACATTAAGCTCT	1320
D	b	1261	GAATGAGAGAAAATTTGATTAACCATCCTGCTGTCTTCTTTAGTGAATACATTAAGCTCT	1320
Q	y	1321	GAATTAAGACTC	1333
D	b	1321	GAATTAAGACTC	1333
RESULT 52				
ADC47191				
ID	ADC47191 standard; cDNA; 1333 BP.			
XX	AC ADC47191;			
XX	18-DEC-2003 (first entry)			
DE	Novel human secreted and transmembrane protein PRO181 cDNA.			
KW	Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;			
KW	vulnery; antiarthritic; pericyte cell proliferation;			
KW	pericyte cell differentiation; chondrocyte cell proliferation;			
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;			
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;			
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;			
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;			
OS	Homo sapiens.			
XX	US2003105288-A1.			
XX	05-JUN-2003.			
PD	13-AUG-2002; 2002US-00219070.			
XX	25-JUL-2000; 2000US-0220666P.			
PR	01-JUN-2001; 2001WO-US017800.			

PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski RJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-801246/75.
DR P-FSDB; ADC47192.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
PT as a hybridization probe, and in gene therapy.
XX
XX Claim 2; Fig 119; 308pp; English.
XX
CC - The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO233, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCGTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCTCATCTTCCTCGCCATTGGCACATTAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCTCATCTTCCTCGCCATTGGCACATTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGAAATCCCTTGACTCCACAGATA 180
DB 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGAAATCCCTTGACTCCACAGATA 180
QY 181 CCTCATCCACGCTTCCTTCGTGTCACTTTCTTTGTGACGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCCTTCGTGTCACTTTCTTTGTGACGAGTGGCTTACACTGGG 240

181 CCTCATCCACGCTTCCTTCGTGTCACTTTCTTTGTGACGAGTGGCTTACACTGGG 240
241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300
241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGATGAG 300
301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTAGCATATTGCA 360
301 TGGCCCGAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTTAGCATATTGCA 360
361 GAAGAGGAGTGGTGCAAAATTTAGCTTTTCTCTTCAGCATTTTCTTACTACCTATATGG 420
361 GAAGAGGAGTGGTGCAAAATTTAGCTTTTCTCTTCAGCATTTTCTTACTACCTATATGG 420
421 CATGATCATGTTTGGTGAGCTCTTTAGAAACAAACACACAGAAAGTGGTCCAGTTAAGT 480
421 CATGATCATGTTTGGTGAGCTCTTTAGAAACAAACACACAGAAAGTGGTCCAGTTAAGT 480
481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCTGTCACAGAGTAGC 540
481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCTGTCACAGAGTAGC 540
541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
601 TTTTCTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
601 TTTTCTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
661 TACGTATATAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
661 TACGTATATAATTAATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGCACTTC 720
721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTTG 780
721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATCTGACTGCTCTAGTACATTTG 780
781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTGGTTCATTGTTGAAACAGATCTAA 840
781 GAAGCTTTGTTTATAGGAACCTTGTAGGCTCATTTGGTTCATTGTTGAAACAGATCTAA 840
841 TTATAAATAGCTCTAGATATCAGTGCTCTCTGATGAAGTGAATGATGATGATGATGATG 900
841 TTATAAATAGCTCTAGATATCAGTGCTCTCTGATGAAGTGAATGATGATGATGATGATG 900
901 TGGAAATCTCATGGGTTTCTCTCTCTCATGTCGATGATTAATATGATGATGATGATGATG 960
901 TGGAAATCTCATGGGTTTCTCTCTCTCATGTCGATGATTAATATGATGATGATGATGATG 960
961 AAAAATAAAGCGGGAATTTCCCTTCCGCTTGAATATATCCCTGATATATTTGATGATGAT 1020
961 AAAAATAAAGCGGGAATTTCCCTTCCGCTTGAATATATATCCCTGATATATTTGATGATGAT 1020
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATCTTCTTAAATCTTAAAGCATATA 1080
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATCTTCTTAAATCTTAAAGCATATA 1080
1081 AGTAAACATGATATAAATAATATGCGAATTAATCTGTGAAGAAATGATTTAAAGCTATT 1140
1081 AGTAAACATGATATAAATAATATGCGAATTAATCTGTGAAGAAATGATTTAAAGCTATT 1140
1141 TTAATGCTGTTTTTATTTGTAAGACATTTATTAAGAAATGCTGTTTATTTATGCTTACTG 1200
1141 TTAATGCTGTTTTTATTTGTAAGACATTTATTAAGAAATGCTGTTTATTTATGCTTACTG 1200
1201 TTCTAATCTGTTGTAAGAGTATTTCTTAAGAAATTTGAGGTAATCTACAGATTTTCAAAC 1260
1201 TTCTAATCTGTTGTAAGAGTATTTCTTAAGAAATTTGAGGTAATCTACAGATTTTCAAAC 1260
1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTTGTGCAATACATAAATCTCT 1320
1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTTGTGCAATACATAAATCTCT 1320

QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 53
 ID ADC78066
 XX ADC78066 standard; cDNA; 1333 BP.
 AC ADC78066;
 XX
 XX 01-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003096972-A1.
 XX
 PD 22-MAY-2003.
 XX
 PF 29-AUG-2002; 2002US-00232234.
 XX
 PR 01-JUN-2003; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-APR-2002; 2002US-00119480.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2003-765529/72.
 DR P-PSDB; ADC78067.
 XX
 PT Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as
 PT molecular weight markers, for treating arthritis and tumor.
 XX
 PS Claim 2; Fig 119; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (1). PRO382, PRO1160, PRO187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e+306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGCGTTCACGTTGCGGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGCTCATCTCTTTCGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 Db 61 CACTGCCGCGCTCATCTCTTTCGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAAGAAATCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCACAGATA 180
 Db 121 TGATTACAAGAAATCCTATAGACCAGTGAATACCCCTGAATCCCTTGTACTCCACAGATA 180
 QY 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGACGAGAGTGCTTACACTGGG 240
 Db 181 CCTCATCCACGCTTCTTCTGTGTCATGTTTCTTGTGACGAGAGTGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGAGTACAGATGATGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGAGTACAGATGATGAG 300
 QY 301 TGGCCACGAGCTCTATGACCCCTTACAAACCATCATGAATCAGATATTTAGCATATTTGTA 360
 Db 301 TGGCCACGAGCTCTATGACCCCTTACAAACCATCATGAATCAGATATTTAGCATATTTGTA 360
 QY 361 GAGGACAGGATGCTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Db 361 GAGGACAGGATGCTGCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATGAGC 540
 Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGATGAGC 540
 QY 541 CTGTGGATCTGATCAGTTACTTTTAAAAAGTACCTCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGATCTGATCAGTTACTTTTAAAAAGTACCTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTTGTGGAAGAGCTGTTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTTGTGGAAGAGCTGTTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATTAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGCACATTC 720
 Db 661 TACGTATTAATTAATATAAATGATTAACCTCTGTTGTTGACAGGTTTGAACCTTGCACATTC 720
 QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATCAATTAATTAATGCTGCTAGTACATTTG 780
 Db 721 TTAAGGAACAGCCATAATCCCTCTGAATGATCAATTAATTAATGCTGCTAGTACATTTG 780
 QY 781 GAAGCTTTTGTATTATAGGAAGCTTTGAGGGCTCATTTTGGTGTTCATTTGAACAGATATCTAA 840

Db 241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATAGTACAGCATGATGAG 300
Qy 301 TGGCCCGAGGACTTATGACCCCTACCAACCATCATGAATGACAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCGAGGACTTATGACCCCTACCAACCATCATGAATGACAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAGGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATCTTTTGGTGGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATCTTTTGGTGGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTTCCAGAGATCTGTGTCAGAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTTCCAGAGATCTGTGTCAGAGTAGC 540
Qy 541 CTGTGGATCTGATCAGTTACTTTTAAATAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTTAAATAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTCAATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCAATGTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATATATAAATGATTAAGTCTCTGTTGAGAGTTTGAATTCGACTTC 720
Db 661 TACGTATAAATATATAAATGATTAAGTCTCTGTTGAGAGTTTGAATTCGACTTC 720
Qy 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATCTGATGCTTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATCTGATGCTTCTAGTACATG 780
Qy 781 GAAGCTTTTGTATAGGAATCTGAGTGGCTTCTGATGAATGAATGATATCTGACTAG 900
Db 781 GAAGCTTTTGTATAGGAATCTGAGTGGCTTCTGATGAATGAATGATATCTGACTAG 900
Qy 841 TATAAATAGCTGTAGATATCAGTGGCTTCTGATGAATGAATGATATCTGACTAG 900
Db 841 TATAAATAGCTGTAGATATCAGTGGCTTCTGATGAATGAATGATATCTGACTAG 900
Qy 901 TGGGAACTTCATGGGTTTCTCTCATCTCATGTCGATGATATATGGAATCAATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCTCTCATCTCATGTCGATGATATATGGAATCAATTTAC 960
Qy 961 AAAATAAAGCGGGAATTTCCCTTCGTTGAATATATATCCCTGTATATGCAATGAT 1020
Db 961 AAAATAAAGCGGGAATTTCCCTTCGTTGAATATATATCCCTGTATATGCAATGAT 1020
Qy 1021 GAGAGATTTCCATATTTCCATCAGATTAATAATATATCTGCTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGATTAATAATATATCTGCTTAAATCTTAAAGCATA 1080
Qy 1081 AGTAACATGATATAAATAATATGCTGAAATTTACCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAATAATATGCTGAAATTTACCTTGTGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAAGTGTGTTTATTTGTAAGACATTAATTTAAGAAATGTTGTTATTTAGCTTACTG 1200
Db 1141 TTAAGTGTGTTTATTTGTAAGACATTAATTTAAGAAATGTTGTTATTTAGCTTACTG 1200
Qy 1201 TTCTAATCTGGGTGAAGGATTTCTTAAGATTTGAGGATGACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGGTGAAGGATTTCTTAAGATTTGAGGATGACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATTTGTAACCACTCTGCTCTTCTTTAGTGCATATACATAAAGCTCT 1320
Db 1261 GAATGAGAGAAAATTTGTAACCACTCTGCTCTTCTTTAGTGCATATACATAAAGCTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 55
ADD10290
ID ADD10290 standard; cDNA; 1333 BP.

XX ADD10290;
AC ADD10290;
XX
DT 01-JAN-2004 (first entry)
XX

Human secreted/transmembrane PRO polypeptide cDNA #1.

ss; gene; human; secreted protein; transmembrane protein;
cardiovascular disorder; endothelial disorder; angiogenic disorder;
myocardial infarction; cardiac hypertrophy; trauma; cancer;
age-related macular degeneration; angiogenesis;
endothelial cell apoptosis; smooth muscle cell growth;
endothelial cell tube formation.

XX Homo sapiens.

OS US2003105011-A1.

XX 05-JUN-2003.

XX 16-AUG-2002; 2002US-00223084.

XX 15-SEP-2000; 2000US-032887P.

XX 20-JUN-2001; 2001WO-US019692.

XX 09-JUL-2001; 2001WO-US021735.

XX 20-FEB-2002; 2002US-00081056.

XX (GETH) GENENTECH INC.

XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;

XX WPI; 2003-810831/76.
DR P-FSDB; ADD10291.

XX New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.

XX Claim 2; SEQ ID NO 1; 493pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGR-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.

CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCCACGCTCCGATGGCGTTTCACGTTTCGCGGCTTCTGCTACATGCTGGCGCTGCTCT 60

Db 1 GCCCACGCTCCGATGGCGTTTCACGTTTCGCGGCTTCTGCTACATGCTGGCGCTGCTCT 60

XX	05-JUN-2003.	
PD		
XX	16-AUG-2002; 2002US-00223090.	
XX		
PR	20-JUN-2001; 2001WO-US019692.	
PR	09-JUL-2001; 2001WO-US021735.	
PR	20-FEB-2002; 2002US-00081056.	
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Ferrara N, Gerber H, Gerlitsen ME, Goddard A;	
PI	Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;	
PI	Watanabe CK, Williams PM, Wood WI, Ye W;	
XX		
DR	WPI; 2003-801242/75.	
DR	P-PSDB; ADD11251.	
XX		
PT	New isolated nucleic acid encoding a secreted and transmembrane	
PT	polypeptide, useful for treating a cardiovascular, endothelial, or	
PT	angiogenic disorder in a mammal, such as cancer or age-related macular	
PT	degeneration.	
XX		
PS	Claim 2; SEQ ID NO 1; 493bp; English.	
XX		
CC	The invention relates to an isolated nucleic acid encoding a secreted and	
CC	transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded	
CC	by the nucleic acid, or an agonist or antagonist, is used to treat a	
CC	cardiovascular, endothelial, or angiogenic disorder in a mammal,	
CC	preferably a human. The human may have suffered a myocardial infarction	
CC	or has cardiac hypertrophy, trauma, a cancer, or age-related macular	
CC	degeneration. The cardiac hypertrophy is characterised by the presence of	
CC	an elevated level of pGf-2 alpha. A PRO polypeptide, given in the	
CC	specification, or an agonist is used to inhibit or stimulate endothelial	
CC	cell growth in a mammal. PRO21 or an agonist is used to induce cardiac	
CC	hypertrophy. PRO136 or PRO149 is used to stimulate angiogenesis.	
CC	PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO	
CC	polypeptide, given in the specification, or an agonist is used to	
CC	stimulate or inhibit smooth muscle cell growth, or to induce endothelial	
CC	cell tube formation. The present sequence represents a cDNA encoding a	
CC	PRO polypeptide of the invention.	
XX		
SQ	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;	
	Query Match 100.0%; Score 1333; DB 9; Length 1333;	
	Best Local Similarity 100.0%; Pred. No. 9.6e-306;	
	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Qy	1 GCCACACGGTCCGATGGCGTTACGCTTCGGCGCTTCCTGCTACATGCTGGCGCTGCTGCT 60	
Db	1 GCCACACGGTCCGATGGCGTTACGCTTCGGCGCTTCCTGCTACATGCTGGCGCTGCTGCT 60	
Qy	61 CACTGCGCGCTCATCTTCTTCGGCATTTGGCACATTATAGCATTTGATGAGCTCAAGAC 120	
Db	61 CACTGCGCGCTCATCTTCTTCGGCATTTGGCACATTATAGCATTTGATGAGCTCAAGAC 120	
Qy	121 TGATTAACAAGAAATCCTATAGACCAAGTGAATACCTGAATCCCTTGTACTCCACAGATGA 180	
Db	121 TGATTAACAAGAAATCCTATAGACCAAGTGAATACCTGAATCCCTTGTACTCCACAGATGA 180	
Qy	181 CCTCATCCACGCTTCTTCTGTGTCATGCTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240	
Db	181 CCTCATCCACGCTTCTTCTGTGTCATGCTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240	
Qy	241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGAATGAG 300	
Db	241 TCTCAATATGCCCTCTTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGAATGAG 300	
Qy	301 TGGCCCGAGCTCTATGACCCCTACAAACCATCATGAATGCAGATATTTCTAGCAATATTGTCA 360	
Db	301 TGGCCCGAGCTCTATGACCCCTACAAACCATCATGAATGCAGATATTTCTAGCAATATTGTCA 360	
Qy	361 GAAGGAAGCATGGTGCAAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420	


```
QY 961 AAAATAAAAGCGGAATTTTCCCTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||||
QY 961 AAAATAAAAGCGGAATTTTCCCTCGCTTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||||
QY 1021 GAGAGATTCCCAATTTCCATCAGAGTAATAAATATATCTTGCCTTAATTTCTTAAGCATA 1080
Db |||||||
QY 1021 GAGAGATTCCCAATTTCCATCAGAGTAATAAATATATCTTGCCTTAATTTCTTAAGCATA 1080
Db |||||||
QY 1081 AGTAAACATGATATAAATAATATATCTGAAATTTCTGTGAGAGATGCAATTAAGCTATT 1140
Db |||||||
QY 1081 AGTAAACATGATATAAATAATATATCTGAAATTTCTGTGAGAGATGCAATTTAAAGCTATT 1140
Db |||||||
QY 1141 TTAATATGCTTTTATTTGTAAGACATATCTTATTAAGAAATGCTTATATGCTTACTG 1200
Db |||||||
QY 1141 TTAATATGCTTTTATTTGTAAGACATATCTTATTAAGAAATGCTTATATGCTTACTG 1200
Db |||||||
QY 1201 TTCTAATCTGTGTTAAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
Db |||||||
QY 1201 TTCTAATCTGTGTTAAAGGTATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
Db |||||||
QY 1261 GAATGAGAGAAATTTGTAAGACATCTCTGCTTCTTTAGTGCAATACATAAACTCT 1320
Db |||||||
QY 1261 GAATGAGAGAAATTTGTAAGACATCTCTGCTTCTTTAGTGCAATACATAAACTCT 1320
Db |||||||
QY 1321 GAAATTAAGACTC 1333
Db |||||||
QY 1321 GAAATTAAGACTC 1333
Db |||||||

RESULT 59
ADDS1029
ID ADDS1029 standard; cDNA; 1333 BP.
XX
AC ADDS1029;
XX
DT
DE 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW Gene therapy.
XX
OS Homo sapiens.
XX
FN US2003105290-A1.
XX
PD 05-JUN-2003.
XX
PF 13-AUG-2002; 2002US-00219527.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH ) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR P-PSDB; ADDS1030.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide (PRO), for use in recombinantly producing a PRO polypeptide,
PT as a hybridization probe, and in gene therapy.
XX
```

```
PS Claim 2; Fig 119; 309pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1474, PRO1517, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4322,
CC PRO9940, PRO6079, PRO8936 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptide of
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGGCTCGATGGCGGTTACCTTCGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
Db |||||||
QY 1 GCCACGGCTCGATGGCGGTTACCTTCGCGCTTCTGTACATGCTGGCGCTGCTGCT 60
Db |||||||
QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db |||||||
QY 61 CACTGCCGCGCTCATCTTCTTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
Db |||||||
QY 121 TGATTACAGAAATCCTATAGACAGTGTAATACCTTGAAATCCCTTGCTACTCCAGAGTA 180
Db |||||||
QY 121 TGATTACAGAAATCCTATAGACAGTGTAATACCTTGAAATCCCTTGCTACTCCAGAGTA 180
Db |||||||
QY 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGTCAGAGAGTGCTTACACTGGG 240
Db |||||||
QY 181 CCTCATCCACGCTTTCTTCTGTGTCATGTTCTTTGTGTCAGAGAGTGCTTACACTGGG 240
Db |||||||
QY 241 TCTCAATATGCCCTCTTTGGCATAATCATATTTGGAGGTATATGAGTAGACAGATGATGAG 300
Db |||||||
QY 241 TCTCAATATGCCCTCTTTGGCATAATCATATTTGGAGGTATATGAGTAGACAGATGATGAG 300
Db |||||||
QY 301 TGCCCCAGGACTCTATGACCCCTACAACTCATGATGATGATGATGATGATGATGATGATGATG 360
Db |||||||
QY 301 TGCCCCAGGACTCTATGACCCCTACAACTCATGATGATGATGATGATGATGATGATGATG 360
Db |||||||
QY 361 GAAGGAAGGATGTCGCAATAGCTTTTATCTTCTTAGCATTTTCTTACTACTATATG 420
Db |||||||
QY 361 GAAGGAAGGATGTCGCAATAGCTTTTATCTTCTTAGCATTTTCTTACTACTATATG 420
Db |||||||
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
Db |||||||
```

```
Db 421 CATGATCATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTGGTCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
Db 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTCTGTTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TACGTATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATAATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCAATTTTGGTTTCATTTGAAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTTAGGGCTCAATTTTGGTTTCATTTGAAACAGATATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
Db 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAAACTTCACTGGTGTTCCTCACTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
Db 901 TGGGAAACTTCACTGGTGTTCCTCACTGTCATGTCATGTCATGTCATGTCATGTCATGTCAT 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTSCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATTTATCCCTGTATATTTSCATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGTTTAAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGTTTAAATTTCTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGCAAGATGCAATTTAAAGTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTCTGCAAGATGCAATTTAAAGTATT 1140
QY 1141 TTAATGCTGTTTTTATTTGTAAGACATTAATTTATTAAGAAATTTGGTTTATGCTTACTG 1200
Db 1141 TTAATGCTGTTTTTATTTGTAAGACATTAATTTATTAAGAAATTTGGTTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTCTTGTAGTCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTCTTGTAGTCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
```

RESULT 60

ADD37043

ID ADD37043 standard; cDNA; 1333 BP.

XX AC

XX ADD37043;

XX DT 15-JAN-2004 (first entry)

XX DE Human secreted/transmembrane PRO polypeptide cDNA #1.

```
XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX Homo sapiens.
XX OS
XX US2003105012-A1.
XX 05-JUN-2003.
XX 16-AUG-2002; 2002US-00223088.
XX 15-SEP-2000; 2000US-0232887P.
XX 20-JUN-2001; 2001WO-US019692.
XX 09-JUL-2001; 2001WO-US021735.
XX 20-FEB-2002; 2002US-00081056.
XX (GETH ) GENENTECH INC.
XX Baker KP, Ferrara N, Gerber H, Gertsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX WPI; 2003-829354/77.
XX P-PSDB; ADD37044.
XX New isolated nucleic acids encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX Claim 2; SEQ ID NO 1; 492pp; English.
XX The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGP-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCGATGGCGTTACGTTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGCGTCGATGGCGTTACGTTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTTCGCCATTTCGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCTATAGACCAAGTAAATACCTGATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAAGATCCTATAGACCAAGTAAATACCTGATCCCTTGTACTCCCAAGATA 180
QY 181 CTTCAATCAAGCTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
Db 181 CTTCAATCAAGCTTCTTCTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGGG 240
```


181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGACAGAGTGCGCTTACACTGGG 240
Qy
241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGATGATGAG 300
Db
241 TCTCAATATGCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGATGATGAG 300
Qy
301 TGGCCCCAGGACTCTATGAGCCCTACAACTCATCATCAATGTCAGATATCTAGCATATTCGA 360
Db
301 TGGCCCCAGGACTCTATGAGCCCTACAACTCATCAATGTCAGATATCTAGCATATTCGA 360
Qy
361 GAAGAGAGGATGATGAGCAATTTAGCTTTTATCTTCTAGCAATTTTAACTACCTATATGG 420
Db
361 GAAGAGAGGATGATGAGCAATTTAGCTTTTATCTTCTAGCAATTTTAACTACCTATATGG 420
Qy
421 CATGATCTATGTTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db
421 CATGATCTATGTTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480
Qy
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
Db
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
Qy
541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTTCCACAT 600
Db
541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCCCTTATTTTAAATGTTTTCCACAT 600
Qy
601 TTTTGTCTTGGAAAGACTGTTTTTCAATGTTTATCTAGTATCTAGTAAAGATTTTAAATGGTAT 660
Db
601 TTTTGTCTTGGAAAGACTGTTTTTCAATGTTTATCTAGTATCTAGTAAAGATTTTAAATGGTAT 660
Qy
661 TACGTATAAATTAATATAAATGATTTACTCTGTTGTTGACAGGTTTGAACCTTCACCTTC 720
Db
661 TACGTATAAATTAATATAAATGATTTACTCTGTTGTTGACAGGTTTGAACCTTCACCTTC 720
Qy
721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 780
Db
721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATTTG 780
Qy
781 GAAGCTTTGTTTATAGGAAGTTGAGGCTCATTTGGTTTCAATGGAACAGATATCTAA 840
Db
781 GAAGCTTTGTTTATAGGAAGTTGAGGCTCATTTGGTTTCAATGGAACAGATATCTAA 840
Qy
841 TTATAAATAGCTCTAGATATCAGTGCTTCTGATGAAGTCAAAATGATATATCTGACTAG 900
Db
841 TTATAAATAGCTCTAGATATCAGTGCTTCTGATGAAGTCAAAATGATATATCTGACTAG 900
Qy
901 TGGAAACTTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATATGATATAC 960
Db
901 TGGAAACTTCATGGGTTTCCATCTGTCATGTCGATGATTAATATATGATATGATATAC 960
Qy
961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAAT 1020
Db
961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATGTCATGAAT 1020
Qy
1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATCTGCTTAACTTTAAAGATA 1080
Db
1021 GAGAGATTTCCATATTTCCATCAGAGTAATAATATCTGCTTAACTTTAAAGATA 1080
Qy
1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGATTTAAAGCTATT 1140
Db
1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGATTTAAAGCTATT 1140
Qy
1141 TTAATGTTTTTATTTGTAAGACATTTATTAAGAAATGCTTATTAATGCTTACTG 1200
Db
1141 TTAATGTTTTTATTTGTAAGACATTTATTAAGAAATGCTTATTAATGCTTACTG 1200
Qy
1201 TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATGATTTTAAAGCT 1260
Db
1201 TTCTAATCTGTTGTAAGGATTTCTTAAGAAATTTGAGGATGATTTTAAAGCT 1260
Qy
1261 GAATGAGAGAAATTTGATATAACCATCTGCTGCTTTTGTGCAATACATAAACTCT 1320
Db
1261 GAATGAGAGAAATTTGATATAACCATCTGCTGCTTTTGTGCAATACATAAACTCT 1320

Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 61

ADD50510
ID ADD50510 standard; cDNA; 1333 BP.

XX ADD50510;

XX AC AC

XX DT 15-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX OS OS

XX US2003096971-A1.

XX 22-MAY-2003.

XX 29-AUG-2002; 2002US-00232229.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Garney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2003-765528/72.

XX P-PSDB; ADD50511.

Novel isolated PRO polypeptide useful for tissue typing, as molecular
weight markers in protein electrophoresis, for treating arthritis, tumor.

XX Claim 2; Fig 119; 308pp; English.

The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a PRO
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGCTCGATGGCGCTTCAAGTTCCGGCGCTTCTCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGCTCGATGGCGCTTCAAGTTCCGGCGCTTCTCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTCGCCATTTGGCACATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGAATACAGATCCCTATAGACAGCTGTAATACCCCTGAATCCCTTGACTCCAGAGTA 180
DB 121 TGAATACAGATCCCTATAGACAGCTGTAATACCCCTGAATCCCTTGACTCCAGAGTA 180

QY 181 CTTCAATCCAGCTTCTTCTGCTGCTATGTTCTTTGTCAGAGTGGCTTACACTGG 240
DB 181 CTTCAATCCAGCTTCTTCTGCTGCTATGTTCTTTGTCAGAGTGGCTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300

QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGCAGATATTTCTAGCATATTTGCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGATGCAGATATTTCTAGCATATTTGCA 360

QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTAGCATATTTGCA 420
DB 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTAGCATATTTGCA 420

QY 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACAACAACAGAGAAATTTGTCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAAGCTCTTAGAACAACAACAGAGAAATTTGTCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCCTAGAGTAGC 540
DB 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTGTCCTAGAGTAGC 540

QY 541 CTGTGAATCTGATCAGTTACTTTTAAAAAANGACTCTTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGAATCTGATCAGTTACTTTTAAAAAANGACTCTTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGCTCTGGAAGAGCTGTTTCTATGTTTATCTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGCTCTGGAAGAGCTGTTTCTATGTTTATCTCAGATAAGATTTTAAATGTTAT 660

QY 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TAGCTATAAATTAATAAATGATTAACCTCTGCTGTTGACAGGTTTGAACCTTGCACTTC 720

QY 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATGATGATGATGATGATG 780
DB 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATGATGATGATGATGATG 780

QY 781 GAAGCTTTTGTATAGGACTGTTAGGCTCATTTTGGTTTCAATTTGAACAGATCTAA 840
DB 781 GAAGCTTTTGTATAGGACTGTTAGGCTCATTTTGGTTTCAATTTGAACAGATCTAA 840

QY 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATAATGATCTAGTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGTGTCTTCTGATGAAGTGAATAATGATCTAGTAG 900

QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCAGATGATTAATGATGATGATGAT 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCAGATGATTAATGATGATGATGAT 960

QY 961 AAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATCCCTGATATTCATGAT 1020
DB 961 AAAAATAAAGCGGAAATTTTCCCTCGCTTGAATATATCCCTGATATTCATGAT 1020

RESULT 62

ADD50264

ID ADD50264 standard; cDNA; 1333 BP.

XX AC ADD50264;

XX AC ADD50264;

XX 15-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX OS US2003096970-A1.

XX PN 22-MAY-2003.

XX PD 29-AUG-2002; 2002US-00232227.

XX PR 26-JUL-2000; 2000US-0220893P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX XX WPI; 2003-765527/72.

XX DR P-PSDB; ADD50265.

XX Novel isolated PRO polypeptides useful as molecular weight markers in
protein electrophoresis, and useful for tissue typing, for treating
arthritis, tumor.

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioeffectors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour).

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
 CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
 CC blood, for stimulating the proliferation or differentiation of
 CC chondrocyte cells, for stimulating the proliferation of or gene
 CC expression in pericyte cells or for stimulating the proliferation of
 CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
 CC technology, in generating transgenic animals or knock-out animals which
 CC may be used in the development and screening of therapeutically useful
 CC reagents, in gene therapy, in chromosome identification, as chromosome
 CC markers and in generating probes. The PRO polypeptides, or anti-PRO
 CC antibodies, are useful for preparing a medicament for treating a
 CC condition which is responsive to the PRO polypeptides or anti-PRO
 CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
 CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
 CC differentiation of chondrocytes. The PRO polypeptides are useful as
 CC molecular markers for protein electrophoresis, and in tissue typing. This
 CC sequence represents a human PRO polynucleotide of the invention.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGCGGTTACAGTTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGCGGTTACAGTTCGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGTCACTCTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGTCACTCTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGAACTCCCTTGCTACCCAGATA 180
 DB 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGAACTCCCTTGCTACCCAGATA 180
 QY 181 CCTCATCCACGCTTCTCTGCTGCTCATCTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCACGCTTCTCTGCTGCTCATCTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACCAAGTATGAG 300
 QY 301 TGGCCACGAGCTCTATGACCCCTACACCATCATGAAATCAGATATTTAGCATATTTGCA 360
 DB 301 TGGCCACGAGCTCTATGACCCCTACACCATCATGAAATCAGATATTTAGCATATTTGCA 360
 QY 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 DB 361 GAAGGAAGGATGGTGCATATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 QY 421 CATGATCTATGTTTGGTGGAGCTCTTAGAAACAACACAGAGAATTTGGTCCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGGAGCTCTTAGAAACAACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAGCCACCAAAATGAGGGATTTCTATCCACAGATCCTGTCAGAGTAGC 540
 DB 481 GCATGCAAAAGCCACCAAAATGAGGGATTTCTATCCACAGATCCTGTCAGAGTAGC 540
 QY 541 CTGTGGAACTCATGAGTACTCTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAACTCATGAGTACTCTTTAAAAAATGACTCCCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGGTTTGAACTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTACCTCTGGTGTGACAGGTTTGAACTTGCACTTC 720

QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGCTGCTCTAGTACATTG 780
 DB 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATGCTGCTCTAGTACATTG 780
 QY 781 GAAGCTTTGTTTATAGGAACCTCTAGGGCTCATTTTGGTTTCAATTTGAAACAGATATCTAA 840
 DB 781 GAAGCTTTGTTTATAGGAACCTCTAGGGCTCATTTTGGTTTCAATTTGAAACAGATATCTAA 840
 QY 841 TTATAAATTAGCTCTAGATATCAGTGCTCTCTGAATGAGTGAATGATATATCTGACTAG 900
 DB 841 TTATAAATTAGCTCTAGATATCAGTGCTCTCTGAATGAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATAC 960
 DB 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATATAC 960
 QY 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 DB 961 AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
 QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAAATACTTTTAAATCTTTAAAGCATATA 1080
 DB 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAAATACTTTTAAATCTTTAAAGCATATA 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGCTTGAATATATCCCTGTATATTTAAAGCATATA 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGCTTGAATATATCCCTGTATATTTAAAGCATATA 1140
 QY 1141 TTAATGCTGTTTTTATTTTGAAGCATATCTTATTAAGAAATTTGTTTATATGCTTACTG 1200
 DB 1141 TTAATGCTGTTTTTATTTTGAAGCATATCTTATTAAGAAATTTGTTTATATGCTTACTG 1200
 QY 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTAATCTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTAATCTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTGTAGTGAATATACATTAACACTCT 1320
 DB 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGCTTCTTGTAGTGAATATACATTAACACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333
 XX ADD51275 standard; cDNA; 1333 BP.
 AC ADD51275;
 XX
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 XX US2003105289-A1.
 XX
 XX 05-JUN-2003.
 PD
 XX 13-AUG-2002; 2002US-00219472.

XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2003-829359/77.
DR P-PSDB; ADD51276.
XX New isolated nucleic acids and their encoded secreted and transmembrane
PT polypeptides (PRO), useful e.g. for stimulating cell proliferation or
PT differentiation and for diagnosis of cancer.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO329, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO247, PRO337, PRO526, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1478, PRO826, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1338,
CC PRO1286, PRO1347, PRO1305, PRO1273, PRO1273, PRO1273, PRO1273, PRO1273,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGTTCAGTTCGCGGCTTCGTACATGTCGCGGTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGTTCAGTTCGCGGCTTCGTACATGTCGCGGTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTCTTCTTCGCAATTTGGCAATATATGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTCTTCTTCGCAATTTGGCAATATATGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAUCCCTATAGACCAAGTGTATACCTGAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAGAAUCCCTATAGACCAAGTGTATACCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTCTCTCTGTCATGTTTCTTTGTGTCAGAGTGGCTTCACTGGG 240
DB 181 CCTCATCCACGCTTCTCTCTCTGTCATGTTTCTTTGTGTCAGAGTGGCTTCACTGGG 240
QY 241 TCTCAATATGCGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCAGTGTAG 300
DB 241 TCTCAATATGCGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCAGTGTAG 300
QY 301 TGGCCGAGGACTCTATAGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
DB 301 TGGCCGAGGACTCTATGACCCCTACAACCATCATGAATGCAGATATTTAGCATATTTGCA 360
QY 361 GAAGAGAGTGGTGAATTTAGCTTTTCTCTCTAGCATTTTCTTCTACTACCTATATGG 420
DB 361 GAAGAGAGTGGTGAATTTAGCTTTTCTCTCTAGCATTTTCTTCTACTACCTATATGG 420
QY 421 CATGATCTATCTTTTGGTGAAGCTCTTAGAAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATCTTTTGGTGAAGCTCTTAGAAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTCTCCAGAGTATGC 540
DB 481 GCATGCAAAAAGCCAAATGAAGGATTTCTATCCAGCAAGATCCTCTCCAGAGTATGC 540
QY 541 CTGTGGAATCTGATCAGTTTCTTAAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTTCTTAAAAAATGACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGAGCTGTTTCTATATGTTTATACTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTGTGGAAGAGCTGTTTCTATATGTTTATACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGTTCGACTTGCACATTC 720
DB 661 TACGTATAAATTAATATAAATGATTAATCTCTGGTGTGACAGTTCGACTTGCACATTC 720
QY 721 TTAAGCAACAGCATAAATCTCTGATGATGATTAATTAATCTGATGCTCTAGTACATG 780
DB 721 TTAAGCAACAGCATAAATCTCTGATGATGATTAATTAATCTGATGCTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAATTTGAGGCTCATTTGGTTCATTTGATGAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAATTTGAGGCTCATTTGGTTCATTTGATGAACAGTATCTAA 840
QY 841 TTAATAATAGCTGTAGATATCAGGCTCTCTGATGAGTGAATATATATCTGACTAG 900
DB 841 TTAATAATAGCTGTAGATATCAGGCTCTCTGATGAGTGAATATATATCTGACTAG 900
QY 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATACATTTAC 960
DB 901 TGGGAAACCTTCATGGGTTTCCCTCATCTGTCATGATGATATATATGATGATACATTTAC 960
QY 961 AAAATAAAGGGAATTTCCCTCGCTTGAATATATATCCCTGATATATGATGATGAT 1020
DB 961 AAAATAAAGGGAATTTCCCTCGCTTGAATATATATCCCTGATATATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAAATAAATACTTCTGCTTAAATCTTAAAGCAT 1080
DB 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAAATAAATACTTCTGCTTAAATCTTAAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTGTGAAGAAATGCAATTTAAAGCTAT 1140
DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTGTGAAGAAATGCAATTTAAAGCTAT 1140
QY 1141 TTAATATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTAC 1200
DB 1141 TTAATATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTATTTATGCTTAC 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATAAACCCTGCTGTTCTTTAGTGAATATAAATAAACTCT 1320


```
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 26-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US0000219.
PR 06-JAN-2000; 2000WO-US0000277.
PR 06-JAN-2000; 2000WO-US0000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004341.
PR 24-FEB-2000; 2000WO-US0005004.
PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US0006319.
PR 21-MAR-2000; 2000WO-US0007532.
PR 30-MAR-2000; 2000WO-US0008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001WO-US0006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00886342.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX (GETH ) GENENTECH INC.
PA
XX
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Query Match 100.0%; Score 1333; DB 9; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCTCCGATGGCGCTTACGTTCCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
Db 1 GCCACGCTCCGATGGCGCTTACGTTCCGGGCTTCTGCTACATGCTGCGCGCTGCTGCT 60
```

Db 1141 TTAATATCTGTTTATTTATTTGTAAGACATTAATTAAGAAATGCTTATATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTCAGGTACTACAGATTTTCAAACCT 1260
Db 1201 TTCTAATCTGCTGTAAGATTTCTTAAGAAATTCAGGTACTACAGATTTTCAAACCT 1260
QY 1261 GAATGAGAGAAAATTCATATAACCATCTGCTGTTCTTTAGTGTCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTCATATAACCATCTGCTGTTCTTTAGTGTCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 65

ADE35409

ID ADE35409 standard; cDNA; 1333 BP.

AC ADE35409;

XX

29-JAN-2004 (first entry)

DE Human cDNA encoding secreted/transmembrane protein, PRO181.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;

KW cytototoxic; ophthalmological; antiarthritic; osteopathic; antirheumatic;

KW vulnary; auditory; tumour growth; retinal disorder;

KW sports-related joint problem; articular cartilage defects;

KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX

OS Homo sapiens.

XX

US2003203434-A1.

XX

30-OCT-2003.

XX

18-OCT-2001; 2001US-00145088.

XX

15-MAY-1998; 98US-0085689P.

PR 08-MAR-1999; 99WO-US005028.

PR 28-APR-1999; 99US-0131445P.

PR 25-AUG-1999; 99US-00380138.

PR 18-FEB-2000; 2000WO-US004341.

PR 30-JUL-2001; 2001US-00918585.

XX

(GETH) GENENTECH INC.

PA

XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Baton DL;

PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI: 2003-875641/81.

DR P-PSDB; ADE35410.

XX

New genes, and its encoded secreted and transmembrane polypeptides,

PT useful for treating e.g. lung or breast tumors, osteoarthritis,

PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,

PT hypoinsulinemia or wounds.

XX

Claim 2; SEQ ID NO 321; 462pp; English.

XX

The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 94 fully defined sequences as given

CC in the specification (including PRO lacking its associated signal

CC peptide, a PRO extracellular domain with or without its associated signal

CC peptide). Also included are nucleic acids encoding the PRO proteins

CC mentioned above, a vector comprising a PRO nucleic acid), a host cell

CC comprising the vector and producing PRO, a chimaeric molecule comprising

CC

CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

SQ

Query Match 100.0%; Score 1333; DB 9; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTCCAGCTTCGCGGCTTCTCTACATGCTGGCGTCTGCT 60

Db 1 GCCACGCGTCCGATGGCGTTCCAGCTTCGCGGCTTCTCTACATGCTGGCGTCTGCT 60

QY 61 CACTGCGGCGTCTCTCTTCGCGATTTGGGCATTTAGCATTTGATGAGCTGAAGAC 120

Db 61 CACTGCGGCGTCTCTCTTCGCGATTTGGGCATTTAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTTACAGAAATCTATAGACCAAGTAAATCCCTGATCCCTGCTACTCCAGAGTA 180

Db 121 TGATTTACAGAAATCTATAGACCAAGTAAATCCCTGATCCCTGCTACTCCAGAGTA 180

QY 181 CCTCATCCAGCTTCTCTCTGTGTCTATGTTTCTTGTGCGAGAGTGGCTTACACTGG 240

Db 181 CCTCATCCAGCTTCTCTCTGTGTCTATGTTTCTTGTGCGAGAGTGGCTTACACTGG 240

QY 241 TCTCATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGTATGAG 300

Db 241 TCTCATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGTATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTGCA 360

Db 301 TGGCCCGAGGACTCTATGACCCCTACAACTCATGAATCAGATATTTCTAGCATATTGCA 360

QY 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTACTACCTATATGG 420

Db 361 GAAGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTACTACCTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480

Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCACCAAGATCCTCTCCAGAGTAGC 540

Db 481 GCATGCAAAAAGCCACCAAAATGAAGGGATTTCTATCCACCAAGATCCTCTCCAGAGTAGC 540

QY 541 CTGTGGAAATCTGATCAGTTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600

Db 541 CTGTGGAAATCTGATCAGTTACTTTTAAAAAATGATCTCTTATTTTAAATGTTTCCACAT 600

Db 541 CTGTGGAATCTGATCAGTTACTTTAAATAATGACTCCTTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGAGCTGTTTTCATATGATCTACTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAAGAGCTGTTTTCATATGATCTACTCAGATAAGATTTTAAATGGTAT 660
QY 661 TACGTATAAATTAATAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TACGTATAAATTAATAATAAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGATGATCATTC 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGATGATCATTC 780
QY 781 GAAGCTTTTGTATATAGGAATTTGTAGGCTCATTTTGTTCATTTGAACAGATCTATA 840
Db 781 GAAGCTTTTGTATATAGGAATTTGTAGGCTCATTTTGTTCATTTGAACAGATCTATA 840
QY 841 TTATAAATTAAGCTGTATATATAGGCTCTCTCTGATGAAGTGAATAATGTATATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTATATATAGGCTCTCTCTGATGAAGTGAATAATGTATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGATGATGATATATATGATGATCATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCTCATCTGTCATGATGATGATATATATGATGATCATTTAC 960
QY 961 AAAAAATAAAGCGGAATTTTCCCTTGGCTTCAATATATATCCCTGATATATGATGATGAT 1020
Db 961 AAAAAATAAAGCGGAATTTTCCCTTGGCTTCAATATATATCCCTGATATATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGCTTTAATTTCTTAAGCATTA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGATTAATCTGTTGAGAGTCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGATTAATCTGTTGAGAGTCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTGTTTATTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATCTTACTG 1200
Db 1141 TTAATATGTGTTTATTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATTAATTAATCTCT 1320
Db 1261 GAATGAGAGAAATTTGTAACCATCTGCTGTTCTTTAGTCAATTAATTAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 66

ADE16523

ID ADE16523 standard; cdna; 1333 BP.

XX AC ADE16523;

XX AC ADE16523;

DT 29-JAN-2004 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO181.

XX Human; ss: gene; secreted protein; transmembrane protein; PRO;
XX cytotactic; ophthalmological; antiarthritis; osteopathic; antirheumatic;
XX vulnary; auditory; tumour growth; retinal disorder;
XX sports-related joint problem; articular cartilage defects;
XX osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

OS Homo sapiens.

XX

PN US2003203435-A1.
XX 30-OCT-2003.
XX 18-OCT-2001; 2001US-00145092.
XX 30-APR-1998; 98US-0083742P.
PR 08-MAR-1999; 99WO-US005028.
PR 23-JUN-1999; 99US-014037P.
PR 25-AUG-1999; 99US-0038013B.
PR 18-FEB-2000; 2000WO-US004341.
XX 30-JUL-2001; 2001US-00918585.
XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrera N, Filvaroff E, Fong S, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875642/81.
DR P-PSDB; ADE16524.
XX New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for treating e.g. lung or breast tumors, osteoarthritis,
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT hypoinsulinemia or wounds.
XX Claim 2; SEQ ID NO 321; 452pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ

Query Match

100.0%; Score 1333; DB 9; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGTCCGATGGGCTTCAAGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCT 60
Db |||||
QY 1 GCCACGGTCCGATGGGCTTCAAGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCT 60
Db |||||
QY 61 CACTCGCGGCTCATCTTCTCGCCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 61 CACTCGCGGCTCATCTTCTCGCCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
Db |||||
QY 121 TGATTACAGAACTCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCCGAGTGA 180
Db |||||
QY 121 TGATTACAGAACTCTATAGACAGTGAATACCTGTAATCCCTTGTACTCCCGAGTGA 180
Db |||||
QY 181 CCTCATCCAGCTTCTTCTGCTGCTATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
Db |||||
QY 181 CCTCATCCAGCTTCTTCTGCTGCTATGTTCTTTGTCAGCAGAGTGGCTTACACTGG 240
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAG 300
Db |||||
QY 301 TGGCCAGAGCTCTATGACCTTACACCATCATGATGAGTGCAGATATTTAGCATTTGTCA 360
Db |||||
QY 301 TGGCCAGAGCTCTATGACCTTACACCATCATGATGAGTGCAGATATTTAGCATTTGTCA 360
Db |||||
QY 361 GAAGGAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db |||||
QY 361 GAAGGAGGATGGTGCATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db |||||
QY 421 CATGATCTATGTTTGGTGGCTCTTGAACAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 421 CATGATCTATGTTTGGTGGCTCTTGAACAACACACAGAGAAATTTGGTCCAGTTAAGT 480
Db |||||
QY 481 GCATGCAAAAGCCACCAATCAAGGATTTCTATCCAGCAGATCTCTGTCAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAGCCACCAATCAAGGATTTCTATCCAGCAGATCTCTGTCAGAGTAGC 540
Db |||||
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAATGACCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAATCTGATCAGTACTTTTAAAAATGACCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTGTTGGGAAAGATGTTTTCATATGTTATATCTAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGTGTTGGGAAAGATGTTTTCATATGTTATATCTAGATAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TACGTATAAATTAATATAAATGATGATCTCTGGGTTGACAGGTTTGAACCTGCACTTC 720
Db |||||
QY 661 TACGTATAAATTAATATAAATGATGATCTCTGGGTTGACAGGTTTGAACCTGCACTTC 720
Db |||||
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGATGCTCTGATGATG 780
Db |||||
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGATTAATTAATGATGCTCTGATGATG 780
Db |||||
QY 781 GAAGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTTCATGTAAGAACAGTATCTAA 840
Db |||||
QY 781 GAAGCTTTGTTTATAGAACTTTGAGGCTCATTTTGGTTTCATGTAAGAACAGTATCTAA 840
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGTCTCTGATGAGTGAATGATGATGATGATGATGATG 900
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGTCTCTGATGAGTGAATGATGATGATGATGATGATG 900
Db |||||
QY 901 TGGGAAACTTCATGGGTTTCTCATCTGCTGATGCTGATGATGATGATGATGATGATGATG 960
Db |||||
QY 901 TGGGAAACTTCATGGGTTTCTCATCTGCTGATGCTGATGATGATGATGATGATGATGATG 960
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTGTAATATATATCCCTGATATATGATGATGAT 1020
Db |||||
QY 961 AAAAATAAAGCGGGAATTTTCCCTTGGCTGTAATATATATCCCTGATATATGATGATGAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTCTTAAATTTCTTAAGCATA 1080
Db |||||

QY 1081 AGTAAACATGATATAAAAAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAAACATGATATAAAAAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATGCTGTTTATTTTGTAAAGACATTAATTAAGAAAATGCTTATGCTTACTG 1200
Db |||||
QY 1141 TTAATGCTGTTTATTTTGTAAAGACATTAATTAAGAAAATGCTTATGCTTACTG 1200
Db |||||
QY 1201 TTTAAATCTGGTGGTAAAGGTATTTTAAAGAAATTTGAGGTAATTAAGAACTTTCAAACT 1260
Db |||||
QY 1201 TTTAAATCTGGTGGTAAAGGTATTTTAAAGAAATTTGAGGTAATTAAGAACTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGCTTCTTGTAGTGCATTAACATAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGCTTCTTGTAGTGCATTAACATAAACTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
RESULT 67
ADD73138
ID ADD73138 standard; cDNA; 1333 BP.
XX
AC ADD73138;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO181.
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
FN US2003203436-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145129.
XX
PR 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kijavini J, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI,
XX WPI; 2003-875643/81.
DR P-PSDB; ADD73139.
XX
PT New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
XX wounds.
PS Claim 2; SEQ ID NO 321; 453pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or

KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX Homo sapiens.
XX US2003194781-A1.

PN 16-OCT-2003.

XX 19-OCT-2001; 2001US-00164929.

XX 30-MAR-1998; 98US-0079920P.

PR 07-OCT-1998; 98WO-US021141.

PR 20-NOV-1998; 98WO-US024855.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 15-APR-1999; 99WO-US010733.

PR 14-MAY-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380138.

PR 30-NOV-1999; 99WO-US028313.

PR 02-DEC-1999; 99WO-US028551.

PR 16-DEC-1999; 99WO-US030095.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US009219.

PR 06-JAN-2000; 2000WO-US009277.

PR 11-FEB-2000; 2000WO-US009376.

PR 18-FEB-2000; 2000WO-US009365.

PR 24-FEB-2000; 2000WO-US009431.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 24-AUG-2000; 2000WO-US023328.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001WO-US006520.

PR 22-MAR-2001; 2001WO-US009552.

PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001WO-US017800.

PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.

PR 30-JUL-2001; 2001US-00918585.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL;

PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Kijavini IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-852598/79.

DR P-PSDB; ADD72497.

XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful

PT for stimulating the release of tumor necrosis factor alpha from human

PT blood and stimulating the proliferation of differentiation of chondrocyte

PT cells.

XX Claim 2; SEQ ID NO 321; 462pp; English.

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

Db 421 CATGATCTATGTTTGGTGAGCTCTTGTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCCAAAATGAAGGAGTCTATCCAGCAAGATCTCTGTCGAAGATAGC 540
Db 481 GCATGCAAAAGCCCAAAATGAAGGAGTCTATCCAGCAAGATCTCTGTCGAAGATAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTTATCTACGATAAAGATTTTAAATGTTAT 660
Db 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTTATCTACGATAAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAATTAATAAATGATTAACCTCTCGGTGTGACAGTTTGAACCTTGCATTC 720
Db 661 TAGCTATAATTAATAAATGATTAACCTCTCGGTGTGACAGTTTGAACCTTGCATTC 720
QY 721 TTAAGGAACAGCCATATCTCTGATGATGATGATTAATTAATTAATTAATTAATTAATG 780
Db 721 TTAAGGAACAGCCATATCTCTGATGATGATGATTAATTAATTAATTAATTAATTAATG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCAATTCGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCAATTCGAAACAGTATCTAA 840
QY 841 TTAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 900
Db 841 TTAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 900
QY 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
Db 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTTCGCTTGAATTAATTAATTAATTAATTAATTAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTTCGCTTGAATTAATTAATTAATTAATTAATTAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGATTAATTAATTAATTAATTAATTAATTAATTAATTA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTCTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATTTACTTCTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATATGTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Db 1141 TTAATATGTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGGTGAAGTATTTCTTAAGATTTGCGAGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATTTGTAACCATCTGCTGTTTCCCTTGAATTAATTAATTAATTAATTAAT 1320
Db 1261 GAATGAGAGAAAATTTGTAACCATCTGCTGTTTCCCTTGAATTAATTAATTAATTAATTAAT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 69

ADE17147

ID ADE17147 standard; cDNA; 1333 BP.

XX

AC ADE17147;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein, PRO181.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO; cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic; vulnery; auditory; tumour growth; retinal disorder; sports-related joint problem; articular cartilage defects; osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX PN US2003203433-A1.

XX PD 30-OCT-2003.

XX PF 18-OCT-2001; 2001US-00145016.

XX PR 06-MAY-1998; 98US-0084414P.

PR 22-DEC-1998; 98US-0113296P.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 12-APR-1999; 99US-00284291.

PR 25-AUG-1999; 99US-00380138.

PR 18-FEB-2000; 2000WO-US004341.

PR 30-JUL-2001; 2001US-00918585.

XX (GETH) GENENTECH INC.

XX PA Ashkenazi AJ, Baker KP, Botstein D, Deenoyers L, Eaton DL; Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME; Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ; Kijavlin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL; Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-875640/81.

DR P-PSDB; ADE17148.

XX New genes, and its encoded secreted and transmembrane polypeptides, useful for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or wounds.

XX Claim 2; SEQ ID NO 321; 459pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of

CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
 CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
 CC sports-related joint problems, articular cartilage defects,
 CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
 CC mammals. The present sequence encodes a PRO protein.

XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 9; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGGTTTCAGTTCGCGGCTTCGTCACATGCTGGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGGGTTTCAGTTCGCGGCTTCGTCACATGCTGGCGCTGCTGCT 60
 QY 61 CACTGCCGCGTCTATCTTTCGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 DB 61 CACTGCCGCGTCTATCTTTCGCGCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
 QY 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
 DB 121 TGATTACAGAAATCCTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTA 180
 QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCAGAGAGTGGCTTACACTGGG 240
 DB 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCAGAGAGTGGCTTACACTGGG 240
 QY 241 TCTCAATATGCCCTCTTGGCATATCAVATTTGGAGGTATATGAGTAGACCGATGATCAG 300
 DB 241 TCTCAATATGCCCTCTTGGCATATCAVATTTGGAGGTATATGAGTAGACCGATGATCAG 300
 QY 301 TGGCCCGAGACTCTATGACCCCTACAAACATCATGATGAGTATTTCTAGCATATTGTCA 360
 DB 301 TGGCCCGAGACTCTATGACCCCTACAAACATCATGATGAGTATTTCTAGCATATTGTCA 360
 QY 361 GAGGAGAGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
 DB 361 GAGGAGAGATGGTCAAAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAAATTTGTCAGTTAAGT 480
 DB 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACACACACAGAAATTTGTCAGTTAAGT 480
 QY 481 GCATGCAAAAGCCAGCAATGAGGATCTATCCAGCAAGACTCTGTCCAGAGTAGC 540
 DB 481 GCATGCAAAAGCCAGCAATGAGGATCTATCCAGCAAGACTCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTTTTAAATGTTTCCACAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 DB 601 TTTTCTGTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATAAATGATTTACCTCTGGTGTGCACAGGTTTGAACCTGCACCTC 720
 DB 661 TACGTATAAATTAATAAATGATTTACCTCTGGTGTGCACAGGTTTGAACCTGCACCTC 720
 QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATTTG 780
 DB 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGTCTAGTACATTTG 780
 QY 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGGTTCATTTGAACACAGTACTTAA 840
 DB 781 GAAGCTTTTGTATAGGAACCTGTAGGCTCATTTTGGTTCATTTGAACACAGTACTTAA 840
 QY 841 TTATAAATTAGCTGTAGATATCAGGCTCTCTCATGAGTGAAGTATATCTGACTAG 900
 DB 841 TTATAAATTAGCTGTAGATATCAGGCTCTCTCATGAGTGAAGTATATCTGACTAG 900
 QY 901 TGGGAAACTTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTATATATGATGATATTTAC 960

DB 901 TGGGAAACTTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTATATGATGATATTTAC 960
 QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATGTCATGAAT 1020
 DB 961 AAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATTAATCCCTGTATATGTCATGAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTGTAAATTTCTTAAGCATTA 1080
 DB 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAAATATATCTTGTAAATTTCTTAAGCATTA 1080
 QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGAAATGCAATTAAGCTATT 1140
 DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGAAATGCAATTAAGCTATT 1140
 QY 1141 TTAATCTGTTTTTATTTGTAAGACATATCTTATTAAGAAATTTGGTATTATGCTTACTG 1200
 DB 1141 TTAATCTGTTTTTATTTGTAAGACATATCTTATTAAGAAATTTGGTATTATGCTTACTG 1200
 QY 1201 TTCTAACTCTGTCGTAAGAGTATTCTTAAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
 DB 1201 TTCTAACTCTGTCGTAAGAGTATTCTTAAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
 QY 1261 GAATGAGAGAAAATGATATAACCACTCTGCTGCTTTAGTGAATTAACATAAATAAACTCT 1320
 DB 1261 GAATGAGAGAAAATGATATAACCACTCTGCTGCTTTAGTGAATTAACATAAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 DB 1321 GAAATTAAGACTC 1333

RESULT 70

ADC48822
 ID ADC48822 standard; cDNA; 1333 BP.

AC ADC48822;

XX AC

XX 15-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnery; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

XX Homo sapiens.

OS US2003092888-A1.

PN 15-MAY-2003.

PD 13-AUG-2002; 2002US-00219468.

PF 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-031186/03.

DR P-PSDB; ADC48823.

XX Novel isolated PRO polypeptide useful for tissue typing, gene therapy, as

PT molecular weight markers in protein electrophoresis, for treating
 XX arthritis, tumor.

Claim 2; SEQ ID NO 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1183, PRO846, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 GCCACGCGTCCGATGCGGTTACGTTTCGGGGCTTCTGCTACATGCTGCGGCTGCTGCT 60
 1 GCCACGCGTCCGATGCGGTTACGTTTCGGGGCTTCTGCTACATGCTGCGGCTGCTGCT 60
 61 CACTGCGCGCTCATCTCTTCCGCTTGGCCATTTGGCATTATAGCATTTGATGAGCTGAGAC 120
 61 CACTGCGCGCTCATCTCTTCCGCTTGGCCATTTGGCATTATAGCATTTGATGAGCTGAGAC 120
 121 TGATTACAGAACTCCTATAGACCACTGTAATACCTGATCCCTCTGCTACTCCACAGTA 180
 121 TGATTACAGAACTCCTATAGACCACTGTAATACCTGATCCCTCTGCTACTCCACAGTA 180
 181 CCTCATCCAGCTTCTCTTCTGTGTCATGTTTCTTTGTGCGAGAGAGTGGCTTACATGGG 240
 181 CCTCATCCAGCTTCTCTTCTGTGTCATGTTTCTTTGTGCGAGAGAGTGGCTTACATGGG 240
 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGATAGCCAGTATGAG 300
 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGATAGCCAGTATGAG 300
 301 TGGCCCGAGGACTCTATGACCTCAACCAATCATGATATTTCTAGCATATTTGCTCA 360
 301 TGGCCCGAGGACTCTATGACCTCAACCAATCATGATATTTCTAGCATATTTGCTCA 360
 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTCTAGTCAATATGG 420

Db 361 GAAGGAGGATGGTGCAAAATAGCTTTTATCTTCTAGCATATTTTCTTACTACTATATGG 420
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATGGTCCAGTTAAGT 480
 Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACAACAAGAAATGGTCCAGTTAAGT 480
 QY 481 GCATCCAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCCTGTCGAAGAGTAGC 540
 Db 481 GCATCCAAAGCCCAAAATCAAGGATTTCTATCAGCAAGATCCTGTCGAAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTAAATGTTTCCACAT 600
 QY 601 TTTTCTGTTGTGAAAGACAGCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTGTTGTGAAAGACAGCTGTTTTCATATGTTTATCTAGATAAAGATTTTAAATGGTAT 660
 QY 661 TAGCTATAAATTAATATAAAATGATTACCTCTGCTGTTTGCACAGGTTTGAACCTTGCACTTC 720
 Db 661 TAGCTATAAATTAATATAAAATGATTACCTCTGCTGTTTGCACAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATG 780
 Db 721 TTAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATCTGACTGCTCTAGTACATG 780
 QY 781 GAAGCTTTTGTATAGGAAGCTTAGGGCTCATTTTGGTTCATTTGATGAACAGTAGTCTAA 840
 Db 781 GAAGCTTTTGTATAGGAAGCTTAGGGCTCATTTTGGTTCATTTGATGAACAGTAGTCTAA 840
 QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGAAATCTCATGGGTTTCTCATCTGTCATGTCATGATTAATATATGATGATACATTTAC 960
 Db 901 TGGAAATCTCATGGGTTTCTCATCTGTCATGTCATGATTAATATATGATGATACATTTAC 960
 QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTTATCCCTGATATATCCCTGATATGCAAT 1020
 Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTTATCCCTGATATATGCAAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATACTATGCTTTTAAATCTTTAAGCAATA 1080
 Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATACTATGCTTTTAAATCTTTAAGCAATA 1080
 QY 1081 AGTAAACATGATATAAAATATATGCTGATTAATCTTGTGAAGATGCAATTAAGCTATT 1140
 Db 1081 AGTAAACATGATATAAAATATATGCTGATTAATCTTGTGAAGATGCAATTAAGCTATT 1140
 QY 1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGGTATTTATGCTTTACTG 1200
 Db 1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGGTATTTATGCTTTACTG 1200
 QY 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 Db 1201 TTCTAATCTGTTGTTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCTTCTAGTGCATATCAATATACTCT 1320
 Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCTTCTAGTGCATATCAATATACTCT 1320
 QY 1321 GAAATTTAAGACTC 1333
 Db 1321 GAAATTTAAGACTC 1333

RESULT 71
 ADE20993
 ID ADE20993 standard; cdna; 1333 BP.
 XX
 AC ADE20993;
 XX

DT 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO181 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation; inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
OS US2003100735-A1.
XX 29-MAY-2003.
XX 28-AUG-2002; 2002US-00230433.
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker JC, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi KP, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008985/01.
XX P-PSDB; A0E20994.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells, PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC

CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCACGCGTCGATGCGGTCACGTCGCGGCTTCTGTCATCATGCTGCGCTGCTGCT 60
Db 1 GCCCACGCGTCGATGCGGTCACGTCGCGGCTTCTGTCATCATGCTGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTCTCTCGCATTTGSCACATTATAGCATTTGATGAGTCAGAGAC 120
Db 61 CACTGCCGCGCTCATCTCTCTCGCATTTGSCACATTATAGCATTTGATGAGTCAGAGAC 120
QY 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAAGAAATCCTATAGACACAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTCTCTGTGTCATGTTTCTTTGTCAGAGAGTGCTTACTACCTGG 240
Db 181 CCTCATCCAGCTTCTCTGTGTCATGTTTCTTTGTCAGAGAGTGCTTACTACCTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTGTAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTGTAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATTTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGACAGATATTTAGCATATTTGCA 360
QY 361 GAAGAGAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
Db 361 GAAGAGAGAGTGTGCAAAATAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
QY 421 CATGATCATCTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTCCTCAGTTAAGT 480
Db 421 CATGATCATCTTTTGGTGAGCTCTTAGAACACACACAGAGAAATTCCTCAGTTAAGT 480
QY 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
Db 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
QY 541 CTGTGGATCTGATCAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTTGTGGAAGAGCTGTTTTCATATGTTTACTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAAATAATAAATAAGATTAAGTCTGTTGTTGACAGGTTTGAACCTTGACTTC 720
Db 661 TACGATATAAATAATAAATAAGATTAAGTCTGTTGTTGACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGGAACAGCCATAAATCCTGATGATGATTAATTAATGCTGCTAGTACATTTG 780
Db 721 TTAAGGAACAGCCATAAATCCTGATGATGATTAATTAATGCTGCTAGTACATTTG 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGGTTCATTGAAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
QY 901 TGGGAACTTCATGGGTTTCCCTCATCTGATGATGATTAATATATGATGATACATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCCCTCATCTGATGATGATTAATATATGATGATACATTTAC 960

QY 961 AAAAAAAGCGGGAATTTTCCCTTGGTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 961 AAAAAAAGCGGGAATTTTCCCTTGGTGAATATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGTAAATCTTAAAGCATATA 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGTAAATCTTAAAGCATATA 1080
Db |||||
QY 1081 AGTAACATGATATATAAATATATGCTGAATTAATCTTGTGAAGATGCATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAACATGATATATAAATATATGCTGAATTAATCTTGTGAAGATGCATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATATGTTTTTATTTGTAAGACATTAATCTTAAAGATTTGTTATATGCTTACTG 1200
Db |||||
QY 1141 TTAATATGTTTTTATTTGTAAGACATTAATCTTAAAGATTTGTTATATGCTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGTTGGTAAAGGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1201 TTCTAATCTGTTGGTAAAGGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGTAACATCTCTGCTGTTCTTTAGTGCAATACAAATAAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGTAACATCTCTGCTGTTCTTTAGTGCAATACAAATAAAACTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 72

AD05837
ID ADE05837 standard; cDNA; 1333 BP.
XX
AC ADE05837;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #60.
XX
KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100728-A1.
XX
PD 29-MAY-2003.
XX
PF 28-AUG-2002; 2002US-00230024.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
XX
XX WPI; 2004-008978/01.
DR P-PSDE; ADE05838.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
XX Claim 2; Fig 119; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and

transmembrane polypeptides) and the PRO polynucleotides encoding them.
The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers and in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as
molecular markers for protein electrophoresis, and in tissue typing. This
sequence represents a human PRO polynucleotide of the invention.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTTCCCTTGGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db |||||
QY 1 GCCACGCGTCCGATGGGTTTCCCTTGGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db |||||
QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
Db |||||
QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
Db |||||
QY 121 TGATTTACAGATTCCTATAGACCGCTGAATACCTGATCCCTTGTACTCCAGAGTA 180
Db |||||
QY 121 TGATTTACAGATTCCTATAGACCGCTGAATACCTGATCCCTTGTACTCCAGAGTA 180
Db |||||
QY 181 CCTCATCCACGCTTTCTTCTGCTGCTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240
Db |||||
QY 181 CCTCATCCACGCTTTCTTCTGCTGCTCATGTTTCTTTGTGCGAGCAGAGTGGCTTACATGGG 240
Db |||||
QY 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300
Db |||||
QY 241 TCTCAATATGCCCTTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300
Db |||||
QY 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
Db |||||
QY 301 TGGCCCGAGGACTCTATGACCTTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
Db |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCAATTTTATCTTCTATATGG 420
Db |||||
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCAATTTTATCTTCTATATGG 420
Db |||||
QY 421 CATGATCTATGTTTTGGTGAAGTCTTTAGAACACACACAGAGAAATTTGTCAGTTAACT 480
Db |||||
QY 421 CATGATCTATGTTTTGGTGAAGTCTTTAGAACACACACAGAGAAATTTGTCAGTTAACT 480
Db |||||
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCCAAGAGTAGC 540
Db |||||
QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCCAAGAGTAGC 540
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db |||||
QY 601 TTTTGTCTGTGGAAGAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAGAGACTGTTTTTCATATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
Db |||||

QY 661 TAGGTAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db 661 TAGGTAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
QY 721 TTAAGGAACAGCCATATCCTCTGAATGATGATTAATTAACCTGCTGCTAGTACATTC 780
Db 721 TTAAGGAACAGCCATATCCTCTGAATGATGATTAATTAACCTGCTGCTAGTACATTC 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
QY 841 TTATAAATTAAGCTGTAGATACAGTCTGCTGATGAAGTGAATGTAATCTATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTAGATACAGTCTGCTGATGAAGTGAATGTAATCTATCTGACTAG 900
QY 901 TGGGAACCTTATCGGTTTCCCTCATCTGTCATGTCGATGATTAATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTATCGGTTTCCCTCATCTGTCATGTCGATGATTAATATGATGATACATTTAC 960
QY 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTAATTAATCCCTGATTAATGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTCCCTTCGCTTGAATTAATTAATCCCTGATTAATGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATTAATTAATTAATTAATTAATTAATTAAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATTAATTAATTAATTAATTAATTAATTAAT 1080
QY 1081 AGTAACATGATATAAAATATATGCTGTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140
Db 1081 AGTAACATGATATAAAATATATGCTGTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140
QY 1141 TTAATGCTGTTTATTTGAACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
Db 1141 TTAATGCTGTTTATTTGAACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1200
QY 1201 TTCTATCTGCTGTAAGTATTTCTTAAGAAATTTGAGGATTAATTAATTAATTAATTAATTAAT 1260
Db 1201 TTCTATCTGCTGTAAGTATTTCTTAAGAAATTTGAGGATTAATTAATTAATTAATTAATTAAT 1260
QY 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTCAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTCCCTTTAGTCAATACATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 73

ADD75066

ID ADD75066 standard; cDNA; 1333 BP.

XX AC ADD75066;

XX AC ADD75066;

DT 29-JAN-2004 (first entry)

XX DE Human PRO polynucleotide #60.

XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytosolic; antiarthritic.

XX OS Homo sapiens.

XX PN US2003100712-A1.

XX PD 29-MAY-2003.

XX PD 29-MAY-2003.

XX PF 09-AUG-2002; 2002US-00216168.

XX

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX (GENTH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008962/01.

DR P-PSDB; ADD75067.

XX New secreted and transmembrane PRO polypeptide useful for preparing a

PT medicament for treating a condition that is responsive to the PRO

PT polypeptide or anti-PRO antibody, e.g. cancer.

XX Claim 2; Fig 119; 309pp; English.

CC The invention relates to human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

CC diagnostics, biosensors or bioreactors. They are particularly useful for

CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,

CC prostate tumour, rectal tumour or liver tumour) in a mammal, for

CC stimulating the release of tumour necrosis factor (TNF)-alpha from human

CC blood, for stimulating the proliferation or differentiation of

CC chondrocyte cells, for stimulating the proliferation of or gene

CC expression in pericyte cells or for stimulating the proliferation of

CC normal human dermal fibroblasts. The PRO nucleic acids are useful as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant

CC technology, in generating transgenic animals or knock-out animals which

CC may be used in the development and screening of therapeutically useful

CC reagents, in gene therapy, in chromosome identification, as chromosome

CC markers and in generating probes. The PRO polypeptides, or anti-PRO

CC antibodies, are useful for preparing a medicament for treating a

CC condition which is responsive to the PRO polypeptides or anti-PRO

CC antibodies, such as pericyte-associated tumours and bone and/or cartilage

CC disorders (e.g. arthritis, sports injuries), involving inducing the re-

CC differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent can also be obtained in electronic

CC format directly from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCTCCGATGGGCTTCAAGTTCGCGGCTTCTGCTACATGCTGCGCTGCTGCT 60

Db 1 GCCACGCTCCGATGGGCTTCAAGTTCGCGGCTTCTGCTACATGCTGCGCTGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTCTTCCCATTTGGCACATTAATAGCATTTGATGAGTGAAGAC 120

Db 61 CACTGCCGCGCTCATCTTCTTCCCATTTGGCACATTAATAGCATTTGATGAGTGAAGAC 120

QY 121 TGATTAACAAGATCCCTATAGACAGTGTAAATCCCTGAAATCCCTTGTACTCCACAGTA 180

Db 121 TGATTAACAAGATCCCTATAGACAGTGTAAATCCCTGAAATCCCTTGTACTCCACAGTA 180

QY 181 CCTCATCCACGCTTTCTTCTGTCATGTTTCTTTGTGTCAGAGAGTGGCTTACATGGG 240

Db 181 CCTCATCCACGCTTTCTTCTGTCATGTTTCTTTGTGTCAGAGAGTGGCTTACATGGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTATGAG 300

Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTGAAGTATGAG 300

QY 301 TGGCCCGAGGACTCTATGACCTTACCAACCATCATGAATGACATATTTCTAGCATATTGTCA 360

Db 301 TGGCCAGGACTCTATGACCCCTACACCCATCATGAATGAGATATTCCTAGCATATGTCAC 360
Qy 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTCTAGCATTTTCTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGAAAAAGCCCAAAATGAAGGATCTCTATCCAGCAAGATCTCTGTCGAAGTAGC 540
Db 481 GCATGAAAAAGCCCAAAATGAAGGATCTCTATCCAGCAAGATCTCTGTCGAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGACTCTCTTATTTTAAAAATGTTTCCACAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATAAATGATTAACCTCTGGTCTGACAGGTTTGAACCTTGCACTTC 720
Db 661 TACGTATAAATTAATAAATGATTAACCTCTGGTCTGACAGGTTTGAACCTTGCACTTC 720
Qy 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTAGTACATG 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTAGTACATG 780
Qy 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCAATTTGGTTTCATTTGAACAGATATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCAATTTGGTTTCATTTGAACAGATATCTAA 840
Qy 841 TTATAAATTAGCTGTAGATACAGTCTCTCTCATGAAGTGAATGTAATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATACAGTCTCTCTCATGAAGTGAATGTAATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960
Qy 961 AAAAATTAAGGCGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCATTCATCAAT 1020
Db 961 AAAAATTAAGGCGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTCATTCATCAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTAAAGCATTA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGTCTTAAATCTTAAAGCATTA 1080
Qy 1081 AGTAACATGATATAAAATATATGCTGGAATTTACTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAACATGATATAAAATATATGCTGGAATTTACTGTGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATCTGTTTATTTGTAAGACATTAATTTAAGAAATTTGGTTATTTATGTTTACTG 1200
Db 1141 TTAATCTGTTTATTTGTAAGACATTAATTTAAGAAATTTGGTTATTTATGTTTACTG 1200
Qy 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACCT 1260
Db 1201 TTCTAATCTGTGTGTAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACCT 1260
Qy 1261 GAATGAGAAAAATGTATATACCAATCTGCTGTTTCTTTAGTGCATTAATAAATCTCT 1320
Db 1261 GAATGAGAAAAATGTATATACCAATCTGCTGTTTCTTTAGTGCATTAATAAATCTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

ADD75812
ID ADD75812 standard; cDNA; 1333 BP.
XX AC
XX ADD75812;
XX DT
XX 29-JAN-2004 (first entry)
XX DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation; lung tumour;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
XX KW gene therapy.
XX OS Homo sapiens.
XX PN US2003100717-A1.
XX PD 29-MAY-2003.
XX PF 13-AUG-2002; 2002US-00219465.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GETH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008967/01.
XX P-PSDB; ADD75813.
XX PT New secreted and transmembrane PRO polypeptide useful for preparing a
XX medicament for treating a condition that is responsive to the PRO
XX polypeptide or anti-PRO antibody, e.g. cancer.
XX PS Claim 2; SEQ ID NO 119; 308pp; English.
XX CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
CC PRO1887, PRO1928, PRO3441, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptide
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue

CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX

SO Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGGCGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGTCTCATCTTCTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCCGCGTCTCATCTTCTCGCCATTTGGCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCCAAGATA 180
Db 121 TGATTACAAGATCCCTATAGACAGTGAATACCCCTGAATCCCTTGTACTCCCAAGATA 180
QY 181 CCTGATCCAGCTTCTTCTGCTGTCATGTTTCTTGTGAGCAGAGTGGCTTACACTGG 240
Db 181 CCTGATCCAGCTTCTTCTGCTGTCATGTTTCTTGTGAGCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATTATCATATTTGGAGGTATATGAGTAGCAGATCATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATTATCATATTTGGAGGTATATGAGTAGCAGATCATGAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATTTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGAATGAGATATTTAGCATATTTGCA 360
QY 361 GAAGGAAGATGGTGAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGATGGTGAATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCATGTTTGTGAGCTCTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480
Db 421 CATGATCATGTTTGTGAGCTCTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480
QY 481 GCATCAAAAGCCCAATGAAGGATTTCTATCCAGCAGATCTGTGCCAAGAGTAGC 540
Db 481 GCATCAAAAGCCCAATGAAGGATTTCTATCCAGCAGATCTGTGCCAAGAGTAGC 540
QY 541 CTGTGGATCTGATCAGTTACTTTAAATAATGACTCTTATTTTAAATGTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTAAATAATGACTCTTATTTTAAATGTTCCACAT 600
QY 601 TTTTGTCTGTGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATAAATAAATGATTTACCTCTGCTGTGACAGGTTTGAACITGCACTTC 720
Db 661 TAGCTATAAATAAATAAATGATTTACCTCTGCTGTGACAGGTTTGAACITGCACTTC 720
QY 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATTTACTGACCTCTAGTACATG 780
Db 721 TTAGGAACAGCCATAATCTCTGAATGATGATTAATTTACTGACCTCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGGAATCTGTAGGCTCATTTTGTGTTTCAATGAACAGATCTAA 840
Db 781 GAAGCTTTTGTATAGGAATCTGTAGGCTCATTTTGTGTTTCAATGAACAGATCTAA 840
QY 841 TTATAAATTAGCTGTAGATACAGGTGCTTCTCATGAAGTGAATAATGTATATCTAGTAG 900
Db 841 TTATAAATTAGCTGTAGATACAGGTGCTTCTCATGAAGTGAATAATGTATATCTAGTAG 900

QY 901 TGGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTATATATGATCATTTAC 960
Db 901 TGGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTATATATGATCATTTAC 960
QY 961 AAAAATAAAAGCGGGAATTTTCCCTTCGGCTTGAATATATCCCTGTATATTCATGAAT 1020
Db 961 AAAAATAAAAGCGGGAATTTTCCCTTCGGCTTGAATATATCCCTGTATATTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAATCTTTAAGCATA 1080
QY 1081 AGTAAACATGATATAAAATATATATGCTGATTTCTGTGAAGAATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAAATATATATGCTGATTTCTGTGAAGAATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTGTTTTTATTTTGAAGCAATTTTAAAGAAATTTGTTATATGTTTACTG 1200
Db 1141 TTAATGTGTTTTTATTTTGAAGCAATTTTAAAGAAATTTGTTATATGTTTACTG 1200
QY 1201 TTCTAATCTGTGTAAGGTAATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGTGTAAGGTAATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATTTGTATTAACCATCTGCTGTTCTTCTGTGCAATACAAATAAACTCT 1320
Db 1261 GAATGAGAGAAAATTTGTATTAACCATCTGCTGTTCTTCTGTGCAATACAAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 75
ADD85044
ID ADD85044 standard; cDNA; 1333 BP.
XX
AC ADD85044;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100722-A1.
XX
PD 29-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219476.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Deanoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;
XX WPI; 2004-008972/01.
DR P-PSDB; ADD85045.

XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
PS
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO228, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO57, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 GCCACGGCTCCGATGGCGTTACGTTCCGGCGCTTCTGTACATCGTGGCGTGTGCT 60
1 GCCACGGCTCCGATGGCGTTACGTTCCGGCGCTTCTGTACATCGTGGCGTGTGCT 60
61 CACTGGCGGCTCATCTTCTTCGCCAATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
61 CACTGGCGGCTCATCTTCTTCGCCAATTGGCCACATTATAGCATTTGATGAGCTGAAGAC 120
121 TGATTAACAAGATCCTATAGACAGGTATATACCTGAAATCCCTGAAATCCCTGAAATCCCTGAAAT 180
121 TGATTAACAAGATCCTATAGACAGGTATATACCTGAAATCCCTGAAATCCCTGAAATCCCTGAAAT 180
181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACCTGGG 240
181 CCTCATCCAGCTTCTTCTGTGTCATGTTCTTGTGTCAGAGTGGCTTACACCTGGG 240
241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATAGTAGAGCCAGTGTAG 300
241 TCTCAATATGCCCTCTTGGCAATCATATTTGGAGGTATATAGTAGAGCCAGTGTAG 300
301 TGGCCCCAGGACTCTATGACCCCTCAACACCATCATGAGATGAGATTTCTAGCATATTGTC 360
301 TGGCCCCAGGACTCTATGACCCCTCAACACCATCATGAGATGAGATTTCTAGCATATTGTC 360

QY 361 GAAGGAGGAGTGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGAGTGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACAACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAAAATGAGGATTTCTATCCAGCAAGATCCCTGTCACAGAGTAGC 540
QY 541 CTGTGGAAATCTGATCAGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAAATCTGATCAGTTACTTTAAAAAATGACTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTCTGTGGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTGTGGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 720 TACGTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTTCACCTTC 720
DB 720 TACGTATAAATTAATAAATGATTTACCTCTGCTGTTGACAGGTTTGAACCTTCACCTTC 720
QY 780 TTAAGGACACGACCATATCTCTGAAATGATGCAATTAATTAATCTGACTGCTAGTACATTTG 780
DB 780 TTAAGGACACGACCATATCTCTGAAATGATGCAATTAATTAATCTGACTGCTAGTACATTTG 780
QY 840 GAAGCTTTTGTATATAGGAACTTTGAGGCTCATTTTGGTTTCATTGGAACAGTATCTAA 840
DB 840 GAAGCTTTTGTATATAGGAACTTTGAGGCTCATTTTGGTTTCATTGGAACAGTATCTAA 840
QY 900 TTATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATATATATCTGACTAG 900
DB 900 TTATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATATATATCTGACTAG 900
QY 960 TGGGAAACTTCATGGTTTCTCTCACTGTCATGTCGATGATTTATATATGGAATATTTAC 960
DB 960 TGGGAAACTTCATGGTTTCTCTCACTGTCATGTCGATGATTTATATATGGAATATTTAC 960
QY 1020 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATTTGCAATGAT 1020
DB 1020 AAAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGATATTTGCAATGAT 1020
QY 1080 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTTCTTTAAATCTTAAAGCATA 1080
DB 1080 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATAATATCTTCTTTAAATCTTAAAGCATA 1080
QY 1140 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
DB 1140 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1200 TTAATATGCTTTTATTTGTTGAAGATTTTAAAGAAATTTGGTTATTTATGCTTACTTG 1200
DB 1200 TTAATATGCTTTTATTTGTTGAAGATTTTAAAGAAATTTGGTTATTTATGCTTACTTG 1200
QY 1260 TTCTAATCTGGTGAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
DB 1260 TTCTAATCTGGTGAAGGATTTCTTAAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
QY 1320 GAATGAGAGAAATTTGTAACCACTCTGCTGTTTCTTTAGTGCATATCAATAAATCTCT 1320
DB 1320 GAATGAGAGAAATTTGTAACCACTCTGCTGTTTCTTTAGTGCATATCAATAAATCTCT 1320
QY 1333 GAAATTAAGACTC 1333
DB 1333 GAAATTAAGACTC 1333

RESULT 76
ADD86870
ID ADD86870 standard; cdna; 1333 BP.
XX

CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGTCGCGTCTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGTCGCGTCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTTGGCCATTGGCCATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAAGATCCTATAGACAGTGTAAATACCTGAAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGCTTTCTTCTGTGTATGTTTGTGTGACGAGTGGCTTACATGGG 240
DB 181 CCTCATCCAGCTTTCTTCTGTGTATGTTTGTGTGACGAGTGGCTTACATGGG 240
QY 241 TCTCAATGATGCGCTTGTGGCATATCATATTTGGAGGTATATGATGACACGATGATGAG 300
DB 241 TCTCAATGATGCGCTTGTGGCATATCATATTTGGAGGTATATGATGACACGATGATGAG 300
QY 301 TGGCCGAGCATCTATAGTCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
DB 301 TGGCCGAGCATCTATAGTCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
QY 361 GAAGGAGGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGATGGTGCATAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTACCAACACACAGAGAAATTTGCTCCAGTAAAT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTACCAACACACAGAGAAATTTGCTCCAGTAAAT 480
QY 481 GCATGCAAAAGACCAACCAATGAGGAGTTCTATCCAGCAAGATCCTGTCCAAGATAGC 540
DB 481 GCATGCAAAAGACCAACCAATGAGGAGTTCTATCCAGCAAGATCCTGTCCAAGATAGC 540
QY 541 CTGTGGAATCTCATCAGTTTCTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTCATCAGTTTCTTTTAAATAAGTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTGTTGGAAGAGCTGTTTCTATATGTTTATCTCAGATAAAGATTTAAATGGTAT 660
DB 601 TTTTGTGTTGGAAGAGCTGTTTCTATATGTTTATCTCAGATAAAGATTTAAATGGTAT 660
QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTGCCTTC 720
DB 661 TACGTATAAATTAATATAAATGATTAATCTCTGTGTTGACAGGTTTGAACCTTGCCTTC 720
QY 721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTAATCTGACCTCTAGTACATTG 780
DB 721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTAATCTGACCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGGAACTTGTAGGCTCATTTTGGTTTCAATTAAGAACTAGTACTAA 840
DB 781 GAAGCTTTTGTATAGGAACTTGTAGGCTCATTTTGGTTTCAATTAAGAACTAGTACTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTGACTAG 900
DB 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATATCTGACTAG 900
QY 901 TGGGAAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTATATATGATGATATTC 960

AC ADD86870;
XX 29-JAN-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO181 CDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
XX US2003100738-A1.
XX 29-MAY-2003.
XX 29-AUG-2002; 2002US-00232222.
XX 15-SEP-2000; 2000US-0232887P.
XX 01-JUN-2001; 2001WO-US0217800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008988/01.
XX P-PSDB; ADD86871.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
XX in gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO331, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO1083, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1419, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1279, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (II) is useful

gene therapy, chromosome identification, tissue typing, or as hybridization probes in chromosome and gene mapping.

Claim 2; Fig 119; 308pp; English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO531, PRO533, PRO531, PRO1083, PRO1309, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1186, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide is useful for treating bone and/or cartilage disorders (e.g., arthritis, sport injuries). This sequence encodes a human secreted and transmembrane PRO polypeptide.

Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match	100.0%	Score 1333	DB 10	Length 1333
Best Local Similarity	100.0%	Pred. No. 9.6e-306	Mismatches 0	Gaps 0
Matches 1333	Conservative 0			
QY	1	GCCACGCGTCCGATGGGTTTCACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT	60	
Db	1	GCCACGCGTCCGATGGGTTTCACGTTCCGCGCTTCTGCTACATGCTGGCGCTGCTGCT	60	
QY	61	CACTCCCGCGCTCATCTTCTTGGCCATTTGGCAGATTAATAGCATTTGATGAGCTGAGAC	120	
Db	61	CACTCCCGCGCTCATCTTCTTGGCCATTTGGCAGATTAATAGCATTTGATGAGCTGAGAC	120	
QY	121	TGATTAAGAATCTTATAGACGAGTGAATACCTGATCCCTGATCCCTTGTATCCCGAGTA	180	
Db	121	TGATTAAGAATCTTATAGACGAGTGAATACCTGATCCCTGATCCCTTGTATCCCGAGTA	180	
QY	181	CCTCATCCACGCTTCTTCTGCTGCTATGTTTCTTGTGAGCAGAGTGGCTTACATGGG	240	
Db	181	CCTCATCCACGCTTCTTCTGCTGCTATGTTTCTTGTGAGCAGAGTGGCTTACATGGG	240	
QY	241	TCTCAATATGCCCTCTTGGCAGATTAATAGCATTTGATGAGCTGAGTATGAG	300	
Db	241	TCTCAATATGCCCTCTTGGCAGATTAATAGCATTTGATGAGCTGAGTATGAG	300	
QY	301	TGGCCCGAGCTCTATGACCCCTACACCATCAATCAATGAGATATCTAGCATTTGTCA	360	
Db	301	TGGCCCGAGCTCTATGACCCCTACACCATCAATCAATGAGATATCTAGCATTTGTCA	360	
QY	361	GAAGGAGGATGGTGCAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCT	420	

Db	901	TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCGATGATTATATATGATACATTTAC	960
QY	961	AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATAT	1020
Db	961	AAAAATAAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATATATATATATATATAT	1020
QY	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATATATATATATATATATAT	1080
Db	1021	GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATATATATATATATATATAT	1080
QY	1081	AGTAAACATGATATAAATAATATATATATATATATATATATATATATATATATATAT	1140
Db	1081	AGTAAACATGATATAAATAATATATATATATATATATATATATATATATATATATAT	1140
QY	1141	TTAAATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATATATAT	1200
Db	1141	TTAAATGCTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATATATATAT	1200
QY	1201	TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTCCAGTACTACAGATTTTCAAACT	1260
Db	1201	TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTCCAGTACTACAGATTTTCAAACT	1260
QY	1261	GAATGAGAGAAATTTGTAAGCAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
Db	1261	GAATGAGAGAAATTTGTAAGCAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCT	1320
QY	1321	GAATTAAGACTC 1333	
Db	1321	GAATTAAGACTC 1333	

RESULT 77

ID	ADE20747	standard; cDNA; 1333 BP.
AC	ADE20747;	
DT	29-JAN-2004	(first entry)
XX	Novel human secreted and transmembrane protein PRO181 cDNA.	
DE	Human; secreted and transmembrane protein; PRO; gene; ss; cytosstatic;	
KW	vulnery; antiarthritic; pericyte cell proliferation;	
KW	pericyte cell differentiation; chondrocyte cell proliferation;	
KW	chondrocyte cell differentiation; tumour necrosis factor alpha release;	
KW	(TNF)-alpha release; dermal fibroblast cell proliferation;	
KW	dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;	
KW	colon tumour; breast tumour; prostate tumour; rectal tumour;	
KW	liver tumour; tissue typing; chromosome mapping; gene mapping;	
KW	gene therapy.	
OS	Homo sapiens.	
XX	US2003100734-A1.	
PN	29-MAY-2003.	
PD		
XX	28-AUG-2002; 2002US-00230427.	
PF		
XX	01-JUN-2001; 2001WO-US017800.	
PR	29-JUN-2001; 2001WO-US021066.	
PR	09-APR-2002; 2002US-00119480.	
XX	(GETH) GENENTECH INC.	
PA	Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;	
XX	Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood MT;	
PI	WPI; 2004-008984/01.	
XX	P-PSDB; ADE20748.	
DR	New PRO polypeptide and nucleic acid encoding the polypeptide, useful in	
XX		
PT		

361	Db	GAAGGAGGATGGTGCAAAATTAGCTTTTATCTCTACGATTTTCTTACTACTATATGG	420
421	Qy	CATGATCTATGTTTTGGTGGAGCTCTTAGAACAACACACAGAGAATTGGTCAGTTAAGT	480
421	Db	CATGATCTATGTTTTGGTGGAGCTCTTAGAACAACACACAGAGAATTGGTCAGTTAAGT	480
481	Qy	GCATGCAAAAAGCCACCAAAATGAGGGATTCATCCAGCAGATCCTGCCAAGAGTAGC	540
481	Db	GCATGCAAAAAGCCACCAAAATGAGGGATTCATCCAGCAGATCCTGCCAAGAGTAGC	540
541	Qy	CTGTGGAAATCTGATCAGTTACCTTTTAAAAAAGACTCCCTTATTTTTTAAATGTTTCCACAT	600
541	Db	CTGTGGAAATCTGATCAGTTACCTTTTAAAAAAGACTCCCTTATTTTTTAAATGTTTCCACAT	600
601	Qy	TTTTTGCTTGCGAAAGACTGTTTTTCATATGTATATACTCAGATAAAGATTTTTAAATGGTAT	660
601	Db	TTTTTGCTTGCGAAAGACTGTTTTTCATATGTATATACTCAGATAAAGATTTTTAAATGGTAT	660
661	Qy	TACGTATAAATTAATATAAATGATTACCTCTGGTGTGTGACAGGTTTGAACTTGACATTC	720
661	Db	TACGTATAAATTAATATAAATGATTACCTCTGGTGTGTGACAGGTTTGAACTTGACATTC	720
721	Qy	TTAAGGAACAGCCCAATACCTCTCGAATGATCATTAAATTACTGACTGTCCTAGTACATTTG	780
721	Db	TTAAGGAACAGCCCAATACCTCTCGAATGATCATTAAATTACTGACTGTCCTAGTACATTTG	780
781	Qy	GAAGCTTTTGTTTATAGAACTTGAGGGCTCAITTTGGTTTCATTGAAAACAGTATCTAA	840
781	Db	GAAGCTTTTGTTTATAGAACTTGAGGGCTCAITTTGGTTTCATTGAAAACAGTATCTAA	840
841	Qy	TTATAAATTAAGCTCTAGATATCAGGTGCTTCTGATGAAGTGAAATGTAATCTGACTAG	900
841	Db	TTATAAATTAAGCTCTAGATATCAGGTGCTTCTGATGAAGTGAAATGTAATCTGACTAG	900
901	Qy	TGGGAAACTTCATCGGGTTTCCTCATCTGTCATGTCGATGATTAATATATGGATACATTTAC	960
901	Db	TGGGAAACTTCATCGGGTTTCCTCATCTGTCATGTCGATGATTAATATATGGATACATTTAC	960
961	Qy	AAAAATAAAAAGCGGGAAATTTTCCTTCGCTTGAATATTAATCCCTGTATATTTGCATGAAT	1020
961	Db	AAAAATAAAAAGCGGGAAATTTTCCTTCGCTTGAATATTAATCCCTGTATATTTGCATGAAT	1020
1021	Qy	GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGCTTTTAATTTCTTAAGCATA	1080
1021	Db	GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTTGCTTTTAATTTCTTAAGCATA	1080
1081	Qy	AGTAAAAATGATATAAAAAATATATGCTGAAATTAATCTGTGGAAGATGCATTTTAAGCTATT	1140
1081	Db	AGTAAAAATGATATAAAAAATATATGCTGGAATTAATCTGTGGAAGATGCATTTTAAGCTATT	1140
1141	Qy	TTAAATGTGTTTTTATTTGTAAGCATTACTTTAAGAAATTTGGTTATTATGCTTACTG	1200
1141	Db	TTAAATGTGTTTTTATTTGTAAGCATTACTTTAAGAAATTTGGTTATTATGCTTACTG	1200
1201	Qy	TTCTTAATCTCGGTAAAGCTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
1201	Db	TTCTTAATCTCGGTAAAGCTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT	1260
1261	Qy	GAATGAGAGAAAAATTTGATAAACCAATCCTGCTGTGTTTCTTTTAGTGCATATACAAATCTCT	1320
1261	Db	GAATGAGAGAAAAATTTGATAAACCAATCCTGCTGTGTTTCTTTTAGTGCATATACAAATCTCT	1320
1321	Qy	GAATTTAAGACTC	1333
1321	Db	GAATTTAAGACTC	1333

RESULT 78

RESULT 78
ADE39044

ID ADE39044 standard; cDNA: 1333 bp.

XX

AC

29-JAN-2004 (first entry)

Novel human secreted and transmembrane protein PRO181 cDNA.

Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic; vulerary; antiarrhythic; pericyte cell proliferation; pericyte cell differentiation; chondrocyte cell proliferation; chondrocyte cell differentiation; tumour necrosis factor alpha release; (TNF)-alpha release; dermal fibroblast cell proliferation; dermal fibroblast cell differentiation inhibitor; tumour; lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour; liver tumour; tissue typing; chromosome mapping; gene mapping; gene therapy.

Homo sapiens.

US2003096362-A1.

22-MAY-2003.

29-AUG-2002; 2002US-00233205.

25-JUL-2000; 2000US-0220585P.

01-JUN-2001; 2001WO-US017800.

29-JUN-2001; 2001WO-US021066.

09-APR-2002; 2002US-00119480.

(GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Smith V, Stephen JF, Watanabe CK, Wood WI;

WPI; 2004-008944/

New isolated, secreted and transmembrane PRO polypeptide for diagnosing, preventing and/or treating tumors, such as lung, colon, breast, prostate, rectal, and/or liver tumors.

Claim 2; Fig 119; 308pp: English.

The invention describes an isolated PRO (secreted and transmembrane) polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are useful for stimulating the proliferation of or gene expression in pericyte cells. PRO357, PRO3229, PRO1272 or PRO4405 polypeptide are useful for stimulating the proliferation or differentiation of chondrocyte cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide are useful for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214, PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080, PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309, PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1312, PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338, PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567, PRO1887, PRO1928, PRO4341, PRO1801, PRO3433, PRO3543, PRO3444, PRO4322, PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for stimulating the proliferation of normal human dermal fibroblasts cells. PRO181, PRO329, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408, PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for inhibiting the proliferation of normal human dermal fibroblast cells. PRO polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc., are useful for detecting the presence of tumour in a mammal which involves comparing the level of expression of the above PRO polypeptides in a test sample of cells taken from the mammal, and a control sample of normal cells of the same cell type, where a higher level of expression of the PRO polypeptides in the test sample as compared to the control sample is indicative of the presence of tumour in the mammal. The tumour is lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour. (I) is useful as molecular weight markers, for tissue typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is useful for chromosome and gene mapping or gene therapy. (II) is useful for generating transgenic animals or knock-out animals which are useful screening useful reagents. PRO357, PRO3229, PRO1272 or PRO4405 polypeptide

CC is useful for treating bone and/or cartilage disorders (e.g., arthritis, CC sport injuries). This sequence encodes a human secreted and transmembrane CC PRO polypeptide.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGGCTCCGATGGCGCTTCCAGCTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGGCTCACTCTTCTGCGCATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGGCTCACTCTTCTGCGCATTTGGCACAATATAGCAATTTGATGAGCTGAAGAC 120

QY 121 TGAATTACAAAGATCCCTATAGACCAGTGAATACCCCTGGAATCCCTTGTACTCCCAAGATA 180
DB 121 TGAATTACAAAGATCCCTATAGACCAGTGAATACCCCTGGAATCCCTTGTACTCCCAAGATA 180

QY 181 CCTCAFCACGCTTCTTCTGCTGTCATGTTCTTTGTGCGACAGAGTGGCTTTACACTGG 240
DB 181 CCTCAFCACGCTTCTTCTGCTGTCATGTTCTTTGTGCGACAGAGTGGCTTTACACTGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAGTGAAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAGTGAAG 300

QY 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGTATGATATTTAGCATATTTGCA 360
DB 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGAGTATGATATTTAGCATATTTGCA 360

QY 361 GAAGAAGATGGTGAATATGAGCTTTTATCTTCTAGCAATTTTCTACTACTATATGG 420
DB 361 GAAGAAGATGGTGAATATGAGCTTTTATCTTCTAGCAATTTTCTACTACTATATGG 420

QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTAACT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTAACT 480

QY 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGAGTAGC 540
DB 481 GCATGCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTGTCCAAAGAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATGACTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATGACTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720
DB 661 TACGTATAAATTAATATAAATGATTACCTCTGTGTTGACAGGTTTGAACCTTGCACTTC 720

QY 721 TTAAGGACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTG 780
DB 721 TTAAGGACAGCCATAATCCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTG 780

QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTTGTAGGGCTCATTTTGGTTTCATTGAAACAGTATCTAA 840

QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTCATGAAGTGAATGATATATCTGACTAG 900
DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTCATGAAGTGAATGATATATCTGACTAG 900

QY 901 TGGGAACACTCATGGTTTCTTCATCTGTCATGTCATGTCATGATATATATGATGATATTTAC 960
DB 901 TGGGAACACTCATGGTTTCTTCATCTGTCATGTCATGTCATGATATATATGATGATATTTAC 960

QY 961 AAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020
DB 961 AAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGCATGAAT 1020

QY 1021 GAGAGATTTCCCATATTTCCATCGAGTAATAAATATATCTTCTTAATTTCTTAAGCATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCGAGTAATAAATATATCTTCTTAAATTTCTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAAATATATCTGCTGAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAATATATCTGCTGAATTTACTTTGTGAAGAATGCAATTTAAAGCTATT 1140

QY 1141 TTAATGTTTTTATTTGTAAGACATTTACTTTTAAGAAATGTTGTTATTTGCTTACTG 1200
DB 1141 TTAATGTTTTTATTTGTAAGACATTTACTTTTAAGAAATGTTGTTATTTGCTTACTG 1200

QY 1201 TTCTAATCTGCTGTAAGGTTATTTAAAGAAATTTGCAGGTACTACAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGCTGTAAGGTTATTTAAAGAAATTTGCAGGTACTACAGATTTTCAAACT 1260

QY 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGAATACAATAAACTCT 1320
DB 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGAATACAATAAACTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 79

ADE05591
ID ADE05591 standard; cDNA; 1333 BP.

XX ADE05591;

XX 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

XX Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

XX Homo sapiens.

XX US2003100727-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00229974.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WL;

XX WPI; 2004-008977/01.

XX P-PSDB; ADE05592.

XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and

XX 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PI 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WJ;
XX WPI; 2004-008961/01.
DR P-PSDB; ADD73577.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
PS Claim 2; Fig 119; 309pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9,6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCGCTTCTGCTACATCGTCGCGTGTGCT 60
DB 1 GCCACGCGTCCGATGCGGTTCACGTTGCGGCGCTTCTGCTACATCGTCGCGTGTGCT 60
QY 61 CACTGCGGCGCTCATCTTCTTCCGCAATTCGACATATAGCAATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGGCGCTCATCTTCTTCCGCAATTTGGCAATTTATAGCAATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGATCCCTATAGACAGTGAATACCTGAATCCCTGCTGATCTCCACAGTA 180
DB 121 TGATTACAAGATCCCTATAGACAGTGAATACCTGAATCCCTGCTGATCTCCACAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTTGTGSCAGAGTGGCTTACCTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTTGTGSCAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGATAGACAGTGTAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGATAGACAGTGTAG 300

QY 301 TGGCCAGGACTCTATGACCCCTACCAACCATCATGATGACAGATATCTTAGCATATTTCTCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACCAACCATCATGATGACAGATATCTTAGCATATTTCTCA 360
QY 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTTAGCATATTTTACTACCTATATGG 420
DB 361 GAAGGAAGGATGGTGCAGAAATAGCTTTTATCTTCTTAGCATATTTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGAGCTCTTGAACAACAACACAGAGAAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGTGAGCTCTTGAACAACAACACAGAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCCTGTCCAAAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAAAATGAAGGATTCATCCAGCAAGATCCCTGTCCAAAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGATCCTTATTTTAAATGTTTCCCAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAAAAATGATCCTTATTTTAAATGTTTCCCAT 600
QY 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTCTTGTGGAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACTTGCACATC 720
DB 661 TAGCTATAAAATTAATATAAAATGATTAACCTCTGGTGTGACAGGTTTGAACTTGCACATC 720
QY 721 TTAAGGAACACGCCATAATCCTCTGAATGATGATTAATTAATCTGATGCTGCTAGTACATG 780
DB 721 TTAAGGAACACGCCATAATCCTCTGAATGATGATTAATTAATCTGATGCTGCTAGTACATG 780
QY 781 GAAGCTTTTGTATAGAACTTGTAGGAGCTGATTTGGTTCATTTGAAACAGATCTAA 840
DB 781 GAAGCTTTTGTATAGAACTTGTAGGAGCTGATTTGGTTCATTTGAAACAGATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
QY 901 TGGGAACCTCAGGGTTTCTCATCTGTCATGTCATGATGATATATATATATGATATGATATGAT 960
DB 901 TGGGAACCTCAGGGTTTCTCATCTGTCATGTCATGATGATATATATATATGATATGATATGAT 960
QY 961 AAAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTCGATGAT 1020
DB 961 AAAAAATAAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTCGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATCTTAAAGCAT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTGCTTTAATCTTAAAGCAT 1080
QY 1081 AGTAACATGATATAAATAATATGCTGAATTTACCTGTCATGTCATGTCATGTCATGTCATGTCAT 1140
DB 1081 AGTAACATGATATAAATAATATGCTGAATTTACCTGTCATGTCATGTCATGTCATGTCATGTCAT 1140
QY 1141 TTAATATGCTTTTATTTTGAAGACATTTTCTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
DB 1141 TTAATATGCTTTTATTTTGAAGACATTTTCTTATTAAGAAATTTGGTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGAGTACTCAGATTTTCAAACT 1260
DB 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGAGTACTCAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATACCATCTGCTGCTTTAGTGCATATCAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGATACCATCTGCTGCTTTAGTGCATATCAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 81

AD48655
ID ADE48655 standard; cDNA; 1333 BP.
XX AC ADE48655;
XX DT 29-JAN-2004 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO181.
XX KW Human; ss; gene; secreted; transmembrane protein; PRO181.
XX KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
XX KW vulnervary; auditory; tumour growth; retinal disorder;
XX KW sports-related joint problem; articular cartilage defects;
XX KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.
XX PN US2003104536-A1.
XX PD 05-JUN-2003.
XX PF 19-OCT-2001; 2001US-00166709.
XX PR 07-OCT-1998; 98WO-US021141.
XX PR 20-NOV-1998; 98WO-US024855.
XX PR 05-JAN-1999; 99WO-US000106.
XX PR 08-MAR-1999; 99WO-US005028.
XX PR 10-MAR-1999; 99WO-US005190.
XX PR 14-MAY-1999; 99WO-US010733.
XX PR 02-JUN-1999; 99WO-US012252.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 05-DEC-1999; 99WO-US031274.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US003565.
XX PR 18-FEB-2000; 2000WO-US004341.
XX PR 24-FEB-2000; 2000WO-US005004.
XX PR 02-MAR-2000; 2000WO-US005841.
XX PR 10-MAR-2000; 2000WO-US006319.
XX PR 21-MAR-2000; 2000WO-US007532.
XX PR 17-MAY-2000; 2000WO-US008439.
XX PR 22-MAY-2000; 2000WO-US013705.
XX PR 30-MAY-2000; 2000WO-US014042.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 28-JUL-2000; 2000WO-US020710.
XX PR 24-AUG-2000; 2000WO-US023328.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 20-DEC-2000; 2000WO-US034956.
XX PR 28-FEB-2001; 2001WO-US006520.
XX PR 22-MAR-2001; 2001WO-US009552.
XX PR 25-MAY-2001; 2001WO-US017092.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 20-JUN-2001; 2001WO-US019692.
XX PR 29-JUN-2001; 2001WO-US021066.
XX PR 09-JUL-2001; 2001WO-US021735.
XX PR 30-JUL-2001; 2001US-00918585.
XX PA (GETH) GENENTECH INC.
XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
XX PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX PI KJavain IU, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
XX PI Stewart TA, Tumas D, Williams PM, Wood W;

WPI; 2004-008994/01.

P-PSDB; ADE48655.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO4993 or PRO337, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 321; 450pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide, a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid, a host cell comprising the vector and producing PRO, a chimaeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule causes death of the cell. PRO337 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO725, PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337 polypeptide is useful for modulating at least one biological activity of the cell expressing PRO337 polypeptide, where the cell is killed. PRO337 polypeptide or anti-PRO4993 polypeptide is useful for modulating the biological activity of the cell expressing PRO4993 polypeptide; PRO725, PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for modulating the biological activity of the cell expressing PRO1559 polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-PRO739 polypeptide is useful for modulating the biological activity of the cell expressing PRO725, PRO700 or PRO739 polypeptide. The polypeptides are useful for inhibiting tumour growth, retinal disorders, sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in mammals. The present sequence encodes a PRO protein.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

	Query Match	100.0%;	Score 1333;	DB 10;	Length 1333;
	Best Local Similarity	100.0%;	Pred. No. 9.6e-306;		
	Matches 1333;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1	GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGCTGCGCGCTGCTGCT	60		
Db	1	GCCACGCGTCCGATGCGGTTACGTTGCGGCGCTTCTGCTACATGCTGCGCGCTGCTGCT	60		
Qy	61	CACGCGCGCTCATCTTCTTCGCGCATTTGCGCATTTAGCATTTGATGAGCTGAAGAC	120		
Db	61	CACGCGCGCTCATCTTCTTCGCGCATTTGCGCATTTAGCATTTGATGAGCTGAAGAC	120		
Qy	121	TGATTACAAGAATCCTATAGACAGGATGTAATACCTGAAATCCCTTGTACTCCAGAGTA	180		
Db	121	TGATTACAAGAATCCTATAGACAGGATGTAATACCTGAAATCCCTTGTACTCCAGAGTA	180		
Qy	181	CCTCATCCAGCTTCTTCTGTCATGTTTCTTTTGTGACGAGAGTGGCTTACACATGGG	240		
Db	181	CCTCATCCAGCTTCTTCTGTCATGTTTCTTTTGTGACGAGAGTGGCTTACACATGGG	240		
Qy	241	TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGATGATAGACAGGATGAG	300		
Db	241	TCTCAATATGCCCTCTTGGCATATCATATTGGAGGTATATGATGATAGACAGGATGAG	300		
Qy	301	TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGACAGATATTCTAGCATATTGTCA	360		

Db 301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCATATTGTCA 360
Qy 361 GAAGGAAGAGTGGTGCAGAAATAGCTTTTATCTCTAGCATTTTTTTTACTACCTATATGG 420
Db 361 GAAGGAAGAGTGGTGCAGAAATAGCTTTTATCTCTAGCATTTTTTTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAAATGGTCCAGTTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATCTTATCCAGCAAGATCTCTGTCACAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATCTTATCCAGCAAGATCTCTGTCACAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTGTTGGAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTTGGAAGACTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATAAATAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGCATCTC 720
Db 661 TACGTATAAATTAATAAATAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGCATCTC 720
Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATGATG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATGATTAATTAATGATGATGATGATGATGATGATG 780
Qy 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTTCATGCAACAGATCTAA 840
Db 781 GAAGCTTTTGTATAGAACTCTGAGGCTCATTTTGGTTTTCATGCAACAGATCTAA 840
Qy 841 TTATAAATTAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
Db 841 TTATAAATTAAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 900
Qy 901 TGGGAATCTCATGGGTTTCTCATCTCATCTCATCTCATCTCATCTCATCTCATCTCATCTCAT 960
Db 901 TGGGAATCTCATGGGTTTCTCATCTCATCTCATCTCATCTCATCTCATCTCATCTCATCTCAT 960
Qy 961 AAAAATAAAGCGGAAATTTTCCCTCGCTGATATTTATCCCTGATATGATGATGATGATGAT 1020
Db 961 AAAAATAAAGCGGAAATTTTCCCTCGCTGATATTTATCCCTGATATGATGATGATGATGAT 1020
Qy 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTTCCATCAGAGTAATAATATATCTGCTTTAATTTCTTAAGCATA 1080
Qy 1081 AGTAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAACATGATATAAATAATATATCTGATGATGATGATGATGATGATGATGATGATGATGAT 1140
Qy 1141 TTAATATGTTTATTTTGAAGATTAATCTTATTAAGAAATGGTATTTATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTTGAAGATTAATCTTATTAAGAAATGGTATTTATGCTTACTG 1200
Qy 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATGATGATGATGATGATGATGATGAT 1260
Db 1201 TTCTAATCTGGTGAAGGATTTCTTAAGAAATTTGAGGATGATGATGATGATGATGATGATGAT 1260
Qy 1261 GAATGAGAGAAATTTGATTAACCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

ADD78416
ID ADD78416 standard; cDNA; 1333 BP.
XX
AC ADD78416;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
DE human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100737-A1.
XX
XX 29-MAY-2003.
XX
XX 28-AUG-2002; 2002US-00230438.
XX
XX 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski P;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood W;
XX WPI: 2004-008987/01.
XX P-PSDB; ADD78417.
XX
XX New PRO polypeptide and nucleic acid encoding the polypeptide, useful for
XX gene therapy, chromosome identification, tissue typing, or as
XX hybridization probes in chromosome and gene mapping.
XX
XX Claim 2; SEQ ID NO 119; 309pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX polypeptides such as PRO6004, PRO4981, PRO174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of expression of the above PRO polypeptides
XX involves comparing the level of expression of the mammal, and a control sample of
XX in a test sample of cells taken from the mammal, where a higher level of expression of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO329, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGCGTTCACGTTCCGCGCTTCTGCTACATGCTGCGCTGCTGCT 60
 DB 1 GCCACGCGTCCGATGCGTTCACGTTCCGCGCTTCTGCTACATGCTGCGCTGCTGCT 60
 QY 61 CACTGCGCGCTCATCTTCTTCCGCAATTCGCAATTCAGCATTTGATGAGCTGAGAC 120
 DB 61 CACTGCGCGCTCATCTTCTTCCGCAATTCGCAATTCAGCATTTGATGAGCTGAGAC 120
 QY 121 TGATTACAGAACTCTATAGACAGTCTAATACCTGAAATCCCTTCTACTCCACAGTA 180
 DB 121 TGATTACAGAACTCTATAGACAGTCTAATACCTGAAATCCCTTCTACTCCACAGTA 180
 QY 181 CTTCAATCCAGCTTCTTCTGTCATGTTTCTTTGTCAGAGAGTGGCTTACATGGG 240
 DB 181 CTTCAATCCAGCTTCTTCTGTCATGTTTCTTTGTCAGAGAGTGGCTTACATGGG 240
 QY 241 TCTCAATATGCCCCCTCTTGGCATATATTTGAGGTATATGATGAGACAGATGATGAG 300
 DB 241 TCTCAATATGCCCCCTCTTGGCATATATTTGAGGTATATGATGAGACAGATGATGAG 300
 QY 301 TGGCCAGGACTCTATGACCCCTACAACTCATGATGCAATGTCATATTTCTGCA 360
 DB 301 TGGCCAGGACTCTATGACCCCTACAACTCATGATGCAATGTCATATTTCTGCA 360
 QY 361 GAAGGAAGGATGGTGCAGAAATGAGCTTTTATCTTCTAGCATTTTCTACCTATATGG 420
 DB 361 GAAGGAAGGATGGTGCAGAAATGAGCTTTTATCTTCTAGCATTTTCTACCTATATGG 420
 QY 421 CATGATCTATGTTTGTGAGCTCTTAGAAACACACAGAGAAATGGTCCAGTAAAT 480
 DB 421 CATGATCTATGTTTGTGAGCTCTTAGAAACACACAGAGAAATGGTCCAGTAAAT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 DB 481 GCATGCAAAAAGCCACCAATGAAGGGATTTCTATCCAGCAAGATCCTCTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCCAT 600
 DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCCAT 600
 QY 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
 DB 601 TTTTGTCTGTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATATAAATGATTAACCTCTGTGTTTGAAGGTTTGAACCTTGCACTTC 720
 DB 661 TACGTATAAATTAATATAAATGATTAACCTCTGTGTTTGAAGGTTTGAACCTTGCACTTC 720
 QY 721 TTAAGGAACAGCAATAAATCTCTGAATGATTAATTAATTAATTAATTAATTAATTAAT 780
 DB 721 TTAAGGAACAGCAATAAATCTCTGAATGATTAATTAATTAATTAATTAATTAATTAAT 780
 QY 781 GAAGCTTTGTTTATAGGAAGCTTGTAGGCTCATTTTGTTCATTTGAAACAGATTAATAA 840
 DB 781 GAAGCTTTGTTTATAGGAAGCTTGTAGGCTCATTTTGTTCATTTGAAACAGATTAATAA 840
 QY 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900

DB 841 TTATAAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATGATATATCTGACTAG 900
 QY 901 TGGGAAACTTTCATGGGTTTCCCTCACTGTCATGTCGATGATATATATGATGATACATTAC 960
 DB 901 TGGGAAACTTTCATGGGTTTCCCTCACTGTCATGTCGATGATATATGATGATACATTAC 960
 QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATCCCTGATATATGATGATGAAT 1020
 DB 961 AAAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATATCCCTGATATATGATGATGAAT 1020
 QY 1021 GAGAGATTTTCCCATATTTCCATCAGAGTAATAAATATACCTGCTTTAAATCTTTAAGCAT 1080
 DB 1021 GAGAGATTTTCCCATATTTCCATCAGAGTAATAAATATACCTGCTTTAAATCTTTAAGCAT 1080
 QY 1081 AGTAACATGATATAAATAATATGCTGAATATGCTGAATATGCTGAATATGCTGAATATGCTGAAT 1140
 DB 1081 AGTAACATGATATAAATAATATGCTGAATATGCTGAATATGCTGAATATGCTGAATATGCTGAAT 1140
 QY 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
 DB 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGTTATTTATGCTTACTG 1200
 QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
 DB 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
 QY 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTTTCTTTAGTGAATACATAAATAAATCT 1320
 DB 1261 GAATGAGAGAAATTTGTAACCATCTCTGCTGTTTCTTTAGTGAATACATAAATAAATCT 1320
 QY 1321 GAAATTAAGACT 1333
 DB 1321 GAAATTAAGACT 1333
 RESULT 83
 ADE41251
 ID ADE41251 standard; cdna; 1333 BP.
 XX AC ADE41251;
 XX DT
 XX 29-JAN-2004 (first entry)
 XX Human secreted/transmembrane PRO polypeptide cDNA #1.
 DE ss; gene; human; secreted protein; transmembrane protein;
 KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
 KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
 KW age-related macular degeneration; angiogenesis;
 KW endothelial cell apoptosis; smooth muscle cell growth;
 KW endothelial cell tube formation.
 XX Homo sapiens.
 OS US2003100497-A1.
 XX PN
 XX 29-MAY-2003.
 XX PF 16-AUG-2002; 2002US-00223085.
 XX XX
 XX 20-JUN-2001; 2001WO-US019692.
 XX PR 09-JUL-2001; 2001WO-US021735.
 XX PR 20-FEB-2002; 2002US-00081056.
 XX XX
 XX (GETH) GENENTECH INC.
 XX PA
 XX Baker KP, Ferrara N, Gerber H, Gerttsen ME, Goddard A;
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
 PI Watanabe CK, Williams PM, Wood WI, Ye W;
 XX WPI; 2004-008957/01.
 DR P-PSDB; ADE41252.
 XX

PT	New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO205 or PRO214, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and for treating disorders involving angiogenesis.
XX	Claim 2; SEQ ID NO 1; 492pp; English.
XX	The invention relates to an isolated nucleic acid encoding a secreted and transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded by the nucleic acid, or an agonist or antagonist, is used to treat a cardiovascular, endothelial, or angiogenic disorder in a mammal, preferably a human. The human may have suffered a myocardial infarction or has cardiac hypertrophy, trauma, a cancer, or age-related macular degeneration. The cardiac hypertrophy is characterised by the presence of an elevated level of pGF-2 alpha. A PRO polypeptide, given in the specification, or an agonist is used to inhibit or stimulate endothelial cell growth in a mammal. PRO21 or an agonist is used to induce cardiac hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis. A PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO polypeptide, given in the specification, or an agonist is used to stimulate or inhibit smooth muscle cell growth, or to induce endothelial cell tube formation. The present sequence represents a cDNA encoding a PRO polypeptide of the invention.
XX	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
QQ	Query Match 100.0%; Score 1333; DB 10; Length 1333;
QQ	Best Local Similarity 100.0%; Pred. No. 9.6e-306;
QQ	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 GCCCACGCGTCCGATGGCGTTTCACGTTCCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
DB	1 GCCCACGCGTCCGATGGCGTTTCACGTTCCGCGCCCTTCGTACATGCTGGCGCTGCTGCT 60
QY	61 CACTGCCGCGCTCATCTCTTCGCGCATTTGGCATTATGCAATTATGATTTGATGCTCAAGAC 120
DB	61 CACTGCCGCGCTCATCTCTTCGCGCATTTGGCATTATGCAATTATGATTTGATGCTCAAGAC 120
QY	121 TGATTACAAGAATCCTATAGACCAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGAGTA 180
DB	121 TGATTACAAGAATCCTATAGACCAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGAGTA 180
QY	181 CCTCATCCACGCTTCTTCTGTGTCACTTTCTTGTGCGACGAGTGGCTTACACTGGG 240
DB	181 CCTCATCCACGCTTCTTCTGTGTCACTTTCTTGTGCGACGAGTGGCTTACACTGGG 240
QY	241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGTATGAG 300
DB	241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCAAGTGTATGAG 300
QY	301 TGGCCCGAGACTCTATGACCCCTPACCAACCATCATGAATGCAGATATTCCTAGCATATTTGCA 360
DB	301 TGGCCCGAGACTCTATGACCCCTPACCAACCATCATGAATGCAGATATTCCTAGCATATTTGCA 360
QY	361 GAAAGGAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACTACTATATGG 420
DB	361 GAAAGGAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTTTACTACTACTATATGG 420
QY	421 CATGATCTATGTTTTTGGTGCAGCTCTTAGAACCAACACACAGAGAAGATTGGTCCAGTTAAGT 480
DB	421 CATGATCTATGTTTTTGGTGCAGCTCTTAGAACCAACACACAGAGAAGATTGGTCCAGTTAAGT 480
QY	481 GCATGCAAAAGCCACCAAATGAAGGGATTCATCCAGCAAGATCCTGTCCAAAGTAGTC 540
DB	481 GCATGCAAAAGCCACCAAATGAAGGGATTCATCCAGCAAGATCCTGTCCAAAGTAGTC 540
QY	541 CTGTGGAAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTTTAAATGTTTCCACAT 600
DB	541 CTGTGGAAATCTGATCAGTTACTTTTAAAAAATGACCTCTTATTTTTTAAATGTTTCCACAT 600
QY	601 TTTTGTCTTGTGAAAGACTGTTTTTCAATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660
DB	601 TTTTGTCTTGTGAAAGACTGTTTTTCAATATGTTTATCTACAGATAAAGATTTTAAATGGTAT 660

XX PD 29-MAY-2003.

XX PF 28-AUG-2002; 2002US-00230435.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;

XX PI Grimaldi JC, Garney AL, Smith V, Stephan JF, Watanabe CK, Wood WT;

XX DR WFI; 2004-008986/01.

XX DR P-PSDB; ADE21240.

XX PT New PRO polypeptides and nucleic acids encoding the polypeptides, useful

XX PT in gene therapy, chromosome identification, tissue typing, or as

XX PT hybridization probes in chromosome and gene mapping.

XX PS Claim 2; Fig 119; 309pp; English.

XX CC The invention describes an isolated PRO (secreted and transmembrane)

CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

CC useful for stimulating the proliferation of or gene expression in

CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

CC for stimulating the proliferation or differentiation of chondrocyte

CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide

CC are useful for stimulating the release of tumour necrosis factor (TNF)-

CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,

CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,

CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,

CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,

CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,

CC PRO2940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for

CC stimulating the proliferation of normal human dermal fibroblasts cells.

CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,

CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for

CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO

CC polypeptides such as PRO6004, PRO4981, PRO1174, PRO5778, PRO4332, etc.,

CC are useful for detecting the presence of tumour in a mammal which

CC involves comparing the level of expression of the above PRO polypeptides

CC in a test sample of cells taken from the mammal, and a control sample of

CC normal cells of the same cell type, where a higher level of expression of

CC the PRO polypeptides in the test sample as compared to the control sample

CC is indicative of the presence of tumour in the mammal. The tumour is lung

CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or

CC liver tumour. (I) is useful as molecular weight markers, for tissue

CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is

CC useful for chromosome and gene mapping or gene therapy. (II) is useful

CC for generating transgenic animals or knock-out animals which are useful

CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide

CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,

CC sport injuries). This sequence encodes a human secreted and transmembrane

CC PRO polypeptide.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGCTCGATGCGCTTCACGTTTCGGCGCTTCTGCTACATGCTGCGCTGCTGCT 60

DB 1 GCCACGCGCTCGATGCGCTTCACGTTTCGGCGCTTCTGCTACATGCTGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTTGCCCATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120

DB 61 CACTGCGCGCTCATCTTCTTGCCCATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120

QY 121 TGATTACAAGATCCCTATAGACCAGTGTATATACCTGAATCCCTCTGTACTCCACAGTA 180

DB 121 TGATTACAAGATCCCTATAGACCAGTGTATATACCTGAATCCCTCTGTACTCCACAGTA 180

QY 181 CCTCATCCACGCTTTCTTCTGTGTATGTTTCTTTGTGACAGAGTGGCTTACCTGGG 240

DB 181 CCTCATCCACGCTTTCTTCTGTGTATGTTTCTTTGTGACAGAGTGGCTTACCTGGG 240

QY 241 TCTCAATATGCTCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAG 300

DB 241 TCTCAATATGCTCCTCTTGGCATATCATATTTGGAGGTATATGATGAGTATGATGAG 300

QY 301 TGGCCACAGGACTCTATGACCTTACCAATCATGATGACAGATATTTCTAGCATATTTCTCA 360

DB 301 TGGCCACAGGACTCTATGACCTTACCAATCATGATGACAGATATTTCTAGCATATTTCTCA 360

QY 361 GAAGGAAGGATGGTGCATAATTTAGCTTTTATCTTTAGCATTTTCTTACCTATATGG 420

DB 361 GAAGGAAGGATGGTGCATAATTTAGCTTTTATCTTTAGCATTTTCTTACCTATATGG 420

QY 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480

DB 421 CATGATCTATGTTTGTGAGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540

DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600

DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGGACTCTTTTCAATGTTTACTCAGATAAGATTTTAAATGTTAT 660

DB 601 TTTTGTCTGTGGAAGGACTCTTTTCAATGTTTACTCAGATAAGATTTTAAATGTTAT 660

QY 661 TACGTATAAATTAATAAATAATGATTACCTCTGCTGTTGACAGGTTTGAACCTGCACCTC 720

DB 661 TACGTATAAATTAATAAATAATGATTACCTCTGCTGTTGACAGGTTTGAACCTGCACCTC 720

QY 721 TTAAGGAACGCCAATATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTTG 780

DB 721 TTAAGGAACGCCAATATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATTTG 780

QY 781 GAAGCTTTGTTTATAGGAATCTTTAGGGCTCATTTTGGTTTCATTGAAACAGATATCTAA 840

DB 781 GAAGCTTTGTTTATAGGAATCTTTAGGGCTCATTTTGGTTTCATTGAAACAGATATCTAA 840

QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900

DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGT 900

QY 901 TGGGAACCTCATGGTTTCTCTCATCTCTCATGTCGATGATTAATATATATGATGATTTAC 960

DB 901 TGGGAACCTCATGGTTTCTCTCATCTCTCATGTCGATGATTAATATATATGATGATTTAC 960

QY 961 AAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATCCCTGTATATTTGATGATTAAT 1020

DB 961 AAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATATATCCCTGTATATTTGATGATTAAT 1020

QY 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATATCTGCTTTAAATCTTTAAGCAT 1080

DB 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATATCTGCTTTAAATCTTTAAGCAT 1080

QY 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTAAT 1140

DB 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAAGCTAAT 1140

QY 1141 TTAATATGTTTATTTTGAAGATTTACTTTATTAAGAAATTTGGTATTTATGCTTACTG 1200

DB 1141 TTAATATGTTTATTTTGAAGATTTACTTTATTAAGAAATTTGGTATTTATGCTTACTG 1200

QY 1201 TTTCTAATCTGGTGTAAAGGTTATTTCTTAAGAAATTTGCAGGTTACTACAGATTTTCAAACT 1260

Db 661 TACGTATAAATTAATAAATAATGATTACCTCTGGTGTGACAGGTTTGAACCTTGCACCTC 720
QY 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAAGTCACTGCTCTAGTACATTC 780
Db 721 TTAAGGAACAGCCATAATCTCTGAATGATGCAATTAATTAAGTCACTGCTCTAGTACATTC 780
QY 781 GAAGCTTTTCTTTATAGGAATCTTGTAGGCTCCTATTTGGTTTCATTTGAACAGATCTAA 840
Db 781 GAAGCTTTTCTTTATAGGAATCTTGTAGGCTCCTATTTGGTTTCATTTGAACAGATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTCTCTGATGAAGTGAATATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTCTCTGATGAAGTGAATATATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGCGATGATTAATATGATGATATTC 960
Db 901 TGGGAACCTTCATGGGTTTCTCTCATCTGATGCGATGATTAATATGATGATATTC 960
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGCTTTAAATCTTAAAGCATA 1080
Db 1021 GAGAGATTTCCATATTTCCATCAGAGTAAATAATATCTGCTTTAAATCTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTGAATATCTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGCTGTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTTATTTATGCTTACTG 1200
Db 1141 TTAATGCTGTTTATTTGTAAGACATTTACTTATTAAGAAATGCTTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAAGAAATTTGCAGGTAATCTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAAGAAATTTGCAGGTAATCTTCAAACT 1260
QY 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGCTTCTTTAGTGAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGCTTCTTTAGTGAATACATAAACTCT 1320
QY 1321 GAATTAAGACTC 1333
Db 1321 GAATTAAGACTC 1333
RESULT 86
ID ADE20501 standard; cDNA; 1333 BP.
AC ADE20501;
XX 29-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO181 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnery; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX Homo sapiens.
XX US2003100733-A1.
FN 29-MAY-2003.
XX

PF 28-AUG-2002; 2002US-00230426.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
PA Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008983/01.
DR P-PSDB; ADE20502.
XX New PRO polypeptides and nucleic acids encoding the polypeptides, useful
PT in gene therapy, chromosome identification, tissue typing, or as
PT hybridization probes in chromosome and gene mapping.
XX Claim 2; Fig 119; 308pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO1084, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO4344, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCCAGCGCTCCGATGGGTTACGTTTCGGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCGCGCTCATCTTCTTCGGCAATTTGGCAATATTAGCATTTGATAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTTCTTCGGCAATTTGGCAATATTAGCATTTGATAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACAGGTGTAATACCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTACAGAAATCCTATAGACAGGTGTAATACCTGAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATGACGCTTTCTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATGACGCTTTCTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATAGTAGTACACAGTATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGAGGTATATAGTAGTACACAGTATGAG 300
QY 301 TGGCCAGGACTATAGACCCCTACACCATCATGAATGCAGANATCTAGCATATTTGCA 360
Db 301 TGGCCAGGACTATAGACCCCTACACCATCATGAATGCAGANATCTAGCATATTTGCA 360
QY 361 GAAGGAGGAGTGGTGAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAGGAGTGGTGAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAAACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
Db 481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCACAGTAGC 540
QY 541 CTGTGGATCTGATCAGTTACTTTTAAATAAAGTCTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGGATCTGATCAGTTACTTTTAAATAAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTGTTGGAAGACTGTTTTCATATGTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAATTAATAAATGATTAATCTCTGTTGTTGACAGTTTGAACCTGCACCTC 720
Db 661 TAGCTATAATTAATAAATGATTAATCTCTGTTGTTGACAGTTTGAACCTGCACCTC 720
QY 721 TTAAGGAACGCCATAATCTCTGAATGATCATTAATTAATGATGCTGCTAGTACATG 780
Db 721 TTAAGGAACGCCATAATCTCTGAATGATCATTAATTAATGATGCTGCTAGTACATG 780
QY 781 GAAGCTTTGTTTATAGAACTGTTAGGGCTCATTTTGGTTTCAATGAACAGATATCTAA 840
Db 781 GAAGCTTTGTTTATAGAACTGTTAGGGCTCATTTTGGTTTCAATGAACAGATATCTAA 840
QY 841 TTTAAATTTAGCTGATATACAGTCTGCTGATGAAATGATGATGATGATGATGATGAT 900
Db 841 TTTAAATTTAGCTGATATACAGTCTGCTGATGAAATGATGATGATGATGATGATGAT 900
QY 901 TGGGAAACTTTCATGCTGCTCATGCTGATGATGATGATGATGATGATGATGATGAT 960
Db 901 TGGGAAACTTTCATGCTGCTCATGCTGATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAATAAAAGCGGAAATTTTCCCTGCTGATGATGATGATGATGATGATGATGATGAT 1020
Db 961 AAAATAAAAGCGGAAATTTTCCCTGCTGATGATGATGATGATGATGATGATGATGAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATATCTGCTTTAATTTCTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATATCTGCTTTAATTTCTTAAGCATA 1080
QY 1081 AGTAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
Db 1081 AGTAACATGATATAAATAATATATCTGCTGATGATGATGATGATGATGATGATGATGAT 1140
QY 1141 TTAATGCTTTTATTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1200
Db 1141 TTAATGCTTTTATTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1200
QY 1201 TTTCTAATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 1260
Db 1201 TTTCTAATCTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG 1260

QY 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTTCGATATCAATAAACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTCTGCTGTTCTTTAGTTCGATATCAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 87
ADD75566
ID ADD75566 standard; cDNA; 1333 BP.
XX AC ADD75566;
XX AC ADD75566;
XX DT 29-JAN-2004 (first entry)
XX DB Human PRO polynucleotide #60.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX FN US2003100064-A1.
XX PD 29-MAY-2003.
XX PF 12-AUG-2002; 2002US-00219060.
XX PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2004-008955/01.
P-PSDB; ADD75567.
XX New nucleic acid, for the manufacture of a medicament for diagnosing or
treating tumor or for measuring or detecting expression of an associated
gene.
XX Claim 2; Fig 119; 308pp; English.
XX The invention relates to human PRO polypeptides (secreted and
transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
diagnostics, biosensors or bioreactors. They are particularly useful for
detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
prostate tumour, rectal tumour or liver tumour) in a mammal, for
stimulating the release of tumour necrosis factor (TNF)-alpha from human
blood, for stimulating the proliferation or differentiation of
chondrocyte cells, for stimulating the proliferation of or gene
expression in pericyte cells or for stimulating the proliferation of
normal human dermal fibroblasts. The PRO nucleic acids are useful as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA, in preparing PRO polypeptides by recombinant
technology, in generating transgenic animals or knock-out animals which
may be used in the development and screening of therapeutically useful
reagents, in gene therapy, in chromosome identification, as chromosome
markers, in generating probes. The PRO polypeptides, or anti-PRO
antibodies, are useful for preparing a medicament for treating a
condition which is responsive to the PRO polypeptides or anti-PRO
antibodies, such as pericyte-associated tumours and bone and/or cartilage
disorders (e.g. arthritis, sports injuries), involving inducing the re-
differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACCGCTCCGATGCGCTTACGTTCCGCGCTTCTGCTACAGTGTGGCGCTGCTGCT 60
DB 1 GCCACCGCTCCGATGCGCTTACGTTCCGCGCTTCTGCTACAGTGTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTCGCATTTGGCAGATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAAGAACTCTATAGACAGTGTAAATCCCTGAAATCCCTTGTACTCCACAGTA 180
DB 121 TGATTACAAGAACTCTATAGACAGTGTAAATCCCTGAAATCCCTTGTACTCCACAGTA 180
QY 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTGAGCAGAGTGGCTTACCTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTGTGTCATGTTTCTTGTGTGAGCAGAGTGGCTTACCTGGG 240
QY 241 TCTCAATATCCCTCTTGGCATATCATTTTGGAGGTATATGAGTATAGTACAGAGTATGAG 300
DB 241 TCTCAATATCCCTCTTGGCATATCATTTTGGAGGTATATGAGTATAGTACAGAGTATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCAATTTCTCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATCTAGCAATTTCTCA 360
QY 361 GAAGGAAGATGTTGCGAAATTTAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
DB 361 GAAGGAAGATGTTGCGAAATTTAGCTTTTATCTTCTAGCATTTTCTACTACCTATATGG 420
QY 421 CATGATCTATCTTGTGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTAAAT 480
DB 421 CATGATCTATCTTGTGTGAGCTCTTAGAACACACACAGAAATTTGGTCCAGTAAAT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTGTCCAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTAAATAGCTCCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTAAATAGCTCCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTGTGGAAGACTGTTTTCATATGTTTACTCAGATAAGATTTTAAATGTTAT 660
QY 661 TAGCTATAAATTAATAAATAGTAACTCTGGTGTGACAGTGTGAACTTGCACCTC 720
DB 661 TAGCTATAAATTAATAAATAGTAACTCTGGTGTGACAGTGTGAACTTGCACCTC 720
QY 721 TTAAGGAACGCCATAATCCCTGAAATGATGATTAATCTAGCTGCTCTAGTACATTG 780
DB 721 TTAAGGAACGCCATAATCCCTGAAATGATGATTAATCTAGCTGCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTATAGAACTTGTAGGCTCATTTTGGTGTTCATTTGAAACAGTATCTAA 840
DB 781 GAAGCTTTTGTATAGAACTTGTAGGCTCATTTTGGTGTTCATTTGAAACAGTATCTAA 840
QY 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
DB 841 TTATAAATTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGTTTCTCATCTGCTCATGTCGATGATATATATGGATACATTTAC 960
DB 901 TGGGAACCTTCATGGTTTCTCATCTGCTCATGTCGATGATATATATGGATACATTTAC 960

DB 901 TGGGAACCTTCATGGTTTCTCATCTGCTCATGTCGATGATATATATGGATACATTTAC 960
QY 961 AAAAAAATAAAGCGGAATTTCCCTTCGCTTGAATATTTATCCCTGTATATTCATCAAT 1020
DB 961 AAAAAAATAAAGCGGAATTTCCCTTCGCTTGAATATTTATCCCTGTATATTCATCAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATACCTTGTAAATTTCTTAAGCAT 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATACCTTGTAAATTTCTTAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATGCTGAATATCTTGTGAAGAAATGCAATTAAGCTATT 1140
DB 1081 AGTAAACATGATATAAATAATATGCTGAATATCTTGTGAAGAAATGCAATTAAGCTATT 1140
QY 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATTATGCTTACTG 1200
DB 1141 TTAATGCTGTTTTTATTTGTAAGACATTTACTTATTAAGAAATTTGGTTATTATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
DB 1201 TTCTAATCTGCTGTAAGGTAATTTCTTAAGAAATTTGAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAATTTGTAACCATCTCTGCTGCTTCTTTAGTGAATACATAAATCTCT 1320
DB 1261 GAATGAGAGAAAATTTGTAACCATCTCTGCTGCTTCTTTAGTGAATACATAAATCTCT 1320
QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 88
ADD74082

ID ADD74082 standard; cDNA; 1333 BP.

XX AC ADD74082;

XX AC 29-JAN-2004 (first entry)

XX DT Human PRO polynucleotide #60.

XX DE Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
XX KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
XX KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
XX KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
XX KW arthritis; sports injury; cytostatic; antiarthritic.

XX OS Homo sapiens.

XX US2003100708-A1.

XX PN 29-MAY-2003.

XX PD 09-AUG-2002; 2002US-00216160.

XX PF 01-AUG-2000; 2000US-0222425P.

XX PR 01-JUN-2001; 2001WO-US017800.

XX PR 29-JUN-2001; 2001WO-US021066.

XX PR 09-APR-2002; 2002US-00119480.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX DR WPI; 2004-008958/01.

XX DR P-PSDB; ADD74083.

XX XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells, for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCGGATGGCGTTCAAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCGGATGGCGTTCAAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCGCGCTCATCTTCTGGCCATTTGGCAGCATATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCGCGCTCATCTTCTGGCCATTTGGCAGCATATAGCATTTGATGAGCTGAAGAC 120

QY 121 TCATTACAGAAATCCTATAGACAGTGAATACCTGTAATCCCTTGATCCCTCCAGAGTA 180
DB 121 TGATTACAGAAATCCTATAGACAGTGAATACCTGTAATCCCTTGATCCCTCCAGAGTA 180

QY 181 CCTCATCCACGCTTCTTCTGTCTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCACGCTTCTTCTGTCTCATGTTCTTTGTGCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTTCTGGCATATCATATTTGGAGGTATATGATGAGCCAGTATGAG 300
DB 241 TCTCAATATGCCCTTCTGGCATATCATATTTGGAGGTATATGATGAGCCAGTATGAG 300

QY 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATGAGCAGATATTTAGCATATTTGCA 360
DB 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATGAGCAGATATTTAGCATATTTGCA 360

QY 361 GAAGGAAGAGTGGTGCAAAATAGCTTTTATCTTCTAGCATTTTATCTTCTTATGAG 420
DB 361 GAAGGAAGAGTGGTGCAAAATAGCTTTTATCTTCTAGCATTTTATCTTCTTATGAG 420

QY 421 CATGATCTATGTTTGGTGGCTCTAGACACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGGCTCTAGACACACACAGAGAAATGGTCCAGTTAAGT 480

QY 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGC 540
DB 481 GCATGCAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGC 540

QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAATGATCCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTGATCAGTTACTTTTAAATAAATGATCCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTCTGTGGAAAGACTGTTTTCATATGTTATCTACAGATAAAGATTTTAAATGGTAT 660
DB 601 TTTTCTGTGTGGAAAGACTGTTTTCATATGTTATCTACAGATAAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACCTC 720
DB 661 TACGTATAAAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACCTC 720

QY 721 TTAAGGACACGCCATAATCTCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACAT 780
DB 721 TTAAGGACACGCCATAATCTCTCTGAATGATGCAATTAATTAATCTGCTGCTAGTACAT 780

QY 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTGGTTTCATTGGAACAGTATCTAA 840
DB 781 GAAGCTTTGTTTATAGAACTTTAGGGCTCATTTGGTTTCATTGGAACAGTATCTAA 840

QY 841 TTATAAATTAAGCTGTAGATATCAGGTCTCTGATGAAGTGAAGTGAAGTGAATGATATCTGACTAG 900
DB 841 TTATAAATTAAGCTGTAGATATCAGGTCTCTGATGAAGTGAAGTGAAGTGAATGATATCTGACTAG 900

QY 901 TGGGAAACTTCATCGGTTTCTCTCATCTGTCATGTCGATGATTAATATATATATGGAATCAATTTAC 960
DB 901 TGGGAAACTTCATCGGTTTCTCTCATCTGTCATGTCGATGATTAATATATATATGGAATCAATTTAC 960

QY 961 AAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTGATATATGATGATGAAT 1020
DB 961 AAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATATCCCTGATATATGATGATGAAT 1020

QY 1021 GAGAGATTTCCCAVATTTCCATCAGAGTAATAAATAATATATCTTGCCTTAATTTCTTAAGCATATA 1080
DB 1021 GAGAGATTTCCCAVATTTCCATCAGAGTAATAAATAATATATCTTGCCTTAATTTCTTAAGCATATA 1080

QY 1081 AGTAACATGATATAAATAATATATCTGTCATATCTGTGAAGATGCAATTTTAAAGCTATT 1140
DB 1081 AGTAACATGATATAAATAATATATCTGTCATATCTGTGAAGATGCAATTTTAAAGCTATT 1140

QY 1141 TTAATGTTGTTTATTTTGAAGACATTAATTAAGAAATGGTATATGCTTACTG 1200
DB 1141 TTAATGTTGTTTATTTTGAAGACATTAATTAAGAAATGGTATATGCTTACTG 1200

QY 1201 TTTCAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260
DB 1201 TTTCAATCTGTGTGTAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260

QY 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGCTTCTTCTTCTGCTGCTTCTTCTTCTTCTTCTTCT 1320
DB 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 89
ADD74328
ID ADD74328 standard; cDNA; 1333 BP.
XX AC ADD74328;
XX DT 29-JAN-2004 (first entry)
XX DE Human PRO polynucleotide #60.
XX KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX OS Homo sapiens.
XX PN US2003100709-A1.

XX 29-MAY-2003.
PD 09-AUG-2002; 2002US-0021612.
PF 25-JUL-2000; 2000US-0220585P.
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PU;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008959/01.
DR P-PSDB; ADD74329.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; Fig 119; 309pp; English.
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioreactors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGGTTTCACGTTCCGGCCCTTCGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGGGTTTCACGTTCCGGCCCTTCGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTCCCGGCTCATCTTCTCGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTCCCGGCTCATCTTCTCGCCATTGGCACATTATAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTACAGAAATCCTATAGACACAGTGTAATACCCGTGAATCCCTTGATCTCCGAGATA 180
DB 121 TGATTACAGAAATCCTATAGACACAGTGTAATACCCGTGAATCCCTTGATCTCCGAGATA 180
QY 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCGACGAGTGCTTACACTGGG 240
DB 181 CCTCATCCAGCTTCTTCTGTCATGTTCTTTGTCGACGAGTGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACCACTGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACCACTGATGAG 300
QY 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATGACAGATATTTCTAGCATATTTGTCA 360
DB 301 TGGCCAGGACTCTATGACCCCTACAAACCATCATGAATGACAGATATTTCTAGCATATTTGTCA 360
QY 361 GAAGGAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
DB 361 GAAGGAGGATGGTGCAAAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAGAAATTTGGTCCAGTTAAGT 480
QY 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
DB 481 GCATCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAGAGTAGC 540
QY 541 CTCTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
DB 541 CTCTGGAATCTGATCAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGTGAAAGACTCTTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
DB 601 TTTTGTCTTGTGAAAGACTCTTTTCAATGTTATCTCAGATAAAGATTTTAAATGTTAT 660
QY 661 TAGGTATAAATTAATAAATGATTAACCTCTGTTGACAGTTTGAAGTTGACCTTC 720
DB 661 TAGGTATAAATTAATAAATGATTAACCTCTGTTGACAGTTTGAAGTTGACCTTC 720
QY 721 TTAAGGAACGCCATATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATTG 780
DB 721 TTAAGGAACGCCATATCTCTGAATGATGCAATTAATTAATCTGACTCTCTCTAGTACATTG 780
QY 781 GAAGCTTTTGTGTTATAGAACTGTTAGGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840
DB 781 GAAGCTTTTGTGTTATAGAACTGTTAGGGCTCATTTTGGTTCATTTGAACAGATATCTAA 840
QY 841 TTATAAATAGCTGATAGATATCAGGTCTCTGATGAGTGAAGTGAATCTATATCTGACTAG 900
DB 841 TTATAAATAGCTGATAGATATCAGGTCTCTGATGAGTGAAGTGAATCTATATCTGACTAG 900
QY 901 TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATACATTAC 960
DB 901 TGGGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATATGATGATACATTAC 960
QY 961 AAAAATAAAGCGGGAAATTTTCCCTTCGTTGAATATTAATCCCTGTATATGTCATGAAT 1020
DB 961 AAAAATAAAGCGGGAAATTTTCCCTTCGTTGAATATTAATCCCTGTATATGTCATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGTTTAACTTCTTAAGCATATA 1080
DB 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATAATATCTGTTTAACTTCTTAAGCATATA 1080
QY 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAAAATATATGCTGAATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
QY 1141 TTAATGTTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTATATGCTTACTG 1200
DB 1141 TTAATGTTGTTTTTATTTGTAAGACATTAATTAAGAAATTTGGTATATGCTTACTG 1200
QY 1201 TTCTAAATCTGGTGTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAAT 1260
DB 1201 TTCTAAATCTGGTGTAAAGGATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAAAT 1260
QY 1261 GAATGAGAGAAAATTTGTATAACCATCTCTGCTGTTCTTCTTGTGCAATTAATTAAGCTCT 1320
DB 1261 GAATGAGAGAAAATTTGTATAACCATCTCTGCTGTTCTTCTTGTGCAATTAATTAAGCTCT 1320
QY 1321 GAAATTAAGACTC 1333

Db 781 GAAGCTTTTGTATAGAACTTTAGGGCTCAATTTGGTTTCATTTGAACAGTAICTAA 840
Qy 841 TTATAAATTAGCTGTAGATATCAGGTGCTTTCTGATGAAGTGAATGATATATCTGACTAG 900
Db 841 TTATAAATTAGCTGTAGATATCAGGTGCTTTCTGATGAAGTGAATGATATATCTGACTAG 900
Qy 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTTATATGATGATCAATTTAC 960
Db 901 TGGGAACTTCATGGGTTTCTCTCATCTGTCATGTCGATGATTTATATGATGATCAATTTAC 960
Qy 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
Db 961 AAAAATAAAGCGGGAATTTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGAAT 1020
Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGATTAATAATATCTGCTTTAATCTTTAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGATTAATAATATCTGCTTTAATCTTTAAGCATA 1080
Qy 1081 AGTAAACATGATATAAATAATATCTGCTGATTAATCTGGAAGTGAATGATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATCTGCTGATTAATCTGGAAGTGAATGATTTAAAGCTATT 1140
Qy 1141 TTAATGTTTATTTTATTTGTAAGACATTAATTAATAATCTGCTTTAATCTTTAAGCTATT 1200
Db 1141 TTAATGTTTATTTTATTTGTAAGACATTAATTAATAATCTGCTTTAATCTTTAAGCTATT 1200
Qy 1201 TTCTAATCTGCTGTTAAAGTATTCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTTAAAGTATTCTTAAAGATTTGCAAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATACCATCTGCTGTTTCTTCTGCAATACATCAATCAATCT 1320
Db 1261 GAATGAGAGAAATTTGATACCATCTGCTGTTTCTTCTGCAATACATCAATCAATCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 91
ADD85550 standard; cDNA; 1333 BP.
ID ADD85550;
AC ADD85550;
XX 29-JAN-2004 (first entry)
XX
XX Novel human secreted and transmembrane protein PRO181 cDNA.
XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;
XX vulnary; antiarthritic; pericyte cell proliferation;
XX pericyte cell differentiation; chondrocyte cell proliferation;
XX chondrocyte cell differentiation; tumour necrosis factor alpha release;
XX (TNF)-alpha release; dermal fibroblast cell proliferation;
XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
XX colon tumour; breast tumour; prostate tumour; rectal tumour;
XX liver tumour; tissue typing; chromosome mapping; gene mapping;
XX gene therapy.
XX
XX Homo sapiens.
XX
XX US2003100721-A1.
XX
XX 29-MAY-2003.
XX
XX 13-AUG-2002; 2002US-00219473.
XX
XX 01-JUN-2001; 2001WO-US017800.
XX 29-JUN-2001; 2001WO-US021066.
XX 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX

XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI; 2004-008971/01.
DR P-PSDB; ADD85551.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
XX polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX useful for stimulating the proliferation of or gene expression in
XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX for stimulating the proliferation or differentiation of chondrocyte
XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX are useful for stimulating the release of tumour necrosis factor (TNF)-
XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
XX PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
XX PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
XX PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
XX PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1340, PRO1338,
XX PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX stimulating the proliferation of normal human dermal fibroblasts cells.
XX PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX PRO5723, PRO5725, PRO1154, or PRO7425 polypeptide are useful for
XX inhibiting the proliferation of normal human dermal fibroblast cells.
XX polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX are useful for detecting the presence of tumour in a mammal which
XX involves comparing the level of expression of the above PRO polypeptides
XX in a test sample of cells taken from the mammal, and a control sample of
XX normal cells of the same cell type, where a higher level of expression of
XX the PRO polypeptides in the test sample as compared to the control sample
XX is indicative of the presence of tumour in the mammal. The tumour is lung
XX tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX liver tumour. (I) is useful as molecular weight markers, for tissue
XX typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX useful for chromosome and gene mapping or gene therapy. (III) is useful
XX for generating transgenic animals or knock-out animals which are useful
XX screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
XX is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX sport injuries). This sequence encodes a human secreted and transmembrane
XX PRO polypeptide.
XX
XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
XX
XX Query Match 100.0%; Score 1333; DB 10; Length 1333;
XX Best Local Similarity 100.0%; Pred. No. 9.6e-306;
XX Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GCCACACGCTCCGATGGGCTTTCAGCTTCGCGCCCTTCTGCTACATGCTGGCGCTCTCTCT 60
XX
XX 1 GCCACGCGCTCCGATGGGCTTTCAGCTTCGCGCCCTTCTGCTACATGCTGGCGCTCTCTCT 60
XX
XX 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
XX
XX 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGCTGAAGAC 120
XX
XX 121 TGATTACAGGATCCTATAGACCACTGTAATACCTCTGAATCCCTTGTACTCCACAGATA 180
XX
XX 121 TGATTACAGGATCCTATAGACCACTGTAATACCTCTGAATCCCTTGTACTCCACAGATA 180
XX
XX 181 CCTCATCCACGCTTTCTTCTGTGTCTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240
XX
XX 181 CCTCATCCACGCTTTCTTCTGTGTCTCATGTTCTTTGTGTCAGCAGAGTGGCTTACACTGG 240
XX
XX 241 TCTCAATATGCCCTCTTGGGCAATATCATATTTGGAGGATATATGATGACACAGTGTATGAG 300
XX

Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGTATATAGAGTACACAGTATGAG 300
QY 301 TGGCCAGGACTCTATAGACCCCTACCAACATCATGAATGAGATATCTAGCATATTTGCA 360
Db 301 TGGCCAGGACTCTATAGACCCCTACCAACATCATGAATGAGATATCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTACTACCTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTCTAGCATATTTTACTACCTATATGG 420
QY 421 CATGATCATATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCATATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
QY 481 GCATGAAAAGCCAAATGAAGGATTTCTATCAGCAAGATCTGTGCAAGATGAGC 540
Db 481 GCATGAAAAGCCAAATGAAGGATTTCTATCAGCAAGATCTGTGCAAGATGAGC 540
QY 541 CTGTGMACTCATGAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGMACTCATGAGTTACTTTTAAAAATGACTCCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGAAAGACTGTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAAGACTGTTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TACGATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGACTTC 720
Db 661 TACGATATAATTAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGACTTC 720
QY 721 TTAAGGAACAGCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGATGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGATGGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATTTGATATCTGACTAG 900
Db 841 TTATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATTTGATATCTGACTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATACATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATATATATGATGATACATTTAC 960
QY 961 AAAATAAAGCGGAATTTTCCCTTGGTGAATATATATCCCTGTATATGATGAAT 1020
Db 961 AAAATAAAGCGGAATTTTCCCTTGGTGAATATATATCCCTGTATATGATGAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTCTTAAGCAT 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATCTGCTTTAAATTTCTTAAGCAT 1080
QY 1081 AGTAAACATGATATAAATAATATATGCTGATTAATTTCTGGAAGATGCAITTAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATATGCTGATTAATTTCTGGAAGATGCAITTAAGCTATT 1140
QY 1141 TTAATATGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
Db 1141 TTAATATGTTTATTTGTAAGACATTAATTAATTAAGAAATTTGGTTATTTATGCTTACTG 1200
QY 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAATTTGAGCTACTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGCTGTAAGGATTTCTTAAGAATTTGAGCTACTACAGATTTTCAAACT 1260
QY 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTAGTGAATACATAAATACTCT 1320
Db 1261 GAATGAGAGAAAATTTGATTAACCATCTGCTGTTTCTTTAGTGAATACATAAATACTCT 1320
QY 1321 GAAATTAAGACTC 1333
|||||

Db 1321 GAAATTAAGACTC 1333
RESULT 92
ADE05099
ID ADE05099 standard; cDNA; 1333 BP.
XX
AC ADE05099;
XX
DT 29-JAN-2004 (first entry)
XX
Human PRO polynucleotide #60.
XX
Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
KW arthritis; sports injury; cytostatic; antiarthritic.
XX
OS Homo sapiens.
XX
PN US2003100726-A1.
XX
PD 29-MAY-2003.
XX
PF 26-AUG-2002; 2002US-00227878.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI: 2004-008976/01.
XX
XX P-PSDB; ADE05100.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX
XX Claim 2; Fig 119; 308pp; English.
XX
XX The invention relates to human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the PRO polynucleotides encoding them.
XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
XX diagnostics, biosensors or bioeffectors. They are particularly useful for
XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
XX prostate tumour, rectal tumour or liver tumour) in a mammal, for
XX stimulating the release of tumour necrosis factor (TNF)-alpha from human
XX blood, for stimulating the proliferation or differentiation of
XX chondrocyte cells, for stimulating the proliferation of or gene
XX expression in pericyte cells or for stimulating the proliferation of
XX normal human dermal fibroblasts. The PRO nucleic acids are useful as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA, in preparing PRO polypeptides by recombinant
XX technology, in generating transgenic animals or knock-out animals which
XX may be used in the development and screening of therapeutically useful
XX reagents, in gene therapy, in chromosome identification, as chromosome
XX markers and in generating probes. The PRO polypeptides, or anti-PRO
XX antibodies, are useful for preparing a medicament for treating a
XX condition which is responsive to the PRO polypeptides or anti-PRO
XX antibodies, such as pericyte-associated tumours and bone and/or cartilage
XX disorders (e.g. arthritis, sports injuries), involving inducing the re-
XX differentiation of chondrocytes. The PRO polypeptides are useful as
XX molecular markers for protein electrophoresis, and in tissue typing. This
XX sequence represents a human PRO polynucleotide of the invention.
XX

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGCTCCGATGGGTTTCAGCTTCGGCGCCTTCGTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGCTCCGATGGGTTTCAGCTTCGGCGCCTTCGTACATGCTGGCGCTGCTGCT 60

QY 61 CACTGCCGCGCTCATCTTCCTTCGCCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120
DB 61 CACTGCCGCGCTCATCTTCCTTCGCCATTTGGCAGATTATAGCATTTGATGAGCTGAAGAC 120

QY 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTTGTACTCCAGAGTA 180
DB 121 TGATTACAGAAATCCTATAGACCACTGTAATACCTGTAATCCCTTGTACTCCAGAGTA 180

QY 181 CCTCATCCAGCGCTTCCTTCCTGTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240
DB 181 CCTCATCCAGCGCTTCCTTCCTGTGTCATGTTCTTGTGTCAGCAGAGTGGCTTACACTGGG 240

QY 241 TCTCAATATGCCCTTCCTTCCTGGCATATCATATTTGGAGGTATATGAGTAGCAGTGTATGAG 300
DB 241 TCTCAATATGCCCTTCCTTCCTGGCATATCATATTTGGAGGTATATGAGTAGCAGTGTATGAG 300

QY 301 TGGCCAGAGCTCTATGACCCCTAGCAACCATCATGATGCAGATATCTTAGCATATTGTCA 360
DB 301 TGGCCAGAGCTCTATGACCCCTAGCAACCATCATGATGCAGATATCTTAGCATATTGTCA 360

QY 361 GAAGGAAGATGGTGCATATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420
DB 361 GAAGGAAGATGGTGCATATAGCTTTTATCTCTAGCATTTTCTTACTACTATATGG 420

QY 421 CATGATCATGTTTGGTGGCTCTTAGAACACACAGAGAATTTGGTCCAGTTAAGT 480
DB 421 CATGATCATGTTTGGTGGCTCTTAGAACACACAGAGAATTTGGTCCAGTTAAGT 480

QY 481 GCATCAAAAGCCACCAATCAAGGATCTCTATCCAGCAGATCTCTGCCAAGTAGTAC 540
DB 481 GCATCAAAAGCCACCAATCAAGGATCTCTATCCAGCAGATCTCTGCCAAGTAGTAC 540

QY 541 CTGTGGAATCTCATCAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAATCTCATCAGTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600

QY 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660
DB 601 TTTTGTCTGTGGAAGACATGTTTTCATATGTTATCTCAGATAAGATTTTAAATGGTAT 660

QY 661 TACGTATAAATTAATATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGACTTC 720
DB 661 TACGTATAAATTAATATAAATGATTAATCTCTGTTGTTGACAGGTTTGAACCTTGACTTC 720

QY 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
DB 721 TTAAGGAACAGCATAATCCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAAT 780

QY 781 GAAGCTTTTGTATAGGAACCTGTAGAGGCTCATTTTGGTTTCAATGAACAGATATCTAA 840
DB 781 GAAGCTTTTGTATAGGAACCTGTAGAGGCTCATTTTGGTTTCAATGAACAGATATCTAA 840

QY 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900
DB 841 TTATAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900

QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATGATGATGATGATGATGATGAT 960

QY 961 AAAAAAAGGGGAAATTTCCCTTCGTTGAATATATCCCTGATATGATGATGATGATGATGAT 1020
DB 961 AAAAAAAGGGGAAATTTCCCTTCGTTGAATATATCCCTGATATATGATGATGATGATGATGAT 1020

QY 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATAATCTTGTCTTAAATCTTAAGCATA 1080
DB 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATAATCTTGTCTTAAATCTTAAGCATA 1080

QY 1081 AGTAAACATGATATAAAAAATATATGCTGTAATCTTGTGAAGAATGCAATTTAAAGCTATT 1140
DB 1081 AGTAAACATGATATAAAAAATATATGCTGTAATCTTGTGAAGAATGCAATTTAAAGCTATT 1140

QY 1141 TTAATGCTGTTTATTTGTAAGACATCTATTATTAAGAAATGCTTATTATGCTTACTG 1200
DB 1141 TTAATGCTGTTTATTTGTAAGACATCTATTATTAAGAAATGCTTATTATGCTTACTG 1200

QY 1201 TTCTAAATCTGCTGTAAAGGATTTCTTAAGAAATTTGAGGTAATCTTGTGAAGAATCTTCAAAACT 1260
DB 1201 TTCTAAATCTGCTGTAAAGGATTTCTTAAGAAATTTGAGGTAATCTTGTGAAGAATCTTCAAAACT 1260

QY 1261 GAATGAGAGAAATTTGTATAACCATCTCTGCTGTTTCTTTAGTGAATACAATAAACTCT 1320
DB 1261 GAATGAGAGAAATTTGTATAACCATCTCTGCTGTTTCTTTAGTGAATACAATAAACTCT 1320

QY 1321 GAAATTAAGACTC 1333
DB 1321 GAAATTAAGACTC 1333

RESULT 93

ADD75312 standard; cDNA; 1333 BP.

AC ADD75312;

DT 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;
tumour; cancer; lung; colon; breast; prostate; rectum; liver;
tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;
pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;
arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003100714-A1.

XX 29-MAY-2003.

XX 13-AUG-2002; 2002US-00219071.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008964/01.

XX P-PSDB; ADD75313.

XX New secreted and transmembrane PRO polypeptide useful for preparing a

XX medicament for treating a condition that is responsive to the PRO

XX polypeptide or anti-PRO antibody, e.g. cancer.

XX Claim 2; Fig 119; 308pp; English.

XX The invention relates to human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the PRO polynucleotides encoding them.

XX The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

XX diagnostics, biosensors or bioeffectors. They are particularly useful for

XX detecting tumours (e.g. lung tumour, colon tumour, breast tumour,

13-AUG-2002; 2002US-00219074.
22-JUN-1999; 99US-0140650P.
30-MAY-2000; 2000WO-US014941.
01-JUN-2001; 2001WO-US017800.
29-JUN-2001; 2001WO-US021066.
09-APR-2002; 2002US-00119480.
(GETH) GENENTECH INC.
Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
WPI; 2004-008965/01.
P-PSDB; ADD76857.
New secreted and transmembrane PRO polypeptide useful for preparing a
medicament for treating a condition that is responsive to the PRO
polypeptide or anti-PRO antibody, e.g. cancer.
Claim 2; SEQ ID NO 119; 308pp; English.
The invention describes an isolated PRO (secreted and transmembrane)
polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
useful for stimulating the proliferation of or gene expression in
pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
for stimulating the proliferation or differentiation of chondrocyte
cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
are useful for stimulating the release of tumour necrosis factor (TNF)-
alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO411, PRO1309,
PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
stimulating the proliferation of normal human dermal fibroblasts cells.
PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
inhibiting the proliferation of normal human dermal fibroblast cells. PRO
polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
are useful for detecting the presence of tumour in a mammal which
involves comparing the level of expression of the above PRO polypeptides
in a test sample of cells taken from the mammal, and a control sample of
normal cells of the same cell type, where a higher level of expression of
the PRO polypeptides in the test sample as compared to the control sample
is indicative of the presence of tumour in the mammal. The tumour is lung
tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
liver tumour. (I) is useful as molecular weight markers, for tissue
typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
useful for chromosome and gene mapping or gene therapy. (III) is useful
for generating transgenic animals or knock-out animals which are useful
screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
is useful for treating bone and/or cartilage disorders (e.g. arthritis,
sport injuries). This sequence encodes a human secreted and transmembrane
PRO polypeptide.
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Fred. No. 9.6e-306; Indels 0; Gaps 0;
Matches 1333; Conservative 0; Mismatches 0;
QY 1 GCCCAGCGCTCCGATGGCGCTTCCAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
DB 1 GCCCAGCGCTCCGATGGCGCTTCCAGTTCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120
DB 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATATAGCATTTGATGAGCTGAGAC 120

QY 121 TGAATTACAGAAATCCTATAGACACAGGTGTAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
DB 121 TGAATTACAGAAATCCTATAGACACAGGTGTAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CTTCAATCCAGCGCTTCTTCTGTGTCTCATGTTTCTTTGTGACGAGAGTGGCTTACATGGG 240
DB 181 CTTCAATCCAGCGCTTCTTCTGTGTCTCATGTTTCTTTGTGACGAGAGTGGCTTACATGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACCATGATGAG 300
DB 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATAGTAGACCATGATGAG 300
QY 301 TGGCCAGAGCTCTATGACCTCAACCATCATGAATGCAGATATTTACATATTTGCTCA 360
DB 301 TGGCCAGAGCTCTATGACCTCAACCATCATGAATGCAGATATTTACATATTTGCTCA 360
QY 361 GAAGGAAGGATGTTGCAAAATAGCTTTTATCTTCTAGCATTTTATTTTATACCTATATGG 420
DB 361 GAAGGAAGGATGTTGCAAAATAGCTTTTATCTTCTAGCATTTTATTTTATACCTATATGG 420
QY 421 CATGATCATGTTTGGTGAAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
DB 421 CATGATCATGTTTGGTGAAGCTCTTAGAACCAACACACAGAGAAATGGTCCAGTTAAGT 480
QY 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCCAGAGTAGC 540
DB 481 GCATGCAAAAAGCCACCAATGAAGGATCTATCCAGCAAGATCTCTGTCCAGAGTAGC 540
QY 541 CTGTGGAAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
DB 541 CTGTGGAAATCTGATCAGTTACTTTTAAATAAGTCTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTGTGGAAAGTCTTTTATGTTTATCTTATCTTATCTTATCTTATCTTATCTTAT 660
DB 601 TTTTGTCTGTGGAAAGTCTTTTATGTTTATCTTATCTTATCTTATCTTATCTTATCTTAT 660
QY 661 TACGTATAAATTTATATAAATGATTAATCTCTGTGTGACAGGTTTGAATCTGCATTC 720
DB 661 TACGTATAAATTTATATAAATGATTAATCTCTGTGTGTTGACAGGTTTGAATCTGCATTC 720
QY 721 TTAAGGAACGCCATTAATCTCTGAATGATGATTAATCTTATCTTATCTTATCTTATCTTAT 780
DB 721 TTAAGGAACGCCATTAATCTCTGAATGATGATTAATCTTATCTTATCTTATCTTATCTTAT 780
QY 781 GAAGCTTTGTTTATAGGAATCTTGTAGGCTTCTTGTGTTTCTTATCTTATCTTATCTTAT 840
DB 781 GAAGCTTTGTTTATAGGAATCTTGTAGGCTTCTTGTGTTTCTTATCTTATCTTATCTTAT 840
QY 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
DB 841 TTATAAATTTAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAAGTGAATGATATCTGACTAG 900
QY 901 TGGGAATCTTATGGGTTTCTCATCTGCTGATGATGATGATGATGATGATGATGATGATGAT 960
DB 901 TGGGAATCTTATGGGTTTCTCATCTGCTGATGATGATGATGATGATGATGATGATGATGAT 960
QY 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATTTATCTTATCTTATCTTATCTTAT 1020
DB 961 AAAAATAAAGCGGGAATTTTCCCTTCCCTTGAATATTTATCTTATCTTATCTTATCTTAT 1020
QY 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTTGTGTTAATCTTAAAGCATTA 1080
DB 1021 GAGAGATTTCCATATTTCCATCAGAGTAATAAATATATCTTGTGTTAATCTTAAAGCATTA 1080
QY 1081 AGTAACATGATATAAATAATATCTGCAATCTTGTGGAAGTGAAGTGAAGTGAAGTGAAGT 1140
DB 1081 AGTAACATGATATAAATAATATCTGCAATCTTGTGGAAGTGAAGTGAAGTGAAGTGAAGT 1140
QY 1141 TTAATATGTTTATTTTGTGAAGATTTACTTTATTAAGAAATGGTGTATTTATGTTTACTG 1200
DB 1141 TTAATATGTTTATTTTGTGAAGATTTACTTTATTAAGAAATGGTGTATTTATGTTTACTG 1200
QY 1201 TTTCTAATCTGGTGTAAAGGTTATCTTAAAGATTTGCGAGTACTACAGATTTTCAAACT 1260

```

Db 1201 TTTAATCTGGTGAAGGATTTCTTAAGAAATTCAGGATACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAAATGTATAACCATCCCTGCTGTTCTTTAGTGAATACATAAACTCT 1320
Db 1261 GAATGAGAGAAAATGTATAACCATCCCTGCTGTTCTTTAGTGAATACATAAACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 95
ADD86624
ID ADD86624 standard; cDNA; 1333 BP.
XX
AC ADD86624;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cDNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100719-A1.
XX
PD 29-MAY-2003.
XX
PF 14-AUG-2002; 2002US-00219469.
XX
XX 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX WPI: 2004-008969/01.
DR P-PSDB; ADD86625.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, or for preparing a medicament for treating a condition
PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
PT cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF) -
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1340, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1387, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,

```

```

CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO788, PRO1194, or PRO7425 polypeptide are useful for
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GCCACGCGTCCGATGGCGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Db 1 GCCACGCGTCCGATGGCGTTACGTTGCGGCGCTTCTGCTACATGCTGGCGCTGCTGCT 60
Qy 61 CACTGCGCGCTCATCTCTTCGCGCATTTGCGCATATAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTGCGCGCTCATCTCTTCGCGCATTTGCGCATATAGCATTTGATGAGCTGAAGAC 120
Qy 121 TGAATTACAAGAAATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGATGCCAGAGTA 180
Db 121 TGAATTACAAGAAATCCTATAGACCAAGTGTAAATACCTCGAATCCCTTGATGCCAGAGTA 180
Qy 181 CCTCATCCAGCTTTCTTCTGTGTCACTTTCTGTCAGAGAGTGTATGAGTAGACAGTGTAG 240
Db 181 CCTCATCCAGCTTTCTTCTGTGTCACTTTCTGTCAGAGAGTGTATGAGTAGACAGTGTAG 240
Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTGTAG 300
Qy 301 TGGCCCCAGGACTCTATGACCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCCAGGACTCTATGACCCCTTACCAACCATCATGAATCAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCACAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCATATGTTTGGTGAGCTCTTAGAACCAACACAGAGAATTTGGTCCAGTTAAGT 480
Db 421 CATGATCATATGTTTGGTGAGCTCTTAGAACCAACACAGAGAATTTGGTCCAGTTAAGT 480
Qy 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
Db 481 GCATCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAGAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCCTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAAAATGACTCCCTTTTAAATGTTTCCACAT 600
Qy 601 TTTTCTGTTGTGAAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTTGTGAAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTAATCCTCTGGTGTGACAGGTTTGAACTTGCACTTC 720

```


Db 121 TGATTACAGAAATCCTATAGACCAGTGTAAATACCTCGAATCCCTTGTTACTCCACAGTA 180
Qy 181 CCTCATCCACCTTCTTCTGTGTCAGTGTCTTTGTGTCAGACAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCCACCTTCTTCTGTGTCAGTGTCTTTGTGTCAGACAGAGTGGCTTACACTGGG 240
Qy 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTATGAG 300
Db 241 TCTCAATATGCCCCCTCTTGGCATATCATATTTGGAGGTATATGATGACACAGTATGAG 300
Qy 301 TGGCCCCAGGACTCTATGACCCCTACAAACCATCATGATCAGATATTTAGCATATTTGCA 360
Db 301 TGGCCCCAGGACTCTATGACCCCTACAAACCATCATGATCAGATATTTAGCATATTTGCA 360
Qy 361 GAAGGAAGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Db 361 GAAGGAAGATGGTGCATATTTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
Qy 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATGCTCCAGTTAAGT 480
Db 421 CATGATCTATGTTTTGGTGAGCTCTTAGAACACACACAGAGAAATGCTCCAGTTAAGT 480
Qy 481 GCATGAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540
Db 481 GCATGAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAAAAAGACCTCTTATTTTAAATGTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAAAAAGACCTCTTATTTTAAATGTTCCACAT 600
Qy 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTCTGTTGGAAGAGCTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGACCTTGCACATC 720
Db 661 TACGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGACCTTGCACATC 720
Qy 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Db 721 TTAAGGAACAGCATATCTCTGATGATGATTAATTAATTAATTAATTAATTAATTAATTA 780
Qy 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTTCATTTGAACAGATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTGTAGGGCTCATTTTGGTTTCATTTGAACAGATCTAA 840
Qy 841 TTATAAATTAAGCTGTAGATATCAGAGTCTCTGATGAAGTGAATGATATCTGACTAG 900
Db 841 TTATAAATTAAGCTGTAGATATCAGAGTCTCTGATGAAGTGAATGATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960
Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCATGATATATATGATGATATTTAC 960
Qy 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTA 1020
Db 961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATTAATTAATTAATTAATTAATTAATTA 1020
Qy 1021 GAGAGATTTCCCATATATTTCCATCAGAGTATTAATTAATTAATTAATTAATTAATTAATTA 1080
Db 1021 GAGAGATTTCCCATATATTTCCATCAGAGTATTAATTAATTAATTAATTAATTAATTAATTA 1080
Qy 1081 AGTAACATCATATAAATAATATATGCTGAATTTACTTGTGAAGATGATTAATTAATTAATTA 1140
Db 1081 AGTAACATCATATAAATAATATATGCTGAATTTACTTGTGAAGATGATTAATTAATTAATTA 1140
Qy 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
Db 1141 TTAATATGTTTTTATTTGTAAGACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1200
Qy 1201 TTCTAATCTGTTGTAAGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260
Db 1201 TTCTAATCTGTTGTAAGATTTCTTAAGAAATTTGAGGATCTACAGATTTTCAAACT 1260

Qy 1261 GAATGAGAGAAATTTGATTAACCATCTCTGTTTCCCTTTAGTCAATAAATACTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACCATCTCTGTTTCCCTTTAGTCAATAAATACTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333
RESULT 97
ADE89756
ID ADB89756 standard; cDNA; 1333 BP.
XX
AC ADE89756;
XX
XX
DT 29-JAN-2004 (first entry)
XX
Human cDNA encoding secreted/transmembrane protein, PRO181.
DE
XX
Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal; disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003130181-A1.
XX
PD 10-JUL-2003.
XX
PF 16-OCT-2001; 2001US-00978375.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081953P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0083466P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 18-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100308P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.

PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003585.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (ASHK/) ASHENNAZI A J.
PA (BAKE/) BAKER K P.
PA (BOTS/) BOTSTEIN D.
PA (DESN/) DESNOYERS L.
PA (EATO/) EATON D L.
PA (FER/) FERRARA N.
PA (FILV/) FILVAROFF E.
PA (FONG/) FONG S.
PA (GAOW/) GAO W.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODORSKI P J.
PA (GIRM/) GIRMALDI J C.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (KLJA/) KLJAVIN I J.
PA (KUOS/) KUO S S.
PA (NAPI/) NAPIER M A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (ROYM/) ROY M A.
PA (SHEL/) SHELTON D L.
PA (STEW/) STEWART T A.
PA (TUMA/) TUMAS D.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX

Query Match

100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGCGTCCGATGGCGTTTCACCTTCGCGCCCTCTCTGCTACATGCTGGCGCTGCTGCT 60
|||||

Db 1 GCCACGGCTCGATGCGGCTTCACTTCGGCGCCCTCTGCTACATGCTGGCGCTGCTGCT 60
QY 61 CACTCGCGCGCTCATCTCTTTCGCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
Db 61 CACTCGCGCGCTCATCTCTTTCGCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
QY 121 TGATTAAGAATCCCTATAGACAGAGTGAATACCTCGAATCCCTGTTGACTCCCGAGATA 180
Db 121 TGATTAAGAATCCCTATAGACAGAGTGAATACCTCGAATCCCTGTTGACTCCCGAGATA 180
QY 181 CCTCATCAGCGCTTCTCTGCTGTCATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGGG 240
Db 181 CCTCATCAGCGCTTCTCTGCTGTCATGTTCTTTGTGCGAGCAGAGTGGCTTACACTGGG 240
QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTATGATGAG 300
QY 301 TGGCCGAGGACTATGACCCCTACACCATCATGATGAGATATCTAGCATATTTGCA 360
Db 301 TGGCCGAGGACTATGACCCCTACACCATCATGATGAGATATCTAGCATATTTGCA 360
QY 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
Db 361 GAAGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACTATATGG 420
QY 421 CATGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAAGCTTTAGAACACACACAGAGAATTTGTCAGTTAAGT 480
QY 481 GATGCAAAAGCCCAAAATGAGGATTTCTATCCAGCAAGATCTGTCGCAAGTAGG 540
Db 481 GATGCAAAAGCCCAAAATGAGGATTTCTATCCAGCAAGATCTGTCGCAAGTAGG 540
QY 541 CTGTGAATCTGATCAGTTACTTTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
Db 541 CTGTGAATCTGATCAGTTACTTTTAAATAAGTACTCTTATTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGAAAGCTGTTTTCATATGTTTATATCTAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAAGCTGTTTTCATATGTTTATATCTAGATAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 720
Db 661 TAGCTATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 720
QY 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
Db 721 TTAAGGAACAGCCATATCTCTGAATGATGATTAATTAATTAATTAATTAATTAATTAAT 780
QY 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTTCATTGGAACAGTATCTAA 840
Db 781 GAAGCTTTTGTATAGGAACCTTGTAGGCTCATTTTGTTCATTGGAACAGTATCTAA 840
QY 841 TTATAAATAGCTGTAGATCAGGTCCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
Db 841 TTATAAATAGCTGTAGATCAGGTCCTTCTGATGAAGTGAAGTGAAGTGAAGTGAAGTGA 900
QY 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
Db 901 TGGGAACCTTCAATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAATTAATTAAT 960
QY 961 AAAAAATAAGCGGGAATTTTCCCTTCTGATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
Db 961 AAAAAATAAGCGGGAATTTTCCCTTCTGATTAATTAATTAATTAATTAATTAATTAATTAAT 1020
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTTCTTAAATCTTTAAAGCATA 1080
Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAAATATATATCTTCTTAAATCTTTAAAGCATA 1080
QY 1081 AGTAAACATGATATAAAAAATATATGCTGAAATTTCTGGAAGATGATTAATTAATTAATTAAT 1140
Db 1081 AGTAAACATGATATAAAAAATATATGCTGAAATTTCTGGAAGATGATTAATTAATTAATTAAT 1140

QY 1141 TTAATGTTGTTTTTATTTGTAAGACATTAATTATTAAGAAATTTGGTTATTTGCTTACTG 1200
Db 1141 TTAATGTTGTTTTTATTTGTAAGACATTAATTATTAAGAAATTTGGTTATTTGCTTACTG 1200
QY 1201 TTCTAAATCTGCTGGTAAAGGTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
Db 1201 TTCTAAATCTGCTGGTAAAGGTATTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
QY 1261 GAATGAGAGAAAAATTTGTAATACCATCTCTGCTGTTCTTTAGTGAATTAATAAACTCT 1320
Db 1261 GAATGAGAGAAAAATTTGTAATACCATCTCTGCTGTTCTTTAGTGAATTAATAAACTCT 1320
QY 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 98

ADD77600

ID ADD77600 standard; cDNA; 1333 BP.

XX AC

XX ADD77600;

XX 29-JAN-2004 (first entry)

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO181 cDNA.

XX human; secreted and transmembrane protein; PRO; gene; ss; cytosolic;

XX humeral; antiarthritic; pericyte cell proliferation;

XX pericyte cell differentiation; chondrocyte cell proliferation;

XX chondrocyte cell differentiation; tumour necrosis factor alpha release;

XX (TNF)-alpha release; dermal fibroblast cell proliferation;

XX dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;

XX colon tumour; breast tumour; prostate tumour; rectal tumour;

XX liver tumour; tissue typing; chromosome mapping; gene mapping;

XX gene therapy.

XX Homo sapiens.

XX OS

XX US2003100729-A1.

XX 29-MAY-2003.

XX 28-AUG-2002; 2002US-00230113.

XX 01-JUN-2001; 2001WO-US017800.

XX 29-JUN-2001; 2001WO-US021066.

XX 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX WPI; 2004-008979/01.

XX P-PSDB; ADD77601.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX in gene therapy, or for preparing a medicament for treating a condition

XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

XX cancer.

XX Claim 2; SEQ ID NO 119; 308pp; English.

XX The invention describes an isolated PRO (secreted and transmembrane)

XX polypeptide (1). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are

XX useful for stimulating the proliferation of or gene expression in

XX pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful

XX for stimulating the proliferation or differentiation of chondrocyte

XX cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide

XX are useful for stimulating the release of tumour necrosis factor (TNF)-

XX alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO214,

CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080.
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309.
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1570, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9,6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60
 Db 1 GCCACGCGTCCGATGGGTTCACTTCGCGGCTTCTGCTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCCGCGTCATCTTCTGCGCATTTGGCACATTTAGCATTTGATGAGCTGAGAC 120
 Db 61 CACTGCCGCGTCATCTTCTGCGCATTTGGCACATTTAGCATTTGATGAGCTGAGAC 120

Qy 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTTGACTCCACAGATA 180
 Db 121 TGATTACAAGAACTCTATAGACCACTGTAATACCTGTAATCCCTTTGACTCCACAGATA 180

Qy 181 CCTCATCCAGCTTCTTCTGTCGATCTTCTTGTGTCAGAGAGTGGCTTACACTGGG 240
 Db 181 CCTCATCCAGCTTCTTCTGTCGATCTTCTTGTGTCAGAGAGTGGCTTACACTGGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATGACAGCAGTGTAGAG 300
 Db 241 TCTCAATATGCCCTCTTGGCATATCATTTGGAGGTATATGATGACAGCAGTGTAGAG 300

Qy 301 TGGCCCGAGACTCTATGACCCCTTACACCATCATGAATCAGATATTTAGCATATTTGCA 360
 Db 301 TGGCCCGAGACTCTATGACCCCTTACACCATCATGAATCAGATATTTAGCATATTTGCA 360

Qy 361 GAAGGAAGGATGGTGCAATAGCTTTTATCTTCTAGCATTTTATTTTACTACCTATATGG 420
 Db 361 GAAGGAAGGATGGTGCAATAGCTTTTATCTTCTAGCATTTTATTTTACTACCTATATGG 420

Qy 421 CATGATCTATGTTTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAGT 480
 Db 421 CATGATCTATGTTTTTGGTGAGCTCTTAGAACACACACAGAGATTTGGTCCAGTTAGT 480

Qy 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCTGTCCAAAGATGAGC 540

Qy 541 CTGTGGATCTGATCAGTTACTTTTAAAAAATGACTCTCTTTATTTTAAATGTTTCCCAT 600
 Db 541 CTGTGGATCTGATCAGTTACTTTTAAAAAATGACTCTCTTTATTTTAAATGTTTCCCAT 600

Qy 601 TTTTGTCTTGGAAAGACTGTTTTTTCATATGTTATATCTCAGATAAGATTTTAAATGCTAT 660
 Db 601 TTTTGTCTTGGAAAGACTGTTTTTTCATATGTTATATCTCAGATAAGATTTTAAATGCTAT 660

Qy 661 TACGTATAAATTAATAATAAATGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTGCACTTC 720
 Db 661 TACGTATAAATTAATAATAAATGATTAACCTCTGCTGTGTGACAGGTTTGAACCTTGCACTTC 720

Qy 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATAACTGACTCTCTCTAGPACATG 780
 Db 721 TTAAGGAACGCCATAATCTCTGAATGATGCAATTAATAACTGACTCTCTCTAGPACATG 780

Qy 781 GAAGCTTTTGTATAGAACTGTTAGGCTCATTTTGTGTTTCTATTCAGAACAGATATCTAA 840
 Db 781 GAAGCTTTTGTATAGAACTGTTAGGCTCATTTTGTGTTTCTATTCAGAACAGATATCTAA 840

Qy 841 TTATAAATTAAGCTGATAGATATCAGGTCTCTGATGAAGTGAAATGATATATCTGACTAG 900
 Db 841 TTATAAATTAAGCTGATAGATATCAGGTCTCTGATGAAGTGAAATGATATATCTGACTAG 900

Qy 901 TGGGAAACTTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960
 Db 901 TGGGAAACTTTCATGGGTTTCTCATCTGTCATGTCGATGATATATATGATGATACATTTAC 960

Qy 961 AAAAATTAAGGCGGAAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020
 Db 961 AAAAATTAAGGCGGAAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020

Qy 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATACTTGTCTTAAATCTTAAAGCATA 1080
 Db 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATACTTGTCTTAAATCTTAAAGCATA 1080

Qy 1081 AGTAAACATGATATAAAAAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140
 Db 1081 AGTAAACATGATATAAAAAATATATGCTGATTAATCTTGTGAAGATGCAATTTAAAGCTATT 1140

Qy 1141 TTAATCTGTTTTTATTTTGAAGACATTTCTTAAAGAAATTTGTTATTTATGCTTACTG 1200
 Db 1141 TTAATCTGTTTTTATTTTGAAGACATTTCTTAAAGAAATTTGTTATTTATGCTTACTG 1200

Qy 1201 TTCTAAATCTGCTGTAAGGTTATTCTTAAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260
 Db 1201 TTCTAAATCTGCTGTAAGGTTATTCTTAAAGAAATTTGCAGGTACTACAGATTTTCAAAACT 1260

Qy 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGCATACATAAAACTCT 1320
 Db 1261 GAATGAGAGAAAATTTGATTAACCATCTCTGCTGTTCTTTAGTGCATACATAAAACTCT 1320

Qy 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 99
 ADD77846
 ID ADD77846 standard; cdna; 1333 BP.
 XX AC ADD77846;
 XX DT 29-JAN-2004 (first entry)
 XX XX
 DE Novel human secreted and transmembrane protein PRO181 cdna.
 XX human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; gene mapping;
 KW gene therapy.

XX OS Homo sapiens.
XX PN US2003100730-A1.
XX PD 29-MAY-2003.
XX PF 28-AUG-2002; 2002US-00230193.
XX PR 01-JUN-2001; 2001WO-US017800.
XX PR 29-JUN-2001; 2001WO-US021056.
XX PR 09-APR-2002; 2002US-00119480.
XX PA (GENTH) GENENTECH INC.
XX PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
XX PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX DR P-PSDB; ADD77847.
XX DR WPI; 2004-008980/01.
XX PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX PT in gene therapy, or for preparing a medicament for treating a condition
XX PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX PT cancer.
XX PS Claim 2; SEQ ID NO 119; 308pp; English.
XX CC The invention describes an isolated PRO (secreted and transmembrane)
XX CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
XX CC useful for stimulating the proliferation of or gene expression in
XX CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
XX CC for stimulating the proliferation or differentiation of chondrocyte
XX CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
XX CC are useful for stimulating the release of tumour necrosis factor (TNF) -
XX CC alpha from human blood. PRO982, PRO357, PRO1083, PRO840, PRO1080,
XX CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1071, PRO1411, PRO1309,
XX CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1192, PRO1274, PRO1412,
XX CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1305, PRO1273, PRO1340, PRO1338,
XX CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
XX CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
XX CC PRO1887, PRO1328, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
XX CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
XX CC stimulating the proliferation of normal human dermal fibroblasts cells.
XX CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
XX CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
XX CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
XX CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
XX CC are useful for detecting the presence of tumour in a mammal which
XX CC involves comparing the level of expression of the above PRO polypeptides
XX CC in a test sample of cells taken from the mammal, and a control sample of
XX CC normal cells of the same cell type, where a higher level of expression of
XX CC the PRO polypeptides in the test sample as compared to the control sample
XX CC is indicative of the presence of tumour in the mammal. The tumour is lung
XX CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
XX CC liver tumour. (I) is useful as molecular weight markers, for tissue
XX CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
XX CC useful for chromosome and gene mapping or gene therapy. (II) is useful
XX CC for generating transgenic animals or knock-out animals which are useful
XX CC screening useful reagents. PRO357, PRO1272 or PRO4405 polypeptide
XX CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
XX CC sport injuries). This sequence encodes a human secreted and transmembrane
XX CC PRO polypeptide.
XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGCGTTCAGCTTCGGCGCTTCGTACATGCTGCGCTGCTGCT 60
DB 1 GCCACGCGTCCGATGCGTTCAGCTTCGGCGCTTCGTACATGCTGCGCTGCTGCT 60

QY 1141 TTAAGTGTGTTTATTTGTAAGACATTAATTAAGAAATGGTATTATGCTTACTG 1200
 Db |||||
 QY 1141 TTAAGTGTGTTTATTTGTAAGACATTAATTAAGAAATGGTATTATGCTTACTG 1200
 Db |||||
 QY 1201 TTCTAATCTGGTGAAGAGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAACT 1260
 Db |||||
 QY 1201 TTCTAATCTGGTGAAGAGTATTTCTTAAGAAATTTGCAGGTACTACAGATTTTCAAACT 1260
 Db |||||
 QY 1261 GAATGAGAGAAATGTATAACCATCTGCTGCTTTAGTGCATACAAATAAACTCT 1320
 Db |||||
 QY 1261 GAATGAGAGAAATGTATAACCATCTGCTGCTTTAGTGCATACAAATAAACTCT 1320
 Db |||||
 QY 1321 GAAATTAAGACTC 1333
 Db |||||
 QY 1321 GAAATTAAGACTC 1333
 Db |||||
 RESULT 100
 ADD85304
 ID ADD85304 standard; cDNA; 1333 BP.
 XX
 AC ADD85304;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO181 cDNA.
 XX
 KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
 KW vulnary; antiarthritic; pericyte cell proliferation;
 KW pericyte cell differentiation; chondrocyte cell proliferation;
 KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
 KW (TNF)-alpha release; dermal fibroblast cell proliferation;
 KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
 KW colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW liver tumour; tissue typing; chromosome mapping; Gene mapping;
 KW gene therapy.
 XX
 OS Homo sapiens.
 XX
 PN US2003100725-A1.
 XX
 PD 29-MAY-2003.
 XX
 PF 26-AUG-2002; 2002US-00227876.
 XX
 PR 15-SEP-2000; 2000US-0232887P.
 XX
 PR 01-JUN-2001; 2001WO-US017800.
 XX
 PR 29-JUN-2001; 2001WO-US021066.
 XX
 PR 09-APR-2002; 2002US-00119480.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
 XX
 DR WPI; 2004-008975/01.
 XX
 DR P-PSDB; ADD85305.
 XX
 PT New secreted and transmembrane PRO polypeptide useful for preparing a
 PT medicament for treating a condition that is responsive to the PRO
 PT polypeptide or anti-PRO antibody, e.g. cancer.
 XX
 PS Claim 2; SEQ ID NO 119; 308pp; English.
 XX
 CC The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO382, PRO1160, PRO187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)-
 CC alpha from human blood. PRO382, PRO357, PRO725, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO526, PRO363, PRO1083, PRO840, PRO1080,

CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO3333, PRO3543, PRO3444, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.
 XX
 SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
 Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 Db |||||
 QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCCTTCTGCTACATGCTGGCGCTGCTGCT 60
 Db |||||
 QY 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGTCAAGAC 120
 Db |||||
 QY 61 CACTGCCGCGCTCATCTTCTTCCGCAATTTGGCACAATTATAGCATTTGATGAGTCAAGAC 120
 Db |||||
 QY 121 TGATTTACAAGAAATCCTATAGACACAGTAAATCCCTGAATCCCTTGTACTCCCAAGATTA 180
 Db |||||
 QY 121 TGATTTACAAGAAATCCTATAGACACAGTAAATCCCTGAATCCCTTGTACTCCCAAGATTA 180
 Db |||||
 QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGACAGAGTGGCTTACACTGGG 240
 Db |||||
 QY 181 CCTCATCCACGCTTCTTCTGTCATGTTCTTTGTGCGACAGAGTGGCTTACACTGGG 240
 Db |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCATGATGAG 300
 Db |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTACAGCATGATGAG 300
 Db |||||
 QY 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
 Db |||||
 QY 301 TGGCCCGAGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTCA 360
 Db |||||
 QY 361 GAAGAAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Db |||||
 QY 361 GAAGAAAGAGTGGTCAAAATAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGG 420
 Db |||||
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db |||||
 QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAACAAACACAGAGAAATTTGGTCCAGTTAAGT 480
 Db |||||
 QY 481 GCATCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTCCAAAGAGTAGC 540
 Db |||||
 QY 481 GCATCAAAAAGCCCAAAATGAAGGATTTCTATCCAGCAAGATCTCTCCAAAGAGTAGC 540
 Db |||||
 QY 541 CTGTGGATCTGATCAGTACTTTTAAAAAATGACTCTTATTTTAAATGTTTCCCAT 600
 Db |||||
 QY 541 CTGTGGATCTGATCAGTACTTTTAAAAAATGACTCTTATTTTAAATGTTTCCCAT 600
 Db |||||

QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTACATAGATAAAGATTTTAAATGGTAT 660
Db |||||
QY 601 TTTTGTCTGTGGAAAGACTGTTTTCATATGTTATCTACATAGATAAAGATTTTAAATGGTAT 660
Db |||||
QY 661 TAGCTATAAATTAAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db |||||
QY 661 TAGCTATAAATTAAATAAATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCACCTTC 720
Db |||||
QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGCAATTAATTAACCTGCTCTAGTACATTC 780
Db |||||
QY 721 TTAAGGAACAGCCATAATCCCTCTGAATGATGCAATTAATTAACCTGCTCTAGTACATTC 780
Db |||||
QY 781 GAAGCTTTTCTTTATAGGAATCTGTAGGGCTCAATTTGGTTTCATTTGAACACAGTACTTAA 840
Db |||||
QY 781 GAAGCTTTTCTTTATAGGAATCTGTAGGGCTCAATTTGGTTTCATTTGAACACAGTACTTAA 840
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGGTCCTCTGATGAAGTGAATAATGATATCTGACTAG 900
Db |||||
QY 841 TTATAAATTAGCTGTAGATATCAGGTCCTCTGATGAAGTGAATAATGATATCTGACTAG 900
Db |||||
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATGATACATTTAC 960
Db |||||
QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATGATACATTTAC 960
Db |||||
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTCAATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 961 AAAAAATAAAGCGGGAATTTCCCTTCGCTTCAATATATCCCTGTATATTCATGAAT 1020
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATGCTTGAATTTCTTAAGCAT 1080
Db |||||
QY 1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATAATGCTTGAATTTCTTAAGCAT 1080
Db |||||
QY 1081 AGTAACATCATATAAATAATATGCTGAATTAATCTGTAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1081 AGTAACATCATATAAATAATATGCTGAATTAATCTGTAAGATGCAATTTAAAGCTATT 1140
Db |||||
QY 1141 TTAATGTGTTTATTTTGAAGCAATTAATTAAGAAATTTGTTTATTTATGTTACTG 1200
Db |||||
QY 1141 TTAATGTGTTTATTTTGAAGCAATTAATTAAGAAATTTGTTTATTTATGTTACTG 1200
Db |||||
QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGTAATGAGATTTCAAAACT 1260
Db |||||
QY 1201 TTCTAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGTAATGAGATTTCAAAACT 1260
Db |||||
QY 1261 GAATGAGAGAAATTTGTATAACCATCTGCTGTTCTTTAGTCAATACAAATAAACTCT 1320
Db |||||
QY 1261 GAATGAGAGAAATTTGTATAACCATCTGCTGTTCTTTAGTCAATACAAATAAACTCT 1320
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||
QY 1321 GAAATTAAGACTC 1333
Db |||||

RESULT 101

ADD73836
ID ADD73836 standard; cDNA; 1333 BP.

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

XX AC
XX AC
XX AC

PD 29-MAY-2003.
XX 09-AUG-2002; 2002US-00216164.
XX 05-JUN-2000; 2000US-0209832P.
PR 15-SEP-2000; 2000US-0232887P.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX (GETH) GENENTECH INC.
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ,
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI WPI; 2004-008960/01.
DR P-PSDB; ADD73837.
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX Claim 2; Fig 119; 309pp; English.
XX The invention relates to human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the PRO polynucleotides encoding them.
CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. They are particularly useful for
CC detecting tumours (e.g. lung tumour, colon tumour, breast tumour,
CC prostate tumour, rectal tumour or liver tumour) in a mammal, for
CC stimulating the release of tumour necrosis factor (TNF)-alpha from human
CC blood, for stimulating the proliferation or differentiation of
CC chondrocyte cells for stimulating the proliferation of or gene
CC expression in pericyte cells or for stimulating the proliferation of
CC normal human dermal fibroblasts. The PRO nucleic acids are useful as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, in preparing PRO polypeptides, by recombinant
CC technology, in generating transgenic animals or knock-out animals which
CC may be used in the development and screening of therapeutically useful
CC reagents, in gene therapy, in chromosome identification, as chromosome
CC markers and in generating probes. The PRO polypeptides, or anti-PRO
CC antibodies, are useful for preparing a medicament for treating a
CC condition which is responsive to the PRO polypeptides or anti-PRO
CC antibodies, such as pericyte-associated tumours and bone and/or cartilage
CC disorders (e.g. arthritis, sports injuries), involving inducing the re-
CC differentiation of chondrocytes. The PRO polypeptides are useful as
CC molecular markers for protein electrophoresis, and in tissue typing. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCCAGCGTCCGATGCGTTCACGTTTCGGGCTTCTGCTACATCGTGGCTGCTGCT 60
Db 1 GCCCAGCGTCCGATGCGTTCACGTTTCGGGCTTCTGCTACATCGTGGCTGCTGCT 60
QY 61 CACTGCCGGGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGTAGCTGAAGAC 120
Db 61 CACTGCCGGGCTCATCTTCTTCGCCATTTGGCACATTATAGCATTTGTAGCTGAAGAC 120
QY 121 TGATTAACAGATCCCTATAGACAGGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
Db 121 TGATTAACAGATCCCTATAGACAGGTGAATACCCCTGAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCAGGCTTCTTCTGTCATGTTCTTTCTGTCAGAGAGTGGCTTACCTGGG 240
Db 181 CCTCATCCAGGCTTCTTCTGTCATGTTCTTTCTGTCAGAGAGTGGCTTACCTGGG 240

241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGATAGACCACTGATGAG 300
241 TCTCAATATGCCCTCTTGGCAATATCATATTTGGAGGTATATGATAGACCACTGATGAG 300
301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTC 360
301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGAATCAGATATTTCTAGCATATTTGTC 360
361 GAAGGAAGATGGTGGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
361 GAAGGAAGATGGTGGCAAAATAGCTTTTATCTTCTAGCATATTTTCTAGCATATTTG 420
421 CATGATCTATCTTTGGTGGAGCTCTTGAACAAACACACAGAGAAATGCTCCAGTTAAGT 480
421 CATGATCTATCTTTGGTGGAGCTCTTGAACAAACACACAGAGAAATGCTCCAGTTAAGT 480
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCAAGAGTAGC 540
481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCAAGAGTAGC 540
541 CTGTGGAATCTGATCAGTATCTTTAAAAAATGACTCTCTATTTTAAATGTTTCCACAT 600
541 CTGTGGAATCTGATCAGTATCTTTAAAAAATGACTCTCTATTTTAAATGTTTCCACAT 600
601 TTTTCTGTTGTGAAGAGACTTTTTCATATGTTTATCTAGTAAAGATTTTAAATGTTAT 660
601 TTTTCTGTTGTGAAGAGACTTTTTCATATGTTTATCTAGTAAAGATTTTAAATGTTAT 660
661 TACGTATAAATTAATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
661 TACGTATAAATTAATATAAATGATTTACCTCTGGTGTGACAGGTTTGAACCTTGCACTTC 720
721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
721 TTAAGGAACAGCCATTAATCTCTGAATGATGATTAATTTACTGACTGCTCTAGTACATG 780
781 GAAGCTTTTGTATAGGAAGCTTTAGAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
781 GAAGCTTTTGTATAGGAAGCTTTAGAGGCTCATTTTGGTTTCAATGAAACAGTATCTAA 840
841 TTAATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATATCTGACTAG 900
841 TTAATAAATAGCTGTAGATATCAGGTGCTTCTGATGAAGTAAATGATATATCTGACTAG 900
901 TGGGAACCTTCATGGGTTTCTCTCATCTGTGATGATGATATATATGATGATCAATTTAC 960
901 TGGGAACCTTCATGGGTTTCTCTCATCTGTGATGATGATATATATGATGATCAATTTAC 960
961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATCTCTGATATATGATGATCAAT 1020
961 AAAAAATAAAGCGGAAATTTCCCTTCGCTTGAATATATCTCTGATATATGATGATCAAT 1020
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGTTTAAATTTCTTAAGCATA 1080
1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAATATATCTGTTTAAATTTCTTAAGCATA 1080
1081 AGTAACATGATATAAATAATATGATGATGATGATGATGATGATGATGATGATGATGAT 1140
1081 AGTAACATGATATAAATAATATGATGATGATGATGATGATGATGATGATGATGATGAT 1140
1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATCTTACTG 1200
1141 TTAATGTTGTTTATTTGTAAGACATTAATTAAGAAATTTGGTTATTTATCTTACTG 1200
1201 TTTCTATCTGTTGTTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
1201 TTTCTATCTGTTGTTAAAGTATTTCTTAAGAAATTTGCGAGTACTACAGATTTTCAAACT 1260
1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTTAGTGCATACATAAATCTCT 1320
1261 GAATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTTAGTGCATACATAAATCTCT 1320
1321 GAAATTAAGACTC 1333

Db 1321 GAAATTAAGACTC 1333

RESULT 102

ADD74574

ID ADD74574 standard; cDNA; 1333 BP.

XX ADD74574;

AC ADD74574;

DT 29-JAN-2004 (first entry)

XX Human PRO polynucleotide #60.

Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide; tumour; cancer; lung; colon; breast; prostate; rectum; liver; pericyte cell; dermal fibroblast; bone disorder; cartilage disorder; arthritis; sports injury; cytostatic; antiarthritic.

OS Homo sapiens.

XX US2003100713-A1.

PN 29-MAY-2003.

PD 13-AUG-2002; 2002US-00219065.

PF 25-JUL-2000; 2000US-0220638P.

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX (GETH) GENENTECH INC.

Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI; WPI: 2004-008963/01.

P-PSDB; ADD74575.

New secreted and transmembrane PRO polypeptide useful for preparing a medicament for treating a condition that is responsive to the PRO polypeptide or anti-PRO antibody, e.g. cancer.

Claim 2; Fig 119; 308pp; English.

The invention relates to human PRO polypeptides (secreted and transmembrane polypeptides) and the PRO polynucleotides encoding them. The PRO polypeptides and polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. They are particularly useful for detecting tumours (e.g. lung tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or liver tumour) in a mammal, for stimulating the release of tumour necrosis factor (TNF)-alpha from human blood, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells or for stimulating the proliferation of normal human dermal fibroblasts. The PRO nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA, in preparing PRO polypeptides by recombinant technology, in generating transgenic animals or knock-out animals which may be used in the development and screening of therapeutically useful reagents, in gene therapy, in chromosome identification, as chromosome markers and in generating probes. The PRO polypeptides, or anti-PRO antibodies, are useful for preparing a medicament for treating a condition which is responsive to the PRO polypeptides or anti-PRO antibodies, such as pericyte-associated tumours and bone and/or cartilage disorders (e.g. arthritis, sports injuries), involving inducing the re-differentiation of chondrocytes. The PRO polypeptides are useful as molecular markers for protein electrophoresis, and in tissue typing. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent can also be obtained in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html.

XX	Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;	
SQ	Query Match 100.0%; Score 1333; DB 10; Length 1333;	
	Best Local Similarity 100.0%; Pred. No. 9.6e-306;	
	Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1 GCCACGGCTCGATGGGCTTACGTTGCGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60	
Db	1 GCCACGGCTCGATGGGCTTACGTTGCGGGCTTCTGCTACATGCTGGCGCTGCTGCT 60	
QY	61 CACTGCCGGCTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTCAAGAC 120	
Db	61 CACTGCCGGCTCATCTTCTCGCCATTTGGCACATTAAGCATTTGATGAGCTCAAGAC 120	
QY	121 TGATTACAGAATCCCTATAGACAGGTAATACCCCTGATCCCTTGATCCCGAGATA 180	
Db	121 TGATTACAGAATCCCTATAGACAGGTAATACCCCTGATCCCTTGATCCCGAGATA 180	
QY	181 COTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGCTTACACTGGG 240	
Db	181 COTCATCCAGCTTCTTCTGTGTCATGTTCTTTGTGTCAGCAGAGTGCTTACACTGGG 240	
QY	241 TCTCAATATGCCCTTCTGCGATATCATATTTGGAGGTATATGAGTACAGTGTATGAG 300	
Db	241 TCTCAATATGCCCTTCTGCGATATCATATTTGGAGGTATATGAGTACAGTGTATGAG 300	
QY	301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATCA 360	
Db	301 TGGCCCGAGGACTCTATGACCCCTACACCATCATGATGATGATGATGATGATGATCA 360	
QY	361 GAAGGAAGGATGTCAGTCTTTTATCTTCTGATGATGATGATGATGATGATGATGAT 420	
Db	361 GAAGGAAGGATGTCAGTCTTTTATCTTCTGATGATGATGATGATGATGATGATGAT 420	
QY	421 CATGATCTATGTTTCTGATGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480	
Db	421 CATGATCTATGTTTCTGATGCTCTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGT 480	
QY	481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGATGAGC 540	
Db	481 GCATGCAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCACAGATGAGC 540	
QY	541 CTGTGGAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 600	
Db	541 CTGTGGAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 600	
QY	601 TTTTGTCTTGTGGAAGACTCTTTTTCATATGTTATCTACATGATGATGATGATGATGAT 660	
Db	601 TTTTGTCTTGTGGAAGACTCTTTTTCATATGTTATCTACATGATGATGATGATGATGAT 660	
QY	661 TAGCTATAAATTAATAAATGAATGATGATGATGATGATGATGATGATGATGATGATGAT 720	
Db	661 TAGCTATAAATTAATAAATGAATGATGATGATGATGATGATGATGATGATGATGATGAT 720	
QY	721 TTAAGGAACGCTATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 780	
Db	721 TTAAGGAACGCTATCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 780	
QY	781 GAAGCTTTTGTGTTATAGGAATCTTGTAGGCTCAATTTGGTTTCAATTTGAAACAGTATCAA 840	
Db	781 GAAGCTTTTGTGTTATAGGAATCTTGTAGGCTCAATTTGGTTTCAATTTGAAACAGTATCAA 840	
QY	841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900	
Db	841 TTATAAATAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 900	
QY	901 TGGGAACCTCATGGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960	
Db	901 TGGGAACCTCATGGTTTCTCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960	
QY	961 AAAAATAAAAGCGGGAATTTTCCCTGCTTGAATATTTATCCCTGATATTTGATGATGAT 1020	

Db	961 AAAAATAAAAGCGGGAATTTTCCCTGCTTGAATATTTATCCCTGATATTTGATGATGAT 1020	
QY	1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTAAATCTTAAAGCATA 1080	
Db	1021 GAGAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTCTTAAATCTTAAAGCATA 1080	
QY	1081 AGTAAACATGATATAAATAATATATGCTGAAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140	
Db	1081 AGTAAACATGATATAAATAATATATGCTGAAATTTACTTGTGAAGAATGCAATTTAAAGCTATT 1140	
QY	1141 TTAATGCTGTTTATTTTGAAGCAATTAATTAAGAAATGCTTATTTATGCTTACTG 1200	
Db	1141 TTAATGCTGTTTATTTTGAAGCAATTAATTAAGAAATGCTTATTTATGCTTACTG 1200	
QY	1201 TTCTAATCTGCTGGTAAAGGTAATTTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260	
Db	1201 TTCTAATCTGCTGGTAAAGGTAATTTTAAAGAAATTTGCAAGTACTACAGATTTTCAAAACT 1260	
QY	1261 GAATGAGAGAAATTTGTAATACCATCTCTGCTGCTTCTTTAGTGCATTAACAATAAACTCT 1320	
Db	1261 GAATGAGAGAAATTTGTAATACCATCTCTGCTGCTTCTTTAGTGCATTAACAATAAACTCT 1320	
QY	1321 GAAATTAAGACTC 1333	
Db	1321 GAAATTAAGACTC 1333	

RESULT 103
ADD77102
ID ADD77102 standard; cdNA; 1333 BP.
XX
AC ADD77102;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO181 cdNA.
XX
KW human; secreted and transmembrane protein; PRO; gene; ss; cytostatic;
KW vulnary; antiarthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN US2003100716-A1.
XX
PD 29-MAY-2003.
XX
PF 13-AUG-2002; 2002US-00219077.
XX
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KD, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
XX Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
XX WPI; 2004-008966/01.
XX P-PSDB; ADD77103.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
XX in gene therapy, or for preparing a medicament for treating a condition
XX that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.
XX cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
PS

XX The invention describes an isolated PRO (secreted and transmembrane)
 CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
 CC useful for stimulating the proliferation of or gene expression in
 CC pericyte cells. PRO357, PRO1272 or PRO4405 polypeptide are useful
 CC for stimulating the proliferation or differentiation of chondrocyte
 CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
 CC are useful for stimulating the release of tumour necrosis factor (TNF)
 CC alpha from human blood. PRO982, PRO357, PRO1306, PRO1419, PRO214,
 CC PRO247, PRO337, PRO326, PRO363, PRO531, PRO1083, PRO840, PRO1080,
 CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
 CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1412,
 CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1379, PRO1340, PRO1338,
 CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
 CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3443, PRO4322,
 CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
 CC stimulating the proliferation of normal human dermal fibroblasts cells.
 CC PRO181, PRO229, PRO788, PRO1194, PRO1272, PRO1488, PRO4302, PRO4408,
 CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
 CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
 CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
 CC are useful for detecting the presence of tumour in a mammal which
 CC involves comparing the level of expression of the above PRO polypeptides
 CC in a test sample of cells taken from the mammal, and a control sample of
 CC normal cells of the same cell type, where a higher level of expression of
 CC the PRO polypeptides in the test sample as compared to the control sample
 CC is indicative of the presence of tumour in the mammal. The tumour is lung
 CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
 CC liver tumour. (I) is useful as molecular weight markers, for tissue
 CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
 CC useful for chromosome and gene mapping or gene therapy. (II) is useful
 CC for generating transgenic animals or knock-out animals which are useful
 CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
 CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
 CC sport injuries). This sequence encodes a human secreted and transmembrane
 CC PRO polypeptide.

SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;
 Best Local Similarity 100.0%; Pred. No. 9.6e-306;
 Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCCACGGTCCGATGGCGTTCACGTTCCGCGCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB |||||
 QY 1 GCCACGGTCCGATGGCGTTCACGTTCCGCGCTCTGCTACATGCTGGCGCTGCTGCT 60
 DB |||||
 QY 61 CACTGCGCGCTCATCTCTCGCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
 DB |||||
 QY 61 CACTGCGCGCTCATCTCTCGCCATTTGGCACATTTAGCATTTGATGAGCTGAAGAC 120
 DB |||||
 QY 121 TGATTAAGAATCTATAGACAGTGTATACCCCTGAATCCCTGTACTCCAGATTA 180
 DB |||||
 QY 121 TGATTAAGAATCTATAGACAGTGTATACCCCTGAATCCCTGTACTCCAGATTA 180
 DB |||||
 QY 181 CTTCTACACGCTTTCTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
 DB |||||
 QY 181 CTTCTACACGCTTTCTCTGTCATGTTCTTTGTGCGAGAGTGGCTTACACTGGG 240
 DB |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTAGAG 300
 DB |||||
 QY 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACAGTAGAG 300
 DB |||||
 QY 301 TGGCCAGAGACTATAGACCTTACACCATCATGAATGAGATTTCTAGCATTTGTCA 360
 DB |||||
 QY 301 TGGCCAGAGACTATAGACCTTACACCATCATGAATGAGATTTCTAGCATTTGTCA 360
 DB |||||
 QY 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTTCTAGCATTTTCTTACTACCTATG 420
 DB |||||
 QY 361 GAAGGAAGATGCTGCAAAATAGCTTTTATCTTTCTAGCATTTTCTTACTACCTATG 420
 DB |||||
 QY 421 CATGATCTATGTTTGGTGAGCTTTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 DB |||||

Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAACACACACAGAGAATTTGGTCCAGTTAAGT 480
 QY 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
 Db 481 GCATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAGAGTAGC 540
 QY 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGATCCCTTATTTTAAAAATTTTCCCAT 600
 Db 541 CTGTGGAATCTGATCAGTTACTTTAAAAAATGATCCCTTATTTTAAAAATTTTCCCAT 600
 QY 601 TTTTCTGTGTGGAAGAGCTGTTTTCATATGTTATATCATAGTAATAAGATTTTAAATGGTAT 660
 Db 601 TTTTCTGTGTGGAAGAGCTGTTTTCATATGTTATATCATAGTAATAAGATTTTAAATGGTAT 660
 QY 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGTCAGAGTTTGAACTTGCACATTC 720
 Db 661 TACGTATAAATTAATAAATGATTAATCCTCTGGTGTGTCAGAGTTTGAACTTGCACATTC 720
 QY 721 TTAAGGAACAGCCATAATCCCTCTGAAATGATCAATTAATCTGACTGTCTTAGTACATTTG 780
 Db 721 TTAAGGAACAGCCATAATCCCTCTGAAATGATCAATTAATCTGACTGTCTTAGTACATTTG 780
 QY 781 GAAGCTTTGTTTATPAGGAATCTGTAGGGCTCATTTGGTTCATTGTAAGACAGTATCTAA 840
 Db 781 GAAGCTTTGTTTATPAGGAATCTGTAGGGCTCATTTGGTTCATTGTAAGACAGTATCTAA 840
 QY 841 TTATAAATAGCTGTAGATATACAGTCTCTGATGAAGTGAATGATAATGATATCTGACATG 900
 Db 841 TTATAAATAGCTGTAGATATACAGTCTCTGATGAAGTGAATGATAATGATATCTGACATG 900
 QY 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTTATATATATGGAATATTTAC 960
 Db 901 TGGGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTTATATATATGGAATATTTAC 960
 QY 961 AAAAATAAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 Db 961 AAAAATAAAAAGCGGGAATTTCCCTCGCTTGAATATATCCCTGTATATGTCATGAT 1020
 QY 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTTGTCTTAATTTCTTAAGCATA 1080
 Db 1021 GAGAGATTTCCCATATTTCCCATCAGAGTAATAAATATATCTTGTCTTAATTTCTTAAGCATA 1080
 QY 1081 AGTAAACATGATATAAAAATATATGCTGAATTTACTTGTGAAGAATGCTATTTAAAGCTATT 1140
 Db 1081 AGTAAACATGATATAAAAATATATGCTGAATTTACTTGTGAAGAATGCTATTTAAAGCTATT 1140
 QY 1141 TTAATATGTTTATTTTGTAAAGACATTTACTTATTAAGAAATTTGGTATTATGCTTACTG 1200
 Db 1141 TTAATATGTTTATTTTGTAAAGACATTTACTTATTAAGAAATTTGGTATTATGCTTACTG 1200
 QY 1201 TTCTAATCTGGTGTGTAAGAGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 Db 1201 TTCTAATCTGGTGTGTAAGAGTATTTCTTAAGAAATTTGCAAGTACTACAGATTTTCAAACT 1260
 QY 1261 GAATCAGAGAAAATTTGTATAACCATTCCTGCTGTTCCCTTTAGTGAATATCAATAAACTCT 1320
 Db 1261 GAATCAGAGAAAATTTGTATAACCATTCCTGCTGTTCCCTTTAGTGAATATCAATAAACTCT 1320
 QY 1321 GAAATTAAGACTC 1333
 Db 1321 GAAATTAAGACTC 1333

RESULT 104

ADD85796

ID ADD85796 standard; cDNA; 1333 BP.

XX

AC ADD85796;

XX

DT 29-JAN-2004 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO181 cDNA.

XX

KW human; secreted and transmembrane protein; PRO; gene; ss; cytotstatic;
KW vulnary; aneurthritic; pericyte cell proliferation;
KW pericyte cell differentiation; chondrocyte cell proliferation;
KW chondrocyte cell differentiation; tumour necrosis factor alpha release;
KW (TNF)-alpha release; dermal fibroblast cell proliferation;
KW dermal fibroblast cell differentiation inhibitor; tumour; lung tumour;
KW colon tumour; breast tumour; prostate tumour; rectal tumour;
KW liver tumour; tissue typing; chromosome mapping; gene mapping;
KW gene therapy.
XX
OS Homo sapiens.
XX
XX US2003100720-A1.
XX
XX 29-MAY-2003.
XX
XX 14-AUG-2002; 2002US-00219471.
XX
XX 18-NOV-1998; 98US-0108849P.
PR 01-SEP-1999; 99WO-US020111.
PR 01-JUN-2001; 2001WO-US017800.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-APR-2002; 2002US-00119480.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
PI P-PSDB; ADD85797.
XX
XX WPI; 2004-008970/01.
DR P-PSDB; ADD85797.
XX
XX New secreted and transmembrane PRO polypeptide useful for preparing a
PT medicament for treating a condition that is responsive to the PRO
PT polypeptide or anti-PRO antibody, e.g. cancer.
XX
XX Claim 2; SEQ ID NO 119; 308pp; English.
XX
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I). PRO982, PRO1160, PRO1187 or PRO1329 polypeptide are
CC useful for stimulating the proliferation of or gene expression in
CC pericyte cells. PRO357, PRO229, PRO1272 or PRO4405 polypeptide are useful
CC for stimulating the proliferation or differentiation of chondrocyte
CC cells. PRO231, PRO357, PRO725, PRO1155, PRO1306 or PRO1419 polypeptide
CC are useful for stimulating the release of tumour necrosis factor (TNF)-
CC alpha from human blood. PRO982, PRO357, PRO725, PRO1306, PRO1419, PRO2114,
CC PRO247, PRO337, PRO526, PRO363, PRO531, PRO1083, PRO840, PRO1080,
CC PRO1478, PRO1134, PRO826, PRO1005, PRO809, PRO1071, PRO1411, PRO1309,
CC PRO1025, PRO1181, PRO1126, PRO1186, PRO1192, PRO1244, PRO1274, PRO1412,
CC PRO1286, PRO1330, PRO1347, PRO1305, PRO1273, PRO1279, PRO1340, PRO1338,
CC PRO1343, PRO1376, PRO1387, PRO1409, PRO1474, PRO1917, PRO1760, PRO1567,
CC PRO1887, PRO1928, PRO4341, PRO1801, PRO4333, PRO3543, PRO3444, PRO4322,
CC PRO9940, PRO6079, PRO9836 or PRO10096 polypeptide are useful for
CC stimulating the proliferation of normal human dermal fibroblasts cells.
CC PRO181, PRO229, PRO7154, or PRO7425 polypeptide are useful for
CC PRO5723, PRO5725, PRO7154, or PRO7425 polypeptide are useful for
CC inhibiting the proliferation of normal human dermal fibroblast cells. PRO
CC polypeptides such as PRO6004, PRO4981, PRO7174, PRO5778, PRO4332, etc.,
CC are useful for detecting the presence of tumour in a mammal which
CC involves comparing the level of expression of the above PRO polypeptides
CC in a test sample of cells taken from the mammal, and a control sample of
CC normal cells of the same cell type, where a higher level of expression of
CC the PRO polypeptides in the test sample as compared to the control sample
CC is indicative of the presence of tumour in the mammal. The tumour is lung
CC tumour, colon tumour, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. (I) is useful as molecular weight markers, for tissue
CC typing, or as therapeutic agents. A polynucleotide (II) encoding (I) is
CC useful for chromosome and gene mapping or gene therapy. (II) is useful
CC for generating transgenic animals or knock-out animals which are useful
CC screening useful reagents. PRO357, PRO229, PRO1272 or PRO4405 polypeptide
CC is useful for treating bone and/or cartilage disorders (e.g., arthritis,
CC sport injuries). This sequence encodes a human secreted and transmembrane
CC PRO polypeptide.

XX Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;
SQ
Query Match 100.0%; Score 1333; DB 10; Length 1333;
Best Local Similarity 100.0%; Pred. No. 9.6e-306;
Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCCCTTCTGTACATGCTGGCGCTCTGCT 60
Db 1 GCCACGCGTCCGATGGCGTTCACGTTCCGCGCCCTTCTGTACATGCTGGCGCTCTGCT 60
QY 61 CACTGCCGCGCTCATCTTCTTGGCCATTTGGCACATTATAGCATTGTAGTGAAGAC 120
Db 61 CACTGCCGCGCTCATCTTCTTGGCCATTTGGCACATTATAGCATTGTAGTGAAGAC 120
QY 121 TGAATTACAGAAATCCTATAGACCAAGTAAATACCTGTAATCCCTTGTACTCCAGAGTA 180
Db 121 TGAATTACAGAAATCCTATAGACCAAGTAAATACCTGTAATCCCTTGTACTCCAGAGTA 180
QY 181 CCTCATCCACGCTTCTTCTGTGTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGG 240
Db 181 CCTCATCCACGCTTCTTCTGTGTGTCATGTTCTTTGTGTCAGAGTGGCTTACACTGG 240
QY 241 TCTCAATATGCCCTCTTGGCATAATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
Db 241 TCTCAATATGCCCTCTTGGCATAATATTTGGAGGTATATAGTAGACAGTGAATGAG 300
QY 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTC 360
Db 301 TGGCCGAGGACTCTATGACCCCTACACCATCATGATGAGATATTTCTAGCATATTTGTC 360
QY 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATG 420
Db 361 GAAGGAAGGATGGTGCAATTTAGCTTTTATCTTCTAGCATTTTCTTACTACTATATG 420
QY 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACACACAGAGAAATTTGTCAGTTAAGT 480
Db 421 CATGATCTATGTTTGGTGAGCTCTTAGAAACACACAGAGAAATTTGTCAGTTAAGT 480
QY 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
Db 481 GCATGCAAAAGCCCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGAGTAGC 540
QY 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600
Db 541 CTGTGGAATCTGATCAGTTACTTTTAAATAATGACTCTTTTAAATGTTTCCACAT 600
QY 601 TTTTGTCTTGGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTTGGAAAGACTGTTTTCATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660
QY 661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGCTTGCACAGGTTTGAACCTGCACTTC 720
Db 661 TAGCTATAAATTAATAAATGATTTACCTCTGCTGCTTGCACAGGTTTGAACCTGCACTTC 720
QY 721 TTAAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAATCTAGTCTAGTCAATTG 780
Db 721 TTAAGGAACAGCCATTAATCTCTGAATGATGCAATTAATTAATCTAGTCTAGTCAATTG 780
QY 781 GAAGCTTTTGTATAGGAACTTGTAGGCTCATTTTGGTTCATTTGTTTCAATGAACACTCTAA 840
Db 781 GAAGCTTTTGTATAGGAACTTGTAGGCTCATTTTGGTTCATTTGTTTCAATGAACACTCTAA 840
QY 841 TTAATAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATATCTAGCTAG 900
Db 841 TTAATAATTAAGCTGTAGATATCAGGTGCTTCTGATGAAGTGAATAATATCTAGCTAG 900
QY 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATATATATGATGATCAATTAC 960
Db 901 TGGGAACCTTCATGGGTTTCTCATCTGTCATGTCATGATGATATATATGATGATCAATTAC 960
QY 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTGAATATTTATCCCTGCTATATTCGATGAAT 1020
Db 961 AAAAAATAAAGCGGGAATTTTCCCTTCGCTGAATATTTATCCCTGCTATATTCGATGAAT

Db 961 AAAATAAAGCGGAATTTCCCTTCGCTTGGAATATATCCCTGTATATGTCATGAAT 1020

Qy 1021 GAGAGATTCCTCATATTCCTAGAGATTAATAATAATACCTGTTTAACTTTAAGCATTA 1080

Db 1021 GAGAGATTCCTCATATTCCTAGAGATTAATAATAATACCTGTTTAACTTTAAGCATTA 1080

Qy 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGGAAGATGCAATTTAAAGCTATT 1140

Db 1081 AGTAAACATGATATAAATAATATATGCTGAATTTACTTTGGAAGATGCAATTTAAAGCTATT 1140

Qy 1141 TTAATGCTGTTTTATTTTGAAGACATTTACTTATTAGAAATGCTTTATATGCTTACTG 1200

Db 1141 TTAATGCTGTTTTATTTTGAAGACATTTACTTATTAGAAATGCTTTATATGCTTACTG 1200

Qy 1201 TTTAAATCTGTTGTAAGGATTTCTTAAAGATTTGAGGATTAACAGATTTTCAAACT 1260

Db 1201 TTTAAATCTGTTGTAAGGATTTCTTAAAGATTTGAGGATTAACAGATTTTCAAACT 1260

Qy 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGAATACAAATAAACTCT 1320

Db 1261 GAATGAGAGAAAATTTGTATAACCATCTGCTGTTCTTTAGTGAATACAAATAAACTCT 1320

Qy 1321 GAAATTAAGACTC 1333

Db 1321 GAAATTAAGACTC 1333

RESULT 105

AD05345

ID AD05345 standard; cDNA; 1333 BP.

XX

AC AD05345;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #60.

XX

KW Human; PRO; gene; ss; secreted polypeptide; transmembrane polypeptide;

KW tumour; cancer; lung; colon; breast; prostate; rectum; liver;

KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell;

KW pericyte cell; dermal fibroblast; bone disorder; cartilage disorder;

KW arthritis; sports injury; cytostatic; antiarthritic.

XX

OS Homo sapiens.

XX

PN US2003100723-Al.

XX

PD 29-MAY-2003.

XX

PF 13-AUG-2002; 2002US-00219482.

XX

PR 26-JUL-2000; 2000US-0220893P.

PR 01-JUN-2001; 2001WO-US017800.

PR 29-JUN-2001; 2001WO-US021066.

PR 09-APR-2002; 2002US-00119480.

XX

PA (GENE) GENENTECH INC.

XX

PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;

PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;

XX

DR WPI: 2004-008973/01.

DR P-PSDB; AD05346.

XX

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful

PT in gene therapy, or for preparing a medicament for treating a condition

PT that is responsive to the PRO polypeptide or anti-PRO antibody, e.g.

PT cancer.

XX

PS Claim 2; Fig 119; 308pp; English.

XX

CC The invention relates to human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the PRO polynucleotides encoding them.

CC The PRO polypeptides and polynucleotides are useful as pharmaceuticals,

CC diagnostics, biosensors or bioreactors. They are particularly useful for

CC detecting tumour, rectal tumour, colon tumour, breast tumour,

CC prostate tumour, liver tumour or liver tumour) in a mammal, for

CC stimulating the release of tumour necrosis factor (TNF)-alpha from human

CC blood, for stimulating the proliferation or differentiation of

CC chondrocyte cells, for stimulating the proliferation of or gene

CC expression in pericyte cells or for stimulating the proliferation of

CC normal human dermal fibroblasts. The PRO nucleic acids are useful as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA, in preparing PRO polypeptides by recombinant

CC technology, in generating transgenic animals or knock-out animals which

CC may be used in the development and screening of therapeutically useful

CC reagents, in gene therapy, in chromosome identification, as chromosome

CC markers, and in generating probes. The PRO polypeptides, or anti-PRO

CC antibodies, are useful for preparing a medicament for treating a

CC condition which is responsive to the PRO polypeptides or anti-PRO

CC antibodies, such as pericyte-associated tumours and bone and/or cartilage

CC disorders (e.g. arthritis, sports injuries), involving inducing the re-

CC differentiation of chondrocytes. The PRO polypeptides are useful as

CC molecular markers for protein electrophoresis, and in tissue typing. This

CC sequence represents a human PRO polynucleotide of the invention.

XX SQ Sequence 1333 BP; 394 A; 240 C; 247 G; 452 T; 0 U; 0 Other;

Query Match 100.0%; Score 1333; DB 10; Length 1333;

Best Local Similarity 100.0%; Pred. No. 9.6e-306;

Matches 1333; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GCCACGCGTCCGATGGCGTTACGTTGCGGGCTTCTGTACATGCTGGCGCTGCTGCT 60

Db 1 GCCACGCGTCCGATGGCGTTACGTTGCGGGCTTCTGTACATGCTGGCGCTGCTGCT 60

Qy 61 CACTGCGCGCTCATCTTCTGCGCATTTGGCAGATTTAGCATTTAGAGCTGAAGAC 120

Db 61 CACTGCGCGCTCATCTTCTGCGCATTTGGCAGATTTAGCATTTAGAGCTGAAGAC 120

Qy 121 TGATTACAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTTGCTACTCCAGAGTA 180

Db 121 TGATTACAGAAATCCTATAGACAGTGTAAATACCTGTAATCCCTTGCTACTCCAGAGTA 180

Qy 181 CCTCATCCAGCGTTTCTTCTGTGTCAUGTTTCTTTGTGCGAGAGTGGCTTACACTGG 240

Db 181 CCTCATCCAGCGTTTCTTCTGTGTCAUGTTTCTTTGTGCGAGAGTGGCTTACACTGG 240

Qy 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300

Db 241 TCTCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGCAGATGATGAG 300

Qy 301 TGGCCCGAGGACTCTATGACCCCTTACAAACCATCATGAATGCAGATATTTAGCATATTGTCA 360

Db 301 TGGCCCGAGGACTCTATGACCCCTTACAAACCATCATGAATGCAGATATTTAGCATATTGTCA 360

Qy 361 GAAGGAAGATGCTGCAAAATAGCTTTTAACTTCTTCTAGCATTTTCTTACTACTATGG 420

Db 361 GAAGGAAGATGCTGCAAAATAGCTTTTAACTTCTTCTAGCATTTTCTTACTACTATGG 420

Qy 421 CATGATCTATGTTTGTGGTGGCTCTTAGAACAACACAGAGAGATTTGGTCCAGTTAAGT 480

Db 421 CATGATCTATGTTTGTGGTGGCTCTTAGAACAACACAGAGAGATTTGGTCCAGTTAAGT 480

Qy 481 GCATGCAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540

Db 481 GCATGCAAAAGCCACCAAAATGAAGGGATTTCTATCCAGCAAGATCCTGTCCAAAGAGTAGC 540

Qy 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGTACCTCTTATTTTAAATGTTTCCACAT 600

Db 541 CTGTGGAATCTGATCAGTACTTTTAAATAAGTACCTCTTATTTTAAATGTTTCCACAT 600

Qy 601 TTTTGTCTGTGGAAGAGCTGTTTCTATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

Db 601 TTTTGTCTGTGGAAGAGCTGTTTCTATATGTTTATCTCAGATAAAGATTTTAAATGGTAT 660

Db 301 TGGCCAGGACTCTATGACCCCTCAACCAATCATGATGACAGATATCTTAGCATATTGTCA 360
Qy 361 GAGGAAGAGTGGGCGAAATAGCTTTTATCTTCTAGCAATTTTTTACTACTATATGG 420
Db 361 GAGGAAGAGTGGGCGAAATAGCTTTTATCTTCTAGCAATTTTTTACTACTATATGG 420
Qy 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAACACAGAGAAATTTGGTCCAGTAAGT 480
Db 421 CATGATCTATGTTTGTGTAGCTCTTAGAACAACACAGAGAAATTTGGTCCAGTAAGT 480
Qy 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCTCAAGTAGC 540
Db 481 GCATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCTCTGCTCAAGTAGC 540
Qy 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTTTAAATGTTTCCCAT 600
Db 541 CTGTGGAATCTGATCAGTACTTTTAAATAATGACTCCTTATTTTTTAAATGTTTCCCAT 600
Qy 601 TTTTGTCTGTGGAAGACTGTTTTTCAATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Db 601 TTTTGTCTGTGGAAGACTGTTTTTCAATATGTTTACTCAGATAAGATTTTAAATGGTAT 660
Qy 661 TACGTATAAATTAATATAAATGATTACCTCTGCTGTTGACAGGTTTGAACCTTGCACATC 720
Db 661 TACGTATAAATTAATATAAATGATTACCTCTGCTGTTGACAGGTTTGAACCTTGCACATC 720
Qy 721 TTAAGGAACCCCAATATCCTCTGAATGATGATTAATCTAGCTGCTCTAGTACATTTG 780
Db 721 TTAAGGAACCCCAATATCCTCTGAATGATGATTAATCTAGCTGCTCTAGTACATTTG 780
Qy 781 GAAGCTTTGTTTATAGAACTGTTGAGGCTTCATTTTGGTTTCAATTTGAACAGATCTTAA 840
Db 781 GAAGCTTTGTTTATAGAACTGTTGAGGCTTCATTTTGGTTTCAATTTGAACAGATCTTAA 840
Qy 841 TTAATAATTAAGCTAGATATCAGTGTCTTCTGATGAAGTGAAGTGAATATATCTGACTAG 900
Db 841 TTAATAATTAAGCTAGATATCAGTGTCTTCTGATGAAGTGAAGTGAATATATCTGACTAG 900
Qy 901 TGGGAACCTTCATGGTTTCCCTCATCTGCTGATGATGATTAATATGATGATATGATTTAC 960
Db 901 TGGGAACCTTCATGGTTTCCCTCATCTGCTGATGATGATTAATATGATGATATGATTTAC 960
Qy 961 AAAAAATAAAGCGGAATTTTCCCTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020
Db 961 AAAAAATAAAGCGGAATTTTCCCTCGCTTGAATATATCCCTGTATATTTGATGATGAAT 1020
Qy 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTTAAGCAT 1080
Db 1021 GAGGATTTCCCATATTTCCATCAGAGTAATAATATATCTGCTTTAAATCTTTAAGCAT 1080
Qy 1081 AGTAAACATGATATAAATAATATGCTCAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
Db 1081 AGTAAACATGATATAAATAATATGCTCAATTTACTTTGTGAAGATGCAATTTAAAGCTATT 1140
Qy 1141 TTAATGATGTTTTTATTTGTAAGCATTTACTTTAAGAAATGTTGTTATTTGCTTACTG 1200
Db 1141 TTAATGATGTTTTTATTTGTAAGCATTTACTTTAAGAAATGTTGTTATTTGCTTACTG 1200
Qy 1201 TTTAAATCTGGTGTAAAGTATTTCTTAAGAAATTTGAGAGTACTACAGATTTTCAAACT 1260
Db 1201 TTTAAATCTGGTGTAAAGTATTTCTTAAGAAATTTGAGAGTACTACAGATTTTCAAACT 1260
Qy 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGTTCTTTTGTGCAATACAAATTAACCTCT 1320
Db 1261 GAATGAGAGAAATTTGATTAACATCTCTGCTGTTCTTTTGTGCAATACAAATTAACCTCT 1320
Qy 1321 GAAATTAAGACTC 1333
Db 1321 GAAATTAAGACTC 1333

RESULT 107
AAX90853

AAAX90853 standard; DNA; 1378 BP.
AAX90853;
17-JAN-2000 (first entry)
cDNA clone pk65_4.
clone pk65_4; pk65_4 protein; human foetal kidney cDNA library;
secreted protein; gene therapy; cytokine; nutritional activity;
tissue growth; cell proliferation; immune stimulation;
immune suppression; hematopoiesis regulation; tumour inhibition; ds.
Homo sapiens.
Key Location/Qualifiers
CDS 44..478
/*tag= a
/product= "pk65_4 protein"
WO9950405-A1.
07-OCT-1999.
30-MAR-1999; 99WO-US006946.
31-MAR-1998; 98US-0080110P.
29-MAR-1999; 99US-00280591.
(GEMY) GENETICS INST INC.
Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;
Merberg D, Treacy M, Agostino MJ, Steininger RJ;
WPI; 1999-610849/52.
P-PSDB; AAY28813.
Polynucleotides encoding secreted human proteins, derived from human
adult brain, human fetal brain, human fetal kidney, and human adult blood
cDNA libraries.
Claim 20; Page 104-105; 122pp; English.
The present nucleotide sequence comprises the full-length protein-coding
sequence of clone pk65_4. pk65_4 was isolated from a human foetal kidney
cDNA library using methods specific for secreted protein cDNAs. This can
be used in gene therapy. The polynucleotide and protein may effect
nutritional activity, cytokine and cell proliferation, immune stimulation
or suppression, hematopoiesis regulation, tissue growth, tumour
inhibition etc
Sequence 1378 BP; 411 A; 258 C; 252 G; 457 T; 0 U; 0 Other;
Query Match 99.1%; Score 1321.4; DB 2; Length 1378;
Best Local Similarity 99.5%; Pred. No. 5.5e-303;
Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
Qy 3 CCACGGCTCCGATCGCTTCCAGTTCGGCGCTTCTGTACATGCTGCGCTGCTGCTCA 62
Db 33 CCTCCCAAGCATGCGTTTACGTTTGGCGCTTCTGTACATGCTGCGCTGCTGCTCA 92
Qy 63 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTATAGCAATTTGATGAGCTGAAGCTG 122
Db 93 CTGCGCGCTCATCTTCTTCCGCCATTTGGCACATTATAGCAATTTGATGAGCTGAAGCTG 152
Qy 123 ATTACAGAATCTTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTACC 182
Db 153 ATTACAGAATCTTATAGACCAAGTGAATACCTGAAATCCCTTGTACTCCAGAGTACC 212
Qy 183 TCATCCACGCTTCTTCTGTCTCATGTTTCTTGTGAGAGAGTGGCTTACACTGGGTC 242
Db 213 TCATCCACGCTTCTTCTGTCTCATGTTTCTTGTGAGAGAGTGGCTTACACTGGGTC 272

QY 243 TCAATATGCCCCCTCTTGCGATATCATATTTGGAGGTATATGAGTATAGACCAAGTATGAGTG 302
Db 273 TCAATATGCCCCCTCTTGCGATATCATATTTGGAGGTATATGAGTATAGACCAAGTATGAGTG 332
QY 303 GCCCAGGACTCTATGACCCCTCAACCAATCATCAATGAGATATCTAGCATATCTCAGA 362
Db 333 GCCCAGGACTCTATGACCCCTCAACCAATCATCAATGAGATATCTAGCATATCTCAGA 392
QY 363 AGGAAGGATGTCGAAATTTAGCTTTTATCTCTTAGCAATTTTTTTTACTACCTATATGGCA 422
Db 393 AGGAAGGATGTCGAAATTTAGCTTTTATCTCTTAGCAATTTTTTTTACTACCTATATGGCA 452
QY 423 TGATCTATGTTTTTGGTGAAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db 453 TGATCTATGTTTTTGGTGAAGCTCTTAGAACCAACACAGAGAAATTTGGTCCAGTTAAGTGC 512
QY 483 ATGCAAAAGCCACCAAAATGAAGGATCTCTCCAGCAAGATCTCTCCAGCAAGTATGCT 542
Db 513 ATGCAAAAGCCACCAAAATGAAGGATCTCTCCAGCAAGATCTCTCCAGCAAGTATGCT 572
QY 543 GTGGAATCTGATCAGTTACTTTAAATAATGACTCTCTTATTTTAAATCTTTCCCAATTT 602
Db 573 GTGGAATCTGATCAGTTACTTTAAATAATGACTCTCTTATTTTAAATCTTTCCCAATTT 632
QY 603 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTACTCAGATTAAGATTTTAAATGGTATTA 662
Db 633 TTGCTTGTGGAAGACTGTTTTCATATGTTATCTACTCAGATTAAGATTTTAAATGGTATTA 692
QY 663 CGTATAAATTAATAAATGATTACTCTCTGGTGTGACAGGTTTCAAGTCTGACATCTCT 722
Db 693 CGTATAAATTAATAAATGATTACTCTCTGGTGTGACAGGTTTCAAGTCTGACATCTCT 752
QY 723 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATGATGCTGCTGATGATGATGGA 782
Db 753 AAGGAACAGCCATTAATCTCTGATGATGATTAATTAATGATGCTGCTGATGATGATGGA 812
QY 783 AGCTTTTGTGTTAGAACTGTGAGGCTCAATTTTGGTTTCATTTGAACAGTATCTAAAT 842
Db 813 AGCTTTTGTGTTAGAACTGTGAGGCTCAATTTTGGTTTCATTTGAACAGTATCTAAAT 872
QY 843 ATAAATTAGCTGATGATATCAGTGCTCTCTGATGAGTGAAGTGAATATCTGATGATG 902
Db 873 ATAAATTAGCTGATGATATCAGTGCTCTCTGATGAGTGAAGTGAATATCTGATGATG 932
QY 903 GGAACTTCATGAGGTTTCCATCTGATGATGATGATTAATATGATGATGATTAACAA 962
Db 933 GGAACTTCATGAGGTTTCCATCTGATGATGATGATTAATATGATGATGATTAACAA 992
QY 963 AAATAAAAGCGGAAATTTTCCCTTCGTTGAATATATATCCCTGATATATGCAATGATGA 1022
Db 993 AAATAAAAGCGGAAATTTTCCCTTCGTTGAATATATATCCCTGATATATGCAATGATGA 1052
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTCTTTAAATTTTAAGCATAAG 1082
Db 1053 GAGATTTCCCATATTTCCATCAGAGTAAATAATATATCTCTTTAAATTTTAAGCATAAG 1112
QY 1083 TAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGATG 1142
Db 1113 TAAACATGATATAAATAATATGCTGATGATGATGATGATGATGATGATGATGATGATG 1172
QY 1143 AAATGTTTTTATTTGTAAGACATTAATTAAGAAATTTGTTATATGCTTACTGTT 1202
Db 1173 AAATGTTTTTATTTGTAAGACATTAATTAAGAAATTTGTTATATGCTTACTGTT 1232
QY 1203 CTAATCTGTTGTTAAAGATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAACTGA 1262
Db 1233 CTAATCTGTTGTTAAAGATTTCTTAAGAAATTTGAGGTTACTACAGATTTTCAAACTGA 1292
QY 1263 ATGAGAAATTTGATATAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1322
Db 1293 ATGAGAAATTTGATATAACATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1352
QY 1323 AATTAAGACTC 1333

Db 1353 AATTAAGACTC 1363

RESULT 108

ABK36005

ID ABK36005 standard; cDNA; 1432 BP.

XX AC ABK36005;

XX DT 08-MAY-2002 (first entry)

XX DE cDNA sequence #336 encoding novel human secreted protein.

XX Human secreted protein; hyperproliferative disorder; autoimmune disorder;
XX immune deficiency disorder; blood disorder; inflammatory disorder;
XX infectious disorder; allergic condition; neurodegenerative disorder;
XX liver fibrosis; coagulation disorder; gene therapy; antimicrobial;
XX tumour; cancer; hepatotropic; immunosuppressive; antirheumatic; gene; ss.

XX OS Homo sapiens.

XX PN WO200177289-A2.

XX PD 18-OCT-2001.

XX PF 29-MAR-2001; 2001WO-US010232.

XX PR 06-APR-2000; 2000US-0195605P.

XX PA (GEMY) GENETICS INST INC.

XX PI Jacobs K, Mccoy JM, Lavallie ER, Collins-Racie LA, Evans C;

XX PI Merberg D, Treacy M, Agostino M, Bowman MR, Spaulding V, Mong GG;

XX PI Clark HF, Fechtel K, Howes SH, Resnick RJ, Gulukota K, Graham JR;

XX DR WPI; 2002-179322/23.

XX Six hundred and twenty three polynucleotides derived from a variety of
human tissue sources which encode secreted proteins, useful for treating
immune deficiencies and disorders such as autoimmune disorders.

Claim 1; Page 296; 393pp; English.

The present invention relates to the isolation of novel cDNA sequences
which encode human secreted proteins. The cDNA sequences have been
derived from a variety of human tissues. The invention also provides a
method for producing proteins from these polynucleotide sequences. The
proteins are useful for identifying compounds that modulate their
activity and production. The sequences of the invention are useful for
treating diseases such as hyperproliferative disorders (e.g. cancer),
immune deficiency disorders (e.g. severe combined immunodeficiency
(SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders
(e.g. thrombocytopenia), inflammatory disorders (e.g. arthritis),
infectious disorders (e.g. hepatitis), allergic conditions (e.g. asthma),
neurodegenerative disorders (e.g. Alzheimer's disease), liver fibrosis,
coagulation disorders (e.g. haemophilia) and tumours. The polynucleotide
sequences of the invention are also useful in gene therapy. ABK3610-
ABK36232 represent the cDNA sequences of the invention that encode for
novel human secreted proteins

Sequence 1432 BP; 404 A; 276 C; 281 G; 471 T; 0 U; 0 Other;

Query Match 99.1%; Score 1321.4; DB 6; Length 1432;

Best Local Similarity 99.5%; Pred. No. 5.5e-303;

Matches 1325; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 3 CCACGCGTCCGATGGCGTTACGTTCCGCGCTTCTGCTACATGCTGGCGTCTGCTCA 62

Db 102 CTTCCCGACGATGGCGTTACGTTCCGCGCTTCTGCTACATGCTGGCGTCTGCTCA 161

QY 63 CTGCCCGCTCATCTTCTTCCGCAATTTGGCAATTATAGCATTTGATGAGTGAAGACTG 122


```
CC deficiency syndrome (AIDS), Addison's disease and asthma), neoplastic
CC disorders (e.g. adenocarcinoma, leukemia, cancers of the breast, lung,
CC testis, ovaries and prostate and melanomas), complications of cancers,
CC bacterial, viral, parasitic, protozoal, helminthic and fungal infections
CC and other disorders such as spina bifida and cataracts
XX
SQ Sequence 1391 BP; 402 A; 266 C; 259 G; 464 T; 0 U; 0 Other;

Query Match 98.8%; Score 1316.8; DB 2; Length 1391;
Best Local Similarity 99.5%; Pred. NO. 6.7e-302;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 CCACGCGTCCGATGCGTTCACGTTCCGGGCTTCTGCTACATGCTGCGCGTGTGCTCA 62
Db |||||
QY 63 CCTCCCGACGATGCGGTTCAGTTCGGGCTTCTGCTACATGCTGCGGTGTGCTCA 122
Db |||||
QY 63 CTGCGCGCTCATCTTCTTCGCAATTTGGCACATTATAGCAATTTGATGAGCTGAAGACTG 122
Db |||||
QY 123 CTGCGCGCTCATCTTCTTCGCAATTTGGCACATTATAGCAATTTGATGAGCTGAAGACTG 182
Db |||||
QY 123 ATTACAGAAATCTTATAGACGAGTGAATACCTGTAATCCCTTGTACTTCCAGATACC 182
Db |||||
QY 183 ATTACAGAAATCTTATAGACGAGTGAATACCTGTAATCCCTTGTACTTCCAGATACC 242
Db |||||
QY 183 TCATCCACGCTTCTCTCTGTGTCATGTTCTTTGTGACGAGTGGCTTACCTGGGTC 242
Db |||||
QY 243 TCATCCACGCTTCTCTCTGTGTCATGTTCTTTGTGACGAGTGGCTTACCTGGGTC 302
Db |||||
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGACGATGAGTG 302
Db |||||
QY 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGATGAGACGATGAGTG 362
Db |||||
QY 303 GCCCAGGACTATGACACCTCAACCATCATGAATGACAGATATTTAGCATATTTGTCAGA 362
Db |||||
QY 363 GCCCAGGACTATGACACCTCAACCATCATGAATGACAGATATTTAGCATATTTGTCAGA 422
Db |||||
QY 363 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA 422
Db |||||
QY 423 AGGAAGGATGGTCAAAATAGCTTTTATCTTCTAGCATTTTTTACTACCTATATGGCA 482
Db |||||
QY 423 TGATCTATGTTTTGGTGAGCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 482
Db |||||
QY 483 TGATCTATGTTTTGGTGAGCTTTAGAACACACACAGAGAAATTTGGTCCAGTTAAGTGC 542
Db |||||
QY 483 ATGGAAAGACCAACCAATGAGGATCTATCCAGCAGATCCCTCCAGAGTAGCT 542
Db |||||
QY 543 ATGGAAAGACCAACCAATGAGGATCTATCCAGCAGATCCCTCCAGAGTAGCT 602
Db |||||
QY 543 GTGGAAATCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTCCACATTT 602
Db |||||
QY 603 GTGGAAATCTGATCAGTTACTTTTAAATAATGACTCTCTTATTTTAAATGTTTCCACATTT 662
Db |||||
QY 603 TTGCTTGTGGAAAGACTGTTTTCATATGTTATATCTACAGATAAGATTTAAATGGTATTA 662
Db |||||
QY 663 TTGCTTGTGGAAAGACTGTTTTCATATGTTATATCTACAGATAAGATTTAAATGGTATTA 722
Db |||||
QY 663 CGTATAAATTAATATAAATGATTAATCTCTGTGTGTGACAGTTTGAATGTCACCTTT 722
Db |||||
QY 723 CGTATAAATTAATATAAATGATTAATCTCTGTGTGTGACAGTTTGAATGTCACCTTT 782
Db |||||
QY 723 AAGGAACAGCCATAATCCCTCGAATGATGATTAATTAATGATGATTAATGATGATTA 782
Db |||||
QY 783 AAGGAACAGCCATAATCCCTCGAATGATGATTAATTAATGATGATTAATGATGATTA 842
Db |||||
QY 783 AGCTTTTGTGTTATAGGAATCTGTAGGCTCAATTTGGTTTCAATGAAACAGTATCTAAT 842
Db |||||
QY 843 AGCTTTTGTGTTATAGGAATCTGTAGGCTCAATTTGGTTTCAATGAAACAGTATCTAAT 902
Db |||||
QY 843 ATAAATTTAGCTGTAGATATCATGCTGCTCTGATGAGTGAAGTGAAGTATATCTGACTAG 902
Db |||||
QY 903 ATAAATTTAGCTGTAGATATCATGCTGCTCTGATGAGTGAAGTGAAGTATATCTGACTAG 962
Db |||||
QY 903 GGAAACTTTCATGGGTTTCCCTCATCTGTCATGTCGATGATTAATATATGATGATTAACAA 962
Db |||||

RESULT 110
AAD31079
ID AAD31079 standard; cDNA; 1391 BP.
XX AC AAD31079;
XX AC AAD31079;
DT 18-JUN-2002 (first entry)
XX Human cornichon protein (CORN) cDNA.
DE Human; cornichon protein; CORN; Cushing's syndrome; muscular dystrophy;
KW developmental disorder; neoplastic; seizure; reproductive; immunological;
KW tubular acidosis; anaemia; polycystic ovary; autoimmune disorder; tumour;
KW breast cancer; prostate; testis; epilepsy; neuropathy; Addison's disease;
KW ulcerative colitis; spermatogenesis; hypothyroidism; cataract; arthritis;
KW infertility; galactorrhea; gynaecomastia; diabetes mellitus; fungicide;
KW dermatitis; acquired immunodeficiency syndrome; AIDS; glomerulonephritis;
KW atherosclerosis; allergy; asthma; bronchitis; haemodialysis; anticonvulsant;
KW gout; Graves' disease; multiple sclerosis; Crohn's disease; auditory;
KW trauma; drug screening; ophthalmological; cytostatic; immunosuppressive;
KW synecological; antiulcer; nephrotropic; neuroprotective; antihelminthic;
KW antibacterial; tranquilizer; osteoporosis; antiparasitic; protozoacide;
KW vulnery; virucide; gene therapy; gene; ss.
XX Homo sapiens.
XX OS
XX FH
XX Key Location/Qualifiers
CDS 74..508
FT /*tag= a
FT /product= "Human CORN"
XX
XX US6348576-B1.
XX
XX PD 19-FEB-2002.
XX
XX PF 02-AUG-1999; 99US-00365705.
XX
XX PR 14-OCT-1997; 97US-00950168.
XX
XX PA (INCY-) INCYTE GENOMICS INC.
XX
```


KW Human; cornichon protein; CORN; bladder cDNA library; BLADNOT04;
 KW Incyte clone 131847; developmental disorder; reproductive disorder;
 KW immunological disorder; autoimmune disorder; neoplastic disorder;
 KW microarray; cytostatic; antiinflammatory; gynaecological;
 KW immunosuppressive; gene; ss.
 XX
 XX Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT CDS 74..508
 FT /*tag= a
 FT /product= "CORN"
 XX
 XX US2002103342-A1.
 XX
 XX 01-AUG-2002.
 XX
 XX 10-JAN-2002; 2002US-00044477.
 XX
 XX 14-OCT-1997; 97US-00950168.
 XX
 XX 02-AUG-1999; 99US-00365705.
 XX
 XX (INCY-) INCYTE PHARM INC.
 XX
 XX Hillman JL, Corley NC, Shah P;
 XX
 XX WPI: 2002-690628/74.
 XX
 XX P-PSDB; ABG31481.
 XX
 XX New human cornichon protein and polynucleotide for diagnosing, preventing
 XX or treating developmental, reproductive, immunological, and neoplastic
 XX disorders.
 XX
 XX Claim 5; Fig 1; 32pp; English.
 XX
 XX The present invention relates to the isolation of human cornichon protein
 XX (CORN), and the polynucleotide sequence encoding it. The sequences are
 XX isolated from bladder cDNA library (BLADNOT04) Incyte clone 131847. The
 XX polynucleotide and polypeptide sequences for CORN are useful in the
 XX diagnosis, prevention, and treatment of developmental disorders (e.g.
 XX anaemia, renal tubular acidosis, Cushing's syndrome, dwarfism, epilepsy,
 XX hypothyroidism, glaucoma, sensorineural hearing loss and cataract),
 XX reproductive disorders (e.g. disorders of prolactin production,
 XX infertility, endometriosis, polycystic ovary syndrome, endometrial and
 XX ovarian tumours, ectopic pregnancy, prostate cancer, prostatitis, and
 XX carcinoma of the male breast and gynaecomastia), immunological disorders
 XX (e.g. autoimmune disorders, acquired immunodeficiency syndrome (AIDS),
 XX adult respiratory distress syndrome, Addison's disease, allergies,
 XX anaemia, asthma, atherosclerosis, gout, myocardial or pericardial
 XX inflammation, osteoporosis, rheumatoid arthritis, scleroderma, systemic
 XX lupus erythematosus, ulcerative colitis, haemodialysis, Crohn's disease,
 XX atopic dermatitis, autoimmune thyroiditis, diabetes mellitus, Graves'
 XX disease, glomerulonephritis, viral, bacterial, fungal, parasitic,
 XX protozoal, helminthic infections and trauma), and neoplastic disorders
 XX (e.g. adenocarcinoma, leukaemia, lymphoma, melanoma, and various
 XX cancers). CORN, fragments of CORN, and antibodies specific for CORN are
 XX useful as elements on a microarray which is useful to monitor or measure
 XX protein-protein interactions, drug-target interactions and gene
 XX expression profiles. The present sequence encodes human CORN
 XX
 XX Sequence 1391 BP; 402 A; 266 C; 259 G; 464 T; 0 U; 0 Other;
 XX
 XX Query Match 98.8%; Score 1316.8; DB 6; Length 1391;
 XX Best Local Similarity 99.5%; Pred. No. 6.7e-302;
 XX Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
 XX
 XX 3 CCACGGCTCGATGGCGTTACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTCTCA 62
 XX |||||
 XX 63 CCTCCCGACGATGGCGTTCCACGTTCCGGCCCTTCTGCTACATGCTGGCGCTGCTCTCA 122
 XX |||||
 XX 63 CTGCGCGGCTCATCTCTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAGACTG 122
 XX |||||
 XX 123 CTGCGCGGCTCATCTCTTCGCGCATTTGGCATTATAGCATTTGATGAGCTGAGACTG 182
 XX |||||

QY 123 ATTACAAGATCCCTATAGACACAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGTACC 182
 |||||
 DB 183 ATTACAAGATCCCTATAGACACAGTGTAAATACCCCTGAATCCCTTGTACTCCACAGTACC 242
 |||||
 QY 183 TCATCCACGCTTTCTTCTGTGTCAATGTTCTTTCTGTGAGCAGAGTGGCTTACACTGGGTC 242
 |||||
 DB 243 TCATCCACGCTTTCTTCTGTGTCAATGTTCTTTCTGTGAGCAGAGTGGCTTACACTGGGTC 302
 |||||
 QY 243 TCAATATGCCCTCTTTGGSCATATCATATTTGGAGGTATATGAGTACAGTATGAGTGC 302
 |||||
 DB 303 TCAATATGCCCTCTTTGGSCATATCATATTTGGAGGTATATGAGTACAGTATGAGTGC 362
 |||||
 QY 303 GCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTCTACATATTTGTGAGA 362
 |||||
 DB 363 GCCCAGGACTCTATGACCCCTACACCATCATGAATGCAGATATTTCTACATATTTGTGAGA 422
 |||||
 QY 363 AGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTCTACCTATATGSCA 422
 |||||
 DB 423 AGGAAGGATGGTGCAAAATAGCTTTTATCTTCTAGCAATTTTTTCTACCTATATGSCA 482
 |||||
 QY 423 TGATCTATGTTTGGTGAGCTCTTAGAACAACAACAACAAGAAATTTGGTCCAGTTAAGTGC 482
 |||||
 DB 483 TGATCTATGTTTGGTGAGCTCTTAGAACAACAACAACAAGAAATTTGGTCCAGTTAAGTGC 542
 |||||
 QY 483 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAGAGTAGCCT 542
 |||||
 DB 543 ATGCAAAAAGCCACCAAAATGAAGGATTTCTATCCAGCAAGATCCCTGTCCAAGAGTAGCCT 602
 |||||
 QY 543 GTGGAACTGTGATCAGTTACTTTTAAAAAAGTACTCCTTATTTTTTAAATTTTCCACATTT 602
 |||||
 DB 603 GTGGAACTGTGATCAGTTACTTTTAAAAAAGTACTCCTTATTTTTTAAATTTTCCACATTT 662
 |||||
 QY 603 TTGCTTTGGAAAGACTGTTTTTCATATGTTTATCTACATTAAGATTTTAAATGATTTA 662
 |||||
 DB 663 TTGCTTTGGAAAGACTGTTTTTCATATGTTTATCTACATTAAGATTTTAAATGATTTA 722
 |||||
 QY 663 CGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATCTTT 722
 |||||
 DB 723 CGTATAAATTAATATAAATGATTAACCTCTGGTGTGACAGGTTTGAACCTTGCATCTTT 782
 |||||
 QY 723 AAGAACAGCCATAATCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAATTAATTA 782
 |||||
 DB 783 AAGAACAGCCATAATCTCTGAATGATGCAATTAATTAATTAATTAATTAATTAATTAATTA 842
 |||||
 QY 783 AGCTTTTCTTTATAGGAACCTTGTGGGCTCATTTTGGTTCATTTGAAACAGTATCTAAT 842
 |||||
 DB 843 AGCTTTTCTTTATAGGAACCTTGTGGGCTCATTTTGGTTCATTTGAAACAGTATCTAAT 902
 |||||
 QY 843 ATAAATTAAGCTGTAGATATCAGGTCCTTCTGATGAAGTGAAATGTATATCTGACTAGTG 902
 |||||
 DB 903 ATAAATTAAGCTGTAGATATCAGGTCCTTCTGATGAAGTGAAATGTATATCTGACTAGTG 962
 |||||
 QY 903 GGAATCTATGGGTTTCTCTATCTGATGTCATGTCGATGATTAATATATGATGATACATTACA 962
 |||||
 DB 963 GGAATCTATGGGTTTCTCTATCTGATGTCATGTCGATGATTAATATATGATGATACATTACA 1022
 |||||
 QY 963 AAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATTCGATCAATGA 1022
 |||||
 DB 1023 AAATAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGATATATTCGATCAATGA 1082
 |||||
 QY 1023 GAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGGCTTTAAATTTCTTAAGCATAAG 1082
 |||||
 DB 1083 GAGATTTCCCATATTTCCATCAGAGTAATAATAATATCTTGGCTTTAAATTTCTTAAGCATAAG 1142
 |||||
 QY 1083 TAAACATGATATAAAATAATATGCTGGAATTTCTTGTGAAGATGCAATTAAGCTATTTT 1142
 |||||
 DB 1143 TAAACATGATATAAAATAATATGCTGGAATTTCTTGTGAAGATGCAATTAAGCTATTTT 1202
 |||||
 QY 1143 AAATGTGTTTTTATTTTGAAGACTTACTTATTAAGAAATTTGGTTATTTATGCTTACTGTT 1202
 |||||
 DB 1203 AAATGTGTTTTTATTTTGAAGACTTACTTATTAAGAAATTTGGTTATTTATGCTTACTGTT 1262
 |||||


```

Db      1012  AAATAAAGCGGGAATTTCCCTTCGCTGAATATTATCCCTGTATATTCATGAATGA 1071
QY      1023  GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTACTTGTCTTTAAATCTTTAAGCATTAAG 1082
Db      1072  GAGATTTCCCATATTTCCCATCAGAGTAATAATATATCTACTTGTCTTTAAATCTTTAAGCATTAAG 1131
QY      1083  TAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTAAGCTATTTT 1142
Db      1132  TAAACATGATATAAAAAATATATGCTGAATTTACTTGTGAAGATGCAATTTAAGCTATTTT 1191
QY      1143  AAATCTGTTTATTTATTTGAAGACATTTACTTATTAAGAAATTCGTTATTTATGTTACTGTT 1202
Db      1192  AAATCTGTTTATTTATTTGAAGACATTTACTTATTAAGAAATTCGTTATTTATGTTACTGTT 1251
QY      1203  CTAATCTGTTGTAAGGTTATTTCTTAAGAAATTCGAGTACTACAGATTTTCAAAACTGA 1262
Db      1252  CTAATCTGTTGTAAGGTTATTTCTTAAGAAATTCGAGTACTACAGATTTTCAAAACTGA 1311
QY      1263  ATGAGAGAAATTTGATTAACGATCTCTGCTGTTCCCTTTAGTGAATACAAATAAACTCTGA 1322
Db      1312  ATGAGAGAAATTTGATTAACGATCTCTGCTGTTCCCTTTAGTGAATACAAATAAACTCTGA 1371
QY      1323  AATTAA 1328
Db      1372  AATTAA 1377

```

RESULT 113

AAZ36228

ID AAZ36228 standard; cDNA; 1320 BP.

XX AAZ36228;

XX

DT 22-FEB-2000 (first entry)

XX

cDNA encoding a bone marrow secreted protein designated hCornichin.

XX Bone marrow secreted protein; bone marrow stromal cell; cytokine;
 KW cell proliferation; cell differentiation; hematopoiesis; anaemia;
 KW myeloid cell deficiency; lymphoid cell deficiency; myeloid cell;
 KW erythroid progenitor cell; colony stimulating factor; granulocyte;
 KW monocyte; macrophage; myelo-suppression; megakaryocyte; platelet;
 KW platelet disorder; thrombocytopenia; hematopoietic stem cell;
 KW stem cell disorder; aplastic anaemia; bone differentiation;
 KW paroxysmal nocturnal hemoglobinuria; bone growth; cartilage; tendon;
 KW ligament; nerve; wound healing; tissue repair; burn; incision; ulcer;
 KW bone fracture; cartilage damage; artificial joint; ss.

XX Homo sapiens.

OS
 XX
 XX
 FH Key Location/Qualifiers
 CDS 2..430

FT /*tag= a
 FT /product= "bone marrow secreted protein"
 FT /note= "no ATG start codon given"

FT sig_peptide 2..85

FT polyA_signal 1292..1297

FT /*tag= c

XX WO9933979-A2.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PI Lin H, Cao L;
 XX WPI; 2000-038344/03.
 DR P-PSDB; AAY53622.
 XX
 PT New isolated human polynucleotide and secreted proteins can induce
 PT production of other cytokines in certain cell populations.
 PS
 PS Claim 11; Page 70; 120pp; English.
 XX
 CC AAZ36228-49 encode bone marrow secreted proteins of human bone marrow
 CC stromal cells. The proteins can exhibit cytokine, cell proliferation, or
 CC cell differentiation activity (either inducing or inhibiting). They can
 CC be used to support colony forming cells or factor-dependent cell lines,
 CC to regulate hematopoiesis, and to treat myeloid or lymphoid cell
 CC deficiencies. In addition, they may be used to support the growth and
 CC proliferation of erythroid progenitor cells, and to treat various
 CC anaemias. They can have colony stimulating factor (CSF) activity and can
 CC be used to support the growth and proliferation of myeloid cells such as
 CC granulocytes, monocytes or macrophages, to prevent or treat myelo-
 CC suppression, to support the growth and proliferation of megakaryocytes
 CC and platelets, thereby allowing prevention or treatment of platelet
 CC disorders such as thrombocytopenia, to support the growth and
 CC proliferation of hematopoietic stem cells, either in place of or in
 CC conjunction with platelet transfusions, to treat stem cell disorders,
 CC such as aplastic anaemia and paroxysmal nocturnal hemoglobinuria, or to
 CC repopulate the stem cell compartment after irradiation or chemotherapy.
 CC They can be used for growth or differentiation of bone, cartilage,
 CC tendon, ligament, or nerve tissue, as well as for wound healing and
 CC tissue repair and replacement, and in the treatment of burns, incisions
 CC and ulcers, to induce cartilage and/or bone growth in circumstances where
 CC bone is not normally formed and thus have an application in healing bone
 CC fractures and cartilage damage or defects, prophylactic use in fracture
 CC reduction and also in the improved fixation of artificial joints
 XX
 XX Sequence 1320 BP; 396 A; 232 C; 242 G; 450 T; 0 U; 0 Other;

Query Match 98.5%; Score 1313.4; DB 3; Length 1320;
 Best Local Similarity 99.9%; Pred. No. 4.2e-301;
 Matches 1314; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 19 GTTCACGTTGCGGCGCTTCTGCTACATGCTGGCGTGTGCTACTCGCGGCTCATCTT 78
 Db 1 GTTCACGTTGCGGCGCTTCTGCTACATGCTGGCGTGTGCTACTCGCGGCTCATCTT 60

QY 79 CTTCCCATTTGGCACATATAGCATTTGATGAGCTGAAGCTGATTACAGAATCCCTAT 138
 Db 61 CTTCCCATTTGGCACATTTGATGAGCTGAAGCTGATTACAGAATCCCTAT 120

QY 139 AGACCAAGTGTAAATACCTGGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTTCIT 198
 Db 121 AGACCAAGTGTAAATACCTGGAATCCCTTGTACTCCAGAGTACCTCATCCAGCTTTCIT 180

QY 199 CTGTGTCATGTTTCTTTGTGAGAGAGTGGCTTACATCGGCTCTCAATATGCCCTCTT 258
 Db 181 CTGTGTCATGTTTCTTTGTGAGAGAGTGGCTTACATCGGCTCTCAATATGCCCTCTT 240

QY 259 GGCATATCATATTTGAGGATATATCAGTAGACACAGTATGAGTGGCCAGAGACTATGA 318
 Db 241 GGCATATCATATTTGAGGATATATGAGTAGACACAGTATGAGTGGCCAGAGACTATGA 300

QY 319 CCCTACAAACCATCATGAATGCAGATATTTCTAGCATATTTGTCAGAAGGAGGATGGTGCAA 378
 Db 301 CCCTACAAACCATCATGAATGCAGATATTTCTAGCATATTTGTCAGAAGGAGGATGGTGCAA 360

QY 379 ATTAGCTTTTATCTTTCTAGCATTTTCTTATCTACCTATATGGCATGATCTATGTTTGGT 438
 Db 361 ATTAGCTTTTATCTTTCTAGCATTTTCTTATCTACCTATATGGCATGATCTATGTTTGGT 420

QY 439 GAGCTCTTAGAACAACACACAGAAATTTGGTCCAGTTAAAGTGCATGCAAAAAGCACCACA 498
 Db 421 GAGCTCTTAGAACAACACACAGAAATTTGGTCCAGTTAAAGTGCATGCAAAAAGCACCACA 480


```

Db      487  GCCACCAATGAAGGATCTTATCCAGCAAGATCTGTCCAAAGTAGCTGTGAACT 546
QY      552  GATCAGTTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACATTTTGTGTG 611
Db      547  GATCAGTTACTTTAAATAAGTACTCTTATTTTAAATGTTTCCACATTTTGTGTG 606
QY      612  GAAAGACTGTTTTCATATCTTATCTACATGATAAGATTTTAAATGGTATTACGTATAAT 671
Db      607  GAAAGACTGTTTTCATATCTTATCTACATGATAAGATTTTAAATGGTATTACGTATAAT 666
QY      672  TAAATATAAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGCACCTTTTAAAGAACAG 731
Db      667  TAAATATAAATGATTAACCTCTGGTGTGACAGTTTGAACCTTGCACCTTTTAAAGAACAG 726
QY      732  CCAATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGCTAGTACATGGAAGCTTTTGT 791
Db      727  CCAATATCTCTGAATGATGCAATTAATTAATCTGACTGTCTGCTAGTACATGGAAGCTTTTGT 786
QY      792  TTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCATTGAAACAGTATCTAATTATAAATTAG 851
Db      787  CTATAGGAACCTTGTAGGGCTCAATTTTGGTTTCATTGAAACAGTATCTAATTATAAATTAG 846
QY      852  CTTGATATACAGTCTCTCTGATGAGTGAAGTGAATAATGTAATCTGACTAGTGGAACTTTC 911
Db      847  CTTGATATACAGTCTCTCTGATGAGTGAAGTGAATAATGTAATCTGACTAGTGGAACTTTC 906
QY      912  ATGGGTTTCTCATCTGTCATGTCGATGATGATTAATATATGATGATACATTTTACAAAAATAAAA 971
Db      907  ATGGGTTTCTCATCTGTCATGTCGATGATGATTAATATATGATGATACATTTTACAAAAATAAAA 966
QY      972  GCGGGAATTTCCCTTCGCTTGAATATATATATATATATATATATATATATATATATATATATAT 1031
Db      967  GCGGGAATTTCCCTTCGCTTGAATATATATATATATATATATATATATATATATATATATATAT 1026
QY      1032  CATATTTCCATCAGAGTAAATATATATATATATATATATATATATATATATATATATATATAT 1091
Db      1027  CATATTTCCATCAGAGTAAATATATATATATATATATATATATATATATATATATATATATAT 1086
QY      1092  TATAAAATATATATATATATATATATATATATATATATATATATATATATATATATATATATAT 1151
Db      1087  TATAAAATATATATATATATATATATATATATATATATATATATATATATATATATATATATAT 1146
QY      1152  TTTATTTGTAAGACATTAATTAATTAAGAAATGGTTTATATATATATATATATATATATATATAT 1211
Db      1147  TTTATTTGTAAGACATTAATTAATTAAGAAATGGTTTATATATATATATATATATATATATATAT 1206
QY      1212  TCGTAAAGGTATTTCTTAAGAAATTCAGGTACTACAGATTTTCAAACTGAATGAGAGAA 1271
Db      1207  TCGTAAAGGTATTTCTTAAGAAATTCAGGTACTACAGATTTTCAAACTGAATGAGAGAA 1266
QY      1272  AATTGTATAACCATCTCTGCTGTTTCTTTAGTGAATACATAATAAACTCTGAAAT 1326
Db      1267  AATTGTATAACCATCTCTGCTGTTTCTTTAGTGAATACATAATAAACTCTGAAAT 1321

```

RESULT 115

ABK35858

ID ABK35858 standard; cDNA; 2916 BP.

XX

AC ABK35858;

XX

DT 08-MAY-2002 (first entry)

XX

DE cDNA sequence #249 encoding novel human secreted protein.

XX

KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;
 KW immune deficiency disorder; blood disorder; inflammatory disorder;
 KW infectious disorder; allergic condition; neurodegenerative disorder;
 KW liver fibrosis; coagulation disorder; gene therapy; antimicrobial;
 KW tumour; cancer; hepatotropic; immunosuppressive; antirheumatic; gene; ss.

XX

OS Homo sapiens.

XX WO200177289-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 29-MAR-2001; 2001WO-US010232.
 XX
 XX 06-APR-2000; 2000US-0195605P.
 XX
 XX (GENY) GENETICS INST INC.
 XX
 XX Jacobs K, Mc Coy JM, Lavallie ER, Collins-Racie LA, Evans C;
 PI Merberg D, Treacy M, Agostino MJ, Bowman MR, Spaulding V, Wong GG;
 PI Clark HF, Fechtel K, Howes SH, Resnick RJ, Gulukota K, Graham JR;
 XX
 XX WPI; 2002-179322/23.
 DR
 XX
 XX Six hundred and twenty three polynucleotides derived from a variety of
 PT human tissue sources which encode secreted proteins, useful for treating
 PT immune deficiencies and disorders such as autoimmune disorders.
 XX
 XX Claim 1; Page 223; 393pp; English.
 XX
 XX The present invention relates to the isolation of novel cDNA sequences
 CC which encode human secreted proteins. The cDNA sequences have been
 CC derived from a variety of human tissues. The invention also provides a
 CC method for producing proteins from these polynucleotide sequences. The
 CC proteins are useful for identifying compounds that modulate their
 CC activity and production. The sequences of the invention are useful for
 CC treating diseases such as hyperproliferative disorders (e.g. cancer),
 CC immune deficiency disorders (e.g. severe combined immunodeficiency
 CC (SCID)), autoimmune disorders (e.g. multiple sclerosis), blood disorders
 CC (e.g. thrombocytopenia), inflammatory disorders (e.g. arthritis),
 CC infectious disorders (e.g. hepatitis), allergic conditions (e.g. asthma),
 CC neurodegenerative disorders (e.g. Alzheimer's disease), liver fibrosis,
 CC coagulation disorders (e.g. haemophilia), and tumours. The polynucleotide
 CC sequences of the invention are also useful in gene therapy. ABK35610-
 CC ABK36232 represent the cDNA sequences of the invention that encode for
 CC novel human secreted proteins
 XX
 SQ Sequence 2916 BP; 894 A; 517 C; 579 G; 926 T; 0 U; 0 Other;

Query Match 97.6%; Score 1301.4; DB 6; Length 2916;

Best Local Similarity 99.8%; Pred. NO. 3.8e-298;

Matches 1313; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

QY 16 GCGGTTCACTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCTCACTCGCGGCTCAT 75

Db 1 GCGGTTCACTTCGCGGCTTCTGCTACATGCTGGGCTGCTGCTCACTCGCGGCTCAT 60

QY 76 CTTCTTCGCCATTTGGCCATTTATAGCATTTTATGAGCTGAAGCTGATTACAAGATCC 135

Db 61 CTTCTTCGCCATTTGGCCATTTATAGCATTTTATGAGCTGAAGCTGATTACAAGATCC 120

QY 136 TATAGCAGGTGTAATACCTGATCCCTTGTACTCCAGATGATCTATCCAGGCTTT 195

Db 121 TATAGCAGGTGTAATACCTGATCCCTTGTACTCCAGATGATCTATCCAGGCTTT 180

QY 196 CTTCTGCTCATGTTTCTTTGTGAGCAGAGTGGCTTACACTGGTCTCAATATGCCCT 255

Db 181 CTTCTGCTCATGTTTCTTTGTGAGCAGAGTGGCTTACACTGGTCTCAATATGCCCT 240

QY 256 CTTGCGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAGTGGCCCGGAGCTCTA 315

Db 241 CTTGCGCATATCATATTTGGAGGTATATGAGTAGACAGTATGAGTGGCCCGGAGCTCTA 300

QY 316 TGACCTTACACCATCATGATGCGATTTCTAGCATATTTCTAGAGGAGGATGGTG 375

Db 301 TGACCTTACACCATCATGATGCGATTTCTAGCATATTTCTAGAGGAGGATGGTG 360

QY 376 CAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCGATGATCTATGTTT 435

Db 361 CAAATTAGCTTTTATCTTCTAGCATTTTCTTACTACCTATATGCGATGATCTATGTTT 420

106	Db		CTGCGGCGCTCATCTTCTTGCCCAATTTGGCCACATTATAGCATTTGATGAGCTGAAGACTG	165
123	Qy		ATTACAAGAAATCCCTATAGACAGAGTGTAATACCCCTGAATCCCTCTGTACTCCACAGAGTACC	182
166	Db		ATTACAAGAAATCCCTATAGACAGAGTGTAATACCCCTGAATCCCTCTGTACTCCACAGAGTACC	225
183	Qy		TCATCCAGCGTTTCTTCTGTGTGTCAATGTTCTTTGTGACGACAGAGTGGCTTACACTGGGTC	242
226	Db		TCATCCAGCGTTTCTTCTGTGTGTCAATGTTCTTTGTGACGACAGAGTGGCTTACACTGGGTC	285
243	Qy		TCAAATATGCCCTCTTGGCATATCATATTTGAGAGTATATCAGTAGACACAGTAGATGATG	302
286	Db		TCAAATATGCCCTCTTGGCATATCAATTTGAGAGTATATCAGTAGACACAGTAGATGATG	345
303	Qy		GCCCAGGACTCTATGACCCCTACACCAATCATGAATGCAGATATTCTTAGCATATTGTCCAGA	362
346	Db		GCCCAGGACTCTATGACCCCTACACCAATCATGAATGCAGATATTCTTAGCATATTGTCCAGA	405
363	Qy		AGGAAGGATGCTGCAAATTTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGGCA	422
406	Db		AGGAAGGATGCTGCAAATTTAGCTTTTATCTTCTAGCATTTTCTTACCTATATGGCA	465
423	Qy		TGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAAGTGC	482
466	Db		TGATCTATGTTTGGTGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAAGTGC	525
483	Qy		ATGCAAAAGCCACCAATGAAGGATTCATCCAGCAAGATCTGTGCCAAGAGTAGCCT	542
526	Db		ATGCAAAAGCCACCAATGAAGGATTCATCCAGCAAGATCTGTGCCAAGAGTAGCCT	585
543	Qy		GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACATTT	602
586	Db		GTGGAATCTGATCAGTTACTTTAAAAAATGACTCCTTATTTTAAAAATGTTTCCACATTT	645
603	Qy		TTGCTTGTGGAAGACATGTTTT-CATATGTTTATCTCAGATAAAGATTTTAAATGGTATT	661
646	Db		TTGCTTGTGGAAGACATGTTTTCCATATGTTTATCTCAGATAAAGATTTTAAATGGTATT	705
662	Qy		ACGTATAAAATTAATATAAAATGATTAAGTCTCTGGGTGTTGACAGGTTTCAAGCTTCCT	721
706	Db		ACGTATAAAATTAATATAAAATGATTAAGTCTCTGGGTGTTGACAGGTTTCAAGCTTCCT	765
722	Qy		TAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATTTGG	781
766	Db		TAAGGAACAGCCATAATCCTCTGAATGATGATTAATTAATGACTGCTCTAGTACATTTGG	825
782	Qy		AAGCTTTTGTATTATAGAACTTGTPAGGCTCATTTTGGTTTCAATGGAACAGATATCTAAT	841
826	Db		AAGCTTTTGTATTATAGAACTTGTPAGGCTCATTTTGGTTTCAATGGAACAGATATCTAAT	885
842	Qy		TATAAATTAAGCTGATATATCAGTGTCTCTGATGAAGTGAATAATGATATCTGACTAGT	901
886	Db		TATAAATTAAGCTGATATATCAGTGTCTCTGATGAAGTGAATAATGATATCTGACTAGT	945
902	Qy		GGGAAACCTTCATGGTTTTCTCATCTCTGATGATTAATATATGGAATACATTTTACA	961
946	Db		GGGAAACCTTCATGGTTTTCTCATCTCTGATGATTAATATATGGAATACATTTTACA	1005
962	Qy		AAAAAT-----AAAAAGCGGAATTTTCCCTTCGCTTGAATATATTCCTCTGATATTCGAT	1016
1006	Db		AAAAATAAAAAAGCGGAATTTTCCCTTCGCTTGAATATATTCCTCTGATATTCGAT	1065
1017	Qy		GAATGAGAGATTTCCCATATTTCCATCAGAGTATAAATATACTTGCTTTAATTT-CTTAA	1075
1066	Db		GAATGAGAGATTTCCCATATTTCCATCAGAGTATAAATATACTTGCTTTAATTTAAG	1125
1076	Qy		GCATAAGTAAACATGATATAAAAAATATATGCTGAAATTTACTTGTGAAGAAATGCAATTAAG	1135
1126	Db		GCATAAGTAAACATGATATAAAAAATATATGCTGAAATTTACTTGTGAAGAAATGCAATTAAG	1185
1136	Qy		CTATTTTAAATGCTTTTATTTGTAAGACATTAATCTTATTAAGAAATTTGGTTATTATGCT	1195

Db	1186	CTATTTTAAATGCTGTTTATTATTGTAAGACATTTACTTTATTAAAGAAATGGTTATTATGCT	1243
Qy	1196	TACGTGTTCTAATCTGGTGGTAAAGGTATTCTTAAAGATTTCAGAGTACTACAGATTTTCA	1255
Db	1246	TACTGTTTCTAATCTGGTGGTAAAGGTATTCTTAAAGATTTCAGAGTACTACAGATTTTCA	1305
Qy	1256	AAACTGAATGAGAGAAAATTTGATAACCATCTCGTCTGTTCTTTTAGTGCATTAACAATAA	1315
Db	1306	AAACTGAATGAGAGAAAATTTGATAACCATCTCGTCTGTTCTTTTAGTGCATTAACAATAA	1365
Qy	1316	ACTCTGAAATTAAGA	1330
Db	1366	ACTNTGAAATTAAGA	1380
RESULT	117		
ADD78291			
ID	AD078291	standard; DNA, 1360 BP.	
XX			
AC	ADD78291;		
XX			
DT	29-JAN-2004	(first entry)	
XX			
DE	Human CGDD-33	coding sequence.	
XX			
KW	Anabolic; Hypertensive; Respiratory; Anti-HIV; Antiallergic;		
KW	Neuroprotective; Nootropic; Antianemic; Antiarteriosclerotic;		
KW	Antiinflammatory; Ophthalmological; Muscular; Hepatotropic;		
KW	Neuroprotective; Antiasthmatic; Anticonvulsant; Virucide; Antibacterial;		
KW	Fungicide; Antiparasitic; Protozoacide; Antihelminthic; Cytostatic;		
KW	Cerebroprotective; Antiparkinsonian; Antipsoriatic; Anticancer;		
KW	Antidiabetic; Antiarrhythmic; Antirheumatic; Osteopathic; Gene therapy;		
KW	human; cell growth; cell differentiation; cell death; CGDD;		
KW	cell proliferative disorder; cancer; developmental disorder;		
KW	neurological disorder; autoimmune disorder; inflammatory disorder;		
KW	infection; reproductive disorder; gene; ds.		
XX			
OS	homo sapiens.		
XX			
PN	W02003077875-A2.		
XX			
PD	25-SEP-2003.		
XX			
PF	14-MAR-2003; 2003WO-US008310.		
XX			
PR	15-MAR-2002; 2002US-0364494P.		
PR	29-MAR-2002; 2002US-0369129P.		
PR	12-APR-2002; 2002US-0372511P.		
XX			
PA	(INCY-) INCYTE GENOMICS INC.		
XX			
PI	Kable AE, Tran UK, Hafalia AJA, Burford N, Honchell CD;		
PI	Lehr-Mason EM, Duggan BM, Ramkumar J, Griffin JA, Richardson TW;		
PI	Elliott VS, Jiang X, Jackson AA, Marquis JP, Chawla NK, Khare R;		
PI	Becha SD, Lee SY, Swarnakar A, Yue H, Warren BA, Baughn MR, Lal PG;		
PI	Lee S, Ho A, Gandhi AR, Yao MG;		
DR	WPI; 2003-779081-73.		
DR	P-PSDB; ADD78252.		
XX			
PT	New polypeptides and polynucleotides associated with cell growth,		
PT	differentiation and death, useful for diagnosing, treating or preventing		
PT	e.g. developmental, neurological, autoimmune, inflammatory or		
PT	reproductive disorders.		
XX			
PS	Claim 5; SEQ ID NO 72; 320pp; English.		
XX			
CC	The present invention relates to novel human proteins (I; ADD78220-		
CC	ADD78258) and their coding sequences (II; ADD78259-ADD78297), which are		
CC	associated with cell growth, differentiation and death, referred to as		
CC	CGDD-n proteins, where n is a number from 1 to 39. The CGDD proteins and		
CC	their coding sequences are useful for diagnosing, treating or preventing		
CC	cell proliferative disorders (e.g. cirrhosis, hepatitis.		


```

;
MEDIUM TYPE: Diskette

```

QY 603 TTGCTGTGGAAAGACGTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 662
DB 663 TTGCTGTGGAAAGACGTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 722
QY 663 CGTATAAATTAATAAATAAAGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTCTTT 722
DB 723 CGTATAAATTAATAAATAAAGATTAACCTCTGGTGTGACAGGTTTGAACCTGCACTCTTT 782
QY 723 AAGGAACAGCCATATCTCTGAATGATGCAATTAATTAACCTGACCTGCTCTAGTACATTTGA 782
DB 783 AAGGAACAGCCATATCTCTGAATGATGCAATTAATTAACCTGACCTGCTCTAGTACATTTGA 842
QY 783 AGCTTTTGTATAGGAACCTGTTAGGCTCAATTTTGGTTTCATTTGAACAGTATCTAATTT 842
DB 843 AGCTTTTGTATAGGAACCTGTTAGGCTCAATTTTGGTTTCATTTGAACAGTATCTAATTT 902
QY 843 ATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATAATTAATTAACCTGACCTAGT 902
DB 903 ATAAATAGCTGTAGATATCAGGTGCTCTGATGAAGTGAATAATTAATTAACCTGACCTAGT 962
QY 903 GGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAACCTGACCTAGT 962
DB 963 GGAAACTTCATGGGTTTCTCATCTGTCATGTCGATGATTAATTAATTAACCTGACCTAGT 1022
QY 963 AAATAAAGAGCGGAATTTTCCCTTCGCTTGAATTAATTAATTAACCTGATTAATTAACCTG 1022
DB 1023 AAATAAAGAGCGGAATTTTCCCTTCGCTTGAATTAATTAATTAACCTGATTAATTAACCTG 1082
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAACCTGATTAATTAACCTG 1082
DB 1083 GAGATTTCCCATATTTCCATCAGAGTAAATAATTAATTAATTAACCTGATTAATTAACCTG 1142
QY 1083 TAAACATGATATAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTT 1142
DB 1143 TAAACATGATATAAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTT 1202
QY 1143 AAATCTGTTTTTATTTTGAAGACATTTACTTAAAGAAATTTGGTTTATTAATTAATTAATTT 1202
DB 1203 AAATCTGTTTTTATTTTGAAGACATTTACTTAAAGAAATTTGGTTTATTAATTAATTAATTT 1262
QY 1203 CTAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGTACTCAGATTTTCAAAACTGA 1262
DB 1263 CTAATCTGGTGAAGTATTTCTTAAGAAATTTGAGGTACTCAGATTTTCAAAACTGA 1322
QY 1263 ATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTTTATGTCATTAATTAATTAATTT 1322
DB 1323 ATGAGAGAAATTTGATTAACCATCTGCTGTTTCTTTTATGTCATTAATTAATTAATTT 1382
QY 1323 AATTAAGA 1330
DB 1383 AATTAAGA 1390

RESULT 2

US-09-365-705-2

; Sequence 2, Application US/09365705

; Patent No. 6348576

; GENERAL INFORMATION:

; APPLICANT: Hillman, Jennifer L.

; Corley, Neil C.

; Shah, Purvi

; TITLE OF INVENTION: HUMAN CORNICHON PROTEIN

; NUMBER OF SEQUENCES: 3

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Incyte Pharmaceuticals, Inc.

; STREET: 3174 Porter Drive

; CITY: Palo Alto

; STATE: CA

; COUNTRY: USA

; ZIP: 94304

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION NUMBER: US/09/365,705
; FILING DATE: 02-Aug-1999
; PRIOR APPLICATION DATA: US/08/950,168
; FILING DATE: 14-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0401 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1391 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: BLADNOT04
; CLONE: 1318847
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
; US-09-365-705-2

Query Match 98.8%; Score 1316.8; DB 4; Length 1391;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1321; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 CCACGGCTCCGATGGCGCTTCCACGTTCCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCTCA 62
DB 63 CCTCCCGAGCATGGCGCTTCCACGTTCCGCGCGCTTCTGCTACATGCTGGCGCTGCTGCTCA 122
QY 63 CTGCGCGGCTCATCTTCTGCGCATTTGGGCATTTAGCATTTAGCATTTAGCATTTAGCATTT 122
DB 123 CTGCGCGGCTCATCTTCTGCGCATTTGGGCATTTAGCATTTAGCATTTAGCATTTAGCATTT 182
QY 123 ATTAACAAGATPCCATATAGACCCAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTACC 182
DB 183 ATTAACAAGATPCCATATAGACCCAGTGTAAATACCCCTGTAATCCCTTGTACTCCAGAGTACC 242
QY 183 TCATCCAGGCTTCTTCTGCTGTCATGTTTCTTGTGACGAGAGTGGCTTACATGGGTC 242
DB 243 TCATCCAGGCTTCTTCTGCTGTCATGTTTCTTGTGACGAGAGTGGCTTACATGGGTC 302
QY 243 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 302
DB 303 TCAATATGCCCTCTTGGCATATCATATTTGGAGGTATATGAGTAGACCATGATGATG 362
QY 303 GCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTCTAGCATATTGTCAGA 362
DB 363 GCCCAGGACTCTATGACCCCTACCAACCATCATGAATGCAGATATTCTAGCATATTGTCAGA 422
QY 363 AGGAAGGATGGTGAATAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATTT 422
DB 423 AGGAAGGATGGTGAATAATAGCTTTTATCTTCTAGCATTTTCTTCTAGCATTTTCTAGCATTT 482
QY 423 TGATCTATGTTTGGTGGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAAGTGC 482
DB 483 TGATCTATGTTTGGTGGAGCTCTTTAGAACCAACACACAGAGAAATGGTCCAGTTAAAGTGC 542
QY 483 ATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGGCT 542
DB 543 ATGCAAAAAGCCACCAATGAAGGATTTCTATCCAGCAAGATCTCTGTCGAAGTAGGCT 602
QY 543 GTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACATTT 602
DB 603 GTGGAATCTGATCAGTTACTTTTAAATAATGATCTCTTATTTTAAATGTTTCCACATTT 662
QY 603 TTGCTGTGGAAAGACGTGTTTTCATATGTTTATATCTCAGATAAAGATTTTAAATGGTATTA 662

Db 892 ATAAATTAGCTGTAGATATCAGCTGCTTCTGATGAAGTGAATGTATATCTGACTAGTG 951
QY 903 GGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATACATTTACAA 962
Db 952 GGAACCTTCATGGGTTTCCCTCATCTGTCATGTCGATGATATATATGGATACATTTACAA 1011
QY 963 AAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAATGA 1022
Db 1012 AAATAAAAGCGGGAATTTCCCTTCGCTTGAATATATCCCTGTATATTTGCATGAATGA 1071
QY 1023 GAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTGGCTTTAAATCTTAAGCATAAG 1082
Db 1072 GAGATTTCCCATATTTCCATCAGAGTAATAAATATATCTTGGCTTTAAATCTTAAGCATAAG 1131
QY 1083 TAAACATGATATAAAATATATGCTGAATTTCTTGAAGATGCAATTTAAAGCTATTTT 1142
Db 1132 TAAACATGATATAAAATATATGCTGAATTTCTTGAAGATGCAATTTAAAGCTATTTT 1191
QY 1143 AAATGTGTTTTTATTTGTAAAGACATTTACTTATTAGAAATTTGGTTATTTATGTTACTGTT 1202
Db 1192 AAATGTGTTTTTATTTGTAAAGACATTTACTTATTAGAAATTTGGTTATTTATGTTACTGTT 1251
QY 1203 CTAATCTGTGTGTAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAAACTGA 1262
Db 1252 CTAATCTGTGTGTAAGGTATTTCTTAAGAAATTTGCGAGGTACTACAGATTTTCAAAACTGA 1311
QY 1263 ATGAGAGAAAATTTGTATAACCATCTGCTGTTCCCTTTAGTGCATATACATTAACCTCTGA 1322
Db 1312 ATGAGAGAAAATTTGTATAACCATCTGCTGTTCCCTTTAGTGCATATACATTAACCTCTGA 1371
QY 1323 AATTAA 1328
Db 1372 AATTAA 1377

Search completed: June 14, 2004, 18:58:03
Job time : 117 secs